NIV 1/4/2

DUTCH NATIONAL SURVEY OF GENERAL PRACTICE

MORBIDITY IN GENERAL PRACTICE

J. van der Velden D.H. de Bakker A.A.M.C. Claessens F.G. Schellevis

August 1992

Netherlands Institute of Primary Health Care (NIVEL)
P.O. Box 1568 - 3500 BN Utrecht - tel. nr. ..-3130319946



bibliotheek drieharingstraat 6 postbus 1568 3500 bn utrechi tel 030 2729 614/615 fax 030 2729729

CIP-GEGEVENS KONINKLIJKE BIBLIOTHEEK, DEN HAAG

Morbidity

Morbidity in general practice: Dutch National Survey of Morbidity and Interventions in General Practice / J. van der Velden (et al.). Utrecht: Netherlands Institute of Primary Health Care (NIVEL)

Met lit. opg.

ISBN 90-6905-189-3

Trefw.: medische statistiek; huisartsgeneeskunde.

Lay-out: Mieke Cornelius

Tekstprocessing: Christine Ruiter

PREFACE

This report of the Dutch National Survey of (diseases and interventions in) general practice bears the title "Morbidity in General Practice".

The report is the third in a series of four reports. The first report contains a detailed description of measuring instruments and procedures followed in data collection. The second report is called "Health status and health behaviour in the practice population and the fourth "Interventions in general practice".

This report gives an overview of the morbidity, presented to general practice. The quantitative information is representative for Dutch general practice. The description of the methods of data-collection has been restricted, because of its comprehensive description in the first report. However, extensive attention has been given to specific calculations carried out for this report (calculation of incidence, prevalence and weighting factors).

Besides a total rate, there is a splitting up in characteristics of the patient and characteristics of general practice. In this way morbidity is represented by subpopulations distinguished to demographic (like age, sex, marital status), socio-economic (like occupational class, educational level, insurance-type) and geographic characteristics of general practice (like region and degree of urbanization).

The data, represented in this report, are the basis to further investigation of the work of the general practitioner and the position of the general practitioner in the health care system of the Netherlands.

Utrecht, August 1992

ACKNOWLEDGEMENTS

Many people contributed to the realization of this report. In the first place this concerns the 161 general practitioners, the 193 practice-assistants, the 90 fieldworkers/datatypists and the fieldwork-organization, who were successfull with each other in the collection and the processing of more than 300.000 episodes of illness of 335.000 patients.

In the quality control of data and production of the final tables of morbidity many people contributed too. This applies especially to Harald Abrahamse, Marleen Foets, Jan Gravestein, Han van Snellenberg, Loek Stokx, Patricia Swords and last but not least Jan van der Steen.

TABLES

2.1	Pagistoring	gonoral	practitioners		-44	abusisions	h	atratification.	wastablaa	
2.1	Redisterna	deneral	practitioners	and	otner	Drivsicians	DV	stratification	variables	

- 2.2 Registering general practitioners and other physicians by season
- 2.3 Response to patient registration by age and sex, stratification variables and season
- 2.4 Significance level of differences in average number of episodes per 1000 patients of each ICPC-chapter between general practices broken down by stratification variables
- 2.5 Practice population National Survey and Dutch population by age and sex
- 2.6 Weighting factors step 1
- 2.7 Calculation of the weighting factors distance from practice address to the hospital by degree of urbanization and region
- 2.8 Calculation of correction factors per registration period
- 2.9 Age/sex distribution of practice population before and after weighting compared with the Netherlands
- 2.10 The investigated practice population by marital status
- 2.11 The investigated practice population by highest level of education attained
- 2.12 The investigated practice population by form of insurance
- 2.13 The investigated practice population by country of birth
- 2.14 The investigated practice population by occupational class
- 2.15 The investigated practice population by current employment status
- 2.16 The investigated practice population by living situation
- 2.17 Practice population by urbanization degree, region and distance from hospital and season
- 2.18 Percentages of agreement by fieldworkers in the classification of diagnoses
- 2.19 Incompatibility of diagnosis/age and of diagnosis/sex in percentages of the contacts and episodes respectively
- 3.1 Incidence and prevalence per ICPC chapter after weighting per 3 months absolute and per 1000 persons
- 3.2 Average incidence/prevalence with including variation coefficient per ICPC-chapter
- 3.3 Incidence per ICPC-chapter by degree of urbanization after weighting per 3 months per 1000 persons
- 3,4 Prevalence per ICPC-chapter by degree of urbanization after weighting per 3 months per 1000 persons
- 3,5 Incidence per ICPC-chapter by region after weighting per 3 months per 1000 persons
- 3.6 Prevalence per ICPC-chapter by region after weighting per 3 months per 1000 persons
- 3.7 Incidence per ICPC-chapter by the distance to hospital after weighting per 3 months per 1000 persons
- 3.8 Prevalence per ICPC-chapter by the distance to hospital after weighting per 3 months per 1000 persons
- 3.9 Incidence per ICPC-chapter by season after weighting per 3 months per 1000 persons
- 3.10 Prevalence per ICPC-chapter by season after weighting per 3 months per 1000 persons
- 3.11 Incidence and prevalence per ICPC chapter by sex after weighting per 3 months per 1000 persons
- 3.12 Incidence and prevalence per ICPC-chapter by age categories after weighting per 3 months per 1000 persons
- 3.13 Incidence and prevalence per ICPC-chapter by marital status after weighting per 3 months per 1000 persons
- 3.14 The 20 highest incident and prevalent diagnoses per 3 months per 1000 persons
- 3.15 The 20 highest incident diagnosis among males and females per 3 months per 1000 persons
- 3.16 The 20 highest prevalent diagnoses among males and females per 3 months per 1000 persons

FIGURES

- 1.1 The professional care process
- 2.1 Contact registration form of the National Survey
- 2.2 Percentage of agreement by general practitioners on paper vignettes
- 3.1 Incidence and prevalence of ICPC-chapters by age and sex after weighting per 3 months per 1000 persons
- 3.2 Incidence and prevalence per ICPC-chapter by form of insurance after weighting per 3 months per 1000 persons
- 3.3 Incidence and prevalence per ICPC-chapter by family status after weighting per 3 months per 1000 persons
- 3.4 Incidence and prevalence per ICPC-chapter by birth country after weighting per 3 months per 1000 persons
- 3.5 Incidence and prevalence per ICPC-chapter by educational level after weighting per 3 months per 1000 persons
- 3.6 Incidence and prevalence per ICPC-chapter by current-employment status after weighting per 3 months per 1000 persons
- 3.7 Incidence and prevalence per ICPC chapter by occupational class after weighting per 3 months per 1000 persons

CONTENTS

001		page
PRE	FACE	
ACK	NOWLEDGEMENTS	
4.	INTRODUCTION	1
1.1	Introduction	1
1.2	Backgrounds and objectives	2
1.3	Outline of the report	4
2.	DATA AND METHODS	5
2.1	Introduction	5
2.2	Sample of general practitioners	5
2.3	The epidemiological numerator 2.3.1 Encounter registration 2.3.2 From problem to episode 2.3.3 Classification of morbidity	7 7 10 10
2.4	2.3.4 Summary The epidemiological denominator 2.4.1 Patient registration 2.4.2 Weighting 2.4.3 Description of denominator per patient characteristic 2.4.4 Description of denominator per practice characteristic 2.4.5 Summary	12 12 14 19 23 24
2.5	Incidence and prevalence	25
2.6	Validity and reliability of data 2.6.1 Validity 2.6.2 Reliability	26 26 28
3.	RESULTS	31
3.1	Introduction	31
3.2	Morbidity per ICPC chapter by practice characteristics and season	31
3.3	Morbidity per ICPC chapter by patients characteristics	41

LITERATURE

Appendix A	A.1 A.2 A.3 A.4	tables of morbidity in general practice of the Netherlands Clarification Abbreviations, used in the basic tables Basic table A: morbidity in general practice by age and sex Basic table B: morbidity in general practice by urbanization degree, region, season and insurance mode
Appendix B	_	oses (numbers) corresponding with ICPC-codes of NIVEL-edition (1989) exford-edition (1987)

1. INTRODUCTION

1.1 Introduction

Statistical information on the health of the population has long been used as an instrument for health policy and planning of health care and evaluation thereof. The presentation of this in the "Nota 2000" may be described as the most recent and telling example of this. The working paper "Epidemiologie en Informatica", a part of the "Kerndocument Gezondheidsbeleid" (1989), elaborates on this tradition and is directed towards the following goals:

- insight into the health status of the population;
- insight into effects and quality of the care;
- systematic evaluation of health policy:
- improvement of the provision of information in health care.

Recently extensive surveys have become available on what is present in the way of health statistics in the Netherlands (Bonte, 1989; Hoogendoorn, 1989; Pieters, 1989; Hofman, 1989).

Broadly speaking, with regard to public health the following data are present structurally and routinely:

- cause-of-death and stillbirth statistics for which there is a legal notification requirement by physicians;
- statistics concerning specific disorders (cancer registration, surveillance of infectious diseases, industrial accidents);
- statistics from medical examinations and checks (absenteeism, incapacity for work, conscripts);
- statistics from specific care situations (diagnosis statistics of hospitals, sentinel stations and morbidity registration by general practitioners, obstetric assistance and place of birth);
- statistics from the population (health surveys, living situation surveys).

This variety of registrations, based on and organized around specific objectives, gives a good but not yet complete insight into public health in the Netherlands. Moreover, various methodological problems play a part in the interpretation of data derived from these registrations on behalf of health policy.

The following gaps have been noted (Bonte, 1989):

- 1. As part of the Health Survey as performed by the Central Statistical Office (CBS): the absence as yet of data on the population living in institutions; observations on health-affecting aspects of life such as eating, drinking and sport; data directed towards certain sections of the population such as migrants.
- 2. Data on the health status of health of the population with regard to the 'objective component' are only fragmentary: surveys of congenital defects and data representative of the population on diseases, disturbances and limitations, as established by physicians, are missing.

- 3. Statistics on incapacity for work are incomplete and not fully geared to each other, while data on occupational diseases are due for revision.
- 4. Differentiation of a number of statistics by socio-economic characteristics is desirable.
- 5. As part of the services supplied the Health Survey to a certain extent fills the gaps regarding consumption in the extramural sector (in the intramural sector registrations by among others the SIG usually supply the necessary data. Special mention should be made of the absence of (diagnostic) data on mental public health and extramural and semi-mural care, such as morbidity data in general practice, outpatient department and day and night nursing.

The importance of data representative of the population on disease, disturbances and limitations, as established by physicians, is emphasized by an increased life expectancy with a simultaneous increased burden of disease. However important registration of disease is in itself, for health policy insight into and evaluation of the existing care are also required, which on the one hand makes it necessary to link disease registration to registration of items of service and on the other hand tries to place disease registration in the perspective of the diseases occurring among the population. The transition from epidemiology to health (services) research is taking shape here and it is in this field that the morbidity registration of the National Survey of Morbidity and Interventions in general practice takes place.

1.2 Backgrounds and objectives

Within (primary) health care in the Netherlands the general practice occupies a key position. On the one hand, via that general practice the greatest number of contacts between population and health care takes place, on the other the general practitioner has the possibilities of making selective use or having selective use made of care that is not directly accessible in the Netherlands. However, at national level there is little good and relevant information available on general practice. As the starting point of study the epidemiological basis of general-practice care in the Netherlands has therefore been taken (van der Velden, 1986; Foets, van der Velden, 1990). The following objectives have been pursued in this (Foets et al., 1986):

- Obtaining insight on a national scale into the presentation of diseases, complaints and problems in general practice and into the actions taken by the general practitioners as a result of these presented problems.
- 2. Obtaining insight into the factors that influence the presentation of health problems in general practice and also the varying reactions by the general practitioners to the problems submitted to them.

This basic report is directed towards the first part of the first objective: obtaining insight on a national scale into the presentation of diseases, complaints and problems in general practice. This can be explained by means of Figure 1.1, showing the chain of the professional aid process. In this report attention is directed towards the demand for professional help and the diagnosis that the general practitioner makes thereby.

Figure 1.1 Chain of the professional aid process

health felt need demand for problem → for help → professional → diagnosis → therapy → result experienced help

The National Survey of morbidity and interventions in general practice (to be referred to further as the National Survey) must be regarded as a study in which a certain sector of health care, in this case the medicine of general practice, is described and analysed. It is thus a typical 'health services research' project, intended above all to acquire information on health care facilities and the use of these; the registration of morbidity is not a goal in itself but an aid to studying the caring process. In this an important position is occupied by the description and explanation of differences between general practitioners, as regards both the morbidity presented to them and interventions.

Morbidity in the National Survey

Morbidity has been registered in general practice, by the general practitioner and his or her practice assistant, by means of a contact registration for three months, whereby reasons for encounter, (differential) diagnosis/working hypothesis and underlying diseases have been recorded. In addition, by means of a health interview survey and a health diary the subjective state of health has been measured in a random sample of the population. Finally, the admission and discharge diagnoses are known of the patients that were admitted and discharged from hospital during the registration period. Because all these data have been collected in the same population and in the same period, this information can be linked at the level of the individual patient.

A morbidity registration as described here has not been performed before in the Netherlands, and it enables us to acquire new insights with regard to the epidemiology of diseases in the Netherlands. However, that does not mean that the most precise incidence/prevalence rates of all disorders in the population can be given. This is due to the fact that problems presented in general practice form a fraction of problems occurring among the population and moreover do not always properly reflect these. For this reason among others, in the health interview survey of the National Survey detailed questions are asked about the state of health, so that a good insight can be obtained into the relation between the health problems in the population and the presentation of problems in general practice: the so-called iceberg phenomenon (van Es, 1983, van de Lisdonk, 1985; Goldberg, Huxley, 1980). This morbidity recorded in the patient survey relates to problems reported by the patient, and, not to any diagnoses made by the general practitioner.

This report will pass over this subjective health status of health of the population. Attention is directed towards the morbidity presented to the general practitioner, with as central question:

What is the epidemiology of diseases in general practice in the Netherlands?

On the basis of the episode-oriented morbidity registration of the National Survey a calculation of incidence and prevalence rate of disease in general practice has been performed. The goals of this basic report may be described as follows in this regard:

- presentation of nationally representative data with regard to morbidity in Dutch general practice;
- description of differences both between sections of the population, distinguished by a number of basic characteristics, and between geographical units in morbidity presented to the general practitioner.

The registration of morbidity in the National Survey is episode-oriented, in emulation of the National Morbidity Surveys in the United Kingdom and Dutch morbidity registration projects (Office of Population Censuses and Surveys, 1974a, 1974b and 1984; van Weel et al., 1986; Lamberts, 1986, Lamberts et al., 1987a). An episode-oriented registration has been opted for in the first place on account of the possibility of recording the trend of morbidity over time whether or not under the influence of diagnostics and therapy. In the second place it is possible by placing episodes side by side to increase insight into the diagnostic and therapeutic action of general practitioners.

The concept disease episode has been further operationalized on behalf of the National Survey, a distinction being made between the concepts 'episode of need' and 'episode of care' (Foets, van der Velden, 1990). On behalf of the morbidity registration in general practice only the concept 'episode of care' is used. This 'episode of care' forms the numerator of the epidemiological fraction. For a description of the way in which morbidity data from the contact registration have been processed into disease episodes see Section 2.3.2. The population data required for calculation of the denominator of the epidemiological fraction have been obtained from the well-described practice populations of the participating practices.

The investigation has been performed among a random non-proportionally stratified sample of 161 established Dutch general practitioners, from 103 general practices, serving a joint practice population of 335,000 patients. They form a 2.5% sample of the Dutch population of general practitioners.

Data collection took place in four registration periods, each of three months, between 01-04-1987 and 31-03-1988. The three months form a balance between required numbers of data per unit of time and the possibilities with respect to the workload of the registering general practitioner and practice assistant and are at the same time a representation of seasons. Computerized processing of morbidity data took place at NIVEL. A 'field worker' who visited the registering general practice once a week formed the important link between the general practice and NIVEL. These field workers helped the GPs with the organization of data collection and checking the completed registration forms. At NIVEL they coded the completed forms and entered them into the computer.

1.3 Outline of the report

In Chapter 1 the background to the morbidity study is presented. In Chapter 2 a justification is given of the way in which the data have been obtained, the processing performed is accounted for and the value of the data is discussed. Successively the realization of the sample (including the weighting), the epidemiological numerator and the epidemiological denominator is explained, the operationalization of the incidence and prevalence is described and the quality of the data is discussed. In Chapter 3 the results, largely in tabular form, are presented.

2. DATA AND METHODS

2.1 Introduction

In this chapter a justification is given of the performance of the National Survey and the processing applied to the data. In Section 2.2 it is explained how a sample of general practitioners was taken so as to obtain data representative of the Netherlands. In Section 2.3 justification of the morbidity registration, or the epidemiological numerator, takes place. The contact registration performed in the participating general practices and the classification system used for the morbidity are discussed. In Section 2.4 determination of the denominator by means of the patient registration performed is described. The denominator has been determined on the basis of data on the patients of all participating general practices. Also discussed are the data collection, the non-response, the representativeness of the data and the applied weighting to the Dutch population. Section 2.5 describes how the incidence and prevalence rates were ultimately calculated. In the last section of this chapter attention is devoted to the quality of the material. A full description of the methodology, the procedure and the measuring instruments of the National Survey is given in the basic report 'Meetinstrumenten en procedures' (Foets and van der Velden, 1990).

2.2 Sample of general practitioners

For the National Survey a random non-proportionally stratified sample of general practitioners was taken. The sample framework was formed by the general practitioner file of NIVEL, which contains all officially registered independently established general practitioners as at 01-01-1985. The sample is meant to give a representative picture of the Dutch general practitioner and his or her practice and should display sufficient variation in GP characteristics, so that differences between general practitioners can be examined with sufficiently large numbers. Use is made of

stratification variables three stratification variables that are known to be connected with morbidity (Lako et al., 1978, van Sonsbeek, 1987) or aspects of GP action (see for instance Wijkel, 1986). The variables are region, distance from the practice address to the nearest hospital and degree of urbanization.

The region variable is divided into;

- north (Groningen, Friesland and Drenthe);
- south (North Brabant and Limburg);
- centre (remaining provinces).

The distance from practice address to nearest hospital variable has the following breakdown:

- hospital in same place as the practice address;
- hospital outside the place and up to 15 km from the practice;
- hospital outside the place and more than 15 km from the practice.

The degree of urbanization variable has the following four (CBS) categories:

- rural (fewer than 30.000 inhabitants);
- suburban (30 000 to 50.000 inhabitants);
- urban (more than 50.000 inhabitants);
- city (Amsterdam, Rotterdam and The Hague).

The non-proportional nature of the sample is intended to guarantee that all sample cells are equally filled. The intention was to recruit 6-7 registering physicians per sample cell.

The recruitment resulted in a participation of 161 established general practitioners from 103 GP practices. Of these 161 general practitioners, 98 come from the sample; the other established general practitioners are colleagues of sample physicians in the same practice (n=57) and volunteers (n=6). The non-established physicians (other physicians) consist of practice assistant GPs (n=10), locums (n=9) and general practitioners in training (n=13). In total 193 general practitioners and other physicians collaborated in the investigation.

Table 2.1 surveys all the registering physicians, broken down by the stratification variables region, distance from practice address to hospital and degree of urbanization.

Theoretically there are 3x3x4 = 36 cells. As the table shows, not all cells are applicable. The cell filling is reasonable, with the exception that one cell in the south region has only one participating GP. In respect of reality GPs and other physicians from the north region, rural areas and GPs and other physicians working at a practice address that is more than 15 km from the nearest hospital are deliberately over-represented.

No morbidity has been registered of the contacts with colleagues' patients. Telephone encounters were registered only if these resulted in a referral or prescription. Encounters consisting only of writing out a repeat prescription were also recorded. The feasibility study that preceded the investigation (Foets et al., 1986) had shown that three months' registration for the short-term episodes is in any case enough. With the long-term episodes (in particular chronic diseases) an under-estimation of the prevalence may occur, because in a number of the patient in question will not have been in the GP's practice during those three months. Since telephone encounters (including requests for repeat prescriptions) have also been registered, the under-estimation will be limited.

On behalf of this report use has been made of the following data:

Patient data:

- age;
- sex.

Encounter data:

- date of the encounter:
- nature of the encounter (first encounter, relapse, repeat encounter, periodical check).

Reasons for encounter and diagnosis/working hypothesis:

- reason(s) for encounter:
- probability diagnosis/working hypothesis at the highest possible diagnostic level (Meyboom, 1979);
- underlying disease, provided that this was relevant in the framework of this encounter.

The total registration period amounted to one calendar year (01-04-1987 to 31-03-1988). In the distribution of the general practitioners over the four registration periods maximum allowance has been made for the distribution among the sample cells (see Table 2.2). In this way seasonal influences have been equally divided among the registering general practitioners.

Table 2.2 Registering GPs and other physicians by season

season	registration period	number of registering GPs and other physicians (n=193)	
spring	01-04-1987 - 30-06-1987	45	
summer	01-07-1987 - 30-09-1987	49	
autumn	01-10-1987 - 31-12-1987	50	
winter	01-01-1988 - 31-03-1988	49	

Of the 161 established GPs and the remaining 32 physicians, one GP performed the registration for only six weeks. This leads to an under-estimation of the incidence and prevalence. Correcting for the duration of the registration is not reliably possible. This practice has therefore not been included in the analyses of the basic report.

General practitioners and practice assistants have registered data per encounter with a patient. As within a encounter more than one problem can be presented, the number of problems exceeds the number of encounters. Per problem a diagnosis has been made by the general practitioner. This diagnosis is the starting point for calculation of the morbidity.

In the National Survey a total of 387,250 encounters (in which 418,750 problems were presented) have been registered. Of these, 780 encounters (in which problems were presented) are encounters of the general practitioner who registered for only six weeks, while 26,000 encounters with colleagues' patients have been recorded. In this report the results of 360,470 encounters (in which 417,850 problems were presented) have ultimately been included.

2.3.2 From problem to episode

The registration of morbidity in the National Survey is episode-oriented in emulation of the National Morbidity Surveys in the United Kingdom and Dutch morbidity registration projects (Office of Population Censuses and Surveys, 1974a, 1974b and 1984; Van Weel et al., 1986; Lamberts et al., 1987a). According to the WONCA (Classification Committee 1981), an episode is a problem or illness in a patient over the entire period of time from its onset to its resolution. Following this definition in an operational sense, the concept 'episode' is confined here to the phase in which professional help is sought (the 'episode of care'). Within one episode one or more than one encounter can take place. The goal of the episode-oriented registration is to give a more accurate picture of the incidence and the prevalence than is possible on the basis of the individual encounters. Registering at episode level results in a reduction in the number of false-positive and false-negative diagnoses because many 'probability diagnoses' crystallize out into definitive diagnoses. The data registered at encounter level make comparisons of the trend within episodes of the same disease among different patients possible.

Arranging the problems of one patient that are presented in one or more encounters into episodes took place afterwards by combining a number of data: patient code, date of the encounter, nature of the encounter (first encounter, encounter in connection with relapse, repeat encounter, encounter in connection with periodical check), reason for encounter, diagnosis, the underlying disease and the degree of certainty of the diagnosis (measured on 5-point scales). The diagnosis of the last encounter in an episode is adhered to as the diagnosis of the whole episode. These episodes form the starting point for determination of the epidemiological numerator. All constructed episodes have been checked and in the case of doubt about their correctness submitted to the general practitioner concerned. The morbidity data in this report are based on 309,125 episodes (see Section 2.3.3).

2.3.3 Morbidity classification

Within medicine, particularly that of general practice, a number of morbidity classifications are available: namely the ICD-9-CM (International Classification of Diseases, 9th revision, Clinical Modification 1980), the E list of the British Royal College of General Practitioners, compiled by Eimerl (College of General Practitioners, 1959), the ICHPPC-2-Defined (International Classification of Health Problems in Primary Care, 1983), the RFEC or Reason for Encounter Classification (Lamberts et al., 1982 and 1984) and the ICPC (International Classification of Primary Care, Lamberts, Wood, 1987b). All the classification systems

mentioned, except the ICD-9-CM, have been specially designed for use in general practice. The ICD-9-CM is strongly clinically oriented and comprises almost exclusively diagnoses and barely complaints and problems that occur often in general practice. Moreover, the coding in the ICD-9-CM is extensive and complicated for semi-trained coders. The recently developed ICPC, on the other hand, is clearly laid out in components and chapters and offers the possibility of coding diagnoses and complaints. The coding-friendly nature and the comparability with other research were the decisive criteria in determination of a choice of a classification system. (Crombie, van der Zee, 1984; Schellevis et al., 1984a; Schellevis, 1984b; Severien, Van der Zee, 1984). This ultimately led to the choice of the ICPC. A shortcoming in 1987 of the then available version of the ICPC was the limited number of diagnosis-categories. The ICPC was therefore adapted to a version of our own with a finer classification that is compatible with the international version (van der Velden et al., 1989). The refinement that has been applied by NIVEL consists of a third figure that has been added in a number of cases. It is important to remark that with the ICPC not only diagnoses can be classified but also reasons for encounter, preventive activities, diagnostic and therapeutical interventions.

ICPC system

An ICPC code consists of a letter followed by two figures (the alfa-numeric code). The 17 letter codes, which refer to an equal number of ICPC chapters, are based on localization (for instance A = general, B = blood etc.). The figure codes follow a corresponding system per chapter as far as possible. For instance, D26 is the code for fear of cancer of the gastrointestinal tract and R26 the code for fear of cancer of the respiratory organs. Further, the component involved can be derived from the figures:

component	codes
1. symptoms/complaints	1-29
2. diagnostic/preventive services	30-49
3. medication/treatment/therapeutical services	50-59
4. results	60-61
5. administrative services	62
6. referrals and other reasons for encounter	63-69
7. diagnoses/diseases	70-99

The basis used is 316,947 episodes of care. Of these, in 309,125 cases a symptom diagnosis or diagnosis could be made, coded in accordance with component one and seven respectively. Further, in 7822 episodes of care it was not possible to code a diagnosis or a symptom, either because the problem entered was not convertible into a diagnosis, e.g. the code for sport (A98) and localization of face (L22) or because there was no question of a disease or a complaint but of a procedure (e.g. preventive activity: codes terminating in 44, 45 and 49). The morbidity data are therefore based on 309.125 episodes of care coded in accordance with components 1 and 7.

On behalf of the presentation of figures in this basic report a number of ICPC codes have been clustered. The clustering of ICPC codes concerns only the symptom diagnoses (ICPC codes from component one). Criteria used in clustering diagnoses are: the prevalence of the disorder, the frequency of encounters, clinical homogeneity and etiological grounds. Component seven has been left intact. The codes are numbered from 1 to 684. In the basic tables the morbidity figures are given per diagnosis thus distinguished. The diagnoses are arranged

per chapter. In Appendix B a description is given per diagnosis number and both the corresponding NIVEL-ICPC code and the corresponding Oxford ICPC code are listed.

2.3.4 Summary

This section has discussed the epidemiological numerator. On the basis of a random non-proportional stratified sample 193 GPs and other physicians, of whom 161 established GPs, have been recruited. During four three-month periods all encounters of patients with these physicians and practice assistants were registered. All problems presented during these encounters have been classified through the ICPC. The problems presented have been arranged in episodes. The episodes form the basis for determination of the numerator of the incidence and the prevalence per 3 months.

2.4 The epidemiological denominator

2.4.1 Patient registration

On behalf of determination of the epidemiological denominator patient registration has been performed. This patient registration consists of the collection of basic data on all patients of the participating physicians. This makes it possible to determine denominators not only for the total population but also for characteristics like age, sex, highest level of education attained, marital status, form of insurance, country of birth, occupational class, current working situation and living situation. The starting point for the patient registration was the GP's patient records. This registration provided for the majority of the patients the characteristics age, sex and form of insurance. This information has been supplemented with the aid of forms, on which in addition to age and sex a number of socio-demographic data could be entered (Foets et al., 1990). The forms were completed as much as possible during a encounter of the patient with the general practitioner or the practice assistant. Patients who during the registration period had no encounter with the GP or for other reasons had not completed a registration form were sent a form upon completion of the registration period. In the final phase the data were further supplemented by means of reminders, telephone encounter with the patient and health insurance fund lists. The ultimate response for the complete set was 91.2%.

For all patients from the practice population age and sex are known via the GP's records. Supplementary patient data were collected by means of the patient registration. The non-response to the patient registration (having completed the form or not) is 8.7%. Table 2.3 shows the (non-)response by age, sex, stratification variables and season. The differences prove to be small in general. The greatest are the differences in the age variable. A higher non-response is seen in the group below the age of five and above the age of 75. A lower non-response is observed in the 5-14 age group. In addition a relatively high non-response has to be reported in the three big cities. A relatively low non-response may be noted in the north region and in the spring (the first registration period). In the other categories the deviation from the average non-response is less than 10%.

Table 2.3 Response to patient registration (form completed or not) by age and sex, stratification variables and season

	respo	nse	non-response			
	n	%	n	%		
total	303.248	91,3	29.055	8,7		
sex						
male	147.040	92,0	12.691	8,0		
female	155.895	90,6	16.190	9,4		
age						
0-4 years	19.694	89,4	2.332	10,6		
5-14 years	39.530	93,6	2.693	6,4		
15-24 years	51.705	90,8	5.261	9,2		
25-44 years	97.617	91,5	9.059	8,5		
45-64 years	58.941	91,8	5.290	8,2		
65-74 years	20.674	90,5	2.162	9,5		
75 years and over	15.042	87,1	2.228	12,9		
degree of urbanization						
rural	116.718	91,0	11.547	9,0		
suburban	121.634	91,6	11.147	8,4		
urban	50.281	91,7	4.577	8,3		
city	14.615	89,1	1.784	10,9		
region						
north	82.355	92,3	6.880	7,7		
centre	111.233	91,2	10.684	8,8		
south	109.660	90,5	11.491	9,5		
distance from hospital						
same place	119.781	91,0	11.891	9,0		
1-15 km	112.432	91,9	9.975	8,1		
> 15 km	71.035	90,8	7.189	9,2		
season						
spring	83.766	93,2	6.142	6,8		
summer	69.587	90,2	7.599	9,1		
autumn	79.987	90,6	8.332	9,4		
winter	69.908	90,9	6.982	9,1		

In this report the morbidity is distinguished by the characteristics age, sex, marital status, living situation, form of insurance and country of birth, level of education, current employment status and occupational class. In the selection of these characteristics two criteria played a part:

- 1. It must be known from the literature that the characteristic in question is connected with morbidity.
- 2. The categories that are distinguished on the basis of the characteristics in question must be of sufficient size to be able to give reasonable estimates of incidence and prevalence.

In Section 2.4.3 the denominators per characteristic used in the calculation of the incidence and prevalence rates will be accounted for. Before this can be done the weighting factors used will be further explained, since the weighting influences the denominators.

2.4.2 Weighting

This report aims at nationally representative figures on morbidity presented in general practice. In principle that is possible because a national sample of GPs collaborated in the National Survey. Since the sample is stratified a weighting may be necessary to arrive at accurate estimates of incidence and prevalence. May be, because if it proves that there is no connection between morbidity and the stratification characteristics used, weighting is not required. In this section, after an analysis has shown that weighting is necessary, the weighting procedure is explained.

To investigate the latter an analysis has been performed. Per practice the number of episodes per ICPC chapter has been determined and related to the number of patients (number of episodes per 1000 patients). Then variance analyses were performed at practice level with as dependent variables these ratios per ICPC chapter and as independent variables region, degree of urbanization and distance from the practice to the hospital (Table 2.4). First region, degree of urbanization and distance from the practice to the hospital were separately related to the number of episodes per 1000 patients. It becomes clear that for each of the three variables there are significant correlations with the number of episodes per 1000 patients. This need not necessarily lead to the conclusion that therefore weighting has to be applied for all three of the variables. For it may be that certain connections cease to apply if the other stratification variables are checked for.

Table 2.4 Significance level of differences in average number of episodes per 1000 patients per ICPC chapter between practices broken down by stratification variables (n=102)

	degree of urbanization		regio	n	distance from hospital
A. General and unspecified	.89	.66	.18	.28	.11 .06
B. Blood	.29	.54	<u>.01</u>	.02	.09 .18
D. Digestive	.53	.54	.20	.22	.07 .05
F. Eye	.02	.03	.30	.77	.86 .65
H. Ear	.24	.32	.38	.45	.73 .85
K. Circulatory	09	.47	.05	.13	<u>.04</u> .17
L. Musculoskeletal	.03	.02	.00	<u>.01</u>	.06 <u>.01</u>
N. Neurological	.01	.21	<u>.05</u>	.26	<u>.01</u> .10
P. Psychological	.72	.63	.38	.31	<u>.00</u> <u>.00</u>
R. Respiratory	.53	.57	.00	.01	.26 .12
S. Skin	.60	.63	.03	.04	.45 .35
T. Endocrine/metabolic/nutritional	.34	.56	.25	.30	.09 .17
U. Urology	.96	.94	.19	.27	.04 .05
W. Pregnancy/family planning	.10	.21	.03	.03	.31 .47
X. Female genital system	.04	.25	.77	.89	<u>.02</u> .18
Y. Male genital system	.21	.20	.57	.35	.11 .19
Z. Social problems	.04	.29	.17	.10	<u>.01</u> .10

p1 = significance of difference between averages

p2 = significance of difference between averages after check for other stratification variables

Consequently analyses have also been performed in which the three stratification variables together have been related to the prevalence rates. In this way it is investigated to what extent a connection exists between a stratification variable and the prevalence rates if a check is made for the other two variables. The table shows that in that case too statistically significant differences in prevalence between practices distinguished by the three stratification variables continue to exist. The conclusion that must be drawn from this is that weighting has to be applied to degree of urbanization, region and distance from the practice to the hospital.

To obtain nationally representative data on morbidity in general practice a second correction is necessary. For the question is to what extent the practice populations of the participating general practitioners reflect the practice populations of all Dutch general practitioners together (assuming that the practice populations of all Dutch GPs together are equivalent to the Dutch population). Through non-response and sample fluctuation it is possible that the population investigated differs in composition from the Dutch population. If the age/sex distribution of the population investigated is compared with the Dutch population the differences are admittedly slight (Table 2.5), but if within a given stratification cell the age/sex distribution of the practice populations of the collaborating physicians is compared with the actual distribution in the population there are considerable differences (this will be made evident later). To arrive at nationally representative figures a weighting by age and sex will therefore have to be applied per stratification cell.

Table 2.5 Practice population National Survey and Dutch population (01-01-1987) by age and sex (absolute and in percentages)

age category	and sex	National S	urvey	Netherlands	Netherlands		
0-4 years	М	11.234	3,4	449.475	3,1		
	F	10.712	3,2	430.920	2,9		
5-14 years	M	21.322	6,4	953.309	6,5		
	F	20.735	6,2	911.655	6,2		
15-24 years	М	27.486	8,3	1.274.319	8,7		
•	F	29.362	8,8	1.221.351	8,4		
25-44 years	M	51.960	15,6	2.353.807	16,1		
•	F	54.643	16,4	2.245.867	15,4		
45-64 years	M	31.519	9,5	1.470.552	10,1		
•	V	32.691	9,8	1.498.584	10,3		
65-74 years	M	9.885	3,0	459.306	3,1		
•	V	12.943	3,9	590.408	4,0		
75 years and							
over	M	6.291	1,9	262.619	1,8		
	F	10.965	3,3	491.585	3,4		
unknown		555	0,2	-	-		
total		332.303	100,0	14.613.757	100,0		

One final correction that possibly has to be made is concerned with the fact that registration has taken place in four successive three-month periods. This was done to incorporate the seasonal factor. If, however, the populations investigated are not evenly divided among the seasons, there is a chance that a seasonal effect will nevertheless occur. Now the collaborating GPs are spread as evenly as possible over the four registration periods, but nevertheless differences may occur in the ultimate size of the practice populations per period. Differences in practice size may be at the bottom of this, but also differences in effects of the other weightings between the registration periods. This should be corrected for too. The weighting procedure consists of three steps. First weighting factors are calculated at patient level on the basis of the stratification characteristics degree of urbanization and region and the variables age and sex. Then weighting factors are calculated at the level of general practices for the stratification variable distance from the practice address to the hospital. Finally, weighting factors per season are determined on the level of the total population.

The first step starts from the following variables:

- region (north, centre, south);
- degree of urbanization (rural, suburban, urban, three big cities);
- sex (male, female);
- age (up to 4 years inclusive, 5 to 14 years inclusive, 15 to 24 years inclusive, 25 to 44 years inclusive, 45 to 64 years inclusive, 65 to 74 years inclusive, 75 years and older).

The variable distance from practice address to the hospital has been left out of consideration, because no population data are available for this to which back-weighting can be applied. For this variable weighting takes place in the second step at the level of GPs. On the basis of the four variables mentioned a $3 \times 4 \times 2 \times 7$ table has been constructed. Per cell the number of patients occurring in the patient registration has been related to the number in the Dutch population (based on CBS data of 1 January 1987). The following formula has been used for this:

weighting factor in cell $x = \frac{\text{number in population in cell } x}{\text{number in patient registration in cell } x}$

The weighting factors calculated in this way are included in Table 2.6. The size of the weighting factors varies from about 10 in the suburban areas in the north of the Netherlands to over 100 in the big cities. The variation among the age-sex categories is much less great, although this differs per age category. In some sample cells the practice populations from the study form a good reflection of the age-sex structure (rural north and suburban north and south). In other sample cells that is much less the case (urban centre and city centre are the peaks). In general the practice populations in urban areas and in the centre of the Netherlands form a less accurate reflection of the total population in the various sample cells than in other areas. By use of the weighting factors given in the table these deviations are corrected for.

Table 2.6 Weighting factors step 1

	rural			suburb			urban			big city
	north	centre	south	north	centre	south	north	centre	south	centre
males 0-4 jr	26,6	56,5	21,3	9,4	83,4	22,8	27,1	58,8	58,4	96,4
females 0-4 jr	27,1	57,7	21,2	9,4	83,3	23,4	25,2	53,9	55,4	103,1
males 5-14 jr	30,0	62,7	24,2	10,7	104,6	27,8	31,4	60,4	69,1	140,8
females 5-14 jr	29,2	64,0	23,2	10,4	100,8	28,1	32,9	57,8	66,6	118,7
males 15-24 jr	28,3	59,1	24,4	10,3	100,8	28,6	31,5	79,1	75,2	127,6
females 15-24 jr	26,6	56,9	22,2	9,2	93,2	25,2	21,7	68,7	63,0	92,8
males 25-44 jr	28,1	64,5	24,0	10,1	91,1	28,3	23,3	70,0	72,0	97,2
females 25-44 jr	26,5	60,8	21,7	9,4	84,5	27,0	17,9	59,7	61,0	80,8
males 45-64 jr	28,0	59,2	24,2	10,4	100,4	30,9	24,5	78,6	72,6	125,6
females 45-64 jr	27,2	58,0	23,2	10,3	97,5	30,7	21,8	78,7	70,7	116,7
males 65-74 jr	27,5	54,0	24,9	10,1	92,5	29,4	20,3	98,4	68,2	112,6
females 65-74 jr	26,0	50,2	22,4	10,6	90,6	29,7	18,4	98,1	61,9	101,7
males 75 jr e.o.	25,8	46,0	27,6	10,1	79,2	26,8	19,4	97,5	54,7	112,6
females 75 jr e.o.	27,7	48,2	24,3	12,2	79,0	26,4	19,1	109,5	56,1	111,9

The second step is the weighting by distance from practice address to the hospital. Because the national distribution of the population among the various categories by distance from practice address to the hospital is unknown, the basis taken here is the national distribution of general practitioners among the various categories. Per stratification cell the number of physicians that collaborated in the National Survey has been related to the number in the Dutch GP population. The ratio thus obtained has been related to the same ratio in cells defined by the variables degree of urbanization and region. In formula:

$$W_{ijk} = \frac{N_{ijk}}{n_{ijk}} / \frac{\sum N_{ij}}{----}$$

Here: Wiik : weighting factor per stratification cell ijk

Nijk : number of GPs in the Netherlands per cell ijk

n_{iik} : numbers of GPs in Study per cell ijk

Σ N_{ii}: number of GPs in cell ij in the Netherlands

Σ n_{ii}: number of GPs in cell ij in Study

jk : subscript of degree of urbanization, region and distance from practice address

to the hospital

The results of the calculation appear in Table 2.7. A sample calculation may make matters clear. The weighting factor for the north/rural/hospital cell in GP's location is equal to the reciprocal of the sample fraction in this cell (71/6) divided by the reciprocal of the sample fraction in the cell defined by only degree of urbanization and region (369/18) and thus equal to 0.577. In other wordsback-weighting to the situation in a degree of urbanization/region cell in the GP population takes place.

Table 2.7 Calculation of the weighting factors distance from practice address to the hospital by degree of urbanization and region

region	urbanization	total	practice address	< 15 km	> 15 km	
north	rural pop.	369	71	204	94	
	N.S.	18	6	6	6	
	factor		0,577	1,659	0,764	
north	suburban pop.	185	71	99	15	
	N.S.	23	6	11	6	
	factor		1,471	1,119	0,311	
north	urban pop.	101	101	-	-	
	N.S.	7	7	-	-	
	factor		1,000	-	-	
centre	rural pop.	1003	254	564	185	
	N.S.	19	3	8	8	
	factor		1,604	1,335	0,438	
centre	suburban pop.	1244	247	885	112	
	N.S.	16	3	10	3	
	factor		1,059	1,138	0,480	
centre	urban pop.	903	830	73	-	
	N.S.	73	7	4	-	
	factor		1,444	0,222	-	
centre	3 cities' pop.	742	742	-	-	
	N.S.	10	10	-	-	
	factor		1,000	-	-	
south	rural pop.	390	58	275	57	
	N.S.	23	8	, 8	7	
	factor		0,428	2,027	0,480	
south	suburban pop.	548	203	300	45	
	N.S.	23	5	12	6	
	factor		1,704	1,049	0,315	
south	urban pop.	341	315	26	-	
	N.S.	5	4	1	-	
	factor		1,155	0,381	•	

The last step is a correction for seasonal influences. After the two preceding steps had been performed it was investigated what the distribution of the patients over the four registration periods was. Then a correction was applied in such a way that the distribution over the four periods became the same (Table 2.8).

Table 2.8 Calculation of correction factors per registration period

	frequency after performance of steps 1 and 2 in %	desired frequency in %	correction factor
period 1	28,0	25,0	0,894
period 2	22,7	25,0	1,100
period 3	31,1	25,0	0,804
period 4	18,2	25,0	1,373

2.4.3 Description of denominators per patient characteristic

In this report the morbidity rates are broken down by patient characteristics such as age, sex, marital status, level of education, form of insurance etc. The subdivisions made are accounted for in this section. At the same time both the unweighted and the weighted denominator is given per population category for which morbidity rates are presented. The size of the unweighted denominator is directly connected with the reliability of the figure presented. According as the denominator is lower the unreliability margins are higher. With the aid of the weighted denominators the morbidity rates in the report can be converted into estimates of the absolute number of prevalent and incident cases as are presented in the Netherlands in general practice.

The age/sex distribution before and after weighting is shown in Table 2.9. By way of comparison the age/sex distribution of the Dutch population at the time of the National Survey is placed alongside it. We see that the age distribution after weighting corresponds almost perfectly to that of the Dutch population, which is logical, since after all the former has been weighted back to the latter. We see the lowest unweighted denominator among the males of 75 years and over. Having regard to this low absolute number wide reliability intervals must be adhered to for this category of the population.

Table 2.9 Age/sex distribution of practice population before and after weighting compared with the Netherlands (CBS, 1-1-1987)

age/sex		before wei	before weighting		nting	Netherlands	
category		absolute	%	absolute	%	%	
0 - 4 yr.	M	11.243	3,4	452.080	3,1	3,1	
0 - 4 yr.	F	10.712	3,2	436.193	3,0	2,9	
5 - 14 yr.	М	21.322	6,4	951.358	6,5	6,5	
5 - 14 yr.	F	20.735	6,2	921.702	6,3	6,2	
15 - 24 yr.	М	27.486	8,3	1.264.573	8,6	8,7	
15 - 24 yr.	F	29.362	8,8	1.230.203	8,4	8,4	
25 - 44 yr.	М	51.960	15,6	2.366.499	16,1	16,1	
25 - 44 yr.	F	54.643	16,4	2.266.671	15,5	15,4	
45 - 64 yr.	М	31.519	9,5	1.463.485	10,0	10,1	
45 - 64 yr.	F	32.691	9,8	1.495.778	10,2	10,3	
65 - 74 yr.	М	9.885	3,0	459.549	3,1	3,1	
65 - 74 yr.	F	12.943	3,9	596.071	4,1	4,0	
75 jr. e.o.	M	6.291	1,9	267.445	1,8	1,8	
75 jr. e.o.	F	10.965	3,3	503.428	3,4	3,4	
unknown		555	0,2	 ₩.	-	-	

A second breakdown that has been made is by the formal marital status as indicated by the patients on the patient registration form (Table 2.10). This breakdown must be carefully distinguished from the living situation (whether or not living together), which is discussed further on. Morbidity rates are given for the single, the married, the divorced and the widowed. The categories 'marital status unknown' and 'marital status child' are left out of consideration. By 'child' males to 17 years inclusive and females to 15 years inclusive are designated. The latter has been done so as not to distort the figures for the single group too strongly.

Table 2.10 The investigated practice population by marital status (before and after weighting)

arital status	before we	before weighting		
	abs.	%	abs.	%
d	74.751	22,5	3.235.323	22,0
le	59.863	18,0	2.722.266	18,6
rried	141.286	42,5	6.039.627	41,2
rced	7.898	2,4	415.709	2,8
owed	15.449	4,6	711.666	4,8
kend	33.056	9,9	1.550.444	10,6
	332.303	100,0	14.657.035	100,0

The respondents were asked to indicate on the patient registration form the highest level of education attained. Because persons up to 17 years inclusive in general have not yet attained their highest level of education, this category has been left out of consideration, as also the category unknown (Table 2.11).

Table 2.11 The investigated practice population by highest level of education attained (before and after weighting)

level of education before weighting	after weighting					
	abs.	%	abs.	%		
age < 18 years	80.668	24,3	3.464.359	23,6		
no/primary education	56.432	17,0	2.413.693	16,4		
secondary education	120.735	36,3	5.242.901	35,7		
nigher professional/university	22.564	6,8	1.128.248	7,7		
unknown	51.904	15,6	2.425.834	16,5		
otal	332.303	100,0	14.675.035	100,0		

Morbidity rates will be given for publicly insured versus privately insured persons (Table 2.12). The group that stated that they were not insured or unknown are left out of consideration in this report on account of the small size.

Table 2.12 The investigated practice population by type of insurance (before and after weighting)

form of insurance	before weighting		after weighting		
	abs.	%	abs.	%	
public	204.245	61,5	8.715.637	59,4	
private	104.415	31,4	4.904.773	33,4	
no insurance	592	0,2	25.158	0,2	
unknown	23.051	6,9	1.029.467	7,0	
total	332.303	100,0	14.675.035	100,0	

Origin has been determined on the basis of the country of birth stated by the respondent (Table 2.1.3). A distinction has been made between the Netherlands, Turkey/Morocco, other Western and other non-Western. (Non-)Western country of birth has not been broken down further by country of origin, although this was asked for, because the numbers of respondents per country were too small.

Table 2.13 The investigated practice population by country of birth (before and after weighting)

origin	before weighting		after wei	ghting
	abs.	%	abs.	%
Netherlands	259.633	78,1	11.121.963	75,8
Turkey/Morocco	2.684	0,8	174.376	1,2
other Western	4.143	1,2	201.026	1,4
other non-Western	6.350	1,9	358.556	2,4
unknown	59.463	17,9	2.819.114	19,2
total	332.303	100,0	14.675.035	100,0

The respondents were asked to indicate their (last practised) occupation. If they did not have one the occupation of the parents (in the case of children living at home) or the partner was included. Use was made of the Occupational Classification 1984 of the CBS. By means of a recoding key this was given an EGP code (class scheme of Erikson, Goldthorpe and Portocarero, 1979, 1982, 1983), running from one to ten. The ten-class distribution has been converted into a three-class distribution. Class 1 represents headwork, class 2 self-employed and farmers and class 3 manual work. It must be noted that the occupation remains unknown for a considerable percentage. In that case the question was looked at that relates to the situation if no occupation is performed (table 2.14).

Table 2.14 The investigated practice population by occupational class (before and after weighting)

	before weighting		after weig	ghting
	abs.	%	abs.	%
occupational class				
headwork: high + medium	60.623	18,2	2.832.566	19,3
headwork: low	57.922	17,4	2.635.720	18,0
self-employed + farmers	15.980	4,8	617.961	4,2
manual work: high + medium	57.502	17,3	2.328.244	15,9
manual work: low	58.343	17,6	2.416.768	16,5
non-classifiable	1.583	0,5	66.678	0,5
other				
age < 16 years	14.899	4,5	727.443	5,0
child/student	4.496	1,4	232.574	1,6
national service	315	0,1	13.497	0,1
housewife/husband	6.413	1,9	298.262	2,0
unemployed	1.894	0,6	98.017	0,7
recipient of disablement benefit	1.105	0,3	51.400	0,4
early retirement/pension	6.512	2,0	294936	2,0
not working/no reason	41	0,0	1.622	0,0
other unknown	44.675	13,4	2.059.347	14,0
total	332.303	100,0	14.675.035	100,0

Morbidity rates are given for working versus non-working persons (broken down into jobless and recipients of disablement benefit). This item has been derived from the question about the occupation and a question concerning the situation if one does not practise that occupation (table 2.15).

Table 2.15 The investigated practice population by current employment status (before and after weighting)

current work situation	before w	eighting	after weighting			
	abs.	%	abs.	%		
working	102.988	31,0	4.627.885	31,5		
unemployed	7.008	2,1	329.856	2,2		
recipient of disablement benefit	8.141	2,4	355.686	2,4		
< 16 years	69.421	20,9	2.981.654	20,3		
child/student	22.573	6,8	994.139	6,8		
national service	878	0,3	38.144	0,3		
nousewife/husband	44.678	13,4	1.820.216	12,4		
early retirement/pension	26.152	7,9	1.209.605	8,2		
not working/no reason	159	0,0	6.946	0,0		
unknown	50.305	15,1	2.310.903	15,7		
otal	332.303	100,0	14.675.035	100,0		

This refers to the form of cohabitation, that is to say whether people live alone, with a partner and children or with a partner without children. Persons living in institutions and communes have been left out of consideration on account of their small numbers. In the tables single persons (including one-parent families) are distinguished from the others (family, (married) couples). To render possible a meaningful comparison of single persons with those living in a family relationship, children below the age of 18 have been left out of consideration (table 2.16).

Table 2.16 The investigated practice population by living situation (before and after weighting)

living situation	before weighting		after weighting	
	abs.	<u></u> %	abs.	%
age < 18 years	80.668	24,3	3.464.359	23,6
single	29.290	8,8	1.512.680	10,3
(married) couple/family	175.860	52,9	7.540.813	51,4
one-parent family	9.445	2,8	444.693	3,0
unknown	37.040	11,1	1.712.491	11,7
total	332.303	100,0	14.675.035	100,0

2.4.4 Description of denominators per practice characteristic

In this section it is indicated how the practice population of the collaborating general practitioners before and after weighting is distributed by region, degree of urbanization and distance from the practice address to the nearest hospital. Because the location of the general practice and not that of the patient has been taken here as point of departure, these data are always known. The denominators used are shown in Table 2.17.

Table 2.17 Practice population by degree of urbanization, region and distance from the hospital and season (before and after weighting)

	before we	eighting	after weig	ghting	
	abs.	%	abs.	%	
degree of urbanization					
rural	128.265	38,6	4.747.055	32,4	
suburban	132.781	40,0	5.031.531	34,3	
urban	54.858	16,5	3.248.938	22,1	
city	16.399	4,9	1.647.511	11,2	
region					
north	89.235	26,9	1.569.723	10,7	
centre	121.917	36,7	9.490.706	64,7	
south	121.151	36,5	3.614.606	24,6	
distance from the hospital					
same place	131.672	39,6	7.226.622	49,2	
-15 km	122.407	36,8	6.127.396	41,8	
> 15 km	78.224	23,5	1.321.017	9,0	
season					
pring	89.908	27,1	3.668.758	25,0	
ummer	77.186	23,2	3.668.759	25,0	
utumn	88.319	26,6	3.668.759	25,0	
vinter	76.890	23,1	3.668.759	25,0	
otal	332.303	100,0	14.675.035	100,0	

2.4.5 Summary

The age and sex are known of practically all patients. Supplementary data are known on 91.2% of the patients through the patient registration. The differences between responding and non-responding patients regarding age, sex, stratification variables and season are slight.

On behalf of the pursuit of nationally representative figures on morbidity in general practice it has been investigated whether weighting is necessary as regards the stratification variables age and sex and season. As significant differences exist in the prevalence between practices in distinguishing the three stratification variables, weighting should be performed for degree of urbanization, region and distance from practice address to hospital. In view of the fact that within a stratification cell the age/sex distribution in the practice population differs from the Dutch population, a correction has also been made for age and sex. In order to eliminate the seasonal factor (differences in population investigated and differences in effects of other weightings), as the final step a correction has been performed in such a way that the distribution of patients over the four registration periods became the same.

In the description of denominators per patient characteristic it proves that among the responding patients the non-response is the highest with the socio-economic variables (level of education, occupational class and current employment status), with the exception of the form of insurance variable. As regards distribution by age and sex category the practice population of the National Survey may be described as representative of the Dutch population.

The total of the known practice populations of the participating physicians forms the epidemiological denominator. For breakdowns by characteristics of the patient such as age, sex and other characteristics the denominator is formed by the number of patients for whom the characteristic in question is known. For breakdowns by geographic characteristics the location of the general practice has been used as a starting point. These data are always known.

2.5 Incidence and prevalence

In this report both the cumulative incidence and the prevalence rate per disorder are indicated. The cumulative incidence and the prevalence rate may be defined as follows (Mausner, 1974):

Cumulative incidence: the number of new cases of disease that occur in the course of a period of time, divided by the number of persons present in the population at the beginning of the period of time considered. In the National Survey this period is three months.

Period-prevalence rate: the number of existing cases of disease in a given period divided by the average population. The period prevalence is built up from the prevalence at a given point in time, plus the number of new cases and relapses in a given period. In the National Survey this period is three months.

The operationalization of the incidence and prevalence in the National Survey may be described as follows. The incidence has been determined by counting those episodes in which the general practitioner indicated in the first encounter of the episode in question that a first encounter for the problem in question or a encounter in connection with a relapse for the problem was involved. The prevalence has been determined by counting the total number of episodes in which identical episodes were also counted once only per patient. As the length of registration was three months, the *incidence and prevalence* have been determined *per three months*.

Conversion of the numbers into figures on an annual basis is possible by multiplying the incidence by a factor of four, by which a cumulative incidence per year is obtained. Conversion of the prevalence of in particular chronic disorders into figures on an annual basis is particularly complicated and can be performed reliably only with further information. As a result of this, the prevalence cannot be roughly multiplied by four. In the case of an acute disorder with a high incidence and a high prevalence the prevalence per 3 months can be multiplied by four to obtain the prevalence per year. As regards a chronic disorder with a low incidence and a high prevalence, the prevalence per 3 months is equal to the prevalence per year. For the other disorders the multiplication factor is in between these.

An important fact is that calculation of perinatal mortality and mortality has been based on the same denominators as for the other disorders. The numbers are therefore not directly comparable with the perinatal mortality and mortality determined in other investigations.

The figures relate to problems presented to the general practitioners in three months. This implies that the figures are not a reflection of the occurrence of diseases and problems among the population, but only insofar as these have been presented to the general practiti-

oner. This has consequences notably for the prevalences of those disorders with which the patient is acquainted but which form a limited reason to consult the general practitioner (within the registration period). As an example the problem of deafness: this is presented to the general practitioner only if there is a '(re-)activation' of the problem of deafness (deterioration, replacement of hearing aid).

In the event of a differential diagnosis, only the diagnosis first reported has been included in the calculation.

Part of the morbidity is presented solely by a request for a repeat prescription. On account of the extent of this service, the repeat prescription was registered by the practice practice assistant only in the first registration period during the whole period and in the other periods only during half of the period. Introduction of a correction factor is therefore necessary. Without correction considerable differences occur in the amount of morbidity between on the one hand period one and on the other periods two, three and four. In period one there is then more morbidity. This relates to disorders for which repeat prescriptions are regularly written out, such as sleep disorders, depressive feelings, hypertension and oral anticonception. Therefore, a correction has been applied to the morbidity data from the second, third and fourth registration periods insofar as these have been generated solely by repeat prescriptions registered by the practice practice assistant. Per practice a correction factor has been determined by taking as a basis the repeat prescriptions recorded in the half period. The number of episodes that consisted exclusively of encounters in which solely repeat prescriptions were registered has been doubled. This has been done after it had emerged from the material of the first period that there was no difference in number of episodes with repeat prescriptions between the first and the second half of the registration period.

2.6 Validity and reliability of the data

2.6.1 Validity

The validity of the morbidity data means the degree in which a diagnosis made by the general practitioner (which is included in the data base coded in accordance with the ICPC) corresponds to the patient's actual disease. This is also referred to as the correctness of the diagnosis.

The validity of GP diagnoses must be seen in the light of the GP's working methods. It is inherent in these methods that many diagnoses are made as working hypotheses (Van der Velden, 1983) and are formulated at a low diagnostic level. According as the episode continues, a more differentiated picture forms and it is possible to make a medical diagnosis that can be fitted into a medico-nosological system.


In the episodic representation of morbidity the 'effect' of the course of time on the validity of the diagnosis is implicitly incorporated. Basing morbidity data on disease episodes increases the validity of those data.

In order to gain insight into the validity of the diagnoses made, 30 'paper vignettes' were submitted to all participating GPs with the request to make a diagnosis of each case. In

addition to an indication of the reliability, the uniformity in the naming of syndromes by the GPs is also to be regarded as an indication of the validity of the diagnoses, despite the absence of a 'gold standard'. Per paper vignette the response varied from 85% to 100%. On account of interpretation problems one paper vignette was not involved in the analysis.

In the following figures the percentage of agreement per case is shown.

Figure 2.2 Percentage of agreement by GPs on paper vignettes



In the case of 27 of the 29 patients the percentage of agreement is 75 or higher; for 21 of the 29 this is 90% or higher. The percentage of agreement is low for the case with dizziness or iridocyclitis as diagnosis (41% and 15% respectively).

In the coding of the morbidity data by the field worker interpretation of data was inevitable, which threatens the validity. In the discussion of the results of the uniformity tests among the field workers (see 2.6.2) attention was devoted to this in the sense of training. The field workers were moreover instructed to consult the registering general practitioner if matters were not clear.

The validity of the morbidity data can be increased by the application of diagnostic criteria by the registering GPs. For this training and verification meetings ought to take place. The scale on which the National Survey was held made this unfeasible.

2.6.2 Reliability

The reliability of the morbidity data means the reproducibility and the accuracy. Various procedures and measurements have been performed to track down systematic errors.

1. The diagnoses were coded 'centrally' by a (para)-medically trained field worker. After training in the use of the ICPC uniformity tests were regularly performed with paper vignettes. Through these tests insight was obtained into the uniformity of the coding. Further instruction was directed towards those points where uniformity left something to be desired. On account of the training aspect deliberate use was made of 'problem cases'. Table 2.18 contains the percentages of agreement of the field workers in coding of diagnoses. The average percentage of agreement is 80 for 'problem' codes of diagnoses at the level of encounters. Through the episode construction used this percentage - viewed theoretically - becomes higher.

Table 2.18 Percentages of agreement of field workers in the classification of diagnoses

checkpoint	number of field workers	average agreement (%)	
		*	
1	38	69	
2	32	81	
3	35	77	
4	38	83	
5	34	80	
6	32	88	

In a qualitative sense acute infectious diseases and the ICPC chapter W (Pregnancy, delivery and lying-in) proved to contain the highest percentages of agreement. The agreement was the lowest for diagnoses from Component one (Symptoms and complaints) of the ICPC chapters A (General and unspecified), P (Psychological) and Z (Social problems).

- The construction of disease episodes was performed by the field worker. In problem cases the GP in question was consulted. The construction of encounter diagnoses into disease episodes was fully checked by four physicians; if necessary the episode diagnosis was changed.
- 3. Data entry was checked by comparing the data input of a sample of 2% of the encounter registration forms with the data on the forms. In 1.1% of the checked forms an error was found that usually concerned one variable.

Incompatibility concerning the combinations diagnosis - age and diagnosis - sex was detected by a computer program. (van Weel, 1986). The results appear in Table 2.19.

Table 2.19 Incompatibility concerning the combinations diagnosis -age and diagnosis - sex in percentages of the encounters and episodes respectively

	% of encounters	% of episodes
diagnosis - age	0,05	
diagnosis - male sex	2,00	0,69
diagnosis - female sex		1,30



3. RESULTS

3.1. Introduction

In this chapter a description is given of the morbidity in Dutch general practice in a predominantly statistical sense. In Sections 3.2 and 3.3 the incidence and the prevalence, weighted to the Dutch population, are presented of the morbidity per ICPC chapter with breakdowns to practice and patient characteristics respectively. In Section 3.4 an overview is given of the twenty most frequent incident and prevalent episodes among men and women respectively. The most detailed incidence and prevalence rates are given in tables in the appendices. In these tables the morbidity has been broken down into 684 diagnoses.

3.2 Morbidity per ICPC chapter by practice characteristics and season

In this section differences between practices in presented morbidity per ICPC chapter are given. After a general overview the size of the variation in incidence and prevalence between practices is described per chapter. Next variations between practices distinguished by geographical characteristics of the location of the practice address are discussed. These geographical characteristics, degree of urbanization, region and distance from the hospital, at the same time form the stratification variables in taking the sample of GPs (see Section 2.2). Finally, the morbidity has been broken down by season. The characteristic season is in the National Survey in fact a practice characteristic, because in the four successive registration periods different practices registered each time.

In Table 3.1 a survey is given of the incidence and prevalence of the episodes per 1000 persons ICPC chapter, weighted to the Dutch population.

Table 3.1 Incidence and prevalence per ICPC chapter after weighting per 3 months absolute and per 1000 persons

ICPC chapter	estimate of incidence absolute	estimate of incidence per 1000 patients	estimate of prevalence absolute	estimate of prevalence per 1000 patients
A. general and unspecified	493.414	33.6	912.700	62,2
B. blood	59.102	4,0	186.168	12,7
D. digestive	541.975	36,9	984.354	67,1
F. eye	229.665	15,7	402.880	27,5
H. ear	373.997	25,5	469.108	32,0
K. circulatory	247.018	16,8	1.684.603	114,8
L. musculoskeletal	1.189.847	81,1	1.837.213	125,2
N. neurological	147.371	10,0	437.327	29,8
P. psychological	331.254	22,6	1.339.119	91,3
R. respiratory	1.240.696	84,5	1.910.728	130,2
S. skin	951.210	64,8	1.465.894	99,9
T. endocrine/metabolic/nutritional	71.511	4,9	435.777	29,7
U. urology	211.993	14,4	335.348	22,9
W. pregnancy & family planning	187.693	12,8	743.911	50,7
X. female genital system	237.435	16,2	438.982	29,9
Y. male genital system	51.256	3,5	80.373	5,5
Z. social problems	103.445	7,0	288.896	19,7
total	6.668.882	454,3	13.953.381	950,8

The incidence per three months is 454.3 per 1000 persons. Low incidences concern the ICPC chapters male genital system, blood, endocrine/metabolic/nutritional and social problems. High incidences, on the other hand, relate to the ICPC chapters respiratory, musculoskeletal and skin. The total prevalence is 950.8 per 1000 persons, despite the nature of the disorder. At ICPC chapter level the prevalence per 3 months varies from 5.5 per 1000 (disorders of male genitals) to 130.2 per 1000 (respiratory). Chapters with high prevalences are respiratory, musculoskeletal, circulatory, skin and psychological. Chapters with low prevalences are male genital system, blood, social problems, urology and eye.

There are differences in incidences and prevalences of ICPC chapters between the practices. This may be the result of actual differences in morbidity presented in general practice. However, differences between GPs in the designation of health problems may also play a part. This can be illustrated by means of the following table, in which the average incidence and prevalence per practice and the corresponding variation coefficient are stated. The variation coefficient is a measure of the size of the standard deviation expressed as a percentage of the average. Unlike the standard deviations, the variation coefficients are comparable with each other.

Table 3.2 Average incidence and variation coefficient and average prevalence and variation coefficient per ICPC chapter (n=102 practices)

ICPC chapter	average incidence	variation coefficient of incidence	average prevalence	variation coefficient of prevalence
A. general and unspecified	34,3	31,1	64,7	32,5
B. blood	3,9	44,6	13,4	41,3
D. digestive	35,9	25,4	66,9	22,0
F. eye	15,9	27,7	28,4	27,4
H. ear	25,9	26,6	32,4	24,4
K. circulatory	16,7	37,3	123,3	36,3
L. musculoskeletal	81,0	22,8	125,9	19,6
N. neurological	10,2	37,6	32,0	36,0
M. psychological	23,0	43,2	95,6	32,0
R. respiratory	85,2	31,6	133,1	27,5
S. skin	65,5	23,9	101,5	20,9
T. endocrine/metabolic/nutritional	4,8	41,9	31,2	34,1
U. urology	14,4	34,7	23,5	31,5
W. pregnancy & family planning	13,0	48,6	49,9	27,3
X. female genital system	16,2	35,1	30,1	29,1
Y. male genital system	3,6	37,5	5,7	28,6
Z. social problems	7,1	58,9	19,3	62,4

The highest variation coefficient of the incidence and the prevalence may be found in the ICPC chapter social problems. This is pre-eminently a chapter in which designation effects may occur. In general the variation coefficients of the incidence are higher than those of the prevalence. The high variation in the pregnancy chapter is connected with the fact whether the GP is obstetrically active or not. The variation coefficients are further high for the ICPC chapters blood, psychological and endocrine/metabolic/nutritional. For the prevalence the variation coefficients are high for the ICPC chapters circulatory, neurological, endocrine/metabolic/nutritional and general and unspecified. The lowest variation coefficients of both incidence and prevalence relate to the ICPC chapters musculoskeletal, skin and digestive.

In the following table the incidence per ICPC chapter is shown by the degree of urbanization of the municipality in which the registering general practice is located.

Table 3.3 Incidence per ICPC chapter by degree of urbanization after weighting per 3 months per 1000 persons

ICPC chapter	degree o	of urbanization		
	rural	suburban	urban	city
A. general and unspecified	30,9	35,9	34,0	33,7
B. blood	3,8	3,5	5,1	4,1
D. digestive	32,8	37,3	43,0	35,8
F. eye	15,8	16,0	16,7	12,3
H. ear	23,7	25,8	28,6	23,4
K. circulatory	15,0	15,4	20,9	18,5
L. musculoskeletal	75,4	85,4	89,9	67,0
N. neurological	10,3	10,2	10,0	8,8
M. psychological	16,7	24,3	26,9	25,5
R. respiratory	78,5	84,5	95,4	80,9
S. skin	61,3	67,4	67,9	61,2
Γ. endocrine/metabolic/nutritional	4,3	4,6	5,4	6,2
J. urology	13,1	13,9	16,9	15,2
N. pregnancy/family planning	15,8	10,8	12,6	10,5
X. female genital system	14,2	16,8	18,3	15,8
/. male genital system	3,1	3,3	3,8	4,6
Z. social problems	5,8	7,0	7,9	9,2
otal	420,5	462,1	503,3	432,7

The total incidence is the highest in towns with more than 50 000 inhabitants, excluding the three cities ('urban'), followed by urbanized rural municipalities ('suburban'), the three cities Amsterdam, Rotterdam and The Hague ('city') and finally the rural municipalities ('rural'). For the ICPC chapters endocrine/metabolic/nutritional, male genital system and social problems the incidence increases with the increase in the degree of urbanization. Further, the relatively low incidences of the ICPC chapters general and unspecified, psychological and respiratory in rural areas and of the ICPC chapters eye and musculoskeletal in the city are striking. Conversely, in urban areas the incidence is high of the ICPC chapters digestive, circulatory, respiratory and blood.

In Table 3.4 the prevalence per ICPC chapter is shown by degree of urbanization.

Table 3.4 Prevalence per ICPC chapter by degree of urbanization after weighting per 3 months per 1000 persons

ICPC chapter	degree of	urbanization		
	rural	suburban	urban city	
A. general and unspecified	59,8	63,3	61,0	68,0
B. blood	15,2	10,1	13,4	12,0
D. digestive	65,7	64,8	74,3	63,7
- eye	29,0	27,0	28,5	22,4
H. ear	30,2	32,0	35,4	30,1
C. circulatory	129,7	102,9	116,5	105,0
musculoskeletal	120,3	126,4	137,3	111,9
I. neurological	35,5	27,5	28,7	22,6
/l. psychological	89,7	87,8	97,4	94,2
R. respiratory	129,1	125,9	141,6	124,1
S. skin	99,9	101,4	101,7	91,7
. endocrine/metabolic/nutritional	32,7	25,8	30,4	31,4
J. urology	23,3	21,8	24,3	21,9
V. pregnancy/family planning	54,8	47,9	51,8	45,3
K. female genital system	27,8	29,4	33,4	30,5
/. male genital system	5,0	5,2	6,0	6,5
Z. social problems	14,7	19,5	23,8	26,3
otal	962,4	918,7	1.005, 5	907,5

It is striking that the prevalence is the highest in urban areas, followed by rural areas, suburban areas and the cities (Table 3.4). As regards the prevalence of the ICPC chapters male genital system and social problems, there is an increase in the prevalence with an increase in the degree of urbanization. In rural areas the high prevalences of blood, circulatory, neurological and pregnancy/family planning are striking. Relatively high prevalences in urban areas relate to the ICPC chapters digestive, ear, musculoskeletal, psychological and respiratory. In the big cities the prevalence of eye disorders is relatively low.

In Tables 3.5 and 3.6 incidence and prevalence respectively by region are presented per ICPC chapter.

Table 3.5 Incidence per ICPC chapter by region after weighting per 3 months per 1000 persons

ICPC chapter	region		
	north	centre	south
A. general and unspecified	34,1	32,5	36,3
B. blood	4,1	4,0	4,0
D. digestive	31,9	36,1	41,2
F. eye	15,7	15,4	16,4
H. ear	25,2	25,3	26,1
K. circulatory	15,9	16,9	17,2
L. musculoskeletal	75,4	77,5	93,0
N. neurological	9,7	9,8	10,9
M. psychological	20,4	23,1	22,2
R. respiratory	77,3	80,1	99,4
S. skin	61,1	63,1	70,8
T. endocrine/metabolic/nutritional	4,1	5,0	4,8
U. urology	14,7	14,4	14,3
W. pregnancy/family planning	12,6	13,4	11,3
X. female genital system	16,0	16,2	16,3
Y. male genital system	3,6	3,4	3,5
Z. social problems	6,7	6,8	7,8
total	428,5	443,0	495,5

The total incidence increases going from the north region to the centre and is the highest in south. In south region the incidence is above all relatively high with the ICPC chapters musculoskeletal, respiratory, skin and social problems.

Table 3.6 Prevalence per ICPC chapter by region after weighting per 3 months per 1000 persons

ICPC chapter	region		
·	north	centre	south
A	00.0	50.0	00.0
A. general and unspecified	68,6	59,6	66,2
B. blood	15,6	12,6	11,7
D. digestive	64,8	65,9	71,1
F. eye	28,1	26,9	28,6
H. ear	31,4	31,6	33,1
K. circulatory	139,0	109,4	118,5
L. musculoskeletal	118,5	120,2	141,3
N. neurological	34,7	28,6	30,7
M. psychological	97,8	92,8	84,5
R. respiratory	129,0	123,9	147,3
S. skin	95,9	97,4	108,2
f. endocrine/metabolic/nutritional	36,0	29,4	27,7
J. urology	26,1	22,3	22,9
N. pregnancy/family planning	47,8	50,9	51,5
K. female genital system	30,3	30,3	28,6
Y. male genital system	5,9	5,4	5,6
Z. social problems	16,7	19,1	22,6
otal	986,2	926,2	1.002,2

The total prevalence is the highest in south region, followed by north region and centre region. North region is striking with a high prevalence of the chapters circulatory and psychological. In south region the prevalences of the chapters musculoskeletal, digestive and respiratory are relatively high.

In Tables 3.7 and 3.8 the incidence and prevalence respectively by distance from the practice address to the nearest hospital are presented per ICPC chapter.

Table 3.7 Incidence per ICPC chapter by the distance from the practice address to the nearest hospital after weighting per 3 months per 1000 persons

ICPC chapter	distance fror	n practice address to	hospital	
	same place	1-15 km	> 15 km	
A. general and unspecified	36,8	30,5	30,8	
B. blood	4,7	3,4	3,6	
D. digestive	39,7	34,5	33,3	
F. eye	15,5	16,0	14,9	
H. ear	26,3	24,7	24,6	
K. circulatory	19,4	14,4	13,8	
L. musculoskeletal	83,1	79,3	78,3	
N. neurological	10,1	10,1	9,6	
P. psychological	25,5	19,7	20,2	
R. respiratory	89,1	80,8	76,8	
S. skin	66,2	63,5	63,6	
T. endocrine/metabolic/nutritional	5,5	4,1	5,0	
U. urology	16,0	13,0	12,8	
W. pregnancy	12,7	12,6	14,4	
X. female genital system	17,0	15,5	15,1	
Y. male genital system	3,8	3,2	3,3	
Z. social problems	8,5	5,6	5,9	
total	479,9	430,9	426,0	

If incidences are compared on distance from the practice address to the hospital it is striking that if the practice address is situated in the same place as the hospital the incidences are higher than when the hospital is located outside the place and further away from the practice address. This is in particular noticeable for the ICPC chapters general and unspecified, blood, digestive, circulatory, psychological, respiratory and social problems.

In Table 3.8 the prevalence per ICPC chapter by distance from the practice address to the nearest hospital is presented.

Table 3.8 Prevalence per ICPC chapter by distance from practice address to nearest hospital after weighting per 3 months per 1000 persons

ICPC chapter	distance from practice address to hospital				
ioi o diaptoi	same place	1-15 km	> 15 km		
A consequence unapposition	67,2	55,1	67,8		
A. general and unspecified	13,7	11,1	14,5		
B. blood	71,7	61,3	68,5		
D. digestive	27,4	26,9	30,2		
F. eye H. ear	32,6	31,1	32,7		
n. ear K. circulatory	117,5	106,5	138,7		
L. musculoskeletal	132,1	116,9	125,9		
N. neurological	28,8	29,6	36,0		
P. psychological	99,3	79,0	104,0		
R. respiratory	137,1	123,0	125,8		
S. skin	100,4	98,3	104,3		
T. endocrine/metabolic/nutritional	31,2	26,7	34,9		
U. urology	24,4	21,0	23,0		
W. pregnancy/family planning	50,4	50,3	54,0		
X. female genital system	31,7	27,6	30,8		
Y. male genital system	6,0	4,9	5,5		
Z. social problems	24,4	14,9	15,9		
total	995,9	8 84,2	1012,5		

In practices located within a distance of 15 kilometres from the nearest hospital (but not in the same place) the total prevalence is lower than further from the hospital and in practices where the hospital is located in the same place. Far from the hospital the prevalence of disorders from the circulatory chapter is high. Social problems are relatively common in practices with a hospital in the same place.

In the following tables the incidence and prevalence by season are presented per ICPC chapter. As already mentioned, in the National Survey season is a practice characteristic because per season registration has been performed by different practices.

Table 3.9 Incidence per ICPC chapter by season after weighting per 3 months per 1000 persons

ICPC chapter	season			
·	spring	summer	autumn	winter
A. general and unspecified	36,0	31,1	34,6	32,8
B. blood	4,1	4.0	4,1	3,9
D. digestive	38,7	34,0	37,3	37,8
F. eye	16,4	14,5	16,6	15,1
H. ear	26,1	23,9	25,6	26,3
K. circulatory	15,7	20,9	16,4	14,3
L. musculoskeletal	77,8	74,9	86,1	85,5
N. neurological	9,2	9,1	11,5	10,4
P. psychological	21,4	20,8	25,4	22,7
R. respiratory	81,6	60,3	101,3	95,0
S. skin	66,2	64,2	69,3	59,5
T. endocrine/metabolic/nutritional	4,1	5,4	5,0	5,0
J. urology	13,3	13,4	16,8	14,3
V. pregnancy/family planning	12,2	14,1	12,5	12,4
K. female genital system	16,4	15,7	17,6	15,0
Y. male genital system	3,7	3,0	3,9	3,4
Z. social problems	6,4	5,6	7,8	8,4
otal	449,3	414,9	491,8	461,8

The total incidence (Table 3.9) is the highest in the autumn and the lowest in the summer. In the summer the incidences are high of the ICPC chapters circulatory and pregnancy/family planning; in the autumn of psychological, respiratory and urology; and in the winter likewise of respiratory and of social problems. The ICPC chapters digestive, ear, musculoskeletal, respiratory and social problems have low incidences in the summer.

Table 3.10 Prevalence per ICPC chapter by season after weighting per 3 months per 1000 persons

ICPC chapter		seas	on	
	spring	summer	autumn	winter
A second and unaccitied	60.6	CO 0	64.0	04.0
A. general and unspecified	62,6	63,3	61,3	61,6
B. blood	12,4	14,7	11,8	11,8
D. digestive	65,8	64,1	68,9	69,6
F. eye	26,8	26,4	29,1	27,5
H. ear	32,7	30,2	31,6	33,4
K. circulatory	97,4	130,1	122,9	108,8
L. musculoskeletal	121,5	117,0	132,1	130,1
N. neurological	26,9	30,0	31,8	30,6
P. psychological	82,2	92,4	97,0	93,4
R. respiratory	123,8	99,3	150,6	147,1
S. skin	101,2	98,1	103,1	97,2
T. endocrine/metabolic/nutritional	25,0	31,0	29,3	33,5
U. urology	19,5	22,9	25,5	23,4
W. pregnancy/family planning	52,2	47,1	50,6	52,9
X. female genital system	29,6	29,5	31,6	29,0
Y. male genital system	5,8	4,7	6,3	5,1
Z. social problems	18,4	15,8	22,5	22,1
total	903,8	916,6	1006,0	977,1

In the autumn and the winter the prevalences for the chapters respiratory and social problems are considerably higher than in the other seasons (Table 3.10). Psychological disorders have the lowest prevalence in the spring. In the summer and autumn the prevalence of disorders of the circulatory are higher than in the spring and winter.

3.3 Morbidity per ICPC chapter by patient characteristics

In this section a presentation follows of the morbidity per ICPC chapter by characteristics of the patient. The patient characteristics are age, sex, form of insurance, marital status, living situation, country of birth, level of education, current employment status and occupational class. The breakdowns by age, sex and form of insurance may also be found in the appendices, but then for the detailed diagnosis clusters.

Table 3.11 Incidence and prevalence per ICPC chapter by sex after weighting per 3 months per 1000 persons

ICPC chapter	incidence		prevalence	•
•	male	female	male	female
A. general and unspecified	27,2	39,8	47,6	76,3
3. blood	2,8	5,2	7,7	17,6
D. digestive	32,8	40,9	58,3	75,5
eye	15,4	15,9	24,9	29,9
l. ear	25,5	25,5	31,4	32,5
circulatory	13,5	20,1	95,8	133,2
musculoskeletal	80,1	82,0	114,6	135,5
I. neurological	8,3	11,8	23,0	36,4
P. psychological	17,3	27,7	63,7	118,0
R. respiratory	80,8	88,1	129,6	130,8
S. skin	62,5	67,0	93,2	106,4
. endocrine/metabolic/nutritional	3,6	6,1	20,5	38,6
J. urology	6,6	22,1	12,4	33,0
V. pregnancy/family planning	•	25,0	-	98,9
K. female genital system	•	31,7	-	58,6
'. male genital system	7,1	-	11,1	-
. social problems	5,6	8,5	14,0	25,2
otal	389,1	517,4	747,8	1146,4

Table 3.11 gives incidence and prevalence rates by sex. In general both the incidences and the prevalences are higher for women than for men. This applies to a stronger extent to the ICPC chapters general and unspecified, blood, digestive, circulatory, psychological, endocrine/metabolic/nutritional and urology. In part this will be connected with the fact that women become older on average and therefore the elderly group is over-represented among women compared to men.

In Table 3.12 it can be seen that after childhood the incidences and the prevalences strongly increase with age. In this respect there are marked differences between the chapters. Disorders of the ear and of the respiratory occur very frequently, relatively speaking, among young children. The disorders that increase the most strongly in incidence and prevalence with increasing age are circulatory disorders.

Table 3.12 Incidence and prevalence per ICPC chapter by age categories after weighting per 3 months per 1000 persons

ICPC chapter	incidenc	е					
	0-4	5-14	15-24	25-44	45-64	65-74	75 and over
A. general and unspecified	87,9	31,8	32,4	28,5	26,3	30,7	42,7
B. blood	4,6	4,7	4,7	4,4	2,5	2,9	5,1
D. digestive	63,5	37,5	31,8	32,9	35,6	39,1	47,7
F. eye	18,6	13,1	16,7	15,5	15,1	16,4	17,1
H. ear	74,2	32,2	15,0	20,6	22,2	26,6	27,4
K. circulatory	1,2	1,1	4,4	10,4	26,2	48,5	72,6
L. musculoskeletal	18,3	46,7	79,2	90,6	102,8	88,7	91,7
N. neurological	5,4	4,7	7,8	10,5	12,8	14,7	15,6
P. psychological	5,1	7,1	21,0	28,4	27,9	24,6	27,0
R. respiratory	220,8	89,6	79,6	77,2	68,2	67,2	61,4
S. skin	87,2	77,2	78,9	61,2	51,8	49,2	56,6
T. endocrine/metabolic/nutrit	tional 4,0	2,7	3,8	4,5	5,9	8,2	8,7
U. urology	9,3	8,1	11,6	12,6	16,7	25,0	32,6
W. pregnancy/family planning	g -	0,6	24,4	26,6	0,6	-	-
X. female genital system	1,3	3,6	23,0	24,6	16,1	5,8	6,1
Y. male genital system	3,4	3,4	2,9	4,2	3,0	3,3	3,7
Z. social problems	2,6	2,3	5,2	7,7	10,1	8,8	11,6
total	607,4	366,4	442,4	460,4	443,8	459,7	527,6

ICPC chapter	prevalen	ce					
101 o chapter	0-4	5-14	15-24	25-44	45-64	65-74	75 and over
	110.1	40.4	40.4	F0.0	60,9	87,7	137,8
A. general and unspecified	112,4	43,4	48,4	50,0		19,6	42,6
B. blood	9,6	8,0	8,6	11,4	11,7	•	,
D. digestive	77,8	44,9	41,7	52,6	80,9	111,9	163,6
F. eye	25,0	22,2	22,6	22,1	28,4	44,4	64,3
H. ear	84,1	40,7	17,7	25,0	29,2	36,1	43,1
K. circulatory	3,5	3,0	9,9	37,2	191,0	429,4	596,9
L. musculoskeletal	26,7	57,0	99,3	124,1	171,6	184,1	236,0
N. neurological	9,7	9,7	15,8	26,3	43,4	55,7	80,2
P. psychological	11,8	14,9	39,9	82,2	142,6	194,5	250,7
R. respiratory	268,5	127,2	108,2	107,9	121,4	166,7	167,1
S. skin	116,4	100,5	120,1	91,0	88,3	94,0	120,0
T. endocrine/metabolic/nutritional 8,5		6,8	10,4	18,1	45,3	86,5	104,3
U. urology	11,4	9,7	14,2	16,3	26,0	48,4	88,5
W. pregnancy/family planning	g -	1,6	118,7	90,2	8,5	-	-
X. female genital system	2,0	4,8	33,4	39,1	38,6	24,1	30,8
Y. male genital system	4,8	4,3	3,6	5,3	5,1	9,5	11,7
Z. social problems	6,3	4,9	12,7	21,0	27,4	31,5	40,2
total	778,5	503,6	725,2	819,8	1120,3	1624,1	2177,8

The combination age/sex in relation to the morbidity presented in general practice is shown in Fig. 3.1. Each chapter will be briefly considered.

general and unspecified

Disorders from the chapter 'General and unspecified' occur (both incidence and prevalence) relatively often among 0-4-year-olds. Further we see an increase in prevalence with increasing age. Per age category disorders from this chapter occur more often among women than among men (with the exception of the 0-4 age group). Disorders that are decisive for the level of the prevalence in this chapter are childhood diseases, unspecified viral diseases, allergies and above all the working hypothesis 'no disease'.

blood, blood-forming organs, lymphatics and spleen

Disorders from the chapter 'blood, blood-forming organs, lymphatics and spleen' (both incidence and prevalence) are relatively infrequent. The prevalences in this chapter increase with age and are somewhat higher for women than for men. Decisive diagnoses are anemias (iron-deficiency anemia, pernicious/other deficiency anemia and not further defined anemias) and to a much smaller extent enlarged lymph glands.


digestive

Digestive disorders occur relatively often among young children (notably incidence) and among the elderly. Among the elderly disorders from this chapter occur more frequently among women than among men. The most common diagnoses are in decreasing order of prevalence other gastrointestinal infections, irritable bowel syndrome, constipation, disorders of stomach function/gastritis, stomach ache, worms/parasites and generalized abdominal pain/cramps.

eve

Disorders of the eye occur equally in all age categories. This applies above all to the incidence; prevalence occurs somewhat more often with increasing age. Women over the age of 65 visit the GP with these disorders more frequently than men from this age category. The most common diagnosis in this chapter is allergic conjunctivitis/not classifiable elsewhere, followed by refractive errors, complaints about vision, other symptoms/complaints of eye.

Figure 3.1 Incidence and prevalence of ICPC chapters by age and sex after weighting per 3 months per 1000 persons



ear

Disorders of the ear often occur above all with children. Beyond childhood there is not much difference between the age groups and between the sexes. Incidence and prevalence rates are not far apart. Common disorders of the ear are ear wax, acute otitis media/myringitis and otitis externa.

circulatory

Incidence and prevalence rates of the circulatory are far apart. Moreover, they are by far the most age-specific disorders. Above the age of 45 the prevalences of the disorders from this chapter rise sharply. For women the prevalences are even somewhat higher than for the men, above all for the group of 75 years and over. The decisive diagnosis is above all uncomplicated hypertension, which takes up more than a third of the episodes from this chapter. Other common (but much less frequent) disorders are angina pectoris, heart failure, old infarction and edema of the extremities.


musculoskeletal

While the incidence rate falls with age, disorders of the musculoskeletal system are more frequently seen in general practice according as age increases. There is a clear difference between men and women here. Whereas the incidence for men rises before the 65th year and then falls, the prevalences increase up to the 45-64 age group and then remain fairly constant above this age group. For women the incidence rises strongly up to 65 years and then falls somewhat, but the prevalences still clearly continue to increase above the age of 65. The most common individual disorder from this chapter is myalgia/fibrositis. Further, sprains and strains often occur (ankle, knee, shoulder/arm, wrist/hand, foot/toes). and to a smaller extent lumbago, tendinitis/synovitis, shoulder syndrome (incl. bursitis) and symptom-s/complaints relating to the back.

neurological

Disorders from the 'neurological' chapter are of relatively infrequent occurrence. This may be noted most strongly with the incidence: this increases slightly with age. The prevalence is higher with older people than with young ones and higher with women than with men. Headache/facial pain, migraine, other diseases of the peripheral neurological and epilepsy are the most common disorders.

Figure 3.1 Continued



psychological

In the 'psychological problems' chapter too incidence and prevalence differ strongly. The incidence occurs above all among adult females and remains constant, whereas with adult males a decline sets in at a greater age. As regards the prevalences, these become higher with increasing age and, as in the case of the musculoskeletal, the increase is stronger among women than among men. The symptom diagnoses 'feeling nervous' and 'disturbances of sleep/insomnia' are the most decisive for this chapter. Other very common diagnoses are depressive disorder and neurasthenia/surmenage.

respiratory

Disorders of the respiratory are relatively common among small children and old males. Because infections determine this chapter, incidence and prevalence rates are relatively close together. Upper respiratory tract infection and acute bronchitis have a high incidence. Less but nevertheless also frequent in occurrence are acute tonsillitis/adenoiditis, influenza, allergic rhinitis and cough. Acute bronchi(oli)tis, sinusitis, chronic bronchitis and asthma have high prevalences. Lung cancer is the most common cancer among males.


skin

Disorders from the skin chapter are very uniformly distributed among the age/sex groups. Both the incidence and the prevalence are somewhat higher among young children, young adults (15 to 24 years) and the elderly. The most common diagnosis in this chapter is eczema (contact dermatitis and above all other eczema). Dermatophytosis/mycosis, warts, acne vulgaris and lacerations/cuts also occur frequently.

endocrine, metabolic/nutritional

Low incidence and high prevalence among the elderly characterize disorders from this chapter, which occur more among women than among men. By far the most common diagnosis is diabetes mellitus. The only other common occurrence is obesity.

Figure 3.1 Continued



WW fomale

M female

urology

Disorders from this chapter occur as regards both incidence and prevalence more among the elderly than among the young and more among women than among men. It is above all the diagnosis cystitis/other urinary infection, non-venereal that is decisive, and to a lesser degree incontinence, urine.

pregnancy, childbearing, family planning

Diagnoses from the pregnancy chapter occurred above all, as was to be expected, among women in the 15-44 age group. The most common episodes relate to the (continuous) use of the contraceptive pill, as a result of which the prevalence rates are so high, followed at a distance by the diagnosis 'pregnancy confirmed', which strongly determines the incidence rates.


genital system

The male and female genital system chapters are shown in one figure. Disorders of the female genital system occur above all in the middle age groups (15 to 64 years), whereby the chronic nature drives incidence and prevalence apart. Disorders of the male genital system occur very infrequently, and then somewhat more often among older men. The acute nature of these disorders brings incidence and prevalence together. Among women urogenital candidiasis and symptoms/complaints relating to menopause are the most common diagnoses. Among men there are no clearly outstanding diagnoses.

social problems


Social problems are relatively little diagnosed in general practice. Women present these problems somewhat more often than men, and a slight rise may be noted with increasing age. There are no clearly outstanding diagnoses. Problems as the result of loss of a partner and problems between partners are the most common occurrences.

Figure 3.1 Continued



In Figure 3.2 the incidence and prevalence per ICPC chapter are shown by form of insurance.

Figure 3.2 Incidence and prevalence per ICPC chapter by form of insurance after weighting per 3 months per 1000 persons



With regard to the breakdown by form of insurance it can be seen that the incidence and prevalence among those who are publicly insured is in all cases higher than with private patients, with the exception of disorders of the male genitals, while the incidence and prevalence of disorders of the ear is the same for both groups.

Morbidity by marital status

In Table 3.13 the incidence and prevalence are broken down by marital status.

The fact that the marital status is strongly related to age finds expression in the difference in the size of in particular the prevalences and the distribution among the chapters.

Table 3.13 Incidence and prevalence per ICPC chapter by marital status after weighting per 3 months per 1000 persons


ICPC chapter	incidence				
	single	married	divorced	widowed	
A. general and unspecified	31,0	28,3	33,3	40,9	
B. blood	4,5	3,6	5,6	4,3	
D. digestive	32,2	35,1	43,3	46,4	
F. eye	14,8	15,5	13,8	18,9	
H. ear	18,8	22,7	20,6	24,1	
K. circulatory	11,1	21,5	27,5	53,8	
musculoskeletal	79,2	95,7	109,6	105,0	
N. neurological	9,3	12,1	12,2	16,1	
P. psychological	25,7	25,2	52,1	33,4	
R. respiratory	73,0	73,7	83,4	71,8	
S. skin	72,6	55,0	68,2	58,6	
T. endocrine/metabolic/nutritional	4,1	5,3	8,7	8,8	
J. urology	12,9	15,8	17,9	33,2	
N. pregnancy/family planning	15,0	18,5	7,5	0,4	
K. female genital system	22,0	18,8	35,1	9,5	
Y. male genital system	3,4	3,7	3,7	1,0	
Z. social problems	6,4	7,7	15,7	15,4	
total	436,0	458,2	558,2	541,6	

ICPC chapter	prevalen ce					
	single	married	divorced	widowed		
A. general and unspecified	53,6	59,1	74,1	124,0		
B. blood	10,1	12,9	16,1	34,8		
D. digestive	53,0	70,6	85,8	142,9		
F. eye	23,5	27,1	29,4	57,7		
H. ear	22,9	29,0	27,3	35,9		
K. circulatory	53,6	150,4	136,4	498,7		
L. musculoskeletal	110,0	149,7	173,4	244,0		
N. neurological	24,9	36,0	37,5	71,0		
P. psychological	75,9	106,3	200,5	256,2		
R. respiratory	105,0	122,9	138,0	157,3		
S. skin	111,3	88,9	107,3	112,2		
T. endocrine/metabolic/nutritional	18,6	34,9	42,2	111,6		
U. urology	18,2	24,5	24,7	72,8		
W. pregnancy/family planning	93,1	56,3	46,6	4,3		
X. female genital system	34,3	35,7	64,9	39,4		
Y. male genital system	4,4	6,3	6,8	3,6		
Z. social problems	15,6	20,0	51,0	62,3		
total	828,0	1030,6	1262,0	2028,7		

Morbidity by living situation

In Figure 3.3 the incidence and prevalence are presented per ICPC chapter by the living situation.

Figure 3.3 Incidence and prevalence per ICPC chapter by living situation after weighting per 3 months per 1000 persons




Whereas the incidences for many chapters display no great differences between single persons and (married) couples-families, the prevalences for all chapters with the exception of the pregnancy chapter are higher for single persons. With regard to the psychological, circulatory and endocrine/metabolic/nutritional chapters the differences are the greatest. The age structure (single persons are on average older) is particularly responsible for this.

Morbidity by country of birth

In Fig. 3.4 the incidence and prevalence by country of birth are given.

Figure 3.4 Incidence and prevalence per ICPC chapter by country of birth after weighting per 3 months per 1000 persons




The incidences and the prevalences vary for people born in the Netherlands and outside the Netherlands. Disorders from the circulatory and psychological chapters occur more frequently (for the first time) among persons born in the Netherlands. The digestive, respiratory and social problems chapters occur more frequently (for the first time) among persons born outside the Netherlands.

Morbidity by level of education

In Figure 3.5 the incidence and prevalence by highest level of education attained are presented.

Figure 3.5 Incidence and prevalence per ICPC chapter by level of education, after weighting per 3 months per 1000 persons



With the exception of the pregnancy/family planning and male and female genital system chapters both the incidence and the prevalence decline and the level of education rises. The difference between those with a secondary and a higher education is less striking than the difference between those with a primary and a secondary education. The circulatory and psychological chapters display the greatest differences.

3.4 The twenty most common incident and prevalent diagnoses

Table 3.14 The twenty highest incident and prevalent diagnoses after weighting per 3 months per 1000 persons

	incidence diagnosis			prevalence diagnosis				
4	war reconstruction treat infection	30,8	1	uncomplicated hypertension	44,9			
1	upper respiratory tract infection	14,4	2	contraceptive pill	35,2			
2	myalgia/fibrositis cystitis/other urinary infection non-venereal	11,6	3	upper respiratory tract infection	33,5			
-	no disease	10,8	4	feeling anxious/nervous	21,0			
4	acute bronchi(oli)tis	9,7	5	disturbances of sleep	19,7			
5	• •	9,1	6	myalgia/fibrositis	19,2			
6 7	cough sinusitis	8,7	7	no disease	18,4			
	ear wax	8,3	8	other eczema	15,8			
8 9	other eczema	7,4	9	acute bronchi(oli)tis	13,0			
10	acute otitis media/myringitis	6,7	10	cystitis/other urinary infection non-venereal	12,9			
	other infection of digestive	6,6	11	diabetes mellitus	12,0			
11	•	6,6	12		10,7			
12	lumbago influenza	6,2	13	chronic bronchitis	10,7			
13		6,0	14	asthma	10,2			
14	acute tonsillitis/adenoïditis		15		9,4			
15	other viral diseases NOS/NEC	5,9		cough ear wax	9,3			
16	dermatophytosis/-mycosis	5,8	16					
17	allergic conjunctivitis NEC	5,4	17	lumbago	8,8			
18	warts	5,0	18	dermatophytosis/-mycosis	8,4			
19	tendinitis/synovitis	4,3	19	depressive disorder	8,3			
20	irritable bowel syndrome	4,0	20	angina pectoris	8,0			

Table 3.14 presents the twenty highest incident and prevalent diagnoses.

Upper respiratory tract infection is in first place in the incidence, but in the prevalence is preceded by episodes in connection with the use of contraception and uncomplicated hypertension. In the interpretation of this table it must be borne in mind that the classification of diagnoses used in the basic tables in Appendix B was used for it. In this classification, for instance, all sprains/strains are broken down by localization. However, as one group they would certainly have ended up in the top ten.

Table 3.15 The twenty highest incident diagnoses among males and females after weighting per 3 months per 1000 persons

	males diagnosis			females diagnosis				
-	gireate							
1	upper respiratory tract infection	29,2	1	upper respiratory tract infection	32,3			
2	myalgia/fibrositis	13,3	2	cystitis/other urinary infection non-venereal	19,3			
3	acute bronchi(oli)tis	9,8	3	myalgia/fibrositis	15,5			
4	ear wax	8,4	4	no disease	13,2			
5	no disease	8,3	5	cough	10,9			
6	lumbago	7,7	6	sinusitis	9,9			
7	sinusitis	7,5	7	acute bronchi(oli)tis	9,6			
8	cough	7,3	8	other eczema	8,3			
9	other infection of the digestive	6,6	9	ear wax	8,2			
10	acute otitis media/myringitis	6,6	10	acute otitis media/myringitis	6,7			
11	other eczema	6,5	11	other infection of the digestive	6,6			
12	dermatophytosis/-mycosis	6,4	12	viral infection unspecified NEC	6,3			
13	influenza	6,0	13	influenza	6,3			
14	acute tonsillitis/adenoïditis	5,8	14	pregnancy confirmed	6,2			
15	viral infection unspecified/NEC	5,4	15	acute tonsillitis/adenoïditis	6,2			
16	laceration/cut	5,1	16	allergic conjunctivitis NEC	6,0			
17	allergic conjunctivitis NEC	4,8	17	irritable bowel syndrome	5,8			
18	warts	4,5	18	contraceptive pill	5,7			
19	tendinitis/synovitis	4,5	19	warts	5,6			
20	sprains/strains/injuries musculoskeletal	4,1	20	lumbago	5,4			

Fifteen of the twenty diagnoses that appear in the top twenty for men also appear in the top twenty of most incident diagnoses for women (Table 3.15). Among the women dermatophytosis/mycosis, lacerations/cuts, tendinitis/synovitis and other sprains/strains/injuries with regard to the musculoskeletal do not occur. Among men cystitis/other urinary infections, pregnancy confirmed, irritable bowel syndrome, contraceptive pill and feeling anxious/nervous do not occur. For both men and women infection of the upper respiratory tract is the most common occurrence.

Table 3.16 The twenty highest prevalent diagnoses for males and females after weighting per 3 months per 1000 persons

males			females					
dia	diagnosis			diagnosis				
1	uncomplicated hypertension	32,9	1	contraceptive pill	68,7			
2	upper respiratory tract infection	31,3	2	uncomplicated hypertension	56,5			
3	myalgia/fibrositis	16,8	3	upper respiratory tract infection	35,6			
4	other eczema	13,6	4	feeling anxious/nervous	28,4			
5	no disease	13,6	5	disturbances of sleep	27,8			
6	acute bronchi(oli)tis	13,3	6	no disease	23,1			
7	feeling anxious/nervous	13,3	7	myalgia/fibrositis	21,5			
8	chronic bronchitis	12,8	8	cystitis/other urinary infection NEC	21,3			
9	disturbances of sleep	11,4	9	other eczema	17,9			
10	asthma	10,6	10	diabetes mellitus	14,6			
11	lumbago	10,0	11	acute bronchi(oli)tis	12,8			
12	diabetes mellitus	9,3	12	sinusitis	12,1			
13	sinusitis	9,3	13	depressive disorder	11,9			
14	ear wax	9,2	14	cough	11,1			
15	dermatophytosis/-mycosis	9,2	15	asthma	9,7			
16	angina pectoris	7,8	16	ear wax	9,3			
17	cough	7,6	17	pregnancy confirmed	9,3			
18	old myocardial infarction	6,9	18	irritable bowel syndrome	8,9			
19	other infection of digestive	6,9	19	obesity	8,8			
20	acute otitis media/myringitis	6,8	20	chronic bronchitis	8,2			

In the top twenty of prevalent disorders among men (Table 3.16) the diagnosis uncomplicated hypertension has by far the highest prevalence (32.9 per 1000), followed by an infection of the upper respiratory tract (31.3 per 1000). Psychological disorders (feeling anxious/nervous and disturbances of sleep), disorders of the respiratory (acute bronchi(oli)tis, chronic bronchitis, asthma, sinusitis), disorders of the musculoskeletal (myalgia/fibrositis and lumbago), diabetes mellitus and eczema all have a prevalence around 10 per 1000. The appearance of 'no disease' in fourth place of prevalent disorders is striking.

The top twenty of prevalent disorders among women is headed by the contraceptive pill (in particular repeat prescriptions). Uncomplicated hypertension scores high (and higher than among the men) with a prevalence of 56.5 per 1000. Psychological disorders (feeling anxious/nervous, disturbance of sleep) and no disease have prevalences around 15 per 1000. It is striking that in the top ten among women only one disorder of the respiratory (infection of the upper respiratory tract) occurs, while with men four disorders of the respiratory occur. For women too 'no disease' is represented in the top ten.



- Bonte JTP. Het CBS als gegevensbron. In: Epidemiologie en Gezondheidsbeleid). Maas PJ van der, Hofman A, Dekker E. (red.) Samson Stafleu, Alphen aan den Rijn, 1989. (The Central Bureau of Statistics as a source of data).
- CBS. Beroepenclassificatie 1984. Voorburg: Centraal Bureau voor de Statistiek, 1985. (Occupational classification 1984. Voorburg: Central Bureau of Statistics).
- Classification Committee WONCA. An international glossary for primary care. Huisarts Wet. 1981, 24:342-6.
- College of General Practitioners. A classification of disease. J Coll Gen Pract 1959; 2: 140 - 159.
- Crombie DL, Zee J van der. The feasibility of a national general-practice morbidity and intervention survey in the Netherlands. Report of a symposium. Utrecht: Institute of the Dutch General Practitioners, 1984).
- Epidemiologie en informatica. Dicussienota. Ontwerp-Kerndocument Gezondheidsbeleid. Ministerie van WVC Rijswijk, 1989. (Epidemiology and Informatics. Working paper. Department of wellfare, Public Health and Culture, Rijswijk, 1989).
- Erikson R, Goldthorpe JH, Portocarero L. Intergenerational class mobility in three west european countries: England, France & Sweden. British Journal of Sociology 1979; 10: 415-41.
- Erikson R, Goldthorpe JH, Portocarero L. Social fluidity in industrial nations: England, France & Sweden. British Journal of Sociology 1982; 33: 1-34.
- Erikson R, Goldthorpe JH, Portocarero L. Intergenerational class mobility and the convergence thesis: England, France & Sweden. British Journal of Sociology 1983; 34: 303-43.
- Es JC van. Patiënt en huisarts. Een leerboek huisartsgeneeskunde. Utrecht: Bohn, Scheltema & Bolkema, 1983. (Patient and General Practitioner. A textbook of medical science of general practice).
- Foets M, van der Velden J, van der Zee J. Morbidity and interventions in general practice. A cross-national survey. Study-design. NIVEL. Utrecht, 1986.
- Foets M, van der Velden J. Basisrapport: Meetinstrumenten en Procedures. Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk). Utrecht, NIVEL, 1990. (Basic report: Measuring instruments and procedures. Dutch National Survey of (Morbidity and Interventions in) general practice).
- Goldberg DP, Huxley P. Mentall illness in the community: the pathway to psychiatric care. London: Travistock Publications Andover Harts, 1980.
- Hofman A. De epidemiologie als basis voor gezondheidsbeleid. In: Epidemiologie en Gezondheidsbeleid. Maas PJ van der, Hofman A, Dekker E. (red.) Samson Stafleu, Alphen aan den Rijn, 1989. (Epidemiology as a base for health policy).
- Hoogendoorn D. Stichting Informatiecentrum voor de Gezondheidszorg (SIG). In: Epidemiologie en Gezondheidsbeleid. Maas PJ van der, Hofman A, Dekker E. (red.) Samson Stafleu, Alphen aan den Rijn, 1989. (Institute Centre for data-handling in health care [SIG]).
- International Classification of Health Problems in Primary Care Defined.
 Oxford: Oxford University Press, 3rd ed 1983.

- International Classification of Diseases (9th revision). Clinical Modification. Washington DC: United States Department of Health and Human Services, 1980.
- Lako CJ, Zonneveld RJ van de, Cluitmans R, Fredrix L, Vasbinder I. Subjectieve gezondheid en medische consumptie van ouderen in grote steden en op het platteland. Tijd Soc Gezondheidsz, 1987, 65, 131-135. (Subjective health and medical consumption of elder people in big cities and rural).

Lamberts M, Meads S, Wood M. The reason for encounters classification for use in primary care. Field trial version July, 1982a.

- Lamberts M, Meads S, Wood M. Waarom gaat iemand naar de huisarts? Een internationale studie met de Reason for Encounter Classification. Huisarts Wet., 1984; 27: 234-44. (Why goes someone to the general practitioner? An international study with Reason for Encounter Classification).
- Lamberts H. Aan de diagnose gebonden informatie uit de huisartspraktijk; van een op de prevalentie naar een op de episode georiënteerde epidemiologie. Ned Tijdschr Geneesk 1986; 130: 292-6. (Data attached to diagnosis from general practice. From prevalence-oriented to episode-oriented epidemiology).

Lamberts H, Brouwer H, Groen ASM, Huisman H. Het transitiemodel in de huisartspraktijk. Huisarts Wet 1987a; 30: 105-13. (The transition model in general practice).

Lamberts H, Wood M. International Classification of Primary Care. Oxford: Oxford University Press, 1987b.

Lisdonk EH van de. Ervaren en aangeboden morbiditeit in de huisartspraktijk. Een onderzoek met dagboeken. [Dissertatie]. Nijmegen: Katholieke Universiteit Nijmegen, 1985. (Experienced and offered morbidity in general practice. An investigation in general practice. An investigation with diaries [dissertation]. Nijmegen: Catholic University Nijmegen, 1985).

Mackenbach JP, Kunst AE, Looman CWN, Habbema JDF, Maas PJ van der. Regional differences in mortality from conditions amenable to medical intervention in the Netherlands: a comparison of four time periods. Journal of Epidemiology and Community Health; 1988, 42, 325-332.

Mackenbach JP, Looman CWN, Kunst AE. Regionale doodsoorzaakprofielen. Soc Gezondheidsz.; 1990, 68, 57-66. (Profiles of regional causes of death).

Mausner JS, Bahn AK. In: Epidemiology, An Introductory Text. Measures of morbidity and mortality. WB Saunders Company Philadelphia / London / Toronto, 1974

Meyboom WA. Registreren op: "a true level of understanding". Huisarts Wet.; 1979, 22, 22-4. (Registering on "a true level of understanding").

Office of Population Censuses and Surveys. Morbidity Statistics from General Practice, Second National Study 1970-71. London: HMSO, 1974a.

Office of Population Censuses and Surveys. Morbidity Statistics from General Practice, Second National Study 1970-71. Manual of Definitions and Procedures. London: OPCS/RCGP, 1974b.

Office of Population Censuses and Surveys. Morbidity Statistics from General Practice, Third National Study 1981. Manual of Definitions and Procedures. London: OPCS/RCGP, 1984.

Pieters JJL. Andere gegevensbronnen. In: Epidemiologie en Gezondheidsbeleid. Maas PJ van der, Hofman A, Dekker E. (red.) Samson Stafleu, Alphen aan den Rijn, 1989. (Other sources of data).

- Royal College of General Practitioners, Office of Population Censuses and Surveys and Department of Health and Social Security. Morbidity Statistics from General Practice 1970-1971. Studies on Medical and Population Subjects No. 26 London: HMSO, 1974.
- Schellevis F, Severien R, Zee J van der. Registratie/classificatie in de huisartspraktijk. Deel V: eindrapport. Utrecht: Nederlands Huisartsen Instituut 1984a. (Registering/classification in general practice. Part V: final report).
- Schellevis F. Registratie/classificatie in de huisartspraktijk. Een vergelijking van de E-lijst met de ICHPPC-2. Utrecht/Nijmegen: Nederlands Huisartsen Instituut/Nijmeegs Universitair Huisartsen Instituut, 1984b. (Registering/classification in general practice. A comparison of the E-list with ICHPPC-2).
- Severien R, Zee J van der. Registratie/classificatie in de huisartspraktijk. Deel III: De haalbaarheid van het centraal coderen van klachten, ziekten en problemen in de huisartspraktijk. Utrecht/Nijmegen: Nederlands Huisartsen Instituut/Nijmeegs Universitair Huisartsen Instituut, 1984. (Registering/classification in general practice. Part III: The feasibility of centralized coding of complaints, diseases and problems in general practice).
- Sonsbeek J van. Gezondheidsverschillen in regionaal perspectief. Maandbericht Gezondheidsstatistiek 1987; no. 1, 5-11. (Differences of health in regional perspective).
- Velden HGM van der. Diagnose of prognose. De betekenis van de epidemiologie voor het handelen van de huisarts. Huisarts en Wet 1983; 26: 125-8. (Diagnosis or prognosis. The significance of the epidemiology for the acting of the general practitioner).
- Velden J van der. Ziekten en Verrichtingen in de huisartspraktijk. Een Nationale Studie. Medisch Contact 1986; 41: 603-6. (Diseases and interventions in general practice. A national study).
- Velden J van der, Schellevis FG, Steen J van der. ICPC (International Classification of Primary Care), tabulaire lijst. NIVEL Utrecht, 1989. (ICPC tabular list).
- Weel C van, van den Bosch WJHM, van den Hoogen HJM. De continue morbiditeitsregistratie Nijmegen. Huisarts Wet 1986); 29: 373-7. (The continuous registration of morbidity Nijmegen).
- Wijkel D. Samenwerken en verwijzen. Dissertatie Rijksuniversiteit Groningen. Utrecht, NIVEL, 1986. (To cooperate and to refer. Dissertation State University of Groningen).

APPENDIX A Basic tables of Morbidity in Dutch general practice

A1 Explanation

This paragraph includes mainly tables. Table A shows the morbidity in Dutch general practice according to age and sex. In table B the morbidity in the Dutch general practice is distinguished to degree of urbanization, region, season and type of insurance. In this table B no standardization to age and sex is applied. Incidence and prevalence per diagnose are defined as follows.

Cumulative incidence (abbreviation i): the number of new cases of disease in a specific period, divided by the number of persons present in the population at the beginning of the considered period. In the Dutch National Survey this period amounts 3 months.

Prevalence-figure of the period (abbreviation p): the number of cases of disease in a specific period divided by the average population. The prevalence of the period is built up from the prevalence of a specific moment increased with the number of new cases and recidives in a specific period. In the Dutch National Survey this period amounts 3 months.

Conversion of the numbers to figures on an annual basis is possible by multiplying the cumulative incidence with factor 4, by which a years cumulative incidence will be obtained. Conversion of the numbers of the prevalence of particularly chronic diseases to figures on an annual basis is very complicated and only reliably feasible with more detailed information. This is because many, and particularly chronic, diseases are going over the period of registration. That is why the prevalence cannot simply be multiplied with 4. An illustration will be given with the following 4 cases.

Case 1: Cystitis

The figure of the incidence represents the total number of new cases of cystitis that came to the knowledge of the general practitioner in a 3-month period. The number of 'new cases' regards cystitis, that appears at a patient for the first time and a relapse of cystitis.

Considering the averaged short duration of the disease and the chance of relapsing, it is possible, that from one patient more than one episode of cystitis has been counted. The figure of the incidence per year can be obtained by multiplying this number by 4. The prevalence represents the total number of cases of cystitis that came within 3 months to the knowledge of the general practitioners.

In this figure of prevalence the known cases of cystitis at the beginning of registering are included. Considering the average short duration of the disease it is understood that prevalence is nearly identical to incidence. So the prevalence a year of cystitis can be obtained by multiplying the figure of prevalence by 4.

Case 2: Chronic bronchitis

The incidence of chronic bronchitis includes the total number of newly diagnosed cases of chronic bronchitis within 3 months, when by the general practitioner himself diagnosed or came to his knowledge. Exacerbations of chronic bronchitis are not considered as 'new cases'. The incidence per year is obtained by multiplying by 4.

The prevalence of chronic bronchitis represents the total number of the known cases of chronic bronchitis measured in a period of 3 months. This concerns the patients at the starting moment of registering known as such to the general practitioner and the new cases of chronic bronchitis in the 3 subsequent months.

By the nature of the registration only that patients with a known chronic bronchitis are taken along in the calculation of the prevalence, who during the registering period:

- visited the general practice because of this disease (anomaly) (for example for control or repeated prescription) or
- consulted the general practitioner, because of another disease, to which the chronic bronchitis as "underlying disease" was esteemed relevant to the general practitioner (for example: a bacterial respiratory tract infection and chronic bronchitis as underlying disease).

The prevalence of chronic bronchitis cannot simply be multiplied by 4 to calculate the prevalence per year; only with the premiss that all patients with chronic bronchitis have a contact with general practice at least once every 3 months, the prevalence figure per 3 month period is equal to the prevalence per year. This isn't however plausible.

Case 3: Fracture of ankle

The incidence of a fracture of the ankle represents the total number of new cases of this disorder, that occurs in 3 months. Both the cases diagnosed by the general practitioner as well as the cases diagnosed in the hospital and about which the general practitioner was informed within the registration period are counted in the calculation. The incidence per year is obtained by multiplying with 4.

The prevalence of an ankle fracture represents the total number known cases of this disorder in a 3 month-period. The cases of an ankle fracture known at the beginning of the registration period are also included. For example, a patient with a healing fracture, who visits his doctor in the first week of the registration for retaping his ankle.

Only with the assumption that an ankle fracture on average has healed after 3 months, the prevalence per year is the fourfold of the prevalence per 3 months.

Case 4: Depression

The incidence of depression is the total number of new cases of depression within 3 months as far as these cases were diagnosed by the general practitioner himself or otherwise came to his knowledge. When a patient earlier in the past got through an episode of depression, than it is a matter of recidive and this will be included in the calculation of the incidence. The incidence per year can be obtained by multiplying with a factor 4.

With the prevalence of depression is meant the total number of the known cases of depression, as far as these cases came to the knowledge of the general practitioner. Though this regards the patients

- who at the beginning of the registration are known with a depression and visited in the following 3 months the general practice because of the depression or a disorder to which the depression as "underlying disease" has been considered relevant by the general practitioner and
- who are diagnosed as depression for the first time or as a recidive within the 3-months registration period.

Because it is unknown which part of the patients with a known depression will visit the general practice in 3 months, the prevalence figure of 3 months cannot be extrapolated to a figure on an annual base.

A.2 Clarification of the used abbreviations in the base tables

Abbreviation	Circumscription
total total abs./ /1000 pers.	weighted estimate of the absolute number of cases in the Netherlands weighted estimate of the number of cases per 1000 persons
sex male female	weighted estimate of the number of cases per 1000 males weighted estimate of the number of cases per 1000 females
age categories 0- 4 5-14 15-24 25-44 45-64 65-74 ≥ 75	weighted estimate of the number of cases per 1000 0- 4 years old weighted estimate of the number of cases per 1000 5-14 years old weighted estimate of the number of cases per 1000 15-24 years old weighted estimate of the number of cases per 1000 25-44 years old weighted estimate of the number of cases per 1000 45-64 years old weighted estimate of the number of cases per 1000 65-74 years old weighted estimate of the number of cases per 1000 ≥ 75 years old
sex/age categories 0- 4 male 0- 4 female 5-14 male 5-14 female 15-24 male 15-24 female 25-44 male 25-44 female 45-64 male 45-64 female 65-74 male ≥ 75 male ≥ 75 female	weighted estimate of the number of cases per 1000 0- 4 years old males weighted estimate of the number of cases per 1000 0- 4 years old females weighted estimate of the number of cases per 1000 5-14 years old males weighted estimate of the number of cases per 1000 5-14 years old females weighted estimate of the number of cases per 1000 15-24 years old males weighted estimate of the number of cases per 1000 15-24 years old females weighted estimate of the number of cases per 1000 25-44 years old males weighted estimate of the number of cases per 1000 25-44 years old males weighted estimate of the number of cases per 1000 25-44 years old females weighted estimate of the number of cases per 1000 45-64 years old females weighted estimate of the number of cases per 1000 45-64 years old males weighted estimate of the number of cases per 1000 65-74 years old males weighted estimate of the number of cases per 1000 ≥ 75 years old males weighted estimate of the number of cases per 1000 ≥ 75 years old females weighted estimate of the number of cases per 1000 ≥ 75 years old females
degree of urbanization rural sub-urban urban big city distance from practice-address to same place 1-15 km ≥ 15 km	weighted estimate of the number of cases per 1000 persons from rural areas weighted estimate of the number of cases per 1000 persons from sub urban areas weighted estimate of the number of cases per 1000 persons from urban areas weighted estimate of the number of cases per 1000 persons from big cities **Ponearest hospital** weighted estimate of the number of cases per 1000 persons with practice address in the same town as the hospital weighted estimate of the number of cases per 1000 persons with hospital out of town and less than 15 km distant from practice-address weighted estimate of the number of cases per 1000 persons with hospital out of town and more than 15 km distant from practice-address
season spring summer autumn winter	weighted estimate of the number of cases per 1000 persons in spring weighted estimate of the number of cases per 1000 persons in summer weighted estimate of the number of cases per 1000 persons in autumn weighted estimate of the number of cases per 1000 persons in winter

insurance-mode

public weighted estimate of the number of cases per 1000 public insurants private weighted estimate of the number of cases per 1000 private insurants

general abbreviations

abdominal abd. abnormal, abnormality abn. abnorm. abnormal acute ac. aden. adenoid adv. adverse all. allergy anom. anomalies appear. appearance arterial art. aspecific/nonspecific attributed aspec. attr. bacterial bact. ben. benign bloodforming bloodf. cer. cerebri, cerebral cerv. cervical chron. chronic circulatory complications, complicated, complicating circ. complic. complaint(s) complt. cond. conditions cong. COPD congenital chronic obstructive pulmonary diseases defic. deficiency deliv. delivery dig., digest. digestive disease, disorder dis. disab. disability disturbance dist. dysfunction dysf. eff. effect end./endocr. endocrine excess. excessive exclusive excl. f.p./fam. plan. family planning female fem. fracture fract. genital gen./genit. gland, glandulae hyperkin. hyperkinetic hypo-/amenorrhea hypo/am. hypochondr. hypochondrical impairm. impairment inf. infection, infectious injection inj. involuntary invol. involv. involvement irreg. irregular irrit. irritable isch. ischemic intra uterine device IUD lig. ligament mamma mm M/morb. Morbus mal. malign, malignant med. medical menstr. menstruation met./metab. metabolic movements mov. multiple musculo-skeletal mult. musc. skel. musc. muscular, musculo-**NEC** not elsewhere classified neighborh. neopl. neighborhood neoplasm(s) nervous nerv. neurological neur. non-obst. non-obstetric non-rheum. non-rheumatic NOS not otherwise specified nutritional nutr. oral anticonception OAC obstetric obst.

obstructive

organs

obstr. org. periph.

peripheral

pernicious

pernic. Pr/D/Pu/Fp pregn.

prim. probl. puerp. pernicious pregnancy, delivery, puerperium/family planning pregnancy primary problem(s) puerperium pyogenes redundant redundant

redund. rel. resp.

pyog.

sens.

religion, religious respiratory sensation/sensibility

soc. spontan. streptoc. subcut. supp. surg.

sympt. syndr.

social spontaneous streptococcus subcutaneous suppurative surgical symptom(s) syndrome system thyrotoxicosis

syst. thyrotox tr. traum. treatm. tymp. ulc. undesc. unkn

tract traumatic treatment tympanic ulcerosa undescended unknown

unspec. URTI unspecified upper respiratory tract infection

urinary vascular vertiginous without urin. vasc. vert. w/o with or without w/wo

w. with wks weeks

Ç ď woman man

A.3 BASIC TABLE A: MORBIDITY IN GENERAL PRACTICE BY SEX AND AGE

. 4

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
001	pain: generalized/unspec.	i p	3803 52184	0.3 3.6	0.2 2.5	0.3 4.6	0.2 0.2	0.1 0.2	0.1 0.7	0.2 2.1	0.4 6.1	0.3 10.2	1.0
002	chills/fever	i p	8988 11737	0.6 0.8	0.6 0.8	0.6 0.8	5.0 5.8	0.8 0.9	0.1 0.1	0.3 0.4	0.3	0.3 0.5	14.7 0.5 1.6
003	general weak-/tiredness	i p	34029 77874	2.3 5.3	1.7 3.0	2.9 7.5	1.5 2.8	2.3 2.7	3.1 4.1	2.1 4.2	1.7 5.5	2.9 10.7	3.8 17.3
004	fainting (syncope)	i P	12412 15305	0.8 1.0	0.6 0.8	1.0 1.3	0.2 0.3	0.6 0.7	1.4 1.6	0.6 0.7	0.9 1.2	0.9 1.4	1.7 2.0
005	symptoms infant	i P	2736 3045	0.2 0.2	0.1 0.2	0.2 0.2	3.0 3.4	:					,
006	allergy NEC	i p	41419 89572	2.8 6.1	2.2 5.0	3.4 7.2	4.7 8.3	2.6 6.7	3.8 8.0	3.0 6.3	1.8 4.8	2.1 3.9	1.8
007	feeling/behaving old/senile	i p	3092 23055	0.2 1.6	0.2 1.0	0.3 2.1				0.0	0.0	0.5 2.9	3.0 24.5
800	fear of disease/death	i p	7107 18148	0.5 1.2	0.3 0.8	0.6 1.7	0.2 0.5	0.0 0.1	0.4 0.7	0.7 1.7	0.5 1.8	0.6 1.7	0.6 1.3
009	disability/impairment NOS	i p	304 2524	0.0 0.2	0.0 0.1	0.0 0.2	:	0.0	0.0 0.0	0.0 0.1	0.1	0.0 0.5	0.3 1.5
010	general sympt./complt. NEC	i P	17038 30725	1.2 2.1	1.0 1.7	1.3 2.5	0.8 1.2	0.6 0.8	1.0 1.5	1.4 2.2	1.3 2.5	1.1 2.5	1.4 5.3
011	tuberculosis, general, excl. lung	i p	145 1121	0.0	0.0	0.0	0.1	:	0.1 0.1	0.0	0.1	. 0.2	
012	measles	i p	2714 2874	0.2	0.2 0.2	0.2	1.5 1.6	0.5 0.5	0.1 0.1	0.0			0.2 0.1 0.1
013	chickenpox	i p	8952 9705	0. 6 0.7	0.6 0.6	0.7 0.7	5.2 5.5	1.5 1.6	0.3	0.2 0.2	0.0	*	. 0.0
014	malaria	i p	294 304	0.0	0.0	0.0 0.0				0.0	0.0		
015	rubella	i p	12796 13697	0.9 0.9	0.9 0.9	0.8 0.9	6.4 6.6	2.8 3.1	0.2 0.2	0.3 0.3	0.0 0.1		•
016	infectious mononucleosis	i p	6818 10999	0.5 0.7	0.4 0.6	0.5 0.9	0.2 0.4	0.7 1.1	1.5 2.3	0.3 0.5	0.1 0.1		
017	viral dis. with exanthems NEC	i p	7209 8530	0.5 0.6	0.5 0.6	0.5 0.6	5.5 6.3	0.9	0.1 0.2	0.1 0.1	. 0.0		
018	viral dis. NOS/NEC	i p	85998 91154	5.9 6.2	5.4 5.7	6.3 6.7	25.9 26.8	7.5 7.9	4.8 5.1	4.4 4.6	3.6 4.0	3.2 3.4	3.3 3.9
019	infectious dis. NOS/NEC	i p	2902 5610	0.2 0.4	0.1 0.3	0.3 0.4	0.4 0.7	0.2 0.3	0.1 0.2	0.2	0.1	0.4 0.4	0.5 1.0
020	carcinomatosis (prim. site unkn)	i p	1254 4137	0.1 0.3	0.1 0.3	0.1 0.3			0.1 0.1	0.0	0.1 0.6	0.3	0.7 1.3
021	accident/injury NOS	i	11049	0.8	0.8	0.7	0.9	0.7	0.8	0.6	0.7	0.6	1.4
022	mult. trauma/internal injury	p i p	17892 260 429	0.0 0.0	1.3 0.0 0.0	0.0 0.0	0.9	0.9	0.0	0.0	1.2	0.1	1.6
023	late effects of trauma	i p	2455 7529	0.2 0.5	0.2 0.6	0.1 0.4	0.1 0.3	0.0 0.1	0.1 0.1 0.5	0.0 0.2 0.7	0.2	0.1	0.0
024	poisoning by/abuse of med. agents	i p	1270 3518	0.1 0.2	0.0 0.2	0.1 0.3	0.1 0.3	. 0.0	0.1 0.3	0.7 0.1 0.2	0.6 0.0 0.2	0.7 0.1 0.2	0.5 0.4 1.1
025	poisoning by benzodiazepines	i p	146 245	0.0	0.0	. 0.0				. 0.0	0.0 0.0	0.0	

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
001	i p			0.1 0.3	0.2 0.2	0.1 0.6	0.1 0.7	0.2 1.4	0.3 2.9	0.3 4.7	0.5 7.4	0.2 7.5	0.4 12.4	0.6 10.9	1.2 16.8
002	i p	4.6 5.5	5.4 6.2	0.8 0.9	0.9 0.9	0.1 0.2	0.1 0.1	0.2 0.3	0.4 0.4	0.3 0.3	0.2 0.4	0.6 0.8	0.1 0.3	0.5 2.3	0.5 1.3
003	i p	1.6 2.3	1.5 3.2	2.1 2.6	2.5 2.8	2.2 2.8	4.0 5.4	1.3 2.5	2.9 6.0	1.5 3.0	1.9 7.9	1.6 4.6	3.9 15.3	3.9 8.6	3.8 21.9
004	i p		0.2 0.2	0.4 0.5	0.8 0.9	1.0 1.2	1.7 2.0	0.3 0.4	0.9 1.0	0.9 1.1	1.0 1.2	0.7 1.0	1.1 1.7	1.9 2.2	1.5 1.9
005	i p	2.3 2.8	3.9 3.9	:				•	:			:		:	
006	i p	5.6 9.9	3.8 6.7	2.5 6.2	2.8 7.1	2.6 6.2	5.0 9.8	2.0	4.0 8.3	1.2 3.5	2.4	1.3 2.8	2.7 4.8	2.5 3.9	1.5
007	i p				•				0.0 0.1	0.0 0.1	0.1 0.5	0.4 2.7	0.6 3.0	3.7 22.1	2.8 2.6 25.8
800	i p	0.2 0.6	0.2 0.3	0.1 0.1	0.0 0.1	0.2 0.4	0.5 1.0	0.5 1.0	1.0	0.3	0.6 2.4	0.6 1.4	0.6 1.9	0.2 0.5	0.8 1.7
009	i p				. 0.0	0.0	. 0.1	0.0 0.2	0.0	0.0	0.1	. 0.6	0.0	0.5 0.9	0.1 1.8
010	i p	0.7 1.1	0.8 1.3	0.7 0.8	0.6 0.8	0.7 1.2	1.3 1.9	1.1	1.7 2.7	1.3 2.2	1.4 2.7	1.3 2.2	0.9 2.7	1.5 4.4	1.3 5.7
011	i			•		0.1	0.0		· .				·		· ·
012	p i p	0.3 1.4 1.5	1.6 1.7	0.1 0.1	0.9 1.0	0.1 0.2 0.2	0.0 0.1 0.1	0.0 0.0 0.0	0.1	0.1	0.2	0.1	0.2	0.1 0.2 0.2	0.2
013	i p	4.7 5.1	5.7 5.9	1.3 1.5	1.6 1.7	0.3	0.4	0.0 0.1 0.2	0.2 0.2		0.0				0.0
014	i p							0.0	0.0 0.1	0.1 0.1					
015	i p	7.0 7.0	5.9 6.2	2.7 2.7	2.8 3.5	0.4 0.4	0.0	0.2	0.4	0.0	0.1 0.1				· ·
016	i	0.3	0.2	0.7	0.7	1.3	1.8	0.3	0.3	0.0	0.1		*	i i	
017	p i	5.3	0.5 5.8	0.8	1.2	0.1	3.1 0.2	0.4	0.6	0.1	0.1				
018	p i p	6.0 27.3 28.2	6.5 24.5 25.4	6.6 7.2	1.2 8.3 8.7	0.2 3.4 3.4	0.2 6.2 6.7	0.1 3.8 4.0	0.1 5.1 5.3	0.1 3.2 3.7	4.0 4.3	3.1 3.1	3.2 3.6	2.4 3.1	3.8 4.3
019	i p	0.2	0.6	0.2	0.1 0.3	0.1 0.3	0.1 0.2	0.1 0.3	0.3 0.5	0.1 0.1	0.2 0.4	0.5 0.5	0.3 0.4	0.2 1.4	0.7 0.8
020	i p			:	:		0.1 0.1	0.0	0.0 0.0	0.1 0.6	0.0	0.6 1.7	0.1 0.7	0.6 1.2	0.8 1.4
021	i	0.9	0.9	0.7	0.7	1.2	0.5	0.8	0.5	0.7	0.7	0.1	1.0	1.0	1.6
022	p i	0.9	0.9	1.0	0.9	0.1	0.9	0.0	1.1	1.1	1.3	0.9	0.1	1.2	1.9
023	p i	0.2 0.2	0.1	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.2	0.3	0.1	0.0	0.0
024	p i	0.2 0.1 0.4	0.4 0.1 0.3	0.1	0.1	0.5	0.5	0.0	0.5	0.7	0.5	0.9	0.6	0.7	0.4
025	p i p	0.4	· .		0.1	0.1	0.5	0.1	0.3 0.0	0.2 0.1 0.1	0.1	0.0	0.3 0.1	1.6	0.9
								•	5.0	J.1	•	•	0.1		

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
026	poisoning by med. agents NOS	i p	1508 2800	0.1 0.2	0.1 0.2	0.1 0.2	0.2 0.3		0.1 0.2	0.0 0.1	0.1 0.2	0.2 0.4	0.7 1.0
027	adv. eff. med. agent proper dose: all.	i P	9612 13025	0.7 0.9	0.5 0.6	0.8 1.2	1.0 1.2	0.4 0.6	0.4 0.4	0.6 0.9	0.7 0.9	0.6 1.1	1.4 2.6
028	adv. eff. OAC	i p	9412 12706	0.6 0.9		1.3 1.7		0.1 0.1	2.1 2.8	0.8 1.1	0.0 0.1		
029	adv. eff. med. agent NEC	i p	18751 34031	1.3 2.3	0.8 1.6	1.7 3.0	1.2 1.9	0.1 0.3	0.8 1.2	0.9 1.6	1.8 3.3	2.3 5.5	4.5 7.6
030	toxic eff. other substances	j p	2663 4715	0.2 0.3	0.2	0.2 0.4	0.3	0.1 0.2	0.1 0.2	0.2 0.3	0.1	0.3	0.0
031	complic. surg./med. treatm.: hematom	a i	484 1195	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.1	0.0 0.1	0.0 0.0	0.1 0.1	0.0 0.0	0.0 0.3	0.2
032	complic. surg./med. treatm.: wounds	i p	2272 5585	0.2 0.4	0.2 0.4	0.1 0.4	0.0	0.0 0.1	0.2 0.3	0.1 0.3	0.3 0.7	0.2 0.5	0.4
033	complic. surg./med. treatm.: NEC	i p	490 35253	0.0 2.4	0.0 2.1	0.0 2.7	0.0 0.9	0.0 8.0	0.0 0.9	0.0 1.9	0.0 3.6	0.0 6.3	0.2 6.3
034	adv. eff. physical factors NEC	i p	4560 9790	0.3 0.7	0.2 0.4	0.4 0.9	0.3	0.6 0.8	0.3 0.7	0.4 0.7	0.2 0.6	0.0 0.3	0.2 0.4
035	adv. eff. prosthetic device	j p	1480 3022	0.1 0.2	0.0	0.2 0.3		0.0	0.1	0.0 0.1	0.2	0.2 0.7	0.6
036	mult.congenital syndromes	i p	189 3802	0.0 0.3	0.0 0.3	0.0 0.2	0.1 1.4	0.0 0.4	0.2	0.3	0.0	0.1	
037	abnormal results investigation NEC	i p	1045 3062	0.1 0.2	0.0 0.1	0.1 0.3	0.1 0.1	0.0 0.0	0.0 0.1	0.0 0.1	0.2 0.4	0.1 0.6	0.3
038	toxoplasmosis	i p	110 574	0.0	0.0	0.0 0.1	*		0.1	0.0 0.1			
039	premat./immature liveborn infant	i p	270 1014	0.0 0.1	0.0 0.1	0.0 0.1	0.3 1.0		•	•			•
040	all perinatal morbidity	i p	1126 3232	0.1 0.2	0.1 0.2	0.1 0.2	1.2 3.5				•	•	
041	perinatal mortality	i p	85 0	0.0	0.0	¥	0.1		•				
042	death (excl. perinatal)	i p	12965 0	0.9	1.0	0.8	0.3	0.0	0.0	0.1	0.8	2.9	8.5
043	no disease	i p	158074 270343	10.8 18.4	8.3 13.6	13.2 23.1	20.7 28.1	8.3 11.0	9.9 13.3	10.1 16.0	10.3 19.9	12.2 29.4	12.0 35.7
044	disease NEC	i p	3610 6639	0.2 0.5	0.2 0.3	0.3 0.6	0.1 0.2	0.2 0.2	0.2 0.3	0.3 0.4	0.3 0.8	0.3 0.6	0.4 0.9

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
045	enlarged lymph gland(s)	i p	14170 17731	1.0 1.2	0.8 1.1	1.1 1.3	1.6 1.8	1.6 1.9	1.7 2.1	0.9 1.2	0.3 0.4	0.3 0.5	0.1 0.1
046	s sympt. lymph glands(s) NEC	i P	381 728	0.0 0.0	0.0	0.0 0.1	0.1 0.2	0.0	0.1 0.1	0.0	0.0	. 0.0	0.0
047	fear of blood/lymph disease	i p	3184 4134	0.2 0.3	0.2 0.3	0.2 0.3		0.1 0.1	0.2 0.3	0.4 0.5	0.1 0.2	. 0.1	0.1
048	disability/impairment blood	i p	0								7e2 •		
049	sympt./complt. blood NOS/NEC	i p	73 246	0.0 0.0	0.0	0.0 0.0			0.0		0.0	0.0 0.0	0.1 0.1
050	acute lymphadenitis/-angitis	i p	8770 9649	0.6 0.7	0.6 0.7	0.6 0.6	1.4	1.0 1.1	0.8	0.5 0.6	0.2	0.5 0.4	0.1 0.1
051	chron. aspec. lymphadenitis	i p	1290 1472	0.1 0.1	0.1 0.1	0.1 0.1	0.2	0.0	0.1 0.1	0.2 0.2	0.0	0.0	0.1 0.1
052	malignant lymphoma	i p	277 2161	0.0 0.1	0.0 0.1	0.0 0.2	:		0.0 0.1	0.0 0.2	0.0 0.2	0.0 0.3	0.0 0.1
053	leukemia	i p	434 3882	0.0 0.3	0.0 0.3	0.1 0.2	0.0 0.1	0.2	0.0 0.0	0.0	0.1 0.4	0.7	0.1 1.7
054	malignant neopl. blood NEC	i p	757 3804	0.1 0.3	0.0 0.2	0.1 0.3	:		0.0 0.0	0.0 0.1	0.1 0.4	0.5 1.3	0.0 1.0
055	benigne neopl. blood/bloodform.org.	i p	216 304	0.0	0.0	0.0	0.0		0.0	0.0	0.0		
056	ruptured spleen	i p	45 45	0.0 0.0	0.0 0.0		*				0.0		
057	injuries blood/bloodform.org. NEC	i p	0 22	0.0		0.0						•	0.0
058	hered. haemolytic anaemias	i p	33 583	0.0	0.0 0.0	0.1	0.0 0.0	0.0	0.1	0.1		ove ove	
059	cong. anom. blood/bloodf. org. NEC	i p	64 539	0.0 0.0	0.0	0.0 0.0	0.2	0.1		0.0	0.0		
060	iron deficiency anemia	i p	16120 67408	1.1 4.6	0.5 1.7	1.7 7.4	0.8 3.6	1.4 2.6	1.0 2.7	1.4 5.4	0.5 3.3	0.8 4.6	1.7 16.3
061	pernic./other deficiency anemia	i p	2303 29629	0.2 2.0	0.1 1.2	0.2 2.8	0.0 0.1	0.0	0.1 0.3	0.1 0.7	0.1 2.6	0.3 6.3	1.0 14.5
062	anemia NOS/NEC	i p	7485 27862	0.5 1.9	0.2 0.8	0.8 2.9	0.3 0.7	0.4 1.5	0.4 1.4	0.6 1.7	0.5 2.0	0.3 3.0	1.2 5.3
063	hemophilia/coagulation disorders	i p	1275 5746	0.1 0.4	0.1 0.4	0.1 0.4	0.1 0.5	0.1 0.3	0.0 0.1	0.0 0.1	0.2 0.7	0.0 1.0	0.1 1.0
064	abnormal white cells	i p	65 638	0.0 0.0	0.0	0.0 0.1	0.0	0.0		0.1	0.0 0.1	0.1	
065	unexplained abn. blood test	i p	650 2025	0.0 0.1	0.1 0.2	0.0		0.0 0.1	0.1 0.1	0.0 0.1	0.1 0.2	0.1 0.3	0.1 0.5
066	abn. blood test NOS	i p	562 3148	0.0 0.2	0.0 0.2	0.0 0.3	0.1 0.2	0.0	0.0 0.1	0.0 0.1	0.0 0.5	0.0	0.0 0.5
067	splenomegaly	i p	164 432	0.0		0.0 0.1			3 0 0	0.0		0.2	0.2 0.3
068	HIV-infection (AIDS/ARS)	i p	39 417	0.0 0.0	0.0 0.1	0.0			0.0 0.0	0.0		0.1	
069	diseases blood/bloodf. org. NOS/NEC	i p	745 3564	0.1 0.2	0.0 0.2	0.1 0.2	0.2	0.1	0.1 0.1	0.0 0.2	0.1 0.4	0.4	0.0 0.8

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
045	i p	1.7 2.0	1.5 1.5	1.8 2.1	1.5 1.8	1.5 1.9	1.9 2.2	0.5 0.6	1.4 1.8	0.3 0.3	0.3 0.4	0.4 0.9	0.2 0.2	0.1 0.1	0.1 0.1
046	i P	0.2 0.2	0.2	0.0	0.0 0.0	0.1 0.1	0.0 0.1	0.0	0.0 0.1	:	0.0 0.0		0.1	0.0	v
047	i p			0.0	0.2 0.2	0.2 0.2	0.3 0.3	0.4 0.6	0.5 0.5	0.1 0.2	0.2 0.3	0.2		0.1 0.1	0.0
048	i P		•	·		•									
049	i p					0.1	:				0.0	0.1	0.0		0.1 0.1
050	i p	1.3 1.7	1.4	1.1 1.3	0.8	0.8 0.8	0.9 0.9	0.5 0.6	0.4 0.6	0.1 0.2	0.4	0.6	0.4	0.3 0.3	
051	i p	0.0	0.4	0.0	0.1 0.1	0.1 0.1	0.1 0.2	0.2 0.2	0.2 0.2		0.0	. 0.0		•	0.1 0.1
052	i p					0.0 0.1		0.2	0.1 0.2	0.0 0.2	0.3	0.0 0.4	0.2	. 0.2	0.0
053	i p	0.0	0.0 0.2	0.2	0.2	0.0		0.1	0.0	0.0 0.5	0.2 0.3	0.9	0.5	2.6	0.2 1.2
054	i p				:	0.0	0.1 0.1	0.0 0.1	0.1	0.0 0.4	0.1 0.4	0.4 1.7	0.5 1.1	0.8	0.c 1.2
055	i p	0.1 0.1				0.0	0.0	0.0	0.0	0.1 0.1		:		:	
056	i p				•		•			0.0					
057	i p		:												0.0
058	i p	0.0	0.1	0.1			0.2	0.0	0.1						·
059	i P	0.3	:	0.0	0.1	:		0.0	0.1		0.0				
060	i p	0.6 4.1	0.9 3.1	1.7 3.3	1.1 1.9	0.0 0.2	2.0 5.3	0.2	2.7 10.4	0.2 1.0	0.8 5.6	0.4	1.2 6.5	2.0 10.0	1.6 19.7
061	i p	0.0 0.1	0.1	0.0	0.0	0.0	0.2 0.6	0.3	0.3 1.2	0.2 1.9	3.3	0.2 5.3	0.5 7.0	0.4 10.7	1.4 16.6
062	i p	0.3 0.8	0.3 0.6	0.4 1.6	0.5 1.3	0.1 0.3	0.7 2.4	0.1 0.3	1.0 3.2	0.2 0.4	0.8 3.5	0.1 2.8	0.5 3.1	0.6 3.9	1.5 6.1
063	i p	0.2 0.7	0.0 0.4	0.4	0.2 0.2	0.0 0.2	0.0 0.1	0.0 0.1	0.0 0.1	0.2 0.6	0.3 0.7	0.0 1.4	0.7	1.1	0.2 0.9
064	i p	**	0.1		0.0			0.1	0.0	0.0	0.0 0.1	<i>.</i> '	0.2	•	
065	i P	•	:	0.0 0.1	0.0	0.0 0.1	0.1 0.2	0.0 0.1	0.0	0.2 0.3	0.0 0.1	. 0.5	0.1 0.1	0.2	0.1 0.6
066	i p	0.2	0.2 0.2	0.0			0.1 0.2	0.0	0.0	0.1 0.3		. 0.3	0.1 0.4	0.1 0.6	0.5
067	i p							:	0.0			:	0.3	,	0.3 0.5
068	i p	:				0.0 0.1		0.1	0.0			0.1			
069	i p	0.3	0.0	0.1	0.1	0.1 0.1	0.0 0.1	0.0 0.2	0.0 0.1	0.0 0.4	0.2 0.4	0.3	0.5	0.0	0.0

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
070	generalized abd. pain/cramps	i	30073	2.0	1.6	2.5	3.2	3.8	2.3	1.6	1.5	1.6	1.3
071	stomach pain	p i	47636 11011	0.8	2.2 0.8 4.5	4.3 0.7 4.2	3.9 0.1 0.2	4.5 0.1 0.2	2.6 0.7 1.4	2.7 0.8 3.0	3.0 1.0 7.9	4.0 1.2 11.6	4.7 1.6 13.7
072	heartburn	p i	63831 5007 20712	4.3 0.3 1.4	0.2 1.2	0.4 1.6		0.2 0.1 0.1	0.2	0.4 1.2	0.3 2.3	0.8 3.7	0.5 4.2
073	peri-anal itching	p i p	4487 7638	0.3	0.3	0.3 0.4	0.1 0.2	0.0	0.3 0.3	0.3 0.5	0.6 1.0	0.4 0.7	0.3
074	localised abd. pain	i p	8273 12281	0.6 0.8	0.5 0.7	0.7 1.0	0.1 0.2	0.3	0.4 0.6	0.7 0.9	0.6 1.1	0.7	0.7 1.6
075	flatulence/belching	i p	2680 3923	0.2 0.3	0.1 0.2	0.3 0.4		0.1 0.1	0.2 0.3	0.2 0.2	0.3 0.4	0.1 0.4	0.2 0.8
076	nausea	i p	3657 9548	0.2 0.7	0.2 0.5	0.3 0.8	0.1 0.2	0.0 0.1	0.3 0.5	0.2 0.5	0.3 0.9	0.4 1.2	0.6 2.0
077	vomiting	i p	3205 6306	0.2 0.4	0.2 0.4	0.2 0.5	0.6 0.7	0.1 0.3	0.2 0.3	0.1 0.3	0.1 0.2	0.2 0.9	0.3 0.8
078	diarrhoea	i p	17540 29374	1.2 2.0	1.1 1.7	1.3 2.3	3.5 5.5	0.6 0.9	0.8 1.3	1.1 1.6	1.0 1.8	1.0 2.6	3.0 4.8
079	constipation	i p	18074 87685	1.2 6.0	0.8 3.8	1.7 8.1	2.8 5.0	0.6 1.2	0.8 1.3	0.8 2.4	1.0 5.7	1.9 16.0	4.8 42.6
080	jaundice	i p	265 367	0.0	0.0	0.0	0.0	0.0	0.0	0.0	. 0.0	0.1 0.1	0.0
081	blood vomiting	i p	86 189	0.0	0.0 0.0	0.0 0.0				0.0			0.1 0.2
082	melena	i p	1378 3310	0.1 0.2	0.1 0.2	0.1 0.2	0.0 0.0		0.0 0.0	0.1 0.1	0.1 0.4	0.4 0.9	0.3 0.8
083	rectal bleeding	i p	1230 2105	0.1 0.1	0.1 0.2	0.1 0.1	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.2 0.4	0.2 0.6
084	fecal incontinence	i p	258 1024	0.0 0.1	0.0 0.1	0.0 0.1			0.0		0.0 0.1	0.1 0.2	0.2 0.5
085	defecation anomalies NEC	i p	2771 3973	0.2 0.3	0.1 0.2	0.2 0.3	0.4 0.5	0.1 0.1	0.1 0.2	0.1 0.2	0.3 0.4	0.1 0.4	0.3 0.7
086	sympt./complt. of teath, gums	i p	4266 10522	0.3 0.7	0.2 0.8	0.3 0.7	1.7 2.9	0.3 0.8	0.3 0.8	0.2 0.7	0.1 0.2	0.2 0.4	0.0 0.2
087	sympt./complt. mouth, tongue, lip	i p	5724 9855	0.4 0.7	0.3 0.5	0.5 0.8	1.4 1.7	0.4 0.8	0.2 0.6	0.3 0.5	0.3 0.6	0.4 0.7	0.2 0.6
880	swallowing problems	i p	5195 7143	0.4 0.5	0.2 0.3	0.5 0.7	0.4 0.5	0.0 0.1	0.3 0.3	0.4 0.5	0.6 0.9	0.4 0.6	0.2 0.3
089	fear of digestive diseases	i P	1759 3786	0.1 0.3	0.1 0.2	0.1 0.3		0.0 0.1	0.0	0.2 0.3	0.1 0.3	0.3 0.7	0.1 0.2
090	digestive disability/impairment	i p	8	0.0		0.0			0.0		*		
091	sympt./complt. digestive NEC	i p	3921 6565	0.3 0.4	0.2 0.4	0.3 0.5	0.2 0.2	0.2 0.2	0.1 0.1	0.3 0.4	0.3 0.7	0.1 0.9	0.4 0.6
092	infectious diarrhoea/dysentery	i p	5542 7328	0.4 0.5	0.3 0.4	0.4 0.6	1.1 1.5	0.3 0.4	0.4 0.5	0.4 0.5	0.3 0.3	0.4 0.4	0.0 0.2
093	mumps	i p	12609 13001	0.9 0.9	0.9 0.9	0.9 0.9	5.0 5.1	3.2 3.2	0.3 0.3	0.2 0.3	0.0 0.0	0.0 0.0	0.2 0.2
094	infectious hepatitis	i p	371 1773	0.0 0.1	0.0 0.1	0.0 0.1		0.1	0.0 0.0	0.1 0.2	0.0 0.2	0.0	0.1

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
070	i p	3.0 4.1	3.4 3.6	3.2 3.4	4.5 5.6	1.5 1.5	3.0 3.7	1.1 1.6	2.1 4.0	1.1 2.2	1.9 3.7	1.4 2.4	1.8 5.2	0.3 2.4	1.8 5.8
071	i p	0.0 0.2	0.1 0.1	0.0 0.2	0.1 0.2	0.5 1.0	0.8 1.8	1.0 3.1	0.6 2.8	1.2 8.7	0.8 7.0	1.1 14.3	1.2 9.4	2.1 15.1	1.4 12.9
072	i p		:	0.1 0.1	0.1 0.1	0.1 0.1	0.3 0.6	0.3 0.9	0.4 1.4	0.3 2.8	0.4 1.7	0.2 2.8	1.3 4.5	0.4 3.3	0.6 4.7
073	i p	0.1 0.2	0.1	0.0	0.1 0.1	0.3 0.4	0.3 0.3	0.3 0.8	0.2 0.3	0.7 1.1	0.5 0.8	0.1 0.4	0.6 0.9	0.1 0.6	0.4 0.7
074	i p	0.2 0.4		0.6 0.6	0.0 0.1	0.2 0.4	0.7 0.9	0.6 0.7	0.9 1.1	0.3 0.8	0.9 1.4	1.0 1.4	0.6 1.0	0.5 1.4	0.8 1.7
075	i p	:	:		0.2 0.2	0.1 0.1	0.4	0.1 0.1	0.2 0.3	0.1	0.4	0.2	0.0	0.1 0.9	0.2
076	i p	0.0 0.2	0.1 0.2	0.1 0.1	0.0	0.3	0.4	0.0	0.3	0.3	0.3 0.9	0.3 1.1	0.5 1.4	0.4 0.6	0.7 2.7
077	i p	0.8	0.5 0.6	0.1	0.2	0.3 0.4	0.0 0.1	0.1 0.2	0.1 0.3	0.1 0.1	0.1 0.2	0.3 1.3	0.1 0.5		0.4 1.2
078	i p	3.5 5.8	3.5 5.3	0.7 1.1	0.6 0.8	0.7 1.1	0.9 1.5	1.2 1.6	1.0 1.7	0.8 1.5	1.2 2.2	0.4 1.1	1.4 3.8	3.0 4.1	3.0 5.1
079	i p	2.9 5.1	2.8 4.9	0.5 0.9	0.7 1.5	0.4 0.5	1.2 2.2	0.3 1.1	1.3 3.6	0.4 3.5	1.6 7.9	1.7 13.6	2.0 17.9	4.4 35.5	5.1 46.4
080	i p	0.0	0.0	0.1 0.1			0.0	0.0		0.1		0.1 0.1	0.1 0.1		0.0
081	i p				:			0.0		:				0.2 0.3	0.0 0.1
082	i p		0.1 0.1				0.0	0.1 0.2	0.0	0.2 0.4	0.1 0.3	0.2 0.7	0.5 1.1	0.2 0.9	0.3 0.8
083	i p		0.2 0.2		0.0	0.1 0.1	0.1	0.1 0.2	0.0	0.1 0.1	0.1 0.1	0.2 0.4	0.1 0.4	0.5	0.3 0.6
084	i p		•			8.	0.1		•)	0.0 0.2	0.0	0.1 0.5	0.0	0.4 0.5	0.1 0.5
085	i	0.3 0.5	0.5 0.6	0.1 0.1	0.1 0.1	0.0	0.2 0.2	0.1 0.1	0.2 0.2	0.2 0.4	0.3 0.4	0.1 0.1	0.1 0.7	0.3 0.5	0.3 0.8
086	p i p	1.4 2.8	2.0 3.0	0.2	0.3	0.1 0.8	0.4	0.3 0.7	0.2 0.7	0.0	0.1	0.3	0.2 0.5	0.0 0.1	0.0 0.2
087	i p	1.2 1.7	1.7 1.7	0.4	0.4 0.9	0.1 0.5	0.3 0.6	0.2 0.3	0.5 0.8	0.2	0.4	0.7 1.0	0.2	0.3	0.2 0.7
088	i p	0.4 0.6	0.3 0.3	0.0	0.0 0.1	0.1 0.1	0.4 0.5	0.2 0.4	0.5 0.7	0.4	0.9 1.3	0.6	0.3 0.5	0.0	0.2 0.4
089	i p	× .	:	:	0.1 0.1		0.1	0.2 0.4	0.2 0.3	0.2 0.3	0.1 0.4	0.6 0.8	0.1	*	0.1 0.3
090	i				* 8		0.0	•	•		·	:		*	· · · · · · · · · · · · · · · · · · ·
091	p i p	0.4 0.4	0.0	0.2 0.2	0.3 0.3	0.0 0.0	0.3 0.3	0.2 0.3	0.5 0.6	0.3 0.7	0.4 0.7	1.0	0.2 0.8	0.9 0.9	0.2 0.5
092	i p	1.1 1.3	1.1 1.8	0.2 0.3	0.4 0.5	0.3 0.3	0.6 0.7	0.4 0.5	0.3 0.5	0.2 0.2	0.3 0.4	0.0	0.7 0.7	0.0 0.1	0.0 0.2
093	i p	5.2 5.2	4.8 5.1	3.2 3.3	3.2 3.2	0.1 0.2	0.4 0.4	0.2 0.3	0.3 0.3	0.1 0.1	0.0		0.0	•	0.4
094	i				. 0.2		0.1 0.1	0.0 0.2	0.1 0.2	0.0	. 0.3		0.0	0.2	3
	р	•						0.2	0.2				0.0	0.2	

no	. episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
098	5 parasites/worms	i p	48290 50949	3.3 3.5	2.9 3.0	3.7 3.9	6.7 6.8	12.2 12.9	2.3 2.4	2.4 2.6	0.7 0.7	0.4 0.5	0.1 0.1
096	other presumed infections	i p	96720 102233	6.6 7.0	6.6 6.9	6.6 7.0	21.8 22.8	6.1 6.5	6.7 6.9	5.3 5.5	5.0 5.5	4.0 4.7	7.6 7.7
097	malign. neopl. stomach	i p	527 3640	0.0 0.2	0.0 0.3	0.0 0.2			:	0.0	0.0 0.4	0.2 0.8	0.3 1.8
098	malign. neopl. colon, rectum	i p	920 10599	0.0 0.7	0.0 0.6	0.0 0.9			0.0	0.1	0.2 1.1	0.3 2.7	0.6 5.6
099	malign. neopl. colon, rectum	i p	425 4508	0.0 0.3	0.0 0.3	0.0 0.3	:			0.0 0.1	0.1 0.6	0.1 0.7	0.1 2.0
100	malign. neopl. pancreas	i p	503 1601	0.0 0.1	0.0 0.1	0.0 0.1	:	:		0.0	0.0	0.3 0.5	0.2 0.7
101	malign. neopl. dig. syst. NEC	i p	1002 6426	0.1 0.4	0.1 0.4	0.1 0.5				0.1	0.1 0.5	0.4 1.7	0.4 3.5
102	benign. neoplasms dig. syst. NEC	i p	452 1389	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.1	0.0 0.0	0.0	0.0 0.0	0.0 0.1	0.1 0.4	0.2 0.3
103	neoplasms dig. syst. NEC	i p	769 2113	0.1 0.1	0.1 0.1	0.0 0.2				0.0 0.1	0.0 0.2	0.1 0.3	0.4 1.1
104	foreign body through orifice	i p	1207 1634	0.1 0.1	0.1 0.1	0.1 0.1	0.8 1.1	0.1 0.1	0.0 0.0	0.1 0.1	0.0	0.0 0.0	* .
105	injuries dig. syst. NEC	i p	203 263	0.0	0.0	0.0	0.1 0.1		0.0	0.0	. 0.0	0.0	,
106	cong. anom. digest. system	i p	566 2200	0.0 0.1	0.0 0.2	0.0 0.1	0.4 0.8	0.0 0.4	0.1	0.0	. 0.1	. 0.1	
107	disease of teeth/gums	i p	13360 20833	0.9 1.4	0.8 1.3	1.0 1.5	0.9 1.8	0.6 1.4	0.9 1.5	1.1 1.7	0.9 1.2	0.8	0.7 0.9
108	disease of mouth/tongue/lips	i p	32400 43043	2.2 2.9	1.9 2.4	2.5 3.5	4.9 6.1	2.8 3.4	2.2 2.6	1.7 2.3	2.2 2.9	1.8 2.4	1.7 3.5
109	disease of esophagus	i p	8660 16790	0.6 1.1	0.6 1.1	0.6 1.2	0.2	0.0 0.1	0.4 0.6	0.5 0.7	1.1 2.2	1.2 2.5	0.9 3.4
110	duodenal ulcer	i p	9653 29761	0.7 2.0	0.9 2.7	0.5 1.4	0.0	0.0	0.4 0.5	0.9 2.2	1.3 4.2	0.7 3.6	0.1 2.3
111	gastric ulcers NEC	i p	2958 12102	0.2 0.8	0.3 0.9	0.2 0.7		0.1 0.1	0.1 0.1	0.2	0.4	0.1 1.3	0.8 3.6
112	peptic ulcers NEC	i p	1484 5793	0.1 0.4	0.1 0.5	0.1 0.3		0.0	0.0 0.1	0.1 0.2	0.3 1.0	0.1 0.8	0.4
113	disord. stomach function	i p	46081 74467	3.1 5.1	3.2 5.3	3.1 4.8	1.7 2.0	1.1 1.2	3.3 4.1	3.7 5.2	3.5 7.2	3.7 8.1	3.9 7.9
114	appendicitis	i p	6175 7328	0.4 0.5	0.4 0.5	0.4 0.5	0.1 0.1	0.9 1.1	0.7 0.8	0.4 0.4	0.1 0.2	0.3 0.4	0.0 0.1
115	inguinal hernia	i	8407	0.6	0.9	0.2	2.0	0.3	0.2	0.4	0.6	0.7	1.6
116	hiatus (diaphr.) hernia	p i p	11613 10787 29973	0.8 0.7 2.0	1.3 0.6 1.3	0.3 0.9 2.7	2.5	0.4	0.4	0.5	0.8	1.5 2.0	2.0
117	abdominal hernia NEC	i p	2929 4164	0.2 0.3	0.2 0.3	0.2 0.3	0.4 0.4	0.1	0.5 0.1 0.1	1.0 0.1 0.2	3.5 0.3 0.4	0.6	9.0 0.3
118	diverticular dis. intestines	i p	5417 12887	0.4 0.9	0.2 0.4	0.5 1.3			0.0	0.2 0.1 0.2	0.4 0.6 1.2	1.1 1.6 3.4	0.7 2.0
119	irritable bowel syndrome	i p	58799 90079	4.0 6.1	2.2	5.8 8.9	0.1 0.1	2.0 2.2	4.8 6.7	4.5 6.8	4.9 8.0	5.0 8.3	6.4 3.0 6.5

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
095	i p	5.4 5.5	8.0 8.2	9.6 10.1	14.9 15.8	1.8 1.9	2.8 2.9	2.4 2.7	2.4 2.6	0.6 0.6	0.7 0.7	0.2 0.2	0.5 0.6	0.0	0.2 0.2
096	i p	22.6 23.8	20.9 21.7	6.2 6.6	6.1 6.4	7.2 7.2	6.2 6.5	5.3 5.4	5.2 5.6	5.1 5.5	4.9 5.5	2.0 2.3	5.5 6.6	6.3 6.5	8.3 8.3
097	i p							0.0	0.0	0.0 0.5	0.4	0.1 1.0	0.3 0.6	0.3 3.3	0.3 1.1
098	i p				*	0.0		0.1	0.0	0.1 0.9	0.3 1.2	0.2 2.7	0.4 2.8	1.0 5.7	0.3 5.6
099	i p							0.1 0.2		0.1 0.4	0.1 0.8	0.0 0.7	0.1 0.8	0.2 2.3	0.1 1.9
100	i										0.0	0.4	0.2		0.3
101	р :							0.0		0.2	0.1	0.6	0.4	0.9	0.6
101	i p							0.1	0.1	0.2 0.6	0.0 0.4	0.4 2.3	0.4 1.3	0.2 3.4	0.5 3.6
102	i p	0.2 0.2	·		0.0		0.0	0.0	0.0 0.1	0.0	0.0 0.2	0.1 0.5	0.0 0.3	0.2 0.3	0.1 0.4
103	i p		:					0.1 0.1	0.0	0.1 0.3	0.1	0.1 0.2	0.2 0.4	0.5 0.6	0.3 1.4
104	i p	0.7 1.1	0.9 1.1	0.1 0.2		0.0	0.0	0.1 0.1	0.0	0.0	0.0 0.1	0 0 0	0.0		:
105	i p	0.1 0.1	0.1 0.1		•	0.1 0.1		0.0	0.0	. 0.0	:	•	0.0		
106	i p	0.5 0.8	0.3 0.7	0.1 0.7	0.1	0.0	0.2	0.0	0.0 0.1	0.1	0.0	•	0.2	€	
107	i	1.1	0.7	0.6	0.6	0.9	0.9	8.0	1.4	8.0	1.1	0.9	8.0	0.4	0.9
108	p i	1.8 4.1	1.7 5.8	1.5 2.8	1.3 2.7	1.7 1.8	1.3 2.6	1.3 1.5	2.1 1.8	1.1 1.7	1.4 2.7	0.9 1.6	0.8 1.9	0.4 0.7	1.1 2.3
	p	5.3	6.9	3.3	3.6	2.1	3.2	2.1	2.6	1.9	3.9	1.8	2.9	1.7	4.5
109	i p	0.3	0.1	0.0	0.1 0.1	0.6 0.7	0.3 0.4	0.4 0.7	0.6 0.7	1.3 2.3	1.0 2.0	0.8 2.0	1.4 3.0	1.2 4.3	0.8 2.9
110	i p	0.0		0.0	0.0	0.4 0.6	0.4	1.2 3.2	0.5 1.2	1.7 6.0	0.9 2.5	0.8 4.2	0.7 3.1	0.4 2.2	2.3
111	i		¥	0.1		0.1	0.0	0.2	0.1	0.4	0.4	0.2	0.1	1.7	0.3
112	p i			0.1		0.1	0.0	0.6 0.1	0.4 0.1	2.1 0.3	1.5 0.2	1.7 0.0	1.0 0.1	4.8 0.3	3.0 0.4
	p				0.0	0.2	0.0	0.3	0.2	1.3	0.8	0.9	0.6	0.9	0.8
113	i p	1.9 2.0	1.5 1.9	0.9 1.2	1.3 1.3	3.5 4.4	3.2 3.8	3.7 5.5	3.7 5.0	3.6 8.3	3.3 6.1	4.0 9.6	3.5 6.9	3.8 5.6	3.9 9.1
114	i p	:	0.3 0.3	1.2 1.4	0.7 0.9	0.7 0.7	0.6 0.9	0.4 0.4	0.5 0.5	0.1 0.2	0.1 0.1	0.4 0.4	0.3 0.4	0.2	0.0 0.1
115	i p	2.4 3.1	1.5 1.9	0.4 0.5	0.3 0.3	0.4 0.7	0.0	0.6 0.8	0.1 0.1	1.2 1.6	0.0	1.4 2.9	0.2 0.4	4.1 5.0	0.3
116	i	0.0		•	0.1	0.2	0.6	0.6	0.6	8.0	1.4	2.5	1.7	1.2	2.5
117	p i	0.0	0.3	0.2	0.1	0.3 0.1	0.7	0.9	1.0 0.1	2.2 0.3	4.7 0.4	5.2 1.1	7.3 0.3	4.8 0.1	11.2 0.4
	p	0.4	0.4			0.1	0.0	0.2	0.1	0.4	0.4	1.7	0.6	0.1	1.0
118	i p					0.0	0.1 0.1	0.0 0.1	0.1 0.3	0.6 0.9	0.6 1.4	0.5 1.8	2.5 4.7	1.5 3.2	2.3 8.1
119	i p	0.1 0.2	0.1	1.3 1.4	2.6 3.1	1.9 2.7	7.9 10.9	2.3 3.4	6.8 10.4	3.4 5.3	6.4 10.7	2.6 5.0	6.9 10.9	1.4 3.8	3.8 7.9

no.	episode		totals	/1000	sex	f., t.	age	5 4 4	15.04	05.44	45-64	65-74	> 7 5
			abs.	pers.	male	female	0-4	5-14	15-24	25-44	45-64	63-74	≥75
120	chron, enteritis/colitis ulc.	i	3069	0.2	0.2	0.2	0.1		0.1	0.4	0.3	0.1	0.1
		р	14445	1.0	8.0	1.2	0.1	0.0	0.6	1.2	1.6	1.1	2.0
121	anal fissure/perianal abscess	i	11085	0.8	0.9	0.6	0.9	0.3	0.7	1.0	0.9	0.5	0.3
	·	р	15971	1.1	1.4	8.0	1.3	0.4	8.0	1.4	1.5	0.7	0.4
122	hepatomegaly	i	211	0.0	0.0	0.0			,	0.0	0.0	0.1	
	. 0,	р	503	0.0	0.0	0.0				0.0	0.1	0.1	0.1
123	cirrhosis/liver disease NEC	i	2708	0.2	0.3	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.4
		р	10172	0.7	8.0	0.6	0.1	0.1	0.4	0.5	1.2	1.7	1.3
124	diseases of gall-bladder/biliary duct	i	8326	0.6	0.3	0.8	0.0	0.0	0.1	0.4	1.1	1.6	1.6
	, ,	р	19698	1.3	0.7	1.9	0.0	0.0	0.1	0.8	2.5	4.3	5.0
125	diseases digestive system NEC	i	7293	0.5	0.4	0.6	0.4	0.1	0.1	0.5	0.6	1.1	1.8
	•	р	17297	1.2	0.9	1.5	0.5	0.4	0.2	0.8	1.8	3.0	4.0

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
120	i	0.1			i a	0.0	0.1	0.4	0.3	0.1	0.6	0.2	0.1	0.1	0.2
	р	0.1	(*)		0.0	0.2	1.1	1.1	1.3	1.5	1.7	0.7	1.3	1.2	2.4
121	i	0.9	1.0	0.5	0.2	0.6	0.9	1.3	0.7	1.0	0.7	8.0	0.2		0.5
	p	1.2	1.4	0.6	0.3	0.7	1.0	2.0	0.9	1.9	1.0	1.2	0.3	0.1	0.5
122	i								0.0		0.1	0.1	0.0		
	р				•			0.0	0.1	*	0.1	0.1	0.0		0.1
123	i		0.2	0.0	0.1	0.3	0.1	0.3	0.1	0.4	0.0	0.3	0.3	0.1	0.5
	р		0.2	0.1	0.1	0.7	0.1	0.6	0.4	1.8	0.6	1.4	2.0	0.6	1.8
124	i		0.0		0.1		0.1	0.3	0.6	0.5	1.7	1.4	1.9	1.7	1.5
	р		0.0		0.1	•	0.2	0.4	1.1	1.1	3.9	3.3	5.1	4.0	5.6
125		0.4	0.3	0.0	0.3	0.1	0.2	0.3	0.6	0.5	0.7	0.4	1.6	2.0	1.6
123	p	0.4	0.3	0.0	0.7	0.2	0.3	0.7	1.0	1.5	2.2	2.4	3.5	3.6	4.2

no.	episode		totals abs.	/1000 per s ,	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
126	complaints of vision	i	12422	0.8	0.7	0.9	0.3	0.9	0.6	0.8	1.0	1.2	1.4
		p	35586	2.4	2.0	2.8	1.6	2.9	1.3	1.6	3.0	4.4	5.8
127	fear of eye disease	i	355	0.0	0.0	0.0		0.0	0.1	0.0	0.0	0.0	
		р	472	0.0	0.0	0.0		0.0	0.1	0.0	0.0	0.0	0.0
128	disability/impairment eye	i	19	0.0		0.0			0.0				
		р	515	0.0	0.0	0.0	•	0.0	0.0	0.0	0.1	0.0	0.0
129	sympt./complt. eye NEC	i	15488 34260	1.1	0.9	1,2	0.9	0.7	1.1	1.1	1.1	1.7	1.1
120	info ations and inches	р		2.3	1.8	2.8	1.6	1.5	1.7	1.9	2.8	4.1	6.0
130	infectious conjunctivitis	i p	26574 28810	1.8 2.0	1.6 1.7	2.0 2.2	4.6 5.2	1.8 1.9	2.2 2.2	1.5 1.6	1.3 1.5	1.5 1.8	1.7 2.2
131	allergic conjunctivitis	i	79393	5.4	4.8	6.0	7.2	5.2	6.3	5.1	4.9	5.1	5.3
		р	88535	6.0	5.2	6.9	7.3	5.4	6.7	5.5	5.7	6.4	7.8
132	blepharitis/stye/chalazion	i	18930	1.3	1.3	1.2	1.2	1.0	1.6	1.3	1.4	0.6	1.2
		р	21661	1.5	1.5	1.4	1.2	1.1	1.8	1.5	1.6	1.1	1.4
133	infection of eye NEC	i	7033 13761	0.5 0.9	0.4	0.6	0.5	0.3	0.6	0.5	0.6	0.4	0.4
404		р			0.8	1.1	1.0	0.5	0.8	8.0	0.9	1.8	2.2
134	corneal ulcer	i p	664 814	0.0 0.1	0.1 0.1	0.0 0.0			0.0	0.1 0.1	0.1 0.1	0.0	•
135	neoplasms of eye/adnexa	i	424	0.0	0.0	0.0	·	0.0	0.0	0.0	0.1		•
100	noopaamo or oyo,aanoxa	р	1392	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1 0.5	0.0
136	contusion/abrasion/black eye	i	9552	0.7	0.8	0.5	0.4	0.5	0.4	0.0	0.0		0.7
100	contaston/abrasion/black eye	p	10880	0.7	0.8 0.9	0.5 0.6	0.4 0.4	0.5 0.6	0.4 0.5	0.9 1.1	0.6 0.7	0.3 0.5	0.7 0.9
137	foreign body in eye	i	20885	1.4	2.6	0.3	0.5	0.5	1.9	2.4	0.9	0.4	0.3
	g,,-	p	23468	1.6	2.9	0.4	0.5	0.5	2.2	2.8	1.0	0.4	0.6
138	injuries eye NEC	i	2902	0.2	0.3	0.1	0.3	0.3	0.1	0.1	0.3	0.3	0.1
		р	4174	0.3	0.4	0.2	0.3	0.3	0.3	0.2	0.3	0.4	0.2
139	blocked lacrimal duct of infants	i	543	0.0	0.0	0.0	0.4						
		р	701	0.0	0.1	0.0	0.5		:(• :1				
140	cong. anom. of eye NEC	i	352	0.0	0.0	0.0	0.1	0.0	.*:	**			
		р	751	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	•	•
141	refractive errors	i	14155	1.0	0.8	1.1	0.3	1.4	1.2	0.7	1.3	0.9	0.4
		р	64538	4.4	3.6	5.1	1.1	5.3	3.9	3.3	6.2	6.1	4.8
142	cataract	i	2640	0.2	0.1	0.2		•	0.0	0.0	0.1	0.8	1.7
		р	17889	1.2	0.7	1.7	•	0.0	0.0	0.1	0.7	5.1	12.8
143	glaucoma	i	2740	0.2	0.1	0.2	*		0.0	0.1	0.3	8.0	0.9
		р	19709	1.3	1.0	1.7		0.1	0.1	0.2	1.5	5.5	10.7
144	blindness, all types	i	124 3393	0.0		0.0			0.0			0.0	0.1
4.45	And the same	р		0.2	0.2	0.3			0.1	0.1	0.1	0.7	2.4
145	strabismus	i p	2182 6301	0.1 0.4	0.1 0.4	0.2 0.4	1.5 3.3	0.2 1.3	0.1 0.1	0.0 0.1	0.0 0.1	0.0	
146	retinopathy	i	2359	0.2	0.1	0.2			0.0	0.1	0.0	0.7	
1.10	Tomopuny	р	6948	0.2	0.1	0.2 0.6	0.0		0.0 0.1	0.1 0.2	0.2 0.5	0.7 2.6	0.8 2.4
147	diseases of eye NEC	i	9930	0.7	0.6	0.7	0.4	0.2	0.4	0.7	0.9	1.5	0.9
		p	18321	1.2	1.1	1.4	0.7	0.5	0.7	0.9	1.6	3.0	3.9

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
126	i P	0.2 1.8	0.4 1.4	0.9 2.8	0.9 2.9	0.5 1.1	0.8 1.4	0.7 1.4	1.0 1.9	1.1 2.9	0.9 3.2	0.8 3.1	1.4 5.3	1.1 3.1	1.5 7.2
127	i p				0.1 0.1	0.0	0.1 0.1	0.0	0.0	0.0			0.0	0.0	
128	i p		*		0.1		0.0 0.0	0.0	0.0	0.0	0.1		0.1	0.0	0.0
129	i p	1.0 1.7	0.8 1.4	0.5 1.1	0.9 1.9	1.3 1.7	0.9 1.7	0.8 1.5	1.4 2.3	0.8 2.3	1.3 3.2	1.1 2.7	2.1 5.2	1.3 3.8	0.9 7. 1
130	i p	4.9 5.0	4.2 5.3	1.4 1.6	2.1 2.1	1.5 1.5	2.9 2.9	1.2 1.3	1.9 1.9	1.5 1.8	1.1 1.2	1.5 1.9	1.6 1.7	1.4 1.4	1.8 2.6
131	i p	7.3 7.5	7.0 7.2	4.4 4.3	6.1 6.5	4.9 5.0	7.7 8.5	4.2 4.4	6.0 6.7	5.2 6.1	4.7 5.3	4.4 5.5	5.7 7.1	4.4 6.2	5.8 8.7
132	i p	0.9 0.9	1.4 1.5	0.9 1.1	1.1 1.2	1.6 1.8	1.5 1.8	1.1 1.3	1.6 1.8	2.0 2.1	0.9 1.0	1.0 1.4	0.3 0.8	1.4 1.4	1.1 1.3
133	i p	0.3 0.6	0.7 1.5	0.2 0.5	0.4 0.5	0.4 0.7	0.7 1.0	0.4 0.6	0.5 0.9	0.5 0.9	0.6 0.9	0.2 2.4	0.6	0.1	0.7 2.7
134	i p		300 3				0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.0		0.0		
135	i p	0.1		0.0	0.0 0.1	0.0 0.1	0.0 0.0	0.0 0.0	0.0 0.1	0.1 0.1	0.1 0.1	0.3	0.1 0.6	0.1	
136	i p	0.2 0.2	0.6 0.6	0.9	0.2 0.2	0.6 0.7	0.2	1.1 1.2	0.8 0.9	0.6	0.6	0.2 0.2	0.5 0.7	0.7 0.9	0.8
137	i p	0.6 0.6	0.4 0.4	0.7 0.7	0.3	3.4 3.8	0.4 0.5	4.4 4.9	0.4 0.5	1.8 1.8	0.1 0.2	0.5 0.5	0.3	0.6 1.2	0.1 0.2
138	i p	0.3 0.3	0.3 0.4	0.4 0.4	0.2 0.2	0.2 0.4	0.1 0.1	0.2 0.3	0.1 0.2	0.5 0.5	0.1 0.1	0.4 0.4	0.2 0.4		0.1 0.3
139	i p	0.3 0.4	0.4 0.7												
140	i p	0.1 0.2	0.0 0.1	0.0 0.0	0.1 0.1	0.0	0.0	0.0	0.0	0.0	0.0			•	
141	i	0.2 0.6	0.5 1.5	0.9 4.7	1.8 5.9	1.3 3.6	1.1	0.5	0.9	0.9	1.7	0.6	1.2	0.8	0.2
142	p i				. 0.1		4.1 0.0 0.0	0.0	0.0	5.0 0.1	7.5 0.2	5.1 1.1	6.9 0.6	4.5 0.6	4.9 2.3
143	p i			0.1	0.1	0.0		0.1	0.0	0.7	0.8	4.5 0.6	5.6 0.9	7.6 0.9	15.6
144	p i					0.0 0.1	0.2	0.2	0.2	1.3	1.7	4.9	5.9 0.0	10.2	0.2
145	p i p	1.5 3.3	1.6 3.3	0.1 1.2	0.3 1.3	0.1 0.1 0.1	0.0 0.1 0.2	0.1 0.0 0.1	0.0 0.0 0.2	0.1 0.0 0.1	0.1 0.0 0.0	0.3	1.0	1.4	3.0
146	i						0.1	0.1	0.1	0.2	0.2	0.7	0.8	0.4	0.9
147	p i	0.7	0.1 0.2	0.2	0. 2	0.1	0.1	0.2	0.1	0.5	0.5	2.2	2.9	2.4	2.4
171	p	0.7	0.6	0.5	0.5	0.3	0.4	0.5 0.6	0.9 1.2	1.0 1.6	0.9 1.5	1.7 3.1	1.4 2.9	1.2 3.2	0.8 4.3

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
148	earache	i p	3738 8693	0.3 0.6	0.2 0.5	0.3 0.7	1.1 2.4	0.4 0.9	0.2 0.3	0.2 0.4	0.2 0.4	0.3 0.7	0.1 0.3
149	hearing complt.	i p	2441 6419	0.2 0.4	0.2 0.4	0.2 0.4	0.4 1.0	0.1 0.6	0.1 0.1	0.2 0.4	0.2 0.4	0.1 0.2	0.1 1.0
150	ringing/buzzing/tinnitus	i p	2797 4244	0.2 0.3	0.2 0.3	0.2 0.2	:		0.0 0.0	0.2 0.2	0.3 0.5	0.9 1.0	0.3 0.6
151	blood/discharge from ear	i p	1763 3614	0.1 0.2	0.2 0.3	0.1 0.2	0.8 1.1	0.3 0.7	0.0 0.0	0.0 0.1	0.1 0.2	0.1 0.1	0.1
152	fear of ear disease	i p	26 277	0.0 0.0	0.0 0.0	0.0	0.2	0.0		0.0			0.0
153	disability/impairment of ear	i p	26 33	0.0		0.0				:	0.0 0.0		
154	symp./complt. of ear NEC	i p	4018 6537	0.3 0.4	0.2 0.5	0.3 0.4	0.6 0.8	0.5 0.7	0.3 0.3	0.3 0.4	0.1 0.4	0.1 0.5	0.2 0.5
155	otitis externa	i p	50202 67925	3.4 4.6	3.7 4.9	3.2 4.4	2.8 3.8	3.0 3.7	2.2 3.1	4.3 5.4	4.0 5.6	3.4 5.1	1.8 3.6
156	acute otitis media/myringitis	i p	97708 102157	6.7 7.0	6.6 6.8	6.7 7.1	51.2 52.2	16.8 17.6	2.8 2.9	1.7 1.9	1.4 1.5	1.1 1.3	0.7 0.9
157	serous otitis media/glue ear	i p	21105 29633	1.4 2.0	1.5 2.0	1.4 2.0	, 8.4 10.6	3.4 6.2	0.9 1.0	0.7	0.4	0.5 0.5	0.3 0.5
158	eustachian tube dysfunction	i p	32787 40382	2.2 2.8	1.9 2.3	2.6 3.2	3.4 4.5	3.3 4.1	2.1 2.5	2.3 2.9	1.7 2.1	1.4 1.7	1.1 1.6
159	infections of ear NEC	i p	4944 9367	0.3 0.6	0.3 0.6	0.4 0.7	1.0 1.6	0.5 1.3	0.3 0.5	0.3 0.5	0.3 0.5	0.2 0.3	0.2 0.2
160	neoplasm of ear	i p	256 423	0.0 0.0	0.0 0.0	0.0 0.0		0.0	0.0 0.0	0.0	0.0	0.1	0.1 0.1
161	foreign body in ear	i p	1806 2083	0.1 0.1	0.2 0.2	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.3 0.3
162	perforation tymp. membrane	i p	2256 4702	0.2 0.3	0.2 0.3	0.1 0.3	0.3 0.5	0.3 0.5	0.2 0.4	0.2 0.3	0.0	0.1 0.3	0.0 0.1
163	superficial injury of ear	i p	470 679	0.0	0.0 0.0	0.0 0.1	0.0 0.0	0.1 0.1	0.0	0.0	0.0		0.2 0.2
164	injuries of ear NEC	i p	890 1061	0.1 0.1	0.1 0.1	0.0 0.1	0.0 0.0	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.1	0.0 0.0	0.1
165	cong. anom. of ear	i p	416 638	0.0 0.0	0.0 0.1	0.0 0.0	0.1 0.2	0.1 0.1	0.0 0.0	0.0	0.0 0.0		
166	ear wax (excessive)	i p	121818 135848	8.3 9.3	8.4 9.2	8.2 9.3	3.3 3.6	2.6 2.8	5.1 5.3	9.0 9.7	10.8 12.4	13.9 15.9	16.8 20.4
167	vertiginous syndromes	i p	8671 16608	0.6 1.1	0.5 0.8	0.7 1.4			0.1 0.1	0.4 0.6	1.2 2.0	2.0 3.8	1.5 4.9
168	otosclerosis	i p	701 1337	0.0 0.1	0.0 0.1	0.1 0.1			0.0 0.1	0.0 0.1	0.0 0.1	0.3 0.3	0.1 0.3
169	presbyacusis	i p	5346 8050	0.4 0.5	0.4 0.5	0.4 0.6	* *				0.3 0.5	1.7 2.6	3.4 5.1
170	acoustic trauma	i p	1188 1310	0.1 0.1	0.1 0.2	0.0 0.0			0.0 0.0	0.1 0.1	0.2 0.2	0.0 0.0	
171	deafness NEC	i P	4539 10525	0.3 0.7	0.4 0.7	0.3 0.7	0.4 1.1	0.3 0.7	0.3 0.5	0.3 0.6	0.4 0.7	0.2 0.8	0.0 1.8
172	disease of ear/mastoid NEC	i p	4084 6563	0.3 0.4	0.3 0.5	0.3 0.4	0.2 0.4	0.3 0.4	0.2 0.3	0.3 0.4	0.4 0.6	0.4 0.6	0.2 0.5

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
148	i p	1.2 2.4	0.9 2.4	0.2 0.5	0.6 1.3	0.1 0.3	0.2 0.3	0.0 0.4	0.3 0.5	0.1 0.4	0.3 0.5	0.3 0.7	0.3 0.7	0.1 0.1	0.1 0.5
149	i p	0.3 1.3	0.6 0.8	0.1 0.5	0.2 0.8	0.0 0.1	0.1 0.1	0.2 0.4	0.1 0.3	0.2 0.5	0.2 0.4	0.0 0.1	0.1 0.3	0.4 0.8	0.0 1.1
150	i p	:	:			0.0	0.0	0.2 0.3	0.1 0.1	0.3 0.6	0.3 0.5	1.1 1.1	0.7 1.0	0.5 1.1	0.2 0.3
151	i p	0.9 1.3	0.7 0.8	0.4 1.0	0.1 0.4	0.0 0.1	0.0 0.0	0.0 0.1	0.0 0.1	0.1 0.3	0.1 0.1	0.1 0.1	0.2	0.2	0.1
152	i p	0.2	0.1	0.0		•	•	0.0	0.0					0.0	
153	i p	:		:				:			0.0				
154	i	0.4	0.8	0.5	0.6	0.1	0.4	0.3	0.2	0.1	0.2	0.1	0.0	0.5	0.1
155	p i	0.5 3.4	1.0 2.3	0.6 2.8	0.8 3.2	0.2 2.4	0.5 2.0	0.5 4.5	0.3 4.0	0.4 4.2	0.3 3.8	0.5 4.6	0.4 2.4	1.1 2.2	0.1 1.6
	p	4.5	3.1	3.7	3.7	3.4	2.7	5.2	5.6	5.6	5.6	6.7	3.9	5.6	2.5
156	i p	51.8 52.3	50.5 52.2	15.5 16.1	18.0 19.2	2.4 2.6	3.2 3.3	1.5 1.6	2.0 2.2	1.5 1.5	1.3 1.6	1.3 1.6	1.0 1.1	0.6 0.9	0.8 0.9
157	i p	9.5 12.8	7.3 8.3	3.3 5.2	3.6 7.2	0.7 0.8	1.1 1.2	0.6 0.7	0.8 0.9	0.4 0.5	0.3 0.5	0.8 0.8	0.3 0.3	0.7 0.9	0.2 0.3
158	i p	2.3	4.4 5.6	3.2 4.1	3.4 4.1	1.3 1.5	3.0 3.5	2.0 2.3	2.7 3.4	1.7 1.9	1.8 2.4	1.2 1.4	1.6 1.9	1.1 1.3	1.2 1.7
159	i p	0.8 1.5	1.3 1.8	0.3 1.2	0.7 1.5	0.2 0.5	0.3 0.5	0.4 0.5	0.2 0.5	0.3 0.4	0.3 0.5	0.1 0.1	0.3 0.5	0.3 0.3	0.1 0.1
160	i p	•			0.1 0.1	0.1 0.1			0.0	0.0	•	0.2		0.2 0.2	<u>.</u>
161	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.2 0.3	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.3 0.3		0.6 0.6	0.1 0.1
162	i p	0.1 0.2	0.4 0.8	0.4 0.5	0.1 0.4	0.1 0.3	0. 2 0.5	0.3 0.4	0.1 0.3	0.0	0.0 0.2	0.2 0.2	0.1 0.3	0.4	0.0
163	i p	0.0	0.0	0.0 0.1	0.1 0.1	0.0	0.0 0.1	0.0	0.0		0.1				0.3
164	i p		0.0	0.1 0.1		0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.0	0.0		*	0.1
165	i p	0.3 0.3		0.1 0.1	0.1 0.1		0.0	0.0		0.0 0.1					
166	i p	3.2 3.4	3.4 3.8	2.0 1.9	3.2 3.6	4.6 4.7	5.6 5.8	9.3 9.8	8.8 9.5	12.2 13.5	9.4 11.4	15.6 17.2	12.5 14.9	17.6 22.8	16.4 19.2
167	i p				·	0.1 0.1	0.1 0.1	0.3 0.5	0.5 0.7	1.0 1.7	1.4 2.3	1.7 3.1	2.1 4.3	1.5 3.2	1.5 5.8
168	i p			•		0.0	0.1 0.1	0.1 0.1	0.0	0.0	0.0	0.0	0.4	0.2 0.2	0.1
169	i p									0.4 0.6	0.2	1.7	1.7	4.3 6.8	2.9 4.2
170	i p					0.1 0.1		0.1 0.1	0.1 0.1	0.4 0.5	0.0	0.1			
171	i p	0.2 0.8	0.7 1.4	0.2 0.5	0.4 0.8	0.5 0.7	0.2	0.4 0.7	0.2 0.4	0.4 0.5	0.5 0.9	0.4 1.3	0.5	1.7	0.0 1.9
172	i p	0.3 0.4	0.2 0.4	0.3 0.4	0.3 0.4	0.2 0.3	0.1 0.2	0.3 0.5	0.2 0.3	0.3 0.6	0.5 0.7	0.5 0.5	0.3 0.7	0.3 0.6	0.2 0.4

no	. episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
173	3 complaints of heart	i		0.5 1.2	0.3 0.9	0.6 1.5	0.0	0.1 0.1	0.3 0.3	0.4 0.9	0.9 2.7	1.1 2.7	0.6 2.0
174	4 edema of extremities	i		0.8 4.7	0.4 2.0	1.3 7.3	0.2 0.3	0.0 0.1	0.1 0.2	0.6 1.6	1.1	2.1 13.5	4.6 35.3
175	5 fear of dis. circ. system	į		0.5 0.9	0.5 0.8	0.5 1.0			0.1 0.1	0.7 1.1	1.0 1.6	0.6 1.7	0.7 1.6
176	disability/impairment circ. syst. NEC	i		0.0	0.0	0.0						0.1	0.1
177	7 sympt./complt. circ. syst. NEC	i	2328 5136	0.2 0.4	0.2 0.3	0.2 0.4	0.0 0.0	0.1	0.1 0.1	0.1 0.2	0.3 0.5	0.2 1.1	0.7 1.5
178	3 infections dis. circ. syst.	i		0.0 0.1	0.0	0.0 0.1			0.0	0.0	0.0	0.0	. 0.2
179	neoplasm circ. syst.	i p	374 756	0.0 0.1	0.0 0.0	0.0 0.1		0.0	0.0 0.1	0.0 0.1	0.0	0.1 0.1	
180	injuries heart/circ. syst.	i p	27 310	0.0 0.0	0.0 0.0	0.0 0.0	·	0.0 0.0			0.0	0.2	0.0 0.0
181	cong. anom. heart/circ. syst.	i p	249 4083	0.0 0.3	0.0 0.2	0.0 0.4	0.0 0.7	0.0 0.4	0.0 0.4	0.0 0.1	0.0 0.1	0.0 0.5	0.2
182	rheumatic fever/heart dis.	i p	292 1331	0.0 0.1	0.0 0.1	0.0 0.1		0.0 0.1	0.0 0.2	0.0 0.1	0.0 0.1		0.2
183	acute myocardial infarction	i p	6581 0	0.5	0.5	0.4				0.1	0.8	2.0	2.6
184	angina pectoris	i p	18736 116735	1.3 8.0	1.3 7.8	1.3 8.1			0.0 0.1	0.5 0.9	2.2 12.5	4.6 35.3	6.4 49.6
185	healed myocardial infarction	i p	0 70603	4.8	6.9	2.8		:	•	0.7	9.5	21.1	21.6
186	chron. ischemic heart dis. NEC	i p	2403 73762	0.2 5.0	0.1 6.1	0.2 4.0				0.0 0.3	0.4 8.6	0.3 23.3	0.9 28.2
187	heart failure	i p	12593 93835	0.9 6.4	0.7 4.9	1.0 7.8	0.0 0.0	0.1	0.0 0.1	0.1 0.3	0.3 3.0	2.8 21.6	10.4 78.4
188	atrial fibrillation/flutter	i p	2977 34835	0.2	0.1	0.3 2.7	*		×	0.1 0.2	0.2 1.7	1.1	1.3
189	paroxysmal tachycardia	i p	3551 9678	0.2	0.2	0.3 0.9	:	0.1 0.1	0.2 0.2	0.2 0.3 0.5	0.4 1.3	11.0 0.4 1.9	22.0 0.1 1.3
190	ectopic beats, all types	i p	2569 6017	0.2 0.4	0.2 0.3	0.2 0.5	0.0	. 0.0	0.0	0.2 0.2	0.3 0.9	0.2 0.9	0.6 1.7
191	heart murmur NOS	i p	965 2657	0.1 0.2	0.1 0.2	0.1 0.1	0.6 1.2	0.1 0.4	0.1 0.1	0.0 0.1	0.0	0.1 0.1	
192	pulmonary heart dis.	i p	108 1747	0.0 0.1	0.0 0.1	0.1		:		0.0	0.2	0.1 0.5	0.1 0.9
193	heart valve dis. NOS, non-rheum.	i p	496 10557	0.0	0.0	0.0		0.0 0.1	0.0 0.2	0.0	0.1 1.1	0.1 2.5	0.1 3.2
194	heart disease NEC	i p	6194 40793	0.4 2.8	0.3 2.5	0.5 3.1	0.1	0.1	0.0 0.2	0.2 0.9	0.6 3.7	1.0 10.1	2.8 18.4
195	elevated blood pressure w.o. hypert.	i p	2833 20697	0.2	0.2	0.2 1.8		0.0	0.0	0.2 1.0	0.4 2.8	0.4 4.7	0.1 3.1
196	uncomplicated hypertension	i p	45815 658779	3.1 44.9	2.5 32.9	3.8 56.5	· ·	0.0 0.3	0.3 2.4	1.7 16.0	6.1 96.5	10.8 166.3	9.8 151.4
197	hypertension with involv.targ. organs	i p	5972 103972	0.4 7.1	0.4 6.3	0.4 7.8		•	0.1	0.0	0.5 8.3	2.0 33.3	2.9 53.8

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
173	i p		0.1		0.3 0.3	0.2 0.2	0.4 0.5	0.3 0.9	0.5 0.9	0.6 2.0	1.2 3.4	1.0 2.7	1.1 2.7	0.3 1.3	0.7 2.4
174	i p	0.4 0.4	0.1	0.0 0.1	0.1 0.1	0.1 0.2	0.1 0.2	0.2 0.4	1.1 3.0	0.5 2.2	1.7 10.4	1.5 7.9	2.6 17.9	2.2 23.0	5.9 41.8
175	i p		:			0.1 0.1	0.2 0.2	0.9 1.3	0.5 0.9	0.9 1.2	1.0 2.0	0.6 1.2	0.7 2.0	0.8 1.5	0.7 1.7
176	i p											0.1			0.1
177	i p	0.0	0.0		0.1	0.0 0.1	0.1 0.2	0.2 0.3	0.0 0.2	0.2 0.5	0.3 0.4	0.3 1.0	0.1 1.2	0.3 1.4	0.9 1.5
178	i p	:	•			0.1	0.0 0.1	0.0	0.0	. 0.1	0.1 0.3		0.1 0.1	· .	. 0.2
179	i p			0.1 0.1	0.0	0.0	0.1		0.1 0.1		0.0 0.1	0.0	0.1 0.2		*
180	i p			0.0				· .		0.1	0.0	0.4		0.0	0.0
181	i p	0.0 0.9	0.0 0.6	0.0 0.3	0.5	0.3	0.0 0.4	0.0	0.1 0.3	0.1	0.0 0.2	0.2	0.0 0.8	0.3	0.1
182	i p			0.2	0.0	0.3	0.0 0.1	0.0 0.1	0.0	0.1 0.1	0.0			0.0	0.3
183	i p	·	•		•			0.1	0.0	1.2	0.3	2.2	1.7	2.9	2.4
184	i p					0.0	0.0 0.1	0.7 1.2	0.2 0.5	2.6 15.3	1.9 9.7	4.5 39.9	4.7 31.7	6.1 48.3	6.6 50.3
185	i p					<i>i</i> •		1.3	0.1	15.5	3.6	34.5	10.7	31.4	16.5
186	i p							0.0 0.4	0.2	0.4 13.0	0.5 4.3	0.5 33.3	0.2 15.6	0.3 32.7	1.2 25.8
187	i p		0.0	0.1	0.1	0.0 0.1	0.0 0.1	0.1 0.3	0.1 0.3	0.3 3.0	0.3 3.1	3.6 25.6	2.3 18.5	9.9 69.7	10.7 82.9
188	i					•		0.1	0.1 0.1	0.1	0.2 1.6	0.6	1.5 10.9	1.1 23.2	1.3 21.4
189	p i p		· ·	0.0	0.1 0.1	0.1 0.1	0.2 0.3	0.3 0.2 0.3	0.3	0.3	0.6 1.8	11.1 0.5 1.6	0.2	0.2 1.1	0.1 1.5
190	i p		0.0 0.0		0.0	0.0	0.0	0.2 0.2	0.1 0.2	0.3 0.6	0.4 1.2	0.2	0.3	0.8	0.5 1.5
191	i p	0.8 1.9	0.4 0.5	0.1 0.5	0.1 0.3	0.1 0.1	0.0 0.1	0.0 0.1	0.1		0.1		0.1 0.2		
192	i p			•	*	:			0.0	0.2	0.1	0.1 0.7	0.3	0.1 1.1	0.8
193	i p		• s	0.0 0.1		0.2	0.0	. 0.3	0.0	0.1 1.0	0.1 1.1	2.5	0.3 2.6	0.1 2.3	0.1
194	i p	*	0.1	0.1 0.1	0.1 0.2	0.1 0.3	0.1	0.1 1.1	0.3	0.5 3.4	0.7	0.9 9.9	1.2 10.2	3.3 19.3	2.5 17.9
195	i p			0.0		0.1 0.2	0.0	0.3 1.0	0.2 0.9	0.3	0.5 3.5	0.4 2.9	0.4 6.1	0.1 1.8	0.1 3.7
196	i p			0.0 0.2	0.0	0.3 2.1	0.2 2.7	2.0 16.9	1.4 15.0	5.1 76.9	7.1 115.6	7.2 120.1	13.5 201.9	6.9 100.5	11.4 178.5
197	i p					0.0	0.1	0.0	0.0	0.6 9.5	0.4 7.0	2.2 37.3	1.9 30.1	2.9 49.0	2.9 56.3

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
198	(postural) hypotension	i p	10216 16173	0.7 1.1	0.5 0.8	0.9 1.4	:		0.9 1.2	0.6 0.9	0.6 1.0	1.2 2.2	2.3 3.6
199	transient cerebral ischemia	i p	8798 24136	0.6 1.6	0.6 1.6	0.6 1.7			0.0 0.0	0.0 0.1	0.5 1.5	2.6 8.1	5.8 14.0
200	cerebrovascular diseases	i P	9886 46526	0.7 3.2	0.5 3.0	0.9 3.3	0.0 0.1	0.0	0.0 0.0	0.1 0.3	0.8 3.3	2.5 12.6	5.5 28.4
201	atherosclerosis, excl. heart/brain	i p	1609 13390	0.1 0.9	0.1 1.0	0.1 0.8	;		0.0	0.0 0.1	0.1 1.0	0.9 5.0	0.5 6.2
202	arterial vascular diseases NEC	i p	8746 45719	0.6 3.1	0.7 3.6	0.5 2.6		·	0.2	0.2 0.6	1.2 4.2	2.0 14.0	2.6 19.8
203	pulmonary embolism	i p	1186 5000	0.1 0.3	0.0 0.2	0.1 0.5			0.0	0.0 0.2	0.1 0.3	0.2 1.5	0.4 2.2
204	(thrombo) phlebitis	i p	6454 10556	0.4 0.7	0.3 0.4	0.6 1.0			0.1 0.1	0.2 0.3	0.9 1.4	1.7 2.8	1.1 2.4
205	venous thrombosis	i p	2795 15854	0.2 1.1	0.2 1.0	0.2 1.2			0.0 0.1	0.1 0.4	0.3 1.6	0.5 4.7	0.9 5.0
206	varicous veins of legs	i p	18747 52605	1.3 3.6	0.5 1.5	2.0 5.6		0.1 0.1	0.6 0.8	1.1 2.5	2.3 5.7	2.3 10.2	3.7 14.7
207	various ulcer of skin	j p	4381 16849	0.3 1.1	0.2 0.6	0.4 1.7		•	0.0	0.0 0.2	0.3 1.0	1.1 3.8	2.6 11.6
208	hemorrhoids	i p	24219 54279	1.7 3.7	1.6 3.5	1.7 3.9	36.	0.1 0.2	0.9 1.4	2.4 4.6	2.6 6.2	1.6 5.2	1.5 6.4
209	dis. circulatory system NEC	i p	7883 26438	0.5 1.8	0.4 1.7	0.7 1.9	0.1	0.1 0.3	0.3 0.5	0.4 0.9	0.7 2.4	1.7 6.7	1.1 8.0

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
		male	lelilae	IIIalo	Idiliaio	maic	Tomak	maio	TOTTICK	mak	Tomas	maio	10111410		
198	i					0.4	1.3	0.3	0.9	0.4	8.0	1.3	1.2	3.7	1.6
	р				•	0.5	1.9	0.4	1.5	8.0	1.3	2.4	2.1	5.8	2.4
199	i					0.0	·	0.0	0.0	0.7	0.4	3.0	2.3	6.9	5.2
	р	1.			,#i	0.0	0.1	0.1	0.1	2.2	0.7	9.0	7.5	15.6	13.1
200	i	0.1				0.0	0.1	0.0	0.1	0.9	8.0	2.4	2.6	3.4	6.6
	р	0.3			0.0	0.0	0.1	0.3	0.3	4.4	2.2	15.3	10.5	28.8	28.1
201	i		127						0.0	0.0	0.1	1.4	0.5	0.2	0.6
	p					0.0		0.1	0.1	1.2	8.0	6.9	3.5	8.2	5.2
202	i					0.1	0.3	0.1	0.2	1.4	0.9	3.0	1.2	4.2	1.7
202	p	·	÷	÷	*	0.1	0.5	0.5	0.7	5.1	3.2	21.3	8.3	28.8	15.0
203	i						0.1		0.1	0.0	0.2	0.1	0.3	0.3	0.5
	р						0.1	0.1	0.3	0.2	0.3	1.6	1.4	0.9	2.9
204	i					0.1	0.0	0.1	0.2	8.0	1.0	0.8	2.5	0.2	1.7
	р					0.2	0.0	0.2	0.4	1.2	1.6	8.0	4.3	0.6	3.4
205	i		_			0.1	0.0	0.1	0.1	0.4	0.3	0.5	0.6	1.3	0.7
	p		·			0.1	0.2	0.4	0.4	1.7	1.5	4.5	4.9	5.5	4.8
206	i		is a	0.0	0.1	0.2	1.0	0.3	2.0	1.4	3.1	0.7	3.5	1.2	5.0
200	p p			0.0	0.1	0.3	1.3	8.0	4.3	3.2	8.1	3.2	15.5	8.7	17.9
207	i							0.0	0.0	0.3	0.4	1.0	1.3	1.9	3.0
201	p					0.0	0.1	0.1	0.2	0.6	1.5	1.9	5.2	0.8	13.5
208	i			0.2		0.9	1.0	2.4	2.4	2.3	2.8	1.9	1.4	1.6	1.4
	p			0.2	0.1	1.1	1.7	4.6	4.7	6.1	6.2	4.3	6.0	7.3	5.9
209	i			0.1	0.2	0.2	0.5	0.3	0.6	0.6	0.9	1.3	2.0	1.1	1.1
_30	p	0.0	0.1	0.3	0.2	0.5	0.5	0.7	1.1	2.5	2.4	7.2	6.4	9.6	7.1

4 ≥75 0.6 1.6 1.9 6.6 0.1 0.3 0.8 1.5 . 0.1 . 0.4 0.5 0.3 1.5 0.5 1.4
1.9 6.6 0.1 0.3 0.8 1.5 . 0.1 . 0.4 0.5 0.3 1.5 0.5 1.4
0.1 0.3 0.8 1.5 0.1 0.4 0.5 0.3 1.5 0.5 1.4
0.8 1.5 0.1
0.1 0.4 0.5 0.3 1.5 0.5
0.4 0.5 0.3 1.5 0.5
0.4 0.5 0.3 1.5 0.5 1.4
1.5 0.5 1.4
1.4
0.0 0.1
. 0.0
0.3 0.7
0.3 2.1
1.7 5.6
0.5 2.5
0.0 0.7
1.1 2.0
14.3 29.2
1.1 2.5
0.8 4.9
0.2
0.6 5.2
0.0
0.2 0.2
12 4 9 3 3 3 9 5 4 6 2 3 5 2 9 1 6 7 1 1 1 1 1 3 1 1 5 2 4

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
210	i p	0.0 0.1	0.2 0.3	0.1 0.1	0.3 0.3	0.6 0.7	0.8 1.0	0.8 1.2	0.9 1.7	0.9 1.8	1.2 2.5	1.3 1.8	1.1 1.6	0.5 1.7	0.6 1.5
211	i p		0.4	0.3 0.3	0.3 0.5	1.5 2.6	1.2 2.0	1.6 3.9	1.9 4.1	1.6 5.4	1.6 6.9	1.0 3.9	1.5 6.2	1.3 4.0	2.2 8.0
212	i P		•	0.0	0.0	0.4 0.4	0.4 0.4	0.2 0.5	0.8 1.2	0.5 0.9	0.7 1.2	0.1 0.1	0.0 0.3		0.2 0.4
213	j p	0.1 0.2		0.1 0.3	0.3	0.6	0.7	1.2	1.0	1.5 1.8	1.4	0.9 1.6	0.5 1.0	0.9 1.2	0.7 1.7
214	i p	0.2	•		0.0	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.3	0.0	0.0		0.3 0.3	0.3	0.1
215	i p							0.0	0.1 0.1		0.0		0.2 0.2	•	
216	i p	0.2 0.2	0.1	0.4 0.5	0.2	0.3 0.4	0.5 0.7	0.2 0.4	0.3 0.7	0.2 0.3	0.3 0.5	0.5 0.8	0.5 0.6	0.2 0.3	0.6 0.6
217	i p			0.1 0.1	0.0 0.0	0.3 0.4	0.2 0.3	0.5 0.8	0.4 0.7	0.4 1.1	0.4 1.2	0.3 1.1	0.3 0.9	0.2 1.1	0.4 1.7
218	i p	0.2 0.2	0.1 0.1	0.0	0.2 0.2	0.1 0.2	0.4 0.6	0.7 1.2	0.6 1.0	0.8 1.4	1.0 2.1	0.2 0.5	0.2 1.1	0.4 0.5	0.5 1.9
219	i p	0.1 0.1		0.1 0.1	0.2 0.3	0.2 0.3	0.1 0.1	0.1 0.3	0.0 0.1	0.2 0.3	0.1 0.1	0.0	F	0.1 0.2	
220	i p	0.0	0.1 0.1	0.1 0.1	0.1 0.3	0.1 0.2	0.0 0.1	0.1 0.1	0.1 0.1	0.0 0.2	0.2 0.3	0.2 0.2	0.1	. 0.1	
221	i p	0.7 0.7	0.2	0.3 0.5	0.4 0.5	0.6 0.8	0.4 0.5	0.6 0.9	0.5 0.8	0.7 1.0	0.3 0.7	0.4 0.9	0.4 1.0	0.5 0.6	0.1 0.8
222	i p	0.2 0.2	0.0 0.2	0.0 0.0	0.0 0.2	0.1 0.1	0.1 0.1	0.1 0.2	0.2 0.3	0.3 0.6	0.4 1.3	0.2 1.8	0.5 2.6	0.1 1.0	0.4 2.6
223	i p	0.3 0.6	0.7 1.2	0.3 0.4	0.2 0.2	0.3 0.6	0.4 0.5	0.3 0.6	0.6 0.8	0.6 1.4	0.9 2.7	0.7 1.6	1.0 4.9	1.4 6.0	1.9 5.3
224	i p	0.2 0.2	0.1 0.1	0.5 0.6	0.6 0.7	1.7 2.1	0.9 1.3	1.1 1.7	0.6 0.8	0.8 1.4	0.7 1.7	0.1 0.2	0.6 2.6	0.2 1.4	0.6 3.1
225	i p	0.3 0.3		0.3 0.3	0.4	0.4 0.5	0.1 0.3	0.2 0.4	0.1 0.1	0.1	0.2 0.3	. 0.3	0.3 0.3		0.1 1.0
226	i p	0.1 0.7	0.1 0.5	0.6 0.7	0.7 0.8	1.0 1.3	1.1 1.3	0.6 1.1	0.5 0.8	0.7 1.4	0.8 1.2	0.3 0.4	0.7 1.9	0.2 0.8	1.6 2.6
227	i p	1.2 1.4	0.2 0.8	3.4 3.9	4.5 4.7	12.5 14.0	14.6 17.0	17.3 20.8	20.0 24.3	17.0 22.9	20.5 30.3	16.0 22.8	16.6 30.6	13.1 23.1	15.0 32.5
228	i p	0.1 0.6	0.3	0.8 0.9	1.2 1.4	1.6 2.2	1.6 2.3	2.6 3.3	2.8 3.7	2.6 4.2	3.2 5.3	1.2 2.5	2.4 3.5	0.1 1.4	1.6 3.1
229	i p	:	0.3 0.3	0.3 0.3	0.1 0.3	0.5 0.6	0.2 0.4	0.6 0.9	1.0 1.4	0.9 1.8	1.1 3.6	0.6 1.5	0.6 5.4	0.4 2.9	1.0 6.0
230	i P		:		0.2 0.2			0.1 0.1		0.1 0.2	. 0.0	0.2 0.2			
231	i p			0.1 0.1	0.1	0.1 0.1	0.1 0.1	0.0	0.2 0.2	0.1 0.2	0.0	0.1	0.0		0.3
232	i p	1.9 2.5	0.8 1.1	1.2 2.8	1.1 2.1	0.9 1.6	2.1 3.3	0.7 1.3	0.9 1.2	0.4 1.2	0.7 1.6	0.3 3.7	1.2 2.7	0.7 3.6	0.5 6.0
233	i p		0.1 0.1	0.1 0.3	0.0 0.1	0.1 0.3	0.1 0.2	0.0 0.1	0.2 0.3	0.1 0.3	0.3 0.6	0.4	0.2 0.7	0.5	0.1 0.1
234	i P	0.5 0.6	0.0	0.3 0.3	0.1 0.2	0.1 0.2	0.1 0.2	0.2 0.3	0.1 0.2	0.0 0.2	0.3 0.6	0.3 0.3	0.2 0.5	0.1 0.2	0.2 0.2

no.	episode		totals abs.	/1000 pers.	sex male	femal e	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75	
235	neoplasms musc. skel. syst.	i p	1489 4280	0.1 0.3	0.0 0.2	0.2 0.4		0.0 0.1	0.1 0.3	0.1 0.3	0.1 0.3	0.1 0.4	0.1 0.6	
236	fracture: radius/ulna	i p	5638 8225	0.4 0.6	0.3 0.4	0.5 0.7	0.5 0.6	0.9 1.2	0.4 0.4	0.1 0.2	0.4 0.6	0.6 0.9	0.3 1.0	
237	fracture: tibia/fibula	i p	3265 6160	0.2 0.4	0.2 0.4	0.2 0.4	0.2 0.3	0.3 0.5	0.5 0.8	0.1 0.4	0.1 0.3	0.1 0.3	0.1 0.2	
238	fracture: hand/foot bones	i p	12193 14694	0.8 1.0	0.9 1.1	0.8 0.9	0.4 0.6	1.5 1.7	0.9 1.1	0.7 0.9	0.7 0.8	1.0 1.3	0.5 0.7	
239	fracture: collum femoris	i p	1883 3701	0.1 0.3	0.1 0.2	0.2 0.3	:	•	0.1 0.1	0.0	0.0 0.2	0.2 0.7	1.9 2.9	
240	fracture: femur NEC	i p	1178 1864	0.1 0.1	0.0 0.1	0.1 0.2	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.0	0.0 0.1	0.2 0.3	0.3 0.8	
241	fracture: skull	i p	257 384	0.0 0.0	0.0 0.0	0.0 0.0		0.0 0.0	0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	
242	fracture: facial bones	i p	1292 1910	0.1 0.1	0.1 0.2	0.0 0.1	0.1 0.1	0. 2 0. 2	0.2 0.2	0.0 0.1	0.0 0.0		0.1 0.1	
243	fracture: spine	i p	1013 2992	0.1 0.2	0.1 0.2	0.1 0.2		0.1	0.1 0.2	0.0 0.1	0.1 0.2	0.7	0.5 0.9	
244	fracture: rib	i p	2155 2607	0.1 0.2	0.1 0.2	0.2 0.2		0.0	0.0	0.2 0.2	0.2 0.3	0.4 0.5	0.4 0.6	
245	fracture: clavicula	i p	1824 2495	0.1 0.2	0.1 0.2	0.1 0.2	0.6 0.6	0.2 0.3	0.2 0.3	0.0 0.1	0.1 0.1	0.1 0.2	0.0 0.1	
246	fracture: humerus	i p	1019 2144	0.1 0.1	0.0 0.1	0.1 0.2	0.1	0.2 0.2	0.0 0.0	0.0	0.1 0.2	0.3 0.5	0.1 0.4	
247	fracture: pelvis	i p	382 834	0.0 0.1	0.0 0.1	0.0 0.1				0.0 0.0	0.0 0.1	0.1 0.2	0.2 0.2	
248	fracture: NEC	i p	8557 11652	0.6 0.8	0.5 0.8	0.6 0.8	0.4 0.4	0.8 0.9	0.7 1.1	0.5 0.7	0.4 0.6	0.7 0.9	0.5 0.9	
249	sprains/strains ankle(s)	i p	46920 56987	3.2 3.9	3.6 4.3	2.8 3.5	1.2 1.4	3.5 4.0	6.0 7.1	3.2 4.1	2.2 2.7	2.0 2.4	0.9 1.5	
250	sprains/strains knee(s)	i p	33464 39117	2.3 2.7	2.7 3.1	1.9 2.3	0.4	2.5 2.7	4.0 4.7	2.5 2.8	1.6 2.2	0.7 1.0	1.6 1.9	_
251	sprains/strains shoulder/arm	i p	20990 24577	1.4 1.7	1.4 1.7	1.4 1.7	0.7 0.7	1.9 1.9	2.4 2.5	1.2 1.4	1.3 1.8	0.8 1.1	0.9 1.5	
252	sprains/strains wrist/hand	i p	40817 45748	2.8 3.1	3.1 3.5	2.5 2.7	1.5 1.9	5.3 5.7	4.3 4.8	2.4 2.7	2.0 2.3	1.0 1.0	1.0 1.2	
253	sprains/strains foot/toe	i p	32805 35642	2.2 2.4	2.5 2.7	1.9 2.2	1.4 1.4	3.4 3.5	3.2 3.5	2.1 2.3	1.8 2.1	1.3 1.4	0.9 1.0	
254	sprains/strains spine, excl. cerv. spine	i p	10979 13241	0.7 0.9	0.7 0.9	0.8 0.9	:	0.6 0.6	1.1 1.2	0.9 1.2	0.5 0.7	0.5 0.5	1.1 1.6	
255	sprains/strains cerv. spine	i p	5256 6926	0.4 0.5	0.3 0.5	0.4 0.5	0.1 0.1	0.2 0.3	0.6 0.8	0.5 0.7	0.2 0.3	0.1 0.1	0.0 0.1	_
256	whiplash calf	i p	5628 6344	0.4 0.4	0.5 0.5	0.3		0.0	0.1 0.2	0.7 0.7	0.6 0.7	0.2 0.2	0.1 0.1	
257	sprains/strains musc. skel. syst. NEC	i p	53142 61422	3.6 4.2	4.1 4.6	3.2 3.8	0.9 1.1	3.0 3.1	4.1 4.5	3.7 4.3	3.7 4.3	3.8 4.7	6.1 7.7	
258	(sub)luxation, dislocation	i p	7246 9772	0.5 0.7	0.5 0.7	0.5 0.7	0.9 1.1	0.3 0.4	0.8 0.9	0.5 0.6	0.3 0.5	0.5 0.7	0.3 0.6	
259	cong. luxation of hip	i p	1428 3438	0.1 0.2	0.1 0.1	0.1 0.4	1.1 2.5	0.0	0.0 0.0	0.0 0.1	0.1 0.1	0.0 0.1	0.1 0.6	

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
235	i p			0.0	0.1 0.1	0.0 0.3	0.2 0.3	0.0 0.2	0.3 0.5	0.1 0.2	0.1 0.5	0.4	0.2 0.5	0.4	0.2 0.6
236	i p	0.3 0.3	0.7 0.8	0.9 1.1	0.9 1.2	0.4 0.4	0.4 0.4	0.2 0.3	0.0 0.1	0.2 0.3	0.6 0.9	0.3 0.3	0.9 1.4	0.0	0.5 1.4
237	i p	0.3 0.3	0.1 0.3	0.2 0.4	0.4 0.6	0.7 1.1	0.4 0.5	0.1 0.4	0.2 0.4	0.1 0.2	0.2 0.4	0.0 0.2	0.1 0.4		0.2 0.4
238	i p	0.3 0.6	0.4 0.6	1.6 1.9	1.4 1.5	1.2 1.5	0. 6 0.7	0.9 1.1	0.5 0.7	0.6 0.7	0.7 0.9	8.0 0.8	1.1 1.6	0.0	0.8 1.1
239	i p	:				0.1 0.1	0.0	0.0		0.0 0.1	0.0 0.2	0.1 0.5	0.3 0.9	1.5 1.9	2.1 3.4
240	i p	0.3 0.3		0.1 0.1	0.1	0.0	0.1 0.1	0.0	0.0	0.0	0.1 0.2	0.2 0.2	0.3 0.4	0.1 0.2	0.5 1.1
241	i p			0.0	0.0	0.0		0.0	0.0		0.0 0.1	0.0	0.0	0.1 0.1	0.0
242	i p	:	0.1 0.1	0.2 0.3	0.2 0.2	0.4 0.5	0.0	0.1 0.3	0.0	0.0	0.0		- :	· .	0.1 0.1
243	i p			0.1		0.2 0.2	0.2	0.1 0.1	0.0 0.1	0.0 0.1	0.1 0.2	0.9	0.5	0.3 0.8	0.6 1.0
244	i p			0.0		0.0	0.0	0.2 0.2	0.1 0.1	0.3 0.4	0.2 0.2	0.0	0.7 0.8		0.6 0.9
245	i p	0.7 0.7	0.5 0.5	0.1 0.2	0.2 0.3	0.2	0.2	0.1 0.1	. 0.1	0.1 0.1	0.0	0.0 0.1	0.2 0.2	0.1	0.1 0.1
246	i p	. 0.2	0.0	0.1 0.2	0.3 0.3	0.0	0.0	0.0	0.0	0.0	0.1 0.4	0.4 0.4	0.3 0.5	0.1	0.2 0.6
247	i p							0.0 0.1	0.0 0.0	0.1	0.0	0.1 0.1	0.3	0.0	0.3 0.3
248	i p	0.2 0.2	0.6 0.6	0.6 0.6	1.1 1.2	0.8 1.3	0.6 0.8	0.5 0.8	0.5 0.6	0.5 0.7	0.3 0.5	0.1 0.4	1.2 1.3	0.2 0.3	0.6 1.3
249	i p	1.0 1.4	1.3 1.4	3.3 3.6	3.8 4.3	7.0 8.2	4.9 5.9	4.2 5.3	2.2 2.9	1.9 2.3	2.6 3.1	1.5 1.5	2.3 3.1	0.1	1.3 2.1
250	i p	0.3 0.3	0.5 0.5	2.6 2.7	2.4 2.6	5.0 5.8	3.0 3.5	3.2 3.6	1.7 2.0	1.6 2.0	1.7 2.4	0.5 0.6	0.9 1.3	1.0 1.3	1.8 2.3
251	i p	0.4	0.9	1.7 1.7	2.1 2.1	2.3 2.4	2.5 2.6	1.2 1.5	1.2 1.4	1.5 2.0	1.1 1.5	0.6 1.0	1.0 1.2	1.2 1.7	0.7 1.4
252	i p	1.9 2.4	1.1 1.3	5.1 5.7	5.5 5.7	5.1 5.8	3.5 3.9	2.9 3.2	1.9 2.1	1.9 2.2	2.0 2.4	1.2 1.2	0.8 0.9	0.3 0.4	1.4 1.7
253	i p	1.3	1.5 1.5	3.3 3.4	3.6 3.7	4.2 4.3	2.2 2.6	2.5 2.7	1.7 1.9	2.0 2.2	1.6 2.0	0.9 0.9	1.6 1.7	0.4 0.4	1.2 1.2
254	i p			0.4 0.4	0.7 0.8	0.8 0.9	1.3 1.5	1.1 1.5	0.7 0.8	0.4 0.6	0.6 0.7	0.5 0.5	0.6 0.6	8.0 8.0	1.2 2.1
255	i p	:	0.2	0.0	0.4	0.7	0.6	0.5 0.6	0.5 0.8	0.2 0.4	0.2 0.3	0.1 0.1	0.1 0.1	0.1 0.1	. 0.2
256	i p			0.0	*	0.3 0.4	0.1	0.7 0.8	0.6 0.7	0.7 0.9	0.5 0.6	0.3 0.3	0.1 0.1	0.2 0.2	
257	i p	1.0 1.0	0.7 1.2	3.4 3.4	2.6 2.7	5.2 5.7	2.9 3.2	5.0 5.8	2.3 2.8	3.1 3.7	4.2 4.8	3.6 4.3	4.0 5.0	4.0 4.8	7.2 9.2
258	i p	0.9	1.0	0.2	0.5 0.7	0.9	0.7	0.6 0.8	0.4 0.5	0.1 0.5	0.4 0.6	0.5 0.8	0.6 0.6	0.4 0.6	0.2 0.6
259	i p	0.7 1.3	1.5 3.8		0.0	0.0	0.0	0.0	0.0 0.1		0.1 0.2		0.0 0.2	0.4	0.2 0.7

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
260	cong. anom. musc. skel. syst. NEC	i p	2303 5787	0.2 0.4	0.2 0.5	0.1 0.3	0.7 1.8	0.2 0.5	0.2 0.3	0.1 0.4	0.1 0.2	0.1	0.0
261	syndromes cervical spine	i p	19294 30193	1.3 2.1	1.0 1.5	1.6 2.6	0.2 0.2	0.4 0.5	0.5 0.6	1.7 2.4	2.2 3.8	1.6 3.2	1.4 2.2
262	osteoarthritis of cervical spine	i p	11617 23420	0.8 1.6	0.5 1.1	1.0 2.0			0.0 0.0	0.2 0.4	1.4 3.0	3.6 6.3	3.6 7.6
263	osteoarthritis of spine NEC	i p	8711 22207	0.6 1.5	0.4 1.0	0.8 2.0	 E		0.0 0.1	0.2 0.5	1.3 3.2	2.0 4.4	2.2 7.1
264	acquired deformities of spine	i p	10004 22683	0.7 1.5	0.6 1.4	0.7 1.7	0.1 0.1	1.1 2.3	1.2 2.2	0.8 1.8	0.2 0.8	0.2 0.8	0.4 1.8
265	back pain with radiating sympt.	i p	6753 12434	0.5 0.8	0.5 0.9	0.4 0.8	:		0.2 0.4	0.8 1.4	0.7 1.2	0.3 0.9	0.4 0.6
266	lumbago	i p	96167 129036	6.6 8.8	7.7 10.0	5.4 7.6		0.3 0.4	5.0 6.0	9.5 12.4	9.7 14.1	6.2 8.6	4.6 6.6
267	sciatica	i p	15490 24969	1.1 1.7	1.0 1.4	1.1 2.0		0.0	0.2 0.3	1.1 1.6	2.3 3.7	1.9 3.6	1.3 2.2
268	slipped lumbar disc	i p	18703 45564	1.3 3.1	1.5 3.6	1.1 2.7		0.0 0.0	0.6 1.1	1.9 4.1	2.4 6.1	0.9 3.6	0.5 2.7
269	ganglion joint/tendon	i p	9883 11897	0.7 0.8	0.5 0.7	0.8 1.0	0.1 0.2	0.3 0.4	1.0 1.1	0.9 1.1	0.6 0.8	0.2 0.4	0.3 0.4
270	rheumatoid arthritis	i p	7975 44673	0.5 3.0	0.3 1.6	0.8 4.4	0.0 0.1	0.1 0.2	0.1 0.3	0.3 1.3	1.2 5.1	1.2 11.0	1.8 13.7
271	spondylitis (ankylosing)	i p	1430 5350	0.1 0.4	0.1 0.4	0.1 0.3		0.1 0.1	0.1 0.1	0.1 0.5	0.1 0.5	0.1 1.1	. 0.2
272	osteoarthritis hip	i P	9987 27153	0.7 1.9	0.5 1.0	0.9 2.7			0.0 0.0	0.1 0.2	1.2 2.6	2.9 7.6	3.9 13.6
273	osteoarthritis knee	i p	16099 36919	1.1 2.5	0.6 1.2	1.6 3.8		:	0.0 0.0	0.3 0.6	1.9 3.2	4.4 9.1	5.4 19.0
274	osteoarthritis NEC	i p	15605 47020	1.1 3.2	0.6 1.5	1.5 4.9		•	0.0 0.2	0.4 0.6	1.8 4.9	2.9 11.0	6.8 22.7
275	arthritis in allied conditions NEC	i p	15818 31789	1.1	0.9 1.5	1.3 2.8	0.2 0.3	0.5 0.6	0.9	1.2 1.9	1.1	2.0 4.6	1.9
276	shoulder syndrome	i p	43679 63275	3.0 4.3	2.8 4.0	3.1 4.6	0.0	0.2 0.2	1.2 1.6	2.9 3.7	7.0 10.6	3.6 5.9	3.2 5.6
277	dis. bursa, excl. shoulder	i p	20376 24914	1.4 1.7	1.8 2.1	1.0 1.3		0.3 0.4	1.0 1.2	1.6 1.9	2.1 2.7	1.8 2.3	2.2 2.7
278	epicondilytis lateralis	i p	25355 34434	1.7 2.3	1.9 2.6	1.5 2.1	0.0 0.0	0.0 0.0	0.4 0.5	2.6 3.3	3.7 5.4	1.3 1.8	0.2 0.3
279	tendinitis/synovitis	i p	63577 78363	4.3 5.3	4.5 5.3	4.2 5.4	0.0 0.0	2.0 2.2	4.1 5.1	5.8 7.1	5.4 6.9	3.9 5.0	3.2 3.7
280	osteochondrosis	i p	3843 7283	0.3 0.5	0.3 0.6	0.2 0.4	0.0	1.0 1.5	0.4	0.2 0.4	0.0 0.1	0.1 0.1	
281	osteoporosis	i p	2834 21165	0.2 1.4	0.1 0.4	0.3 2.4				0.4 0.0 0.2	0.1 0.2 2.1	0.1 0.9 5.5	1.5 10.2
282	ac. traum. meniscus/lig. knee	i p	17885 20196	1.2 1.4	1.5 1.7	0.9 1.0		0.2 0.2	1.9 2.2	1.6 1.8	1.4 1.7	1.0 1.1	0.2 0.2
283	retropatellar chondropathy	i p	14111 19080	1.0 1.3	0.9	1.0		1.0 1.4	2.2	1.1 1.4	0.5 0.7	0.2 0.2	0.1 0.2
284	chron. internal knee derangement	i p	4148 6344	0.3 0.4	0.3 0.5	0.2 0.4	•	0.2 0.2	0.3 0.4	0.4 0.5	0.4	0.1 0.7	0.2 0.5

no.		0-4 male	0-4 fema le	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
260	i p	0.7 2.2	0.7 1.5	0.3 0.6	0.1 0.4	0.1 0.4	0.2 0.3	0.2 0.4	0.1 0.3	0.1 0.2	0.1 0.2		0 <i>2</i>	0.1	0.0
261	i P	0.1 0.1	0.4 0.4	0.3 0.4	0.5 0.7	0.4 0.4	0.6 0.8	1.1 1.5	2.3 3.4	1.8 2.9	2.6 4.6	1.5 2.9	1.8 3.4	1.7 2.0	1.2 2.3
262	i p		•			0.0		0.2 0.4	0.2 0.5	1.1 2.8	1.7 3.3	2.6 4.4	4.3 7.8	2.5 4.8	4.1 9.0
263	i p				*	0.0 0.1	0.1 0.1	0.2 0.6	0.3 0.5	1.2 3.0	1.3 3.4	0.5 1.7	3.1 6.4	1.8 3.1	2.4 9.2
264	i p		0.2 0.3	0.7 1.5	1.5 3.0	1.5 2.3	0.8 2.0	0.8 1.8	0.8 1.8	0.1 0.6	0.3 1.0	0.1 0.5	0.3 1.1	0.1 0.7	0.6 2.4
265	i p	:	:	:		0.1 0.3	0.3 0.5	1.1	0.5 1.0	0.6 1.0	0.7 1.5	0.3	0.3 0.8	1.1	0.0 0.2
266	i p			0.4 0.5	0.3 0.3	5.7 7.0	4.3 5.0	11.6 14.6	7.4 10.0	11.2 15.5	8.3 12.8	6.8 8.5	5.8 8.6	4.7 6.0	4.5 6.9
267	i p	:		0.1 0.1	0.0 0.0	0.1 0.1	0.4 0.5	1.2 1.6	0.9 1.7	1.7 2.9	3.0 4.6	2.1 3.3	1.7 3.9	2.3 2.8	0.7 1.9
268	i p			0.0 0.1	0.0	0.7 1.3	0.5 0.8	2.3 5.1	1.5 3.1	2.8 7.2	2.0 5.0	0.5 3.0	1.2 4.1	0.3 1.1	0.7 3.6
269	i p	0.0	0.2 0.5	0.1 0.1	0.6 0.7	0.6 0.7	1.4 1.5	1.0 1.1	0.9 1.1	0.5 0.6	0.8 1.0	0.2 0.5	0.2 0.4	0.1 0.1	0.4 0.6
270	i p	0.0 0.1	0.1	0.0	0.1 0.2	. 0.0	0.1 0.6	0.2 0.8	0.4 1.8	0.7 3.3	1.8 6.9	0.4 7.2	1.8 13.9	0.7 5.8	2.3 18.0
271	i p			0.2 0.2	0.0	0.1 0.1	0.1	0.1 0.5	0.1 0.5	0.1 0.6	0.1 0.4	0.2 2.0	0.0 0.4	0.0	0.2
272	i p	•	*		· ·	0.0	0.0 0.0	0.1 0.2	0.1 0.2	0.8 1.8	1.6 3.3	1.9 4.3	3.7 10.2	4.2 8.7	3.7 16.2
273	i P					0.0	0.1 0.1	0.4 0.8	0.3 0.5	1.2 2.2	2.6 4.2	2.5 4.8	6.0 12.4	1.4 6.1	7.5 25.9
274	i p			:	•	0.1 0.2	0.2	0.4 0.6	0.4 0.6	1.2 3.1	2.3 6.6	1.6 4.5	3.9 16.0	2.9 9.3	8.8 29.9
275	i p	0.3	0.1 0.2	0.6 0.7	0.3 0.5	0.7 0.9	1.2 1.4	1.4 1.9	0.9 2.0	0.7 1.7	1.6 3.4	0.9	2.9 6.1	1.0	2.4 10.7
276	i p	0.0		0.1 0.1	0.2	0.9	1.4 1.7	2.7 3.5	3.1 4.0	7.1 10.3	6.9 10.8	3.4 5.6	3.7 6.2	2.3	3.7 6.6
277	i p		· :	0.4 0.5	0.3	1.4 1.6	0.7 0.8	2.3 2.5	0.9 1.2	2.3 3.0	1.8 2.4	2.2 2.6	1.4	3.6 3.7	1.5 2.2
278	i p	0.0		0.0	0.0	0.2	0.5 0.7	2.8	2.3 2.6	4.0 5.6	3.4 5.2	1.9 2.8	0.8 1.0		0.2
279	i p	0.0	0.1 0.1	1.5 1.6	2.4 2.8	3.8 4.6	4.5 5.6	6.6 7.8	5.0 6.5	5.3 6.4	5.6 7.3	3.9 4.4	3.9 5.4	2.7 3.0	3.5 4.1
280	i	0.1 0.1	•	1.1 1.5	0.8	0.6 1.1	0.3	0.2	0.1 0.4	0.0	0.0		0.1		
281	p i			•	1.5	•	0.6	0.4	0.0	0.2 0.1	0.0 0.3 3.5	0.3	0.1 1.3	0.8 3.3	1.9 13.9
282	p i n			0.1 0.1	0.3 0.3	2.4 2.9	1.3 1.4	0.2 2.1 2.3	0.3 1.0 1.2	0.7 1.6 1.9	3.5 1.3 1.4	1.2 1.0 1.0	8.8 1.1 1.2	0.1	0.3
283	p i n		*	0.9	1.1 1.7	2.9 2.1 2.9	2.4 3.1	1.0 1.3	1.1 1.5	0.4 0.7	0.6 0.8	0.1 0.1	0.2 0.2	0.1 0.1 0.3	0.3 0.1 0.1
284	p i p			0.2	0.2 0.3	0.3 0.5	0.2	0.5 0.7	0.3 0.4	0.7 0.4 0.5	0.8 0.3 0.4	0.0	0.2 0.2 0.7		0.1 0.3 0.8

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
285	acquired deformities of limbs	i p	25365 37875	1.7 2.6	1.4 2.1	2.1 3.1	1.9 2.7	2.5 3.3	1.3 2.1	1.4 2.0	1.9 2.7	1.9 3.2	2.3 4.3
286	dis. musc. skel. system NEC	i p	20549 32407	1.4 2.2	1.2 2.0	1.6 2.4	0.2 0.4	1.1 1.4	1.5 1.9	1.7 2.4	1.7 2.9	1.0 2.3	0.8 2.8

L MUSCULOSKELETAL

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
285	i p	2.2 2.9	1.6 2.5	2.4 3.1	2.5 3.6	1.2 1.8	1.5 2.3	1.1 1.8	1.7 2.3	1.3 2.0	2.5 3.4	0.9 1.6	2.7 4.4	1.6 1.9	2.8 5.6
286	i p	0.4	0.4 0.4	0.9 1.0	1.3 1.8	1.2 1.7	1.7 2.2	1.6 2.4	1.8 2.5	1.3 2.6	2.2 3.3	1.0 2.3	1.0 2.4	0.7 2.4	0.8 3.0

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
287	headache/facial pain	i p	23008 77413	1.6 5.3	1.2 3.5	1.9 7.0	0.2 0.2	1.2 1.8	2.0 3.7	1.8 5.5	1.7 8.3	1.3 8.2	1.3 7.8
288	sensibility disturbance	i p	5279 11221	0.4 0.8	0.4 0.7	0.3 0.8	0.0	0.1 0.1	0.3 0.3	0.3 0.5	0.6 1.2	0.6 2.0	0.6 2.6
289	restless legs syndrome	i p	5413 14671	0.4 1.0	0.3 0.6	0.5 1.4			0.0 0.0	0.2 0.3	0.9 2.1	1.1 3.4	0.7 4.3
290	convulsions	i p	1859 2798	0.1 0.2	0.2 0.2	0.1 0.2	1.8 2.7	0.1 0.1					
291	symptoms sense/smell/taste	i p	275 283	0.0	0.0 0.0	0.0				0.0 0.0	0.1 0.1	0.0 0.0	
292	vertigo	i p	23140 61455	1.6 4.2	1.1 2.4	2.1 5.9	0.0 0.1	0.3 0.5	1.0 1.2	1.2 1.9	2.5 5.8	3.3 10.9	4.7 26.2
293	paralysis	i p	1317 7086	0.1 0.5	0.1 0.6	0.0 0.4	0.3	0.1	0.0 0.1	0.1 0.3	0.2 0.8	0.3 1.2	0.0 1.5
294	sympt./complt. speech	i p	2947 5811	0.2 0.4	0.2 0.4	0. 2 0.3	0.4 0.7	0.6 1.2	0.2 0.3	0.1 0.2	0.0 0.1	0.1 0.3	0.3 0.5
295	fear of neurological disease	i p	616 1446	0.0 0.1	0.0 0.1	0.1 0.1	:	0.1 0.1	0.0	0.1 0.2	0.0 0.0	0.0 0.2	0.1
296	disability/impairment neurol. syst.	i p	30 274	0.0	0.0	0.0 0.0		0.0		0.0	0.0	0.0	0.2
297	sympt./complt. neurol. syst. NEC	i p	903 2612	0.1 0.2	0.1 0.2	0.1 0.2	0.0	. 0.0	. 0.0	0.0 0.1	0.2	0.3	0.3
298	poliomyelitis	i p	0 1094	0.1	. 0.0	. 0.1			:	0.1	. 0.1	. 0.3	. 0.3
299	meningitis/encefalitis	i p	542 1369	0.0 0.1	0.1 0.1	0.0 0.1	0.4 0.5	0.0 0.1	0.0 0.0	0.0	0.1	. 0.0	. 0.2
300	tetanus	i p	0 13	0.0	0.0	•			0.0				
301	infections neur. syst. NEC	i p	84 297	0.0	0.0	0.0 0.0	•		0.0 0.0	0.0 0.0	0.0	E	0.1
302	malignant neoplasm neur. syst.	i p	471 2492	0.0 0.2	0.1 0.2	0.0 0.1	0.1 0.1		0.1	0.0 0.1	0.0 0.3	0.3 0.4	. 0.6
303	benigne neopl. neur. syst.	i p	555 1595	0.0 0.1	0.0 0.1	0.0 0.1	0.1		0.0 0.0	0.0 0.0	0.1 0.2	0.2 0.2	0.4
304	unspecified neopl. neur. syst.	i p	611 1641	0.0 0.1	0.0 0.1	0.0 0.1		0.0 0.0	0.1 0.1	0.0 0.1	0.0 0.2	0.1 0.1	0.1 0.1
305	concussion: commotio cer.	i p	8056 9982	0.5 0.7	0.6 0.7	0.5 0.7	1.2 1.3	1.1 1.3	0.7 0.8	0.5 0.6	0.1 0.2	0.2 0.5	0.4 0.7
306	concussion: contusio cer.	i p	1386 2175	0.1 0.1	0.1 0.2	0.1 0.1	0.2 0.2	0.1 0.2	0.2 0.3	0.0 0.1	0.0 0.1	0.0 0.2	0.1 0.1
307	head injury NOS/NEC, w/o skull fract.	i p	1501 1746	0.1 0.1	0.1 0.1	0.1 0.2	0.5 0.5	0.3 0.3	0.0	0.1 0.1	0.0		0.1
308	injuries neur. syst. NEC	i p	774 1323	0.1 0.1	0.0	0.1 0.1		0.0	0.0	0.0	0.1 0.2	0.2 0.2	0.1 0.2
309	cong. anom. neur. syst.	i p	296 3542	0.0 0.2	0.0 0.2	0.0	0.2 0.7	. 0.4	0.0 0.4	0.0	0.0	. 0.1	0.2
310	multiple sclerosis	i p	844 6856	0.1 0.5	0.1	0.1 0.5			0.0	0.1 0.6	0.1 0.9	0.0	. 0.4
311	Parkinsonism	i p	1728 19870	0.1 1.4	0.2	0.1 1.6				0.0 0.2	0.1 1.0	0.7 5.1	0.9 13.3

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 ma le	≥75 female
287	i p	0.2 0.2	0.2 0.2	1.0 1.4	1.4 2.3	1.2 2.5	2 .8 5 .0	1.4 3.7	2.1 7.4	1.4 6.4	1.9 10.1	1.5 4.6	1.2 11.0	0.7 3.3	1.6 10.1
288	i p	0.0	0.0	0.1 0.1	0.1 0.1	0.3 0.4	0.2 0.3	0.4 0.6	0.2 0.4	0.7 1.1	0.6 1.3	0.1 1.0	1.0 2.7	0.8 3.3	0.5 2.2
289	i p			<u>.</u>		0.0	0.1 0.1	0.1 0.2	0.3 0.4	0.7 1.2	1.2 2.9	0.9 2.7	1.1 3.9	0.3 2.8	0.8 5.2
290	i p	2.2 3.1	1.4 2.2	0.1 0.1	0.1 0.1		•	:	•			·			
291	i p		:		:			0.0	0.0 0.0	0.1 0.1	0.0	0.1 0.1	0.0		
292	i p	0.0	0.0	0.1 0.1	0.5 0.9	0.7 0.8	1.3 1.7	0.8 1.3	1.6 2.4	1.7 3.4	3.3 8.1	1.8 5.2	4.4 15.3	5.4 21.9	4.3 28.6
293	i	. 0.4	. 0.2	. 0.1	. 0.1	0.0	0.0 0.1	0.1 0.3	0.0 0.2	0.3 0.9	0.1 0.8	0.5 1.9	0.2 0.7	0.1 2.7	0.0 0.9
294	i p	0.2 0.6	0.6 0.8	0.9 1.7	0.3 0.7	0.1 0.3	0.3 0.4	0.1 0.2	0.1 0.2	0.0	0.1 0.2	0.2 0.3	0.0 0.3	0.4 0.9	0.3 0.3
295	i p			•	0.1 0.1	0.0	0.0	0.1 0.1	0.1 0.2	0.0	0.0 0.1		0.0 0.3	0.3	
296	i p				0.0	:	;	0.0	•	0.0	0.0		0.1	0.2	0.1
297	i p	, 0.0	0.0	0.1		0.0	. 0.0	0.0	0.0 0.1	0.1 0.4	0.3 0.3	0.7 0.9	0.7	0.3	. 0.4
298	i p				:		:	0.1	0.0	0.1	0.1		0.6	0.1	0.5
299	i p	0.6 0.9	0.1 0.1	0.0 0.1	0.0	0.0	0.0 0.1	0.0	0.0 0.1	0.1	0.1	0.1		0.5	
300	i p	•		*	*	0.0				:	:	•	:	.*	
301	i p			/ ● 3 (● 3		:	0.0	0.0	0.0 0.1	0.0	*	•			0.2
302	i P	. 0.0	0.2 0.2	•		. 0.1		0.0	0.1	0.1	0.3	0.6 0.8	. 0.1	1.3	0.2
303	i p	. 0.2		•		0.0	•	0.0	0.0	0.0	0.1 0.4	0.4 0.5	0.0	0.5	0.4
304	i p			0.0 0.0		0.1 0.1	0.0 0.0	0.1	0.1 0.2	0.1 0.3	0.0	0.0	0.2 0.2	0.2 0.2	<u>s</u> .
305	i p	1.7 1.9	0.6 0.6	1.1 1.2	1.2 1.4	0.9	0.6 0.8	0.5 0.6	0.5	0.0	0.2	0.2 0.2	0.1 0.7	0.5 0.5	0.3 0.7
306	i p	0.1 0.1	0.3 0.3	0.2	0.0 0.2	0.2 0.2	0.3 0.3	0.1 0.2	0.0 0.1	0.0	0.1 0.1	0.1 0.4			0.1 0.1
307	i	0.4	0.6	0.1	0.4	0.0	0.0	0.1	0.1		0.1		•	us.	0.2
308	p i n	0.4	0.6	0.1 0.0 0.1	0.4	0.0 0.1 0.1	0.0	0.1 0.0 0.1	0.2 0.1 0.1	0.1 0.1	0.1 0.1 0.2	0.1 0.1	0.3 0.3	0.3	0.2 0.2
309	p i p	0.5	0.3 0.9	. 0.3	0.5	0.1 0.3	. 0.4	. 0.2	0.0 0.1	. 0.2	0.0		0.2	. 0.2	. 0.1
310	i p				•	*	. 0.1	0.1 0.5	0.1 0.7	0.0	0.1 1.0	0.1 0.9	1.0		0.6
311	i p		:					0.0 0.1	0.3	0.1 1.2	0.0 0.9	1.4 6.2	0.2 4.3	1.1 11.5	0.9 14.3

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75	
312	epilepsy, all types	i p	4222 50891	0.3 3.5	0.3 3.8	0.3 3.2	0.2 1.3	0.2 1.7	0.4 2.8	0.3 4.1	0.2 3.9	0.5 5.4	0.2 4.2	
313	migraine	i p	18002 62359	1.2 4.2	0.6 1.9	1.9 6.5	:	0.5 0.9	1.4 2.8	1.8 5.3	1.6 7.8	0.5 4.0	0.4 2.7	
314	facial paralysis, Bell's palsy	i p	1383 2080	0.1 0.1	0.1 0.1	0.1 0.1	:	0.0	0.1 0.2	0.1 0.1	0.2 0.3	0.0 0.1	0.4 0.5	
315	trigeminal neuralgia	i P	1582 4033	0.1 0.3	0.1 0.1	0.2 0.4			0.0 0.0	0.1 0.2	0.2 0.5	0.3 0.7	0.1 1.1	
316	carpal tunnel syndrome	i p	4050 6737	0.3 0.5	0.1 0.2	0.4 0.8			0.1 0.1	0.4 0.5	0.5 0.8	0.5 1.0	0.5 0.9	
317	cluster headache	i p	502 965	0.0 0.1	0.0 0.1	0.0 0.1			0.1 0.1	0.1 0.1	0.0 0.1	0.1		
318	dis. of periph. nerv. syst. NEC	i p	32173 56890	2.2 3.9	2.1 3.7	2.3 4.0	0.2 0.4	0.1 0.3	1.2 1.7	2.9 4.2	3.1 6.5	3.1 6.6	3.7 7.7	
319	dis. of central nerv. syst. NEC	i p	3808 14310	0.3 1.0	0.3 1.0	0.2 1.0	0.1 0.5	0.0 0.3	0.1 0.4	0.2 0.7	0.2 1.3	1.0 2.6	0.9 3.0	

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
312	i	0.0 1.2	0.4 1.5	0.3 1.9	0.1 1.6	0.3 2.4	0.5 3.2	0.3 4.5	0.3 3.6	0.2 4.2	0.1 3.6	0.9 7.7	0.2 3.7	0.3 5.2	0.2 3.7
313	p i p			0.4	0.5 1.0	0.5	2.3 4.3	0.9 2.4	2.7 8.2	0.6 2.8	2.5 12.6	0.2 1.5	0.7 5.8	1.8	0.7 3.2
314	i p			0.0	•	0.1 0.2	0.1	0.1 0.1	0.1 0.1	0.2 0.2	0.2 0.3	0.1 0.3	0.0	0.1 0.1	0.6 0.7
315	i p						0.0 0.1	0.1 0.1	0.1 0.3	0.1 0.3	0.4 0.7	0.4 0.4	0.3 1.0	0.0 0.2	0.2 1.5
316	i p				•	0.0 0.1	0.1 0.2	0.2 0.2	0.5 0.8	0.1 0.2	0.8 1.4	0.0 0.3	0.8 1.5	0.3 0.5	0.6
317	i p			· .			0.1 0.1	0.1 0.1	0.0	0.0	0.0 0.2	0.2			
318	i p	0.4 0.6	0.1	0.1 0.4	0.1 0.2	0.9 1.4	1. 5 2.1	3.0 4.2	2.9 4.2	2.9 6.5	3.3 6.5	3.1 6.3	3.1 6.8	3.0 7.7	4.0 7.7
319	i p	0.1 0.4	0.2 0.5	0.1 0.1	0.0 0.5	0.1 0.5	0.1 0.3	0.2 0.7	0.2 0.7	0.3 1.4	0.2 1.3	1.5 2.7	0.7 2.5	1.3 4.2	0.7 2.4

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
320	feeling anxious/nervous/tense	i p	57024 307605	3.9 21.0	2.4 13.3	5.3 28.4	0.5 1.0	1.3 1.7	2.8 6.1	4.4 17.0	5.4 39.1	5.5 49.3	6.4 54.1
321	acute stress (transient) reaction	i p	26541 66992	1.8 4.6	1.3 3.2	2.3 5.9	0.0 0.0	0.3 0.3	1.7 2.7	2.6 5.7	2.3 7.1	1.4 6.7	1.5 6.0
322	feeling depressed	i p	5612 24390	0.4 1.7	0.3 1.2	0.5 2.1			0.2 0.6	0.4 1.5	0.6 3.0	0.7 3.6	0.7 4.0
323	feeling/behaving irritable	i p	2938 14879	0.2 1.0	0.2 0.8	0.2 1.2	0.1 0.3	0.1 0.2	0.2 0.3	0.1 0.5	0.2 1.3	0.5 2.8	0.8 5.5
324	suicide attempt	i p	1663 1889	0.1 0.1	0.1 0.2	0.1 0.1		0.1 0.1	0.0 0.0	0.1 0.2	0.2 0.2	0.2 0.2	0.2 0.2
325	disturbances of sleep	i p	15100 289739	1.0 19.7	0.8 11.4	1.3 27.8	1.2 2.6	0.1 0.5	0.5 1.5	0.8 6.8	1.4 32.2	2.6 71.7	2.7 104.5
326	sexual problems	i p	4368 7192	0.3 0.5	0.3 0.5	0.3 0.5		0.1	0.4 0.5	0.4 0.6	0.5 0.8	0.3 0.4	0.3
327	hypochondr. dis./probl. with being ill	i p	2505 12408	0.2 0.8	0.2 0.9	0.1 0.8		0.0 0.1	0.3 0.7	0.2 1.1	0.2 1.1	0.2 0.9	0.0 1.1
328	tension headache	i p	31359 47028	2.1 3.2	1.3 2.1	2.9 4.3		0.9 1.2	3.1 4.1	2.8 4.3	2.2 3.8	1.4 2.2	1.2 1.7
329	hyperventilation	i p	30074 46680	2.0 3.2	1.6 2.2	2.5 4.1	0.0 0.0	0.5 0.7	2.6 3.5	3.2 4.9	2.0 3.4	1.2	1.2 1.8
330	enuresis	i p	3829 13655	0.3 0.9	0.3	0.2 0.9	0.6 1.5	1.5 5.2	0.1 0.6	0.0 0.2	, 0.0	. 0.1	0.0 0.2
331	anorexia nervosa/boulimia	i p	1837 4199	0.1 0.3	0.0 0.0	0.2 0.5	•	0.1 0.1	0.4 0.9	0.1 0.3	0.0	. 0.0	
332	eating/feeding probl. NEC	i p	678 1717	0.0 0.1	0.0 0.1	0.1 0.2	0.0 0.1		0.1 0.2	0.0 0.1	0.1	0.1	0.1 0.3
333	chronic alcohol abuse	i p	5468 26142	0.4 1.8	0.6 2.6	0.2 0.9			0.2 0.4	0.6 2.4	0.6 3.7	0.3 2.0	0.2
334	acute alcohol abuse	i p	759 1376	0.1 0.1	0.1 0.1	0.0 0.0			0.0 0.1	0.0 0.1	0.2 0.2	0.0	
335	tobacco abuse	i p	7211 31086	0.5 2.1	0.5 2.2	0.4 2.0		0.0 0.1	0.3 1.4	0.9 3.1	0.6 3.6	0.2 1.4	0.0
336	drug abuse	i p	676 5311	0.0 0.4	0.1 0.5	0.0 0.2	•		0.2 0.6	0.0 0.7	0.2	0.1	
337	medicinal abuse	i p	484 6393	0.0 0.4	0.0 0.3	0.1 0.6			0.0 0.1	0.0 0.5	0.0 0.8	0.1 0.8	0.0 1.1
338	abuse substances NEC	i p	20 539	0.0 0.0	0.0	0.0 0.1	0.0		0.0	0.0			0.1
339	dist. memory/concentration	i p	1648 7227	0.1 0.5	0.1 0.4	0.1 0.6		0.0 0.0	0.0 0.1	0.1 0.2	0.0 0.3	0.1 1.2	0.9 4.9
340	disturbance behaviour child	i p	2424 3770	0.2 0.3	0.2 0.3	0.1 0.2	1.3 1.8	0.6 0.9	0.0 0.1		:		
341	sympt./complt. behaviour adolescent	i p	1157 2812	0.1 0.2	0.1 0.1	0.1 0.2		0.1 0.3	0.4				
342	sympt./complt. adult	i p	2161 9038	0.1 0.6	0.1 0.6	0.2 0.6			0.2 0.6	0.1 0.6	0.2 0.7	0.2 1.0	0.4 1.7
343	phase of live problem adult	i p	752 4008	0.1 0.3	0.0 0.2	0.1 0.4			0.1 0.2	0.0 0.2	0.1 0.3	0.1 0.4	0.3 1.5
344	dist. learning/mental development	i p	582 3470	0.0 0.2	0.1 0.2	0.0 0.2	0.3 1.1	0.1 0.6	0.0 0.2	0.1	0.2	0.1	0.1

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
320	i p	0.3 0.6	0.6 1.3	1.2 1.5	1.4 2.0	1.3 4.1	4.3 8.2	3.2 11.1	5.6 23.2	3.3 25.8	7.5 52.2	2.8 34.2	7.6 61.0	3.2 34.9	8.1 64.3
321	i p	0.0		0.1 0.2	0.5 0.5	0.9 1.7	2.5 3.9	2.1 4.5	3.2 7.0	1.9 5.1	2.7 9.2	0.8 3.3	1.9 9.4	0.8 2.9	1.8 7.7
322	i p		•			0.0 0.5	0.3 0.7	0.4 1.1	0.4 1.9	0.3 2.2	0.9 3.8	0.8 2.4	0.6 4.6	0.7 2.5	0.7 4.8
323	i p	0.4	0.3 0.3	0.2 0.3	0.0 0.0	0.1 0.3	0.3 0.3	0.1 0.7	0.1 0.4	0.1 0.9	0.3 1.7	0.7 3.0	0.3 2.6	1.1 3.1	0.7 6.7
324	i p			0.1 0.1	•	0.0	0.0	0.2 0.2	0.1 0.1	0.2 0.2	0.1 0.2	0.1 0.1	0.2 0.2	0.5 0.5	0.0
325	i p	0.9 2.3	1.4 2.9	0.3 0.7	0.0 0.3	0.2 0.6	0.7 2.3	0.8 5.2	0.8 8.5	1.1 19.9	1.6 44.2	1.2 44.1	3.7 92.9	1.4 68.6	3.4 123.5
326	i p				0.1	0.1 0.1	0.7 0.9	0.3 0.5	0.5 0.8	0.7 1.2	0.2 0.3	0.6 0.8	· ·	0.5	0.2
327	i p			0.1	0.0 0.1	0.5 0.8	0.2 0.5	0.1 1.0	0.2 1.2	0.3 1.5	0.1 0.8	0.7	0.3 1.0	0.1 0.8	1.3
328	i p			0.5 0.7	1.4 1.8	1.6 2.1	4.5 6.1	1.7 2.7	4.0 5.9	1.7 2.9	2.7 4.6	0.3 0.8	2.3 3.2	1.4 1.6	1.0 1.7
329	i p	0.0	0.0	0.4 0.4	0.5 0.9	1.5 2.0	3.7 5.0	2.7 3.8	3.6 6.0	1.4 2.3	2.5 4.5	0.5 1.2	1.8 3.6	0.9 1.3	1.3 2.1
330	i p	0.7 1.6	0.6 1.5	1.9 5.9	1.1 4.5	0.1 0.5	0.1 0.7	0.0 0.1	0.0	0.0	0.0	0.0	. 0.1		0.0
331	i p				0.2 0.2	0.0	0.8 1.7	0.1 0.1	0.2 0.5		0.1 0.3		0.0	*	
332	i p	0.1 0.1	0.2			0.1 0.1	0.2 0.3		0.1 0.3	0.1	0.1	0.2 0.2	0.0	0.1 0.1	0.1 0.4
333	i p					0.3 0.5	0.2 0.4	0.9 3.4	0.3 1.4	0.8 5.9	0.4 1.5	0.8 3.0	1.2	0.3 2.1	0.2 0.6
334	i p		*		:	0.1 0.1		0.1 0.2	0.0 0.1	0.2 0.2	0.1 0.1	0.1			:
335	i p			. 0.0	0.1 0. 2	0.3 1.4	0.3 1.3	0.9 2.8	0.9 3.5	0.8 4.3	0.5 3.0	0.4 1.6	1.3	0.1 2.4	. 0.3
336	i p					0.2 0.5	0.1	0.0	0.0	. 0.2	. 0.2	0.2			
337	i p	:	:				0.0 0.2	0.4	0.1 0.6	0.1 0.5	0.0 1.1	0.8	0.1 0.8	0.1	0.0 1.7
338	i p		0.0			0.0	0.1	0.0	0.1		0.1	0.0	0.1		0.2
339	i p	:		0.1 0.1	0.0	0.1 0.2	3	0.1 0.3	0.1 0.2	0.0 0.1	0.0 0.4	0.1 0.9	0.2 1.5	1.1 4.3	0.9 5.2
340	i p	1.4 1.9	1.1 1.6	1.0 1.6	0.2 0.2	. 0.1	0.1 0.1	:							
341	i p			0.0 0.1	0.1 0.5	0.4 0.5	0.4								
342	i p					0.1 0.4	0.3	0.1 0.7	0.1 0.5	0.3 0.8	0.2 0.7	1.5	0.3 0.7	0.5 1.6	0.3 1.8
343	i p					0.0 0.1	0.1 0.2	0.0 0.1	0.0 0.4	0.1 0.3	0.0 0.4	0.1 0.4	0.0 0.4	0.0 1.0	0.4 1.7
344	i p	0.2 0.9	0.4 1.3	0.2 0.9	0. 2	0.2	0.0 0.2	0.0	0.2	0.1	0.2	0.2	•		0.1

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	2 5-44	45-64	65-74	≥75
345	fear of mental disorder	i p	273 475	0.0 0.0	0.0 0.0	0.0 0.1			0.0	0.0 0.0	0.0 0.0	:	0.1
346	psychic disability/impairment	i p	37 517	0.0 0.0	0.0	0.0 0.0			0.0 0.0	0.0	0.0	0.2	
347	psychic sympt./complt. NEC	i p	7170 24320	0.5 1.7	0.2 0.8	0.7 2.4	0.3 0.3	0.3 0.4	0.5 1.3	0.5 1.7	0.6 2.0	0.6 3.8	0.4 2.9
348	dementia (pre)senile	i p	2793 15776	0.2 1.1	0.2 0.7	0.2 1.5		•		0.0 0.1	0.0 0.1	0.8 3.0	2.2 15.5
349	organic psychosis	i p	700 3022	0.0 0.2	0.1 0.2	0.0 0.2	:	0.1	0.0	0.1 0.2	0.1 0.4	0.2 0.3	0.0 0.6
350	schizophrenia, all types	i p	1487 8650	0.1 0.6	0.1 0.5	0.1 0.6			0.1 0.2	0.1 0.7	0.1 0.9	0.2 1.3	0.4 1.3
351	affective psychosis	i p	3147 13570	0.2 0.9	0.2 0.7	0.3 1.1		0.1	0.1 0.1	0.2 0.9	0.4 2.0	0.3 1.8	0.5 1.7
352	unspecified psychosis NEC	i p	2009 16662	0.1 1.1	0.1 0.9	0.2 1.3		0.1	0.2 0.4	0.2 1.2	0.1 1.6	0.3 2.6	0.1 2.9
353	anxiety disorder/anxiety state	i p	3609 10877	0.2 0.7	0.2 0.5	0.3 1.0	0.0 0.1	0.1 0.1	0.0 0.2	0.3 0.7	0.3 1.3	0.4 1.8	0.7 1.8
354	hysterical/hypochondriacal dis.	i p	4310 21040	0.3 1.4	0.2 1.0	0.4 1.9	(* *	0.0 0.1	0.2 0.6	0.3 1.3	0.5 2.3	0.4 3.6	0.6 3.6
355	depressive disorder	i p	33150 121941	2.3 8.3	1.3 4.6	3.2 11.9		0.1 0.2	1.2 2.4	2.7 8.2	3.6 14.1	4.2 18.7	3.0 20.7
356	mental retardation	i p	342 10934	0.0 0.7	0.0 0.7	0.0 0.8	0.1 1.0	0.0 0.7	0.8	0.0 0.7	0.0 0.9	0.4	0.5
357	neurasthenia, surmenage	i p	51155 90831	3.5 6.2	3.0 5.5	3.9 6.9	•	0.3 0.4	3.9 5.3	5.7 9.6	3.9 8.4	1.6 4.0	1.7 3.5
358	personality disorder	i p	739 3385	0.1 0.2	0.1 0.2	0.0 0.3			0.2 0.2	0.1 0.3	0.0 0.3	0.1 0.2	0.2
359	phobia/neurotic disorder NEC	i p	6214 27812	0.4 1.9	0.3 1.3	0.5 2.5	0.2 0.2	0.1 0.2	0.4 1.1	0.6 2.9	0.5 2.5	0.2 2.2	0.5 1.7
360	mental/psychological dis. NEC	i p	7248 29762	0.5 2.0	0.5 1.6	0.5 2.5	0.1 0.4	0.3 0.4	0.5 1.2	0.5 2.3	0.8 3.3	0.3 2.9	0.2 2.5

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
345	i p			:			0.1	0.0	0.1 0.1	0.0	0.1 0.1			•	0.2
346	i p			:	•		0.0 0.1	0.0	0.0	0.1	0.0	0.2	0.2		
347	i p	0.1 0.1	0.4 0.4	0.1 0.1	0.6 0.8	0.1 0.7	0.8 1.9	0.4 1.2	0.7 2.1	0.3 1.0	0.8 2.9	0.1 0.7	1.0 6.2	0.1 1.0	0.6 4.0
348	i p			:				0.0	0.0 0.1	0.0 0.2	0.1	1.0 2.9	0.6 3.1	2.3 12.0	2.2 17.4
349	i p	;		0.1		0.0	0.0	0.1 0.2	0.1 0.3	0.1 0.6	0.0 0.2	0.3 0.4	0.1 0.2	0.1 0.5	0.6
350	i p		:	:		0.1	0.0 0.2	0.1 0.7	0.0	0.1 0.9	0.1 1.0	. 0.8	0.4 1.7	0.3 1.2	0.4 1.3
351	i p				0.1	0.2 0.2		0.1 0.5	0.3 1.3	0.5 2.1	0.4 2.0	0.1 1.0	0.5 2.4	0.3 1.1	0.7 2.0
352	i p				0.1	0.1 0.4	0.2 0.4	0.1 1.1	0.3 1.2	0.1 1.6	0.1 1.6	0.0 1.3	0.5 3.6	0.1 1.4	0.1 3.7
353	i p	0.1	0.0	0.0 0.1	0.1 0.2	0.0 0.1	0.1 0.3	0.1 0.3	0.5 1.0	0.3 0.9	0.3 1.6	0.6 1.5	0.2 1.9	0.1 0.8	1.0 2.4
354	i p	:		0.0 0.1	0.0 0.1	0.1 0.5	0. 2 0.7	0.2 1.0	0.5 1.7	0.4 1.5	0.6 3.1	0.5 2.8	0.3 4.2	0.4 2.2	0.7 4.3
355	i p	:		0.1 0.3	0.2 0.2	0.4	2.0 3.7	1.6 4.9	3.8 11.6	2.2 8.5	4.9 19.6	2.6 10.0	5.4 25.4	1.6 11.5	3.8 25.6
356	i p	0.2 1.0	1.0	0.0	0.0 0.5	0.8	0.9	0.0 0.7	0.0 0.7	0.0 0.6	0.0 1.2	0.6	0.3	1.0	0.2
357	i p			0.4 0.5	0.1 0.3	2.5 3.6	5.3 7.1	5.3 8.8	6.0 10.5	3.5 8.3	4.3 8.6	0.8 2.3	2.3 5.3	1.3 2.3	2.0 4.2
358	i p		•			0.2 0.3	0.1 0.1	0.1 0.3	0.0 0.4	0.0 0.2	0.0	0.0	0.1 0.4	:	0.4
359	i p	0.1 0.2	0.2 0.2	0.1 0.1	0.2 0.4	0.4 0.7	0.4 1.5	0.5 1.8	0.7 4.0	0.5 2.0	0.6 3.0	1.3	0.4 2.9	0.1 0.6	0.6 2.3
360	i p	0.0 0.5	0.2	0.2 0.4	0.4 0.5	0.5 0.7	0.6 1.7	0.6 1.7	0.5 3.0	0.9 2.9	0.6 3.7	0.5 2.7	0.1 3.1	1.1	0.3

361 pain attr. to respiratory system i 318 0.0 0.0 0.0 0.0 . 0.0 . 0.0 0.0 p 473 0.0 0.0 0.1 . 0.0 . 0.0 0. 362 shortness of breath, dyspnoe i 4288 0.3 0.3 0.3 0.1 0.3 0.2 0.1 0. p 13798 0.9 1.0 0.9 0.5 0.5 0.5 0.5 1. 363 wheezing i 169 0.0 . 0.0 0.1 0.0 0 0. p 667 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0	0 0.1 0. 3 1.0 0. 0 3.2 3. 0 . 0. 0 . 0. 0 0.1 0. 1 0.3 0.	0.2 0.2 0.9 6.4 0.0 0.1
362 shortness of breath, dyspnoe i 4288 0.3 0.3 0.3 0.1 0.3 0.2 0.1 0.0 p 13798 0.9 1.0 0.9 0.5 0.5 0.5 0.5 1. 363 wheezing i 169 0.0 . 0.0 0.1 0.0 0.	3 1.0 0. 0 3.2 3. 0 . 0. 0 . 0. 0 0.1 0. 1 0.3 0.	0.9 0.4 0.0 0.1
	0 . 0. 0 0.1 0. 1 0.3 0.	.1
p 667 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.	1 0.3 0.	
364 breathing problems NEC i 1507 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	8 121 10	.2
365 cough i 133305 9.1 7.3 10.9 20.3 9.1 6.5 6.7 9. p 137700 9.4 7.6 11.1 20.6 9.2 6.6 6.9 10.		.6 .6
366 epistaxis/nose bleed i 7029 0.5 0.6 0.4 0.4 1.2 0.6 0.1 0. p 8614 0.6 0.7 0.5 0.6 1.3 0.7 0.2 0.5		
367 sneezing/nasal congestion i 4379 0.3 0.3 0.3 0.5 0.3 0.4 0.3 0.5 p 10744 0.7 0.7 0.8 1.6 0.6 0.5 0.8 0.5		
368 sympt./complt. nose NEC i 3843 0.3 0.2 0.3 0.4 0.3 0.4 0.2 0.1 p 6051 0.4 0.4 0.4 0.4 0.4 0.6 0.4 0.6		
369 sympt/complt. sinus (incl. pain) i 1889 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0. p 2564 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.3 0.3		
370 sympt/complt.throat i 19498 1.3 1.1 1.6 0.7 1.2 1.7 1.4 1.6 p 38324 2.6 2.2 3.0 1.1 1.9 3.1 2.8 3.0		
371 sympt./complt. tonsils i 834 0.1 0.0 0.1 0.3 0.2 0.0 0.0 0.0 0.0 p 1185 0.1 0.1 0.1 0.5 0.2 0.0 0.0 0.0		
372 sympt./complt. voice/vocal cords i 4354 0.3 0.1 0.5 0.1 0.3 0.5 0.2 0.4 p 6250 0.4 0.2 0.6 0.2 0.4 0.6 0.3 0.6	0.3 0.2	2
373 haemoptysis i 772 0.1 0.1 0.0 0.0 0.1 0.1 0.1 p 1052 0.1 0.1 0.1 0.0 0.1 0.1		
374 abnormal sputum/phlegm NEC i 2906 0.2 0.2 0.2 0.6 0.2 0.1 0.2 0.2 0.5 p 9188 0.6 0.5 0.7 1.1 0.5 0.2 0.3 0.5		
375 fear of respiratory disease i 1919 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 p 3676 0.3 0.3 0.2 0.3 0.1 0.1 0.3 0.3	=	
376 disability/impairment resp. syst. i 133 0.0 0.0 0.0 . 0.1 0.0		
377 sympt./complt. resp. syst. NEC i 3827 0.3 0.3 0.2 0.8 0.3 0.3 0.2 0.2 0.8 0.3 0.3 0.2 0.2 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.5 0.6 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	0.3 0.4	
378 tuberculosis resp. (excl. A70) i 336 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0		6
379 whooping cough i 4454 0.3 0.2 0.4 1.8 0.8 0.2 0.1 0.1 p 6848 0.5 0.4 0.5 2.9 1.4 0.2 0.1 0.1		
380 scarlet fever i 3667 0.2 0.3 0.2 1.9 1.0 0.0 0.0 . p 4235 0.3 0.3 0.3 2.3 1.1 0.0 0.0 .		
381 streptoc. inf. throat NEC i 857 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1	0.0 . 0.0 0.0)
382 boil/abscess nose i 768 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 p 850 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1	0.1 . 0.1 0.1	
383 URI (head cold) i 451996 30.8 29.2 32.3 105.6 33.4 31.0 26.4 21.3 p 491827 33.5 31.3 35.6 109.9 35.4 32.9 28.4 24.7	20.3 15.0 25.5 18.6)
384 sinusitis acute/chronic i 127580 8.7 7.5 9.9 4.6 5.4 9.2 13.5 7.6 p 157505 10.7 9.3 12.1 5.4 6.8 10.9 16.5 9.8	3.4 2.4 4.8 3.4	ļ.
385 acute tonsillitis/adenoiditis i 87855 6.0 5.8 6.2 20.1 10.8 7.1 4.8 2.7 p 90927 6.2 6.0 6.4 20.3 11.1 7.3 5.0 2.8	1.0 1.1 1.4 1.2	

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	2 5-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
361	i p				0.0	:		0.0	0.1 0.1	0.0	:		0.1		0.2 0.4
362	i p	0.1 0.4	0.0 0.5	0.2 0.4	0.4 0.7	0.2 0.5	0.1 0.4	0.1 0.4	0.1 0.6	0.4 1.3	0.2 0.8	1.0 3.0	1.1 3.3	2.0 6.1	0.4 2.0
363	i p	, 0.1	0.2 0.3		0.0		0.1	0.1			0.0 0.0			0.2	0.0
364	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.2	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.1	0.0 0.1	0.0	0.3	0.2 0.3	0.3 0.3	0.1 0.1
365	i p	18.0 18.4	22.7 23.0	7.6 7.7	10.6 10.9	5.5 5.5	7.5 7.8	4.5 4.9	8.9 9.0	7.2 7.7	12.5 13.2	12.6 13.5	11.6 12.6	11.3 12.8	9.8 10.9
366	i p	0.4 0.7	0.5 0.5	1.3	1.1 1.2	1.0	0.1 0.2	0.2	0.1	0.6	0.4	0.2 0.4	0.6 1.1	0.8 1.3	0.6
367	i	0.7 1.2	0.3 2.0	0.3 0.6	0.3 0.6	0.2 0.4	0.6 0.6	0.3	0.2 0.8	0.2 0.6	0.4 0.7	0.4 0.4	0.3 0.8	0.5	0.1 0.6
368	i p	0.3 0.3	0.6 0.6	0.1 0.1	0.6 0.6	0.5 0.7	0.3 0.5	0.2 0.3	0.2 0.4	0.3 0.6	0.2 0.5	0.1 0.2	0.1 0.1	0.0 -	0.0
369	i p		0.2 0.2	0.1 0.1	0.0 0.1	0.1 0.2	0.2 0.3	0.2 0.2	0.3 0.3	0.0	0.1 0.2		0.0		
370	i p	0.3 0.6	1.1	0.8	1.6 2.6	1.2	2.3 3.6	1.3 2.6	1.5 3.1	1.2 2.6	1.4 3.4	0.3 1.6	1.7 3.0	0.6 1.3	0.9 2.4
371	i p	0.1 0.3	0.6 0.7	0.2 0.2	0.1 0.3	0.0	0.1 0.1	0.0	0.0	0.0	0.1 0.1		*		
372	i p	0.1 0.1	0.2 0.2	0.2 0.4	0.5 0.5	0.1 0.1	0.9 1.1	0.1 0.1	0.3 0.4	0.2 0.3	0.5 0.8	0.3 0.8	0.2 0.5	0.0	0.3 0.4
373	i p			:		0.1 0.1		0.1 0.1	0.0 0.1	0.1 0.2	0.1 0.1	0.2 0.2	*	0.2 0.2	0.1 0.2
374	i p	0.8 1.0	0.5 1.2	0.2 0.3	0.2 0.8	0.0 0.1	0.1 0.2	0.2 0.2	0.1 0.3	0.1 0.4	0.2 0.5	0.4 2.1	0.2 1.6	0.5 3.1	0.4 2.7
375	i p	0.1 0.6	0.0	0.1	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.3	0.1 0.4	0.3 0.3	0.2 0.3	0.1 0.2	0.0 0.1	ě	0.2 0.2
376	i			0.1	0.0	0.0								•	
377	p i	1.1	0.5	0.1	0.0	0.0	0.3	0.1	0.0	0.2	0.0	0.5	0.1	0.5	0.3
378	p i	1.5	0.8	0.6	0.4	0.7	0.5	0.3	0.4	0.6	0.3	2.0	0.3	0.8	0.9
379	p i	1.1	0.2 2.5	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.3	0.1	0.5	0.3	0.7
380	p i p	1.7 2.0 2.5	4.1 1.8 2.1	1.7 1.1 1.2	1.1 0.9 1.0	0.0 0.0 0.0	0.5 0.0 0.0	0.1	0.1 0.0 0.0	0.1	0.1	0.2	0.2	•	0.1
381	i	0.0		0.0	0.2	200	0.2	0.0	0.1	0.1	0.0	,	0.0		
382	p i	0.2	0.1	0.0	0.2	0.0	0.2	0.0	0.1	0.1	0.0	0.2	0.0	•	0.0
383		105.4	0.1	31.1	0.1 35.8	0.0 26.5	35.7	0.0 24.0	0.1 28.8	20.7	0.1 21.9	19.5	21.0	16.2	0.1 14.4
384	i	4.0	110.1 5.2	33.0 5.0	37.9 5.7	28.0 6.8	38.0	25.5 11.4	31.5 15.6	23.3 6.7	26.0 8.6	22.9	27.6 4.1	19.4	18.2
385	p i	4.8 20.6	6.0 19.6	6.9 10.4	6.6 11.3	8.2 5.7	13.6 8.5	13.9 4.7	19.2 4.8	8.7 2.5	10.8 2.9	4.0 0.6	5.5 1.4	2.9 1.5	3.7 1.0
	Р	20.8	19.8	10.6	11.6	5.9	8.7	4.9	5.1	2.6	3.1	1.0	1.6	1.6	1.0

no.	episode		totals	/1000	sex		age						
			abs.	pers.	male	female	0-4	5-14	15-24	25-44	45-64	65-74	≥75
386	acute laryngitis/tracheitis/croup	i	51964	3.5	3.3	3.8	9.2	3.3	3.2	3.4	3.2	2.6	2.2
		р	54709	3.7	3.5	4.0	9.9	3.4	3.2	3.6	3.5	2.8	2.3
387	acute bronchi(oli)tis	i	141965 191330	9.7 13.0	9.8 13.3	9.6 12.8	30.9 36.6	10.1 13.2	6.4 8.1	6.9 9.0	9.5 13.9	10.2 16.5	11.1 18.0
		р :											
388	influenza w/o pneumonia	i p	90889 92355	6.2 6.3	6.0 6.1	6.3 6.5	7.7 7.7	4.0 4.1	5.2 5.2	7.0 7.1	7.2 7.4	6.0 6.1	4.9 5.1
389	pneumonia	i	30974	2.1	2.3	1.9	6.0	2.4	0.9	1.3	1.8	3.8	5.0
000	priodirection	p	32449	2.2	2.4	2.0	6.0	2.4	0.9	1.4	1.8	3.9	5.5
390	pleurisy all (excl. R70)	i	781	0.1	0.1	0.0			0.1	0.1	0.1	0.1	
		р	1585	0.1	0.1	0.1	4	•	0.1	0.1	0.1	0.4	0.1
391	infection resp. syst. NEC	i	10809	0.7	0.8	0.7	2.2	0.8	0.5	0.6	0.6	0.8	1.4
		р	18663	1.3	1.4	1.2	3.0	1.1	0.7	1.0	1.4	1.7	1.9
392	mal. neopl. bronchus/lung	i	1530	0.1	0.2	0.0					0.2	0.4	0.5
		р	14823	1.0	1.7	0.3	•		•	0.2	1.6	5.3	4.8
393	mal. neopl. resp. syst. NEC	i	554	0.0	0.0	0.0		•	0.0	0.0	0.1	0.1	0.1
		р	3772	0.3	0.4	0.2	7945	•	0.0	0.0	0.5	0.9	1.1
394	ben. neopl. resp. syst.	i p	379 900	0.0 0.1	0.0 0.0	0.0 0.1	0.1 0.1	0.0 0.0	0.0 0.1	0.0 0.0	0.1 0.1	0.1 0.2	
005	Sed and sed						0.1	0.0	0.1				
395	unspecified neopl. resp. syst.	i p	468 2055	0.0 0.1	0.1 0.1	0.0 0.2		0.0	0.0	0.0 0.1	0.0 0.2	0.0 0.5	0.2 0.5
													
396	foreign body resp. syst.	i	808	0.1	0.1	0.0	0.5	0.1	0.0	0.0	0.0		0.1
		р	911	0.1	0.1	0.0	0.6	0.1	0.0	0.0	0.0		0.1
397	injuries resp. syst. NEC	i	648	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	*	
		р	698	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0		
398	cong. anom. resp. syst.	i	115 445	0.0 0.0	0.0 0.0	0.0	0.0 0.1	1.00	0.0 0.0	0.0 0.0	0.1	0.0 0.0	•
200	house the debag int Associated as	р :						1.0	0.4	0.2	0.0	0.1	•
399	hypertrophy/chron. inf. tonsills/aden.	i p	9393 14342	0.6 1.0	0.5 0.9	0.7 1.1	5.8 8.2	1.0	0.4	0.2	0.0	0.1	0.0
400	chronic bronchitis	i	14787	1.0	1.2	0.8	1.6	0.6	0.5	0.5	1.3	2.0	3.4
		р	153518	10.5	12.8	8.2	8.8	7.1	4.9	4.7	13.8	28.2	35.6
401	pleural effusion NOS	i	1026	0.1	0.1	0.1		0.1	0.0	0.0	0.1	0.4	
		p p	1529	0.1	0.1	0.1		0.1	0.0	0.0	0.2	0.5	0.1
402	emfysema	i	3008	0.2	0.3	0.1			0.1	0.0	0.4	8.0	1.1
	-	р	46250	3.2	4.9	1.5		0.1	0.1	0.4	3.6	16.6	20.1
403	asthma	i	26701	1.8	1.9	1.7	3.6	3.1	1.6	1.3	1.3	1.9	2.1
		р	149170	10.2	10.6	9.7	14.6	13.2	7.2	6.6	9.9	18.5	18.2
404	allergic rhinitis/hay fever	i	31500	2.1	1.9	2.4	0.8	1.9	3.5	2.9	1.1	1.1	0.8
		Р	96600	6.6	6.5	6.6	1.9	7.1	10.1	8.2	4.4	3.0	2.8
405	diseases resp. syst. NEC	i	8464 21915	0.6 1.5	0.7 1.9	0.5 1.1	0.6 0.9	0.3 0.6	0.6 1.3	0.7 1.4	0.7 1.9	0.5 3.1	0.5 1.9
		р	21910	1.5	1.9	1.1	0.5	0.0	1.0	1.7	1.3	0.1	1.5

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
386	i p	9.3 10.2	9.1 9.6	3.5 3.5	3.1 3.2	2.9 2.8	3.5 3.5	3.0 3.1	3.8 4.1	2.8 3.1	3.6 3.9	2.5 2.8	2.6 2.8	1.3 1.5	2.7 2.7
387	i p	32.7 37.6	29.1 35.6	10.5 13.8	9.7 12.6	6.4 8.1	6.5 8.0	6.4 8.5	7.5 9.5	9.9 14.8	9.2 13.0	10.4 16.7	10.0 16.4	13.5 24.1	9.9 14.8
388	i p	8.8 8.8	6.4 6.5	3.4 3.5	4.7 4.7	5.0 5.0	5.3 5.3	7.4 7.5	6.6 6.6	6.6 6.8	7.9 8.0	3.8 3.8	7.8 7.9	3.9 3.9	5.4 5.8
389	i p	6.4 6.5	5.3 5.5	2.7 2.7	2.0 2.1	1.0 1.0	0.8 0.8	1.3 1.5	1.2 1.3	1.9 1.9	1.7 1.8	4.6 4.8	2.9 3.1	7.1 8.0	2.9 4.1
390	i p					0.1 0.2	0.0	0.1 0.1	0.0 0.1	0.1 0.1	0.0 0.1	0.2 0.2	0.1 0.6		0.2
391	i p	2.4 3.1	2.0 2.9	0.7 1.0	0.9 1.3	0.6 0.9	0.3 0.5	0.6 1.2	0.5 0.9	0.5 1.3	0.6 1.4	0.9 2.1	0.6 1.4	2.3 3.0	0.9 1.3
392	i p							0.1	0.2	0.5 2.8	0.4	0.6 11.1	0.0 0.9	0.9 10.7	0.1 1.7
393	i p	•					0.1 0.1	0.0	0.0 0.1	0.1 0.8	0.0 0.3	0.3 1.7	0.3	2.4	0.1 0.5
394	i p		0.2 0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0 0.1	0.1 0.1	0.1 0.1	0.0 0.2		
395	i p		*:	0.0		0.1		0.0	0.0 0.2	0.1 0.3	0.1	0.1 0.2	0.7	0.6 0.6	0.5
396	i p	0.7	0.4 0.5	0.2 0.2	0.0	0.0			0.0	0.0	0.0			0.0	0.1 0.1
397	i p	0.0		0.0	0.2 0.2	0.0	0.1 0.1	0.0	0.1 0.1	•	0.0			, .	
398	i p	0.0	0.1		:	0.0	0.0	0.0			0.1	0.1 0.1			
399	i p	5.3 8.8	6.4 7.6	0.7 1.6	1.3 2.3	0.4 0.4	0.4 0.9	0.1 0.2	0.3 0.5	0.0	0.0 0.1		0.2 0.2	0.1	•
400	i p	1.9 10.8	1.4 6.8	0.9 8.6	0.3 5.5	0.6 5.4	0.5 4.4	0.6 5.1	0.4 4.4	1.5 17.3	1.1 10.5	2.2 40.2	1.9 19.0	6.9 61.9	1.4 21.6
401	i			. 0.1	0.1 0.1	0.0	:	0.0	0.0	0.1 0.2	0.2 0.3	0.5 0.7	0.2 0.3	0.1	. 0.1
402	p i			. 0.1	. 0.2	0.1 0.2	0.0	0.0 0.5	0.0	0.5 5.9	0.2	1.7 30.8	0.1 5.6	2.9 39.9	0.1 9.5
403	p i	4.5	2.7	4.1	2.2	1.4	1.8	1.0	1.5 7.6	1.1 9.7	1.6 10.2	2.6 23.4	1.4 14.8	2.8 24.9	1.8 14.7
404	p i	18.6	0.6	15.6	10.8 2.0	7.1 2.9	7.4 4.1	5.5 2.6	3.3	0.9 3.8	1.2 4.9	1.0 2.7	1.1 3.2	0.6 3.1	1.0
405	p i p	1.7 0.7 1.3	2.2 0.5 0.5	7.6 0.2 0.6	6.6 0.3 0.6	10.4 0.7 1.8	9.7 0.5 0.7	7.7 0.8 1.5	8.7 0.6 1.2	1.0 2.3	0.3 1.6	0.6 4.9	0.5 1.7	0.5 3.7	0.5 0.9

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
406	pain/tenderness of skin	i p	834 1586	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.1	0.1 0.2	0.0 0.1		0.1 0.2
407	pruritus, skin itching	i p	12621 28063	0.9 1.9	0.7 1.3	1.0 2.5	0.7 0.9	0.6 0.7	0.5 0.8	0.9 1.6	0.9 2.8	1.6 3.6	1.2 5.9
408	warts	i p	73978 99882	5.0 6.8	4.5 6.0	5.6 7.6	2.7 3.2	15.2 21.2	7.0 9.1	3.1 4.2	2.4 3.2	2.2 3.3	2.2 3.0
409	condyloma acuminata	i P	5112 5166	0.3 0.4	0.5 0.5	0.2 0.2	0.1 0.1	0.2 0.2	0.7 0.6	0.5 0.5	0.2 0.2	0.0 0.0	(E)
410	local swelling/papul/lump	i p	7071 9410	0.5 0.6	0.4 0.5	0.6 0.8	0.5 0.6	0.5 0.7	0.6 0.7	0.6 0.7	0.4 0.5	0.4 0.4	0.2 0.7
411	multiple swelling/papul/lump	i p	1680 3065	0.1 0.2	0.1 0.2	0.2 0.3	0.3 0.5	0.0 0.3	0.1 0.3	0.1 0.2	0.2 0.2	0.1 0.1	0.1 0.1
412	local redness/erythema	i p	9498 16733	0.6 1.1	0.5 0.9	0.8 1.4	1.7 2.3	0.8 1.0	0.6 1.0	0.5 0.9	0.5 1.2	0.8 1.2	0.6 1.4
413	general redness/erythema	i p	2917 6051	0.2 0.4	0.2 0.3	0.2 0.5	0.8 1.0	0.3 0.3	0.2 0.3	0.1 0.3	0.1 0.5	0.2 0.4	0.5
414	changes in skin color NEC	i p	1964 2680	0.1 0.2	0.1 0.1	0.1 0.2	0.1 0.1	0.2 0.2	0.1 0.2	0.1 0.2	0.1 0.2	0.3 0.5	0.0
415	local infection finger/toe	i p	22399 23753	1.5 1.6	1.6 1.6	1.5 1.6	1.3 1.6	2.1 2.2	1.5 1.5	1.6 1.7	1.4 1.5	0.8 0.9	1.3 1.5
416	boil/carbuncle/cellulitis	i p	28261 34636	1.9 2.4	2.1 2.5	1.7 2.2	1.3 1.5	1.3 1.7	2.8	2.2 2.9	1.8	1.3 1.5	1.2
417	local infection skin NEC	i p	17679 24033	1.2	1.2 1.5	1.2	1.6 2.2	1.0 1.3	1.3 1.5	1.2 1.6	1.1	1.4 1.9	1.5 1.3 2.6
418	insect bite	i p	16605 17969	1.1 1.2	0.9 0.9	1.4 1.5	1.9 1.9	1.6 1.6	1.5 1.7	0.9	0.8	0.9	0.9
419	animal/human bite	i p	8158 9045	0.6 0.6	0.6 0.7	0.5 0.6	0.6 0.6	0.6 0.6	0.6 0.6	0.6 0.6	0.8 0.9	0.1 0.2	0.0
420	burns/scalds	i p	11661 16469	0.8 1.1	0.8 1.1	0.8 1.1	1.4 2.1	0.6 0.8	1.3 1.8	0.7 1.0	0.6 1.0	0.7 0.8	0.5 0.7
421	foreign body in skin	i p	6889 7920	0.5 0.5	0.5 0.6	0.4	0.6 0.6	0.5 0.5	0.6	0.6 0.7	0.4	0.2	0.2
422	bruise/contusion intact skin	i p	29953 33812	2.0 2.3	1.6 1.8	2.5 2.8	1.6 1.6	1.7 1.9	2.8 2.9	1.5 1.7	0.4 2.0 2.4	0.3 2.7 3.2	0.2 3.1 4.0
423	abrasion/scratch/blister	i p	13784 14985	0.9	1.0	0.9	0.6 0.7	1.7 1.8	1.6 1.6	0.5 0.5	0.5 0.6	1.0	1.7 2.1
424	laceration/cut	i p	54115 59890	3.7 4.1	5.1 5.5	2.3 2.7	6.9 7.1	5.4 5.8	4.9 5.3	3.2 3.8	2.2 2.5	1.8 2.2	2.8
425	injury to skin NEC	i p	27703 42007	1.9 2.9	2.3 3.4	1.5 2.3	4.0 5.1	2.6 3.6	2.1 3.1	1.6 2.3	1.1	1.7	1.9 4.2
426	corns/callosities	i	12557 15616	0.9	0.7	1.0	0.3	0.6	0.7	0.9	0.8	1.1	2.2
427	sympt./complt. of skin texture	p i p	8041 19511	1.1 0.5 1.3	0.8 0.4 1.0	1.3 0.7 1.7	0.3 0.8 2.2	0.7	0.8	0.6	0.4	1.5 0.6	2.7 1.2
428	sympt./complt. nails	i p	2420 3908	0.2 0.3	0.2 0.2	0.1 0.3	0.1 0.2	0.8 0.3 0.4	0.8 0.2 0.2	1.1 0.2 0.3	0.9 0.1 0.2	1.9 0.2	5.3 0.0
429	losing hair/baldness	i p	3319 7763	0.2 0.5	0.2	0.3 0.7		0.4 0.1 0.1	0.2 0.3 0.4	0.4 0.8	0.2 0.1 0.5	0.4 0.2 0.9	0.3
430	sympt./complt. hair NEC	i p	1969 5288	0.1 0.4	0.0 0.2	0.2 0.5	0.0 0.1	0.0	0.4 0.2 0.4	0.8 0.2 0.5	0.5 0.1 0.4	0.9	0.7 0.0 0.2
													0.0

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
406	i p		0.2 0.2	0.0 0.0	0.1 0.1	0.1 0.1	0.0 0.0	0.0 0.1	0.1 0.2	0.1	0.1 0.1		:	0.0 0.1	0.2 0.3
407	i p	0.5 0.7	0.9 1.1	0.6 0.8	0.6 0.6	0.5 0.7	0.6 1.0	0.6 0.9	1.2 2.2	0.8 2.2	1.1 3.4	1.1 2.6	1.9 4.4	1.2 4.1	1.2 6.8
408	i p	2.5 2.7	2.9 3.8	13.6 19.2	16.8 23.2	6.8 8.3	7.2 10.0	2.3 3.1	4.0 5.3	2.1 2.7	2.7 3.8	1.6 3.0	2.6 3.6	1.9 2.3	2.4 3.3
409	i p	0.2 0.2	0.0	0.2 0.2	0.2 0.2	0.9 0.9	0.5 0.4	0.8 0.8	0.2 0.2	0.1 0.1	0.2 0.2	0.1 0.1			
410	i p	0.4 0.4	0.6 0.8	0.5 0.8	0.5 0.6	0.4 0.5	0.8 0.9	0.4 0.5	0.7 0.9	0.3 0.5	0.4 0.6	0.2 0.2	0.5 0.5	0.1 0.4	0.2 0.9
411	i p	0.2	0.4 0.4	. 0.3	0.1 0.3	0.2	0.2 0.4	0.0 0.1	0.2 0.3	0.1 0.1	0.2 0.2		0.1 0.2	0.2 0.2	
412	i p	1.5 2.5	1.9 2.2	0.5 0.6	1.0 1.4	0.3 0.6	0.9 1.3	0.3 0.5	0.7 1.4	0.4 1.2	0.6 1.3	0.6 1.0	0.9 1.3	0.4 1.8	0.7 1.3
413	i p	0.5 0.6	1.0 1.3	0.2 0.2	0.5 0.5	0.2 0.3	0.2 0.3	0.1 0.3	0.1 0.3	0.0 0.3	0.3 0.7	0.4	0.4	0.6	0.5
414	i p	:	0.1 0.1	0.4 0.4	0.1 0.1	0.1 0.1	0 .1 0.2	0.0 0.1	0.1 0.3	0.1 0.1	0.2 0.2	0.5 0.5	0.2 0.5	0.0	
415	i p	1.4 1.5	1.2 1.7	2.3 2.4	1.9 2.0	1.8 1.8	1.2 1.1	1.5 1.5	1.7 1.9	1.6 1.6	1.3 1.4	0.2 0.2	1.3 1.5	1.2 1.6	1.4 1.4
416	i p	1.8 1.8	0.7 1.3	1.6 2.1	0.9 1.2	3.2 3.5	2.4 2.7	2.2	2.2 2.9	2.0	1.5 2.1	1.0	1.4 1.6	0.9 1.2	1.4 1.7
417	i p	1.8 2.3	1.4	1.1	0.9	1.2 1.5	1.4	1.0	1.3 1.8	1.4 1.8	0.8 1.4	0.9 0.9	1.8 2.6	1.7 2.3	1.1 2.7
418	i p	2.0 2.0	1.8 1.8	1.2 1.2	2.0 2.1	1.3 1.3	1.8 2.1	0.7 0.7	1.2 1.3	0.5 0.5	1.0 1.2	0.2 0.5	1.4 1.5	0.4 0.4	1.1 1.1
419	i p	8.0 8.0	0.4 0.4	0.5 0.6	0.6 0.7	0.8 0.8	0.4 0.4	0.5 0.5	0.7 0.8	1.1 1.2	0.5 0.6	0.2 0.3	0.2	0.1 0.3	0.0
420	i p	1.5 2.5	1.2 1.7	0.7 0.9	0.4 0.6	1.2 1.5	1.4 2.1	0.8 1.1	0.6 0.8	0.3 0.6	0.9 1.4	0.6 0.6	0.7 0.9	0.6 1.1	0.4 0.5
421	i p	0.7 0.7	0.6	0.5 0.6	0.5 0.5	0.7 0.8	0.4	0.6 0.8	0.5 0.5	0.4	0.4	0.2 0.2	0.2	3	0.2 0.2
422	i p	1.8 1.8	1.4 1.4	1.8 2.0	1.6 1.9	2.2 2.3	3.4 3.6	1.4 1.6	1.7 1.9	1.2 1.3	2.9	2.2 2.7	3.1 3.6	1.0 2.1	4.2 5.1
423	i p	0.5 0.5	0.7 1.0	2.2	1.2	2.0	1.2 1.2	0.6 0.6	0.4 0.4	0.4	0.6	0.6	1.2 1.4	0.9	2.1
424	i p	8.7 8.7	5.0 5.5	8.0 8.5	2.8	7.3 7.8	2.5 2.7	4.3 5.0	2.1 2.5	2.8 3.2	1.6 1.7	2.5 2.7	1.3 1.9	1.7	3.3 4.1
425	i p	4.9 6.5	3.1 3.7	3.6 4.9	1.6 2.2	2.3 3.6	1.9 2.5	1.9 2.7	1.3 1.8	1.3 2.6	0.9 1.6	1.7 2.8	1.8 3.3	2.2 3.5	1.7 4.6
426	i	0.2	0.4	0.5	0.8	0.3	1.1	0.8	1.0	0.6	0.9	1.5	0.9	1.5	2.6
427	p i	1.1	0.4	0.5	0.8	0.4	0.7	0.4	0.8	0.8	1.4 0.5	0.5	0.7	0.9	3.1 1.3
428	p i	0.1	2.3 0.2	0.4	0.6	0.6	0.1	0.9	1.3 0.2	0.6	0.2	1.4	0.3	0.0	6.5 0.0
429	p i	0.1	0.3	0.4	0.3	0.3	0.1	0.3	0.2	0.2	0.2	•	0.8	0.0	0.5
430	p i		0.0	0.0	0.0	0.4	0.5	0.7	0.8	0.2	0.9		1.6	0.1	0.0
	р	•	0.2	0.0	0.0	0.0	0.8	0.3	0.7	0.3	0.5	0.5	0.3	0.0	0.3

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
431	fear of skin disease	i p	389 849	0.0 0.1	0.0 0.0	0.0 0.1	*	0.0 0.0	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.1	*
432	disability/impairment of skin	i p	0 125	0.0	0.0	0.0				0.0	0.0	æ.	0.1
433	sympt./complt. of skin NEC	i p	4226 9419	0.3 0.6	0.2 0.6	0.4 0.7	0.6 0.8	0.2 0.3	0.4 0.6	0.3 0.7	0.3 0.6	0.1 0.8	0.2 0.7
434	herpes zoster	i p	14617 19029	1.0 1.3	0.8 1.0	1.2 1.6	0.2 0.2	0.8 0.8	0.7 0.7	0.7 0.9	1.3 1.7	2.0 3.2	2.4 4.1
435	herpes (simplex) lip/mouth	i p	10565 19915	0.7 1.4	0.3 0.7	1.1 2.0	0.2 0.3	0.6 1.0	1.2 2.2	0.8 1.5	0.6 1.4	0.7 0.8	0.2 0.3
436	herpes simplex genitalis	i p	1701 2471	0.1 0.2	0.1 0.1	0.1 0.2		0.0 0.0	0.3 0.3	0.1 0.2	0.1 0.2		
437	herpes simplex NEC	i p	2873 4824	0.2 0.3	0.1 0.2	0.3 0.5	0.5 0.5	0.2 0.2	0.3 0.4	0.2 0.3	0.1 0.4	0.0 0.3	0.1 0.2
438	scabies/other ascariasis	i p	2353 3174	0.2 0.2	0.2 0.2	0.2 0.2	0.1 0.1	0.2 0.3	0.2 0.3	0.2 0.3	0.1 0.1	0.1	0.1 0.1
439	pediculosis/skininfestation	i p	5307 6780	0.4 0.5	0.4 0.5	0.4 0.5	0.4 0.5	0.7 1.1	0.8 0.9	0.3 0.3	0.1 0.1	0.0	0.2 0.2
440	dermatophytosis/dermatomycosis	i p	84885 123444	5.8 8.4	6.4 9.2	5.2 7.7	4.9 6.0	5.7 6.9	7.0 9.1	6.7 9.4	5.3 9.2	3.2 6.4	3.3 6.6
441	moniliasis/candidiasis (excl. GU)	i p	12989 19224	0.9 1.3	0.9 1.4	0.8 1.2	3.8 4.9	0.5 0.5	0.6 1.0	0.7 0.9	0.7 1.4	1.1 1.9	0.8 1.6
442	erysipelas	i p	11164 14689	0.8 1.0	0.7 0.8	0.9 1.2	0.1 0.1	0.2 0.2	0.4 0.5	0.4 0.6	1.3 1.8	1.7 2.3	2.5 3.2
443	mollusca contagiosa	i p	10726 11947	0.7 0.8	0.8 0.8	0.7 0.8	2.3 2.5	4.4 4.9	0.1 0.2	0.0 0.0	0.0 0.0		
444	infection skin NEC	i p	8808 11970	0.6 0.8	0.6 0.8	0.6 0.9	1.1 1.3	0.6 0.9	0.5 0.6	0.7 0.9	0.5 0.6	0.4 0.9	0.5 1.0
445	malign. neoplasm skin	i p	3582 8892	0.2 0.6	0.3 0.6	0.2 0.6			0.0 0.1	0.1 0.3	0.5 0.9	0.8 2.2	0.8 2.7
446	lipoma	i p	12344 14566	0.8 1.0	1.1 1.2	0.6 0.8	0.1 0.1	0.2 0.3	0.6 0.7	1.3 1.5	0.9 1.1	1.3 1.5	0.3 0.5
447	benign. neoplasm skin NEC	i p	21247 25230	1.4 1.7	1.2 1.4	1.7 2.0	0.7 0.9	1.1 1.1	1.2 1.4	2.0 2.3	1.6 1.8	1.1 1.7	0.7 1.1
448	unspecified neoplasm skin	i p	1427 2006	0.1 0.1	0.1 0.2	0.1 0.1		0.0 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.2 0.2	0.3 0.4
449	hemangioma/lymfangioma	i P	2246 2488	0.2 0.2	0.1 0.1	0.2 0.2	0.5 0.5	0.2 0.2	0.0 0.0	0.1 0.1	0.3 0.3	0.1 0.1	
450	nevus/mole	i p	11790 15283	0.8 1.0	0.5 0.6	1.1 1.5	0.4 0.4	1.0 1.4	1.1 1.3	1.1 1.4	0.4 0.7	0.4 0.5	0.2 0.4
451	cong. anom. of skin NEC	i p	260 443	0.0	0.0	0.0	0.0 0.1	**	¥1				
452	impetigo	i p	21724 22357	1.5 1.5	1.4 1.5	1.5 1.6	7.4 7.6	3.7 3.7	1.3 1.3	0.7 0.8	0.4 0.4	0.3 0.3	0.4 0.4
453	pilonidal cyst/fistula	i p	1323 2316	0.1 0.2	0.1 0.2	0.1 0.1			0.1 0.2	0.1 0.2	0.1 0.2	0.0	0.0 0.4
454	seborrheic dermatitis	i p	15261 23454	1.0 1.6	1.2 1.7	0.9 1.5	1.4 1.6	0.7 0.8	1.0 1.4	1.4 2.3	0.9 1.4	0.7 1.3	0.4 1.1
455	atopic dermatitis/eczema	i p	16862 31750	1.1 2.2	1.0 1.9	1.3 2.4	6.0 12.2	2.0 3.3	1.2 2.1	0.6 1.2	0.4 0.8	0.2 0.5	0.7 1.2

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
431	i p				0.0	0.1 0.1	0.0 0.1	0.0	0.0 0.1	0.0 0.1	0.0 0.1	0.3 0.3			
432	i p	*		,				0.0		:	0.0				0.2
433	i p	0.5 0.9	0.6 0.8	0.0 0.1	0.3 0.4	0.1 0.2	0.7 1.0	0.4 0.8	0.2 0.7	0.1 0.4	0.4 0.8	0.1 0.9	0.2 0.7	0.5 1.1	0.6
434	i p		0.4 0.4	0.7 0.7	0.8 0.9	0.5 0.5	0.8 0.9	0.7 0.8	0.8 1.0	0.8 1.1	1.8 2.2	1.8 3.0	2.2 3.4	2.9 4.1	2.1 4.0
435	i p	0.1 0.1	0.3 0.5	0.3 0.5	0.9 1.6	0.4 0.8	2.0 3.7	0.4 0.9	1.2 2.2	0.3 0.7	0.9 2.0	0.4 0.6	0.9 1.0	0.2 0.2	0.2 0.4
436	i p		*	• •	0.0	0.2	0.3	0.1	0.2	0.1 0.2	0.2 0.2			×	
437	i p	0.7 0.7	0.3 0.3	0.1 0.1	0.3 0.3	0.1 0.2	0.5 0.6	0.1	0.3 0.5	0.0	0.2 0.7	0.0	0.0 0.5		0.1 0.3
438	i p	0.2 0.2	0.1 0.1	0.2 0.2	0.2 0.4	0.1 0.2	0.3 0.3	0.2 0.2	0.2 0.3	0.1 0.2	0.1 0.1	0.2	:	0.2 · 0.2	•
439	i p	0.6 0.6	0.1 0.3	0.2 0.5	1.2 1.8	0.9 1.0	0.7 0.7	0.4 0.5	0.2 0.2	0.0 0.2	0.1 0.1		0.0	0.0	0.3 0.3
440	i p	4.1 5.3	5.8 6.8	5.6 7.0	5.8 6.7	7.8 9.9	6.1 8.3	7.6 10.5	5.7 8.2	6.0 10.0	4.5 8.3	3.4 6.1	3.0 6.6	3.4 8.1	3.2 5.9
441	i p	4.1 5.0	3.5 4.7	0.7	0.3 0.3	0.7 1.2	0.4	0.7 1.0	0.7 0.8	0.6 1.3	0.8	1.1 1.5	1.1 2.2	0.8 1.6	0.9 1.5
442	i p		0.1 0.1	0.2 0.2	0.1 0.1	0.5 0.5	0.4 0. 5	0.6 0.7	0.3 0.5	1.2 1.4	1.5 2.2	1.4 1.6	2.0 2.8	1.0 1.2	3.3 4.3
443	i p	2.2 2.5	2.4 2.5	4.4 4.6	4.4 5.1	0.2 0.2	0.0 0.1	0.0	0.0	0.1 0.1					
444	i p	0.7 1.0	1.4 1.6	0.8 0.9	0.5 0.8	0.4 0.5	0.7 0.8	0.7 1.0	0.7 0.8	0.4 0.5	0.5 0.6	0.4 0.9	0.5 0.9	0.6 1.2	0.4 0.9
445	i p				:	0.0	0.1 0.1	0.1 0.3	0.2 0.4	0.8 1.1	0.2 0.7	1.2 2.4	0.5 2.0	1.0 3.5	0.7 2.3
446	i	0.2 0.2	0.0	0.1 0.2	0.2 0.4	0.8	0.4	1.8	0.8	1.0 1.2	0.8	1.4 1.6	1.3 1.5	0.5 0.5	0.2 0.5
447	p i p	0.4	1.0 1.4	0.9	1.2 1.3	1.0 1.2	1.3 1.6	1.4	2.7	1.5 1.7	1.7	1.1 1.6	1.0 1.8	1.1 1.8	0.4 0.7
448	i p	٠		0.0 0.1		0.2	0.0 0.1	0.1 0.1	0.1 0.2	0.1 0.2	0.0	0.4 0.3	0.0 0.2	0.6 0.6	0.2 0.3
449	i p	0.7 0.7	0.3	0.2	0.2 0.2	0.0	0.0	0.1 0.1	0.1 0.2	0.2 0.2	0.4 0.4		0.1 0.1		
450	i p	0.4	0.3 0.5	0.8 0.9	1.3 1.8	0.5 0.6	1.7 2.1	0.6 0.8	1.5 2.0	0.2 0.4	0.6 0.9	0.1 0.1	0.7 0.8	0.1 0.1	0.3 0.5
451	i	0.0 0.2			*			*					•	ž .	
452	p i p	6.1 6.4	8.7 8.8	4.2 4.1	3.3 3.3	1.1 1.2	1.5 1.5	0.7 0.7	0.7 0.9	0.3 0.3	0.4 0.4	0.1 0.1	0.4	0.5 0.5	0.3 0.3
453	i p	ŧ				0.2	0.0 0.1	0.2	0.1 0.2	0.1 0.2	0.1		0.0	0.0	0.0
454	i p	1.1 1.3	1.7 2.0	0.7 0.8	0.6 0.8	1.1	0.9	1.5 2.5	1.3	1.1 1.5	0.7 1.2	1.0 1.6	0.4 1.1	0.2 0.7	0.6 1.3
455	i p	5.6 12.6	6.4 11.8	1.7 2.8	2.3 3.7	0.7 1.4	1.7 2.8	0.5 0.8	0.8	0.4 0.7	0.3 0.9	0.3 0.7	0.1 0.3	0.3 0.5	0.9 1.5

no.	episode		totals abs.	/1000 per s ,	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
456	contact dermatitis	i p	18681 27597	1.3 1.9	0.8 1.3	1.8 2.5	0.9 1.3	1.0 1.2	2.0 2.8	1.5 2.2	0.9 1.6	0.7 1.1	0.9 1.7
457	eczema NEC	i p	109004 232076	7.4 15.8	6.5 13.6	8.3 17.9	10.5 17.0	6.8 10.8	7.8 14.7	7.4 14.7	7.1 17.6	6.6 20.7	7.3 23.6
458	diaper rash	i p	7217 11035	0.5 0.8	0.5 0.7	0.5 0.8	8.1 12.1	0.0	0.0	0.0 0.0	0.0 0.0	•	0.0 0.0
459	pityriasis rosea	i p	5626 7376	0.4 0.5	0.3 0.5	0.4 0.5	0.1 0.1	0.5 0.5	0.7 0.9	0.3 0.5	0.4 0.5	0.1 0.2	0.1 0.2
460	psoriasis w/wo arthropathy	j p	6651 27904	0.5 1.9	0.5 2.0	0.4 1.8	0.2 0.3	0.3 0.4	0.4	0.6 1.7	0.5 3.0	0.6 4.3	0.5 2.9
461	pompholyx/dis. sweat glands	i p	5932 7289	0.4 0.5	0.3 0.3	0.5 0.7	0.1 0.1	0.2 0.3	0.8 1.0	0.5 0.7	0.2 0.3	0.1 0.1	0.0 0.0
462	sebaceous cyst	i p	35350 41375	2.4 2.8	2.6 3.1	2.2 2.6	0.2 0.2	0.7 0.8	3.1 3.5	3.0 3.6	2.7 3.2	2.1 2.5	2.1 2.7
463	ingrown toenail/dis. of nail NEC	i p	13981 18523	1.0 1.3	1.1 1.4	0.8 1.2	0.3 0.4	1.3 1.5	1.9 2.5	0.6 0.9	0.7 1.0	0.7 0.9	0.9 1.4
464	alopecia/folliculitis/dis, of hair NEC	i p	13317 18378	0.9 1.3	0.9 1.3	0.9 1.2	0.7 0.7	0.6 0.9	0.9 1.3	1.3 1.7	0.9 1.3	0.1 0.3	0.5 1.1
465	acne vulgaris	i p	24230 83884	1.7 5.7	1.5 5.6	1.8 5.9	0.3 0.3	1.6 4.3	5.7 22.2	1.3 3.9	0.2 0.7	0.1 0.1	0.1 0.3
466	chron. ulcer skin, incl. varicose	i p	5410 16996	0.4 1.2	0.3 0.9	0.4 1.4	0.2 0.4	0.0 0.1	0.3 0.3	0.2 0.3	0.3 1.0	0.7 3.1	2.2 10.1
467	urticaria	i p	17634 20868	1.2 1.4	1.1 1.3	1.3 1.5	3.1 3.3	1.8 1.9	1.5 1.7	0.9 1.2	0.7 0.9	0.7 0.9	1.0 1.3
468	seborrheic warts	i p	3466 4270	0.2 0.3	0.1 0.2	0.4 0.4	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.4 0.5	0.7 0.8	0.8 1.0
469	acne rosacea	i p	3768 5889	0.3 0.4	0.2 0.3	0.3 0.5	0.3 0.3	0.2 0.3	0.1 0.2	0.2 0.3	0.4 0.8	0.4 0.5	0.4 0.5
470	dis. skin/subcut. tissue NEC	i p	21089 36547	1.4 2.5	1.2 2.0	1.7 3.0	1.3 2.0	1.0 1.2	1.8 2.7	1.3 2.5	1.4 2.7	1.2 2.5	2.6 4.6

no.		0-4 male	0-4 fem a le	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
456	i	1.1	0.7	0.8	1.2	0.6	3.4	1.0	2.1	0.7	1.1	0.2	1.0	0.6	1.1
	p	1.5	1.1	1.1	1.3	1.2	4.4	1.3	3.0	1.5	1.6	0.5	1.6	1.4	1.9
457	i	10.1	10.9	5.6	8.0	5.5	10.1	6.0	8.8	7.0	7.1	7.0	6.3	9.2	6.3
	p	17.0	17.0	9.7	11.9	9.9	19.7	12.3	17.1	15.6	19.5	21.3	20.3	27.4	21.6
458	i p	7.4 11.1	8.8 13.3	0.1		0.1	:		0.0		0.0	•			0.0
459	i p	0.0 0.1	0.2 0.2	0.5 0.7	0.4 0.4	0.6 0.7	0.9 1.2	0.2 0.3	0.5 0.7	0.5 0.7	0.3 0.3	0.1 0.1	0.2		0.2 0.3
460	i p	0.4 0.6	0.0	0.3 0.6	0 .2 0.3	0.4 1.1	0.3 1.3	0.7 2.0	0.4 1.5	0.5 3.1	0.5 3.0	0.2 4.6	0.9 4.1	1.1 2.7	0.3 3.0
461	i p	0.2 0.2	0.1 0.1	0.1 0.1	0.4 0.4	0.4 0.4	1.3 1.5	0.4 0.5	0.6 0.9	0.2 0.2	0.3 0.4		0.2	0.0	
462	i	0.1	0.3	0.8	0.5	3.8	2.5	3.0	3.1	3.0	2.4	2.6	1.7	2.7	1.7
	p	0.2	0.5	0.8	0.7	4.2	2.9	3.5	3.6	3.6	2.8	3.0	2.0	3.5	2.4
463	i	0.4	0.2	1.4	1.2	2.7	1.1	0.7	0.5	0.5	0.9	0.4	0.9	0.4 ·	1.2
	p	0.7	0.2	1.6	1.3	3.3	1.6	1.0	0.9	0.7	1.3	0.5	1.2	1.2	1.4
464	i	0.5	0.9	0.4	0.8	0.9	1.0	1.4	1.3	1.0	0.8	0.0	0.1	0.3	0.6
	p	0.5	0.9	0.8	1.0	1.3	1.3	1.8	1.6	1.6	1.1	0.3	0.4	0.4	1.5
465	i p	0.5 0.5	0.1 0.1	1.3 2.5	1.9 6.1	5.8 24.1	5.6 20.2	0.8 2.6	1.8 5.3	0.2 0.7	0.2 0.7		0.1 0.2	0.2 0.2	0.0 0.4
466	i	0.3	0.1	0.0	0.1	0.4	0.2	0.2	0.2	0.3	0.3	0.5	0.9	2.0	2.4
	p	0.4	0.4	0.1	0.1	0.4	0.3	0.2	0.4	1.3	0.7	3.1	3.2	6.2	12.2
467	i	4.1	2.0	2.3	1.3	1.0	1.9	0.5	1.4	0.7	0.7	0.5	0.8	1.9	0.5
	p	4.1	2.4	2.3	1.5	1.2	2.1	0.8	1.7	0.8	1.0	0.6	1.1	2.1	0.8
468	i p		0.1 0.1	0.1	0.1 0.1	0.0	0.1 0.1	0.0 0.1	0.2 0.2	0.2 0.3	0.6 0.7	8.0 8.0	0.6 0.8	0.1 0.1	1.1 1.4
469	i	0.4	0.2	0.1	0.3	0.0	0.1	0.2	0.3	0.5	0.3	0.4	0.4	0.1	0.6
	p	0.4	0.2	0.2	0.4	0.1	0.3	0.2	0.4	0.6	0.9	0.5	0.5	0.3	0.7
470	i	1.8	0.9	1.1	0.9	1.2	2.5	1.0	1.6	1.0	1.7	1.2	1.3	2.1	2.8
	p	2.3	1.7	1.5	1.0	1.8	3.7	1.9	3.1	2.0	3.3	2.5	2.4	3.8	5.1

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
471	excessive thirst	i p	593 694	0.0 0.0	0.0 0.0	0.0 0.1	0.2 0.2	0.0 0.0		0.1 0.1	0.0 0.0	0.1 0.1	
472	excessive appetite, excl. boulimia	i p	300 1198	0.0 0.1	0.0 0.0	0.0 0.1	0.2 0.2	0.0 0.0	0.0 0.0	0.0 0.2	0.0		
473	loss of appetite, excl. anorexia nerv.	i p	1027 2148	0.1 0.1	0.1 0.1	0.1 0.2	0.3 0.5	0.0 0.1	0.1 0.1	0.0	0.1 0.1	0.0 0.4	0.1 0.5
474	feeding problem infant, excl. P11	i p	1948 3227	0.1 0.2	0.2 0.3	0.1 0.2	1.7 2.6	0. 2 0.4	. ·				
475	feeding problem adult, excl. T06	i p	1779 5049	0.1 0.3	0.1 0.2	0.1 0.5			0.2 0.3	0.1 0.2	0.0 0.4	0.6	0.3 1.4
476	feeding problem NEC	i p	428 1429	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.2	0.0 0.0	0.0 0.1	0.0 0.1	0.0 0.1	0.2	0.0
477	weight gain, excl. T82	i p	1050 2071	0.1 0.1	0.0 0.0	0.1 0.2	:		0.1 0.3	0.1 0.1	0.1 0.3	0.1	0.0
478	weight loss, excl. T06	i p	1699 3840	0.1 0.3	0.1 0.2	0.1 0.3	:	0.1	0.2 0.3	0.1 0.3	0.0 0.2	0.1 0.5	0.4 0.9
479	weight problem NEC	i p	2037 5822	0.1 0.4	0.1 0.1	0.2 0.7	0.1	0.0	0.2 0.4	0.2 0.5	0.2 0.6	0.1 0.6	0.2
480	failure to thrive	i p	1965 4270	0.1 0.3	0.2 0.4	0.1 0.2	0.7 1.4	0.6 1.3	0.1 0.1	*			
481	dehydration	i p	347 975	0.0 0.1	0.0 0.1	0.0	0.0 0.1		0.0	0.0	0.0		0.3 0.8
482	thyroid lump/mass	i p	455 455	0.0 0.0	0.0 0.0	0.1 0.1			•	0.1 0.1	0.0 0.0	0.1 0.1	
483	fear of endocr. metab. nutr. dis.	i p	1188 1699	0.1 0.1	0.0 0.0	0.1 0.2	0.0 0.0	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.2	0.0 0.3	0.1 0.1
484	disability/impairment end. gl.	i p	0 52	0.0		0.0					0.0		•
485	sympt./complt. end./met./nutr. NEC	i p	2449 3811	0.2 0.3	0.1 0.2	0.2 0.3	0.1 0.2	0.6 1.0	0.3 0.5	0.0	0.0	0.1 0.1	
486	infectious dis. endocrine glands	i p	0 10	. 0.0		0.0		:					. 0.0
487	malign. neopl. thyroid	i p	159 837	0.0 0.1	0.0	0.0 0.1			0.0	0.0	0.0 0.1	0.0 0.1	0.3
488	benign. neopl. thryroid	i p	9 51	0.0		0.0 0.0		:		0.0	0.0		
489	unspecified neopl. endocr. NEC	i p	331 916	0.0 0.1	0.0	0.0 0.1			•	0.1	0.1 0.2	0.1	0.0
490	injury thyroid	i p	0 93	0.0	0.0	0.0		•	•		0.0	•	0.1
491	thyroglosal duct(cyst)	i p	238 416	0.0	. 0.0	0.0 0.1	:		0.0	0.0	0.1 0.1	•	. 0.0
492	cong. anom. endocr. NEC	i p	53 445	0.0	0.0	0.0	0.1 0.1	0.1	0.0	0.0			
493	goiter/module w/o thyrotox	i p	784 3350	0.1 0.2	0.0 0.1	0.1 0.4		0.0 0.0	0.0 0.0	0.1 0.1	0.1 0.4	0.1 0.8	. 0.4
494	obesity/overweight	i p	20265 84663	1.4 5.8	0.6 2.7	2.1 8.8	0.1	0.7 1. 2	1.5 3.9	1.9 6.4	1.7 10.5	1.0 7.9	0.6 4.9
495	hyperthyrroidism/thyrotoxicosis	i p	2210 18829	0.2 1.3	0.0 0.3	0.3 2.2	0.2	0.0 0.0	0.1 0.3	0.2 1.0	0.2 1.8	0.1 3.2	0.1 5.8

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
471	i p	0.1 0.1	0.2 0.2		0.1 0.1			0.0	0.1 0.1	0.0	**	0.2 0.2	0.1 0.1		9
472	i p	0.2 0.2	0.2 0.2	0.0	0.1 0.1		0.0 0.0	0.0	0.0 0.3		0.1		•		
473	i p	0.5 0.6	0.2 0.4	0.0 0.1	:	•	0.2 0.2	0.0	0.0 0.1	0.1 0.1	0.1 0.1	0.3	0.0 0.5	0.3 0.5	0.0 0.4
474	i p	1.8 2.8	1.5 2.3	0.3 0.5	0.1 0.2		2 . 0		*		·				· ·
475	i p				•	0.2 0.2	0.1 0.3	0.2 0.2	0.1 0.3	0.1 0.3	0.0 0.5	0.7	0.6	0.4 0.4	0.3 1.9
476	i p	0.3 0.5			0.0 0.1	*	0.1 0.2	0.0	0.1	0.1 0.1	0.1	0.0	0.3		0.0
477	i p		*	*			0.3 0.5	0.0	0.1 0.2	0.1 0.1	0.1 0.4		0.2	0.1	cur cur
478	i p			0.1		0.3 0.3	0.1 0.3	0.1 0.2	0.2 0.4	0.0 0.1	0.0 0.3	0.2 0.5	0.1 0.5	0.9 · 1.2	0.2 0.8
479	i p		0.2		0.0	0.1 0.1	0.3 0.7	0.1 0.2	0.4 0.7	0.1 0.2	0.3 1.0	0.1	0.1 1.0		0.3
480	i p	1.0 1.8	0.5 1.0	0.7 1.6	0.4 1.0	0.1 0.2	0.0						•		7. * 5. *
481	i p	0.1 0.2	0.0				. 0.0	. 0.1	0.0	0.1 0.1	:			0.1 0.2	0.4 1.1
482	i p		:		:			0.0	0.1 0.1		0.0		0.2 0.2		•
483	i p		0.0 0.1	0.0	•	0.0	0.1 0.1	0.0	0.2 0.2	0.1 0.1	0.2 0.3	0.1 0.1	0.0 0.5		0.2 0.2
484	i p				:				•		0.0		*	•	e E
485	i p	0.2 0.2	0.1 0.2	0.4 0.6	0.9 1.4	0.3 0.6	0.3 0.4	0.0	0.1 0.1	0.0	0.0	0.1 0.1	0.0 0.1		•
486	i p				:			:							0.0
487	i p	•	:			0.0	0.0	0.0	0.1	0.0	0.1 0.2	0.0	0.1 0.2	0.1	0.4
488	i p							:	0.0		0.0				5• 50°
489	i p		981					0.0	0.1	0.1 0.2	0.1 0.2		0.2	•	0.0
490	i p									0.0	:				0.2
491	i					•	0.0		0.0 0.1		0.1 0.2		æ.	0.0	ē
492	p i	0.1 0.1	0.1		0.2	0.1		0.0	0.1			·			
493	p i p				0.1 0.1	. 0.0	0.0 0.1	. 0.0	0.1 0.3	0.0 0.3	0.1 0.6	0.1 0.1	0.2 1.4		0.7
494	i p	0.0	0.3	0.4 0.5	1.0 1.9	0.6 1.5	2.4 6.4	0.7 3.0	3.1 9.8	0.6 5.2	2.7 15.6	0.9	1.1 11.4	0.7 2.4	0.5 6.2
495	i p	. 0.3	. 0.1	0.0		0.1 0.2	0.2	0.0	0.4 1.9	0.6	0.3 3.0	1.1	0.2 4.9	, 1.1	0.2 8.3

no.	episode		totals abs.	/1000 pe rs .	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
496	hypothyroidism/myxedema	i p	1068 21860	0.1 1.5	0.0 0.5	0.1 2.5	0.3	0.1	0.1 0.2	0.1 0.8	0.1 2.8	0.1 4.6	0.0 5.5
497	hypoglycemia	i p	1925 3489	0.1 0. 2	0.1 0.2	0.2 0.3		0.0 0.0	0.0 0.1	0.1 0.2	0.2 0.3	0.3 0.4	0.7 1.2
498	renal glucosuria	i p	100 289	0.0 0.0	0.0	0.0 0.0	•		0.0 0.0	0.0 0.0	0.0	0.0 0.0	
499	diabetes mellitus	i p	13087 175879	0.9 12.0	0.8 9.3	1.0 14.6	0.0 0.3	0.1 1.0	0.3 2.3	0.4 3.7	1.4 16.9	3.4 49.1	3.2 63.5
500	vitamin defic./nutr. dis. NEC	i p	1690 20239	0.1 1.4	0.1 0.9	0.1 1.8	0.0 0.5	0.1 0.3	0.1 0.2	0.1 0.8	0.1 1.7	0.3 4.9	0.6 6.7
501	gout	i p	6605 17617	0.5 1.2	0.6 1.7	0.3 0.7			0.1 0.1	0.2 0.6	0.8 2.0	1.6 3.9	1.9 5.8
502	lipid metabolism dis.	i p	2201 23130	0.2 1.6	0.2 1.8	0.1 1.3		0.1 0.1	0.0 0.2	0.2 1.3	0.3 3.9	0.2 4.0	1.3
503	dis. thyroid NEC	i p	757 5944	0.1 0.4	0.0 0.1	0.1 0.7	0.0	0.0 0.4	0.0	0.0 0.2	0.1 0.7	0.2 1.5	0.9
504	dis. endocr. gland NEC	i p	1274 7899	0.1 0.5	0.0 0.2	0. 2 0.8	0.0	0.0 0.1	0.1 0.6	0.2 0.6	0.0 0.8	0.5	0.0 0.6
505	metabolic disease NEC	i p	1486 13078	0.1 0.9	0.1 0.6	0.1 1.1	0.4 1.3	0.0 0.4	0.1 0.3	0.1 0.5	0.0 1.0	0.2 2.5	0.2 3.5

T ENDOCRINE/METABOLIC/NUTRITIONAL

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
496	i p	0.0	0.6		0.2	0.1	0.1 0.3	0.0 0.1	0.2 1.4	0.0 0.8	0.2 4.7	3.2	0.1 5.6	1.8	0.0 7.4
497	i p				0.0	0.1	0.1 0.1	0.1 0.2	0.1 0.2	0.2 0.3	0.1 0.2	0.2 0.2	0.5 0.5	0.2 0.3	0.9 1.6
498	i p						0.1 0.1	0.0	0.0		0.0	0.0 0.1			*
499	i p	0.4	0.0 0.1	0.0 1.2	0.1 0.8	0.2 2.4	0.4 2.1	0.5 4.3	0.4 3.1	1.1 14.4	1.6 19.4	3.1 39.4	3.7 56.5	3.7 50.8	2.9 70.2
500	i p	0.5	0.1 0.5	0.0 0.1	0.1 0.5	0.1 0.3	0.0 0.1	0.1 0.6	0.1 1.0	0.0 1.2	0.2 2.2	0.6 3.0	0.1 6.3	0.7 5.7	0.5 7.2
501	i p					0.0	0.1 0.1	0.3 1.2	0.1 0.1	1.2 3.4	0.5 0.7	2.8 5.8	0.7 2.4	2.6 7.4	1.6 4.9
502	i p			0.0	0.1 0.1	0.0 0.1	0.2	0.4 1.8	0.0 0.7	0.2 4.5	0.3 3.3	0.1 3.8	0.3 4.2	1.8	1.0
503	i p	: •	0.0	0.1	0.1 0.7		0.0		0.1 0.4	0.1 0.2	0.1 1.2	0.3 0.7	0.2 2.0	. *	1.4
504	i p	0.0	0.0	0.0 0.1	0.0 0.1	0.4	0.3 0.9	0.2	0.3 1.0	0.0 0.3	0.1 1.3	0.2	0.7	0.0	0.7
505	i p	0.6 1.0	0.2 1.5	0.0 0.2	0.0 0.6	0.4	0.1 0.2	0.1 0.5	0.1 0.5	0.0	0.0 1.4	0.3 1.9	0.1 3.0	2.1	0.4 4.3

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
506	complaints urination	i p	6117 10600	0.4 0.7	0.5 0.8	0.3 0.6	0.3 0.4	0.4 0.6	0.3 0.5	0.3 0.4	0.5 0.8	0.9 2.1	0.9 2.2
507	incontinence (excl. P12)	i p	4672 54669	0.3 3.7	0.1 1.6	0.5 5.8	0.2	0.0 0.3	0.1 0.5	0.2 1.0	0.5 2.8	1.0 9.2	1.5 38.6
508	anuria/oliguria	i p	44 44	0.0 0.0	0.0	0.0 0.0	:			0.0 0.0			0.0 0.0
509	complaints of urine	i p	2742 4430	0.2 0.3	0.2 0.4	0.1 0.2	0.1 0.1	0.1 0.1	0.0 0.1	0.2 0.3	0.3 0.4	0.5 0.9	0.5 1.0
510	sympt./complt. bladder NEC	i p	1043 3399	0.1 0.2	0.0 0.2	0.1 0.3	0.0	0.1 0.1	0.0 0.1	0.0 0.1	0.1 0.2	0.0	0.2 1.1
511	sympt./complt. kidney	i p	224 620	0.0 0.0	0.0 0.0	0.0 0.1		0.0 0.0	0.0	0.0 0.0	0.0 0.0	0.2	
512	fear of urinary diseases	i p	460 781	0.0 0.1	0.0 0.0	0.0 0.1	•	· ·	0.0 0.0	0.0 0.1	0.1 0.1	0.2	
513	disability/impairment urinary syst.	i p	12 32	0.0	0.0	0.0 0.0				0.0 0.0	•		*
514	sympt./complt. urin. syst. NEC	i p	209 1198	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.1	0.0		0.1	0.0 0.1	0.3	0.2
515	acute pyelonefritis/pyelitis	i p	4246 5237	0.3 0.4	0.1 0.2	0.5 0.5		0.1	0.4 0.5	0.2 0.3	0.4	0.5	0.6
516	cystitis/urinary inf. NEC	i p	170350 189740	11.6 12.9	3.7 4.3	19.3 21.3	8.6 9.7	6.7 7.3	9.8 10.3	10.2 10.9	12.9 14.6	19.7 24.3	25.1 29.0
517	non-specific urethritis	i p	4846 5654	0.3 0.4	0.5 0.6	0.1 0.2	0.1 0.1	0.1 0.1	0.5 0.6	0.4 0.5	0.4 0.4	0.2 0.3	0.3 0.3
518	malign. neoplasm kidney	i p	108 2592	0.0 0.2	0.0 0.1	0.0 0.2	0.1	0.0	0.0	0.0 0.1	0.3	0.1 0.7	0.5
519	malign. neoplasm bladder	i p	643 3987	0.0 0.3	0.1 0.5	0.0 0.1			• 91	0.0	0.4	0.3 1.3	0.5 1.8
520	malign. neoplasm urinary tract NEC	i p	297 835	0.0 0.1	0.0 0.1	0.0 0.1	•	0.0		0.0	0.0 0.1	0.0 0.2	0.1
521	benign. neoplasm urinary tract	i p	186 513	0.0 0.0	0.0 0.0	0.0 0.0			:	0.0 0.0	0.0 0.0	0.1 0.1	0.1 0.3
522	unspecified neopl. urin. tract	i p	213 1007	0.0 0.1	0.0 0.1	0.0 0.0				0.0	0.0 0.1	0.0 0.4	0.2 0.3
523	injury urinary tract	i p	169 188	0.0 0.0	0.0 0.0	0.0 0.0		0.0	0.0 0.0		0.0 0.0	•	
524	cong. anom. urinary tract	i p	97 1232	0.0 0.1	0.0 0.1	0.0 0.1	0.0 0.2	0.0 0.2	0.1	0.0 0.1	0.0 0.1	0.0	
525	glomerulonephritis/neph rosis	i p	555 3895	0.0 0.3	0.0 0.3	0.0 0.3	0.1	0.1 0.1	0.1	0.0 0.1	0.0 0.5	0.1 0.5	0.1 0.7
526	orthostatic albuminuria	i p	126 190	0.0 0.0	0.0	0.0 0.0		:	0.0	0.0	0.0 0.0		. 0.1
527	urin, calculus, all types/sites	i p	8419 16766	0.6 1.1	0.8 1.5	0.4 0.8		0.1 0.1	0.3 0.4	0.6 1.4	1.1 2.2	1.0 1.7	0.4 0.8
528	abnormal urine test/findings NOS	i p	1295 3436	0.1 0.2	0.1 0.2	0.1 0.3	0.1	0.1 0.2	0.0 0.2	0.1 0.2	0.1 0.2	0.0 0.2	0.5 0.9
529	dis. urinary system NEC	i p	4921 24304	0.3 1.7	0.2 1.4	0.4 1.9	0.1 0.5	0.1 0.3	0.1 0.6	0.2 0.7	0.5 2.2	0.6 4.2	1.6 9.4

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
506	i p	0.2 0.3	0.4 0.4	0.4 0.5	0.5 0.6	0.2 0.4	0.3 0.6	0.2 0.2	0.4 0.6	0.8 1.2	0.1 0.4	1.9 3.7	0.1 0.9	1.7 3.7	0.5 1.4
507	i p	0.1	0.2	0.0 0.2	0.0 0.5	0.0 0.3	0.1 0.8	0.1 0.6	0.3 1.5	0.2 1.0	0.8 4.6	0.6 4.4	1.3 12.9	0.7 23.0	2.0 46.9
508	i p				:				0.0		•		•	0.1 0.1	
509	i p		0.1 0.1	0.1 0.1	0.0	0.0	0.1 0.1	0.2 0.3	0.2 0.2	0.3 0.6	0.2 0.2	1.0 1.6	0.1 0.3	0.7 1.2	0.3 0.8
510	i p		0.1 0.1	0.0	0.1		0.0	0.0	0.1	0.1	0.1 0.2	1.0	0.0	1.3	0.4 1.0
511	i p			:	0.1 0.1	*	0.1	0.0	0.0 0.1	0.0	0.1 0.1	0.2	0.1		
512	i p	*	*			0.0	0.0	0.0	0.0 0.1	0.1 0.1	0.0		0.4		
513	i p	•	•				*	0.0	0.0		:	÷			
514	i p	0.2 0.2			0.0	•	Ē.	0.1	0.1	0.1 0.1	0.0 0.1	0.3	0.2		0.3
515	i p			0.1 0.1	0.1 0.1	0.0	0.8 0.9	0.1 0.2	0.4 0.4	0.3 0.3	0.4 0.4	0.1 0.4	0.8 1.1	0.2	1.0
516	i p	4.5 4.9	12.8 14.7	2.4 2.6	11.1 12.1	1.3 1.3	18.6 19.7	2.6 2.8	18.2 19.3	4.9 5.7	20.7 23.4	8.4 11.1	28.5 34.4	13.2 16.3	31.4 35.7
517	i p	0.2 0.2		0.3 0.2	:	0.7 0.8	0.3 0.4	0.7 0.8	0.1 0.1	0.5 0.6	0.2 0.3	0.2 0.3	0.2 0.2	0.3 0.5	0.2 0.2
518	i p	0.1			0.1		0.1	0.0 0.1	0.1	0.4	0.3	0.4	0.2 0.8	0.5	0.5
519	i p					•		0.0	•	0.7	0.1	0.4 2.6	0.1 0.3	1.4 4.0	0.0 0.6
520	i p				0.1 0.1				0.0	0.0	0.0 0.1	0.3	0.1 0.1	0.2	0.2
521	i p								0.0	. 0.1	0.0	0.1	0.1 0.2	0.3 0.6	0.1
522	i p				•	•		0.0		0.0 0.1	0.0	0.0 0.7	0.2	0.3	0.3 0.4
523	i p				0.1 0.1	0.1 0.1	0.0			0.0	0.0				
524	i p	0.1 0.4		0.1	0.0 0.2	0.1	0.1	0.0	0.1	0.0	0.1		0.0		
525	i p	0.1	•	0.1 0.1	0.1	0.1	0.0	0.0 0.1	0.1 0.2	0.0 0.6	0.0 0.5	0.2 0.8	0.3	0.4	0.2 0.9
526	i		*			0.1 0.1		0.0			0.0	£	140	:	0.1
527	p i			0.2 0.2	0.1	0.3	0.3 0.4	0.7 1.7	0.5 1.1	1.6 2.9	0.6 1.5	1.8 3.0	0.3 0.8	0.4 1.0	0.4
528	p i				0.1	0.5	0.0	0.1	0.1	0.1	0.1		0.1 0.3	0.5 0.6	0.5 1.1
529	p i p	0.1 0.5	0.0 0.2 0.5	0.0 0.1 0.4	0.4 0.1 0.3	0.2 0.1 0.4	0.2 0.2 0.9	0.2 0.2 0.5	0.3 0.4 1.0	0.3 0.5 2.2	0.1 0.4 2.2	0.2 0.5 3.8	0.3 0.7 4.5	0.8 0.9 11.4	1.9 8.4
	۲	0.0				- * *			-						

no.	episode		totals	/1000	sex		age						
			abs.	pers.	male	female	0-4	5-14	15-24	25-44	45-64	65-74	≥75
530	question of pregnancy (excl. W02)	i p	3410 3968	0.2 0.3		0.5 0.5			0.4 0.5	0.5 0.6	0.0 0.0		
531	fear of being pregnant	i	2044	0.1		0.3			0.5	0.1	0.1		
		р	3052	0.2		0.4			0.6	0.2	0.1		
532	ante-partum bleeding	i	1395	0.1		0.2		0.1	0.2	0.2			
		р	1691	0.1		0.2		0.1	0.3	0.2	•		•
533	vaginal discharge in pregn.	i	1167	0.1		0.2			0.1	0.2			
		р	1148	0.1		0.2	*		0,1	0.2			
534	vomiting/nausea of pregn.	i	622	0.0	,	0.1			0.1	0.1	*		
		р	1280	0.1	*	0.2	*	•	0.2	0.2	•		ē
535	wanted pregnancy	i	3887	0.3	•	0.5	•		0.4 0.6	0.6 1.3	0.0		
		р	7396	0.5		0.9						•	•
536	morning-after pill	i	2070	0.1	*	0.3	•	0.1 0.1	0.5 0.7	0.1 0.3	0.0 0.1	•	•
		р	3418	0.2	·	0.5	•						
537	fam. plan./oral contraceptive	i	42773	2.9	*	5.7	•	0.2	9.9 98.7	3.6 53.1	0.3 7.2		*
		р	516121	35.2	•	68.7	•	1.1					
538	fam. plan./IUD	i	6135	0.4		0.8	•	•	0.3	1.1	0.1	•	
		р	22261	1.5	•	3.0		•	1.0	4.0	0.3	•	•
539	fam. plan./sterilization 9	i	3328	0.2		0.4	•	•	0.1	0.6	0.0	•	•
		р	5457	0.4	•	0.7	•	•	0.2	1.1	0.1	5*1	
E40	form plan NEC 0	i	1889	0.1		0.2		0.1	0.2	0.3	0.0		
540	fam. plan. NEC 9	р	10310	0.1 0.7		1.4		0.1	0.2	1.5	0.4		•
					•			0.1			•••		•
541	sub-/infertility \$	i p	3749 11592	0.3 0.8		0.5 1.5			0.4 0.8	0.6 2.0	0.1		
							•	·			0	ė	
542	heavy post-partum bleeding	i p	450 688	0.0 0.0		0.1 0.1	•	•	0.1 0.1	0.1 0.1	•	•	
					•		•	•			•	•	•
543	complt. post partum NEC	i	789 1303	0.1 0.1	•	0.1 0.2			0.0 0.1	0.2 0.3		1.00	
		р					•	•				•	•
544	sympt./complt. lactation	i	872 2151	0.1 0.1		0.1 0.3	•	-	0.1 0.1	0.1 0.4	9	•	•
		р	2131	U. I	•	0.3		•	U. I	0.4	•	1.07	
545	sympt./complt. breast in pregn. NEC	i	745	0.1		0.1			0.1	0.1			
343	sympt./compit. broast in progn. NEO	p	1163	0.1		0.1		•	0.1	0.2	·		
EAC	stating delivery	i	387			0.1			0.0	0.1			
546	starting delivery	p	643	0.0 0.0		0.1	•	·	0.0	0.1			
E 4.7	fear of complic of pregn./deliv.	:					•				0.0		
547	rear of complic of pregn./deliv.	p	901 1495	0.1 0.1	•	0.1 0.2		•	0.1 0.1	0.1 0.3	0.0		
540	1: - 1: 114 - 15	-						-				15	-
548	disability/impairment Pr/D/Pu/Fp	i p	0 12	0.0		0.0	*	•		0.0		*	
F 40	D-/D/D /F NEO						•				•		
549	sympt./complt. Pr/D/Pu/Fp NEC	i p	1410 2489	0.1 0.2		0.2 0.3	*	•	0.2 0.2	0.2 0.4	0.0		*
		Р		U.E	•		•	•					
550	infect. dis. urinary tr. pregn./puerp.	i	2871	0.2		0.4	_	_	0.3	0.5	2		_
550	and the triang in prograppions.	p	3200	0.2	,	0.4	*		0.3	0.5			
551	infect. dis. pregn. NEC	i	2300	0.2		0.3		_	0.4	0.3	2	-	
001	and die. progra NEO	p	2641	0.2	:	0.4			0.4	0.3			
552	malign, neoplasm pregn.	i	0										las.
002	mangii, noopiaam piegii.	p	3	0.0		0.0				0.0			
550	honian noonloom progr	i	56	0.0		0.0				0.0			
553	benign. neoplasm pregn.	p	56	0.0		0.0			•	0.0		2	•
E	injuries complication are	·		- · ·			1290	*		-		**	***
554	injuries complicating pregn.	i p	0 0					:	:		•		
		Р	v			•	5.5				•		

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
530	i p						0.9 1.0		1.0 1.2		0.0		*		
531	i p						1.0 1.3	•	0.3 0.5		0.1 0.3	•	:	•	*
532	i p				0.1 0.1		0.5 0.5		0.3 0.4					•	
533	i p						0.2 0.2	*	0.4 0.4					•	
534	i p						0.2 0.4		0.1 0.3	*		*			
		•	•	•			0.9		1.2						
535	j p	:			•		1.2		2.4	•	0.1 0.0				1.0
536	i p				0.1 0.2	:	1.0 1.4		0.3 0.6	ě	0.1	•			
537	i p				0.5 2.2		19.9 198.7	•	7.4 107.7		0.6 13.9		·		*
538	i p			•			0.7 2. 0		2.2 8.3	•	0.1 0.5	•	ř		
539	i p						0.3 0.3	:	1.1 1.9	•	0.0 0.1)@7 :•8		6 0 0
540	i				0.3		0.3	,	0.5	•	0.1 0.9		in.		10
541	p i				0.3	•	0.8		3.0			*			1.07
542	p i						1.6 0.1		0.1		0.1	•			
543	p i						0.2 0.1		0.2 0.3						*
544	p i						0.1 0.1		0.5 0.3		•		•		
	р	•	•		į		0.2		0.8	(*,		·	*		•
545	i p						0.2 0.3		0.2 0.4			:			•
546	i p						0.1 0.1		0.1 0.2					•	•
547	i p						0.2 0.2		0.3 0.5				*	,	
548	i p								0.0						
549	i p						0.4 0.4		0.4 0.9		0.0	*			
550	i		-				0.6		1.0		Ne"	•	•		
	р		:		*		0.7		1.0	•		•			a a
551	i p						0.9	•	0.7	ě	(*	•			
552	i p								0.0	•					
553	i P	•			.ec	•	•		0.0			3 . €		•	*
554	i p		:	•		•						•			

no.	episode		totals	/1000	sex		age						
			abs.	pers.	male	female	0-4	5-14	15-24	25-44	45-64	65-74	≥75
555	cong. anom. of mother/complic. pregn.	i	144	0.0	•	0.0				0.0	-		
		р	376	0.0	•	0.0		*	•	0.1	3		1
556	non-obst. cond. complic. pregn. NEC	i	2181	0.1	•	0.3		*	0.2	0.4		*	
		p	3266	0.2	•	0.4	•	*	0.2	0.6		•	*
557	pregnancy: confirmed	i	46480	3.2		6.2		0.0	5.1	7.3	0.1		• *
		р	69407	4.7	•	9.3	•	0.1	7.2	11.0	0.1	•	
558	unwanted pregnancy: confirmed	i	2388	0.2	•	0.3			0.3	0.3	0.0		
		р	3003	0.2	•	0.4	•	•	0.4	0.4	0.0		*
559	ectopic pregnancy	i	911	0.1		0.1	•		0.1	0.1 0.2		•	
		р	1284	0.1	z. •	0.2		·	0.1	0.2			
560	toxemia/(pre)eclampsia	i	473	0.0	•	0.1			0.0	0.1			
		р	1491	0.1		0.2			0.2	0.2			
561	abortion, imminens/spontan.	i	5414	0.4		0.7		0.0	0.5	0.9			
		p	7600	0.5	•	1.0	•	0.0	0.7	1.2	0.0	*	*
562	abortion, (il)legally induced	i	1259	0.1		0.2		0.1	0.2	0.2			*
		p	2399	0.2		0.3	•	0.1	0.4	0.3	•		•
563	pregnancy, high risk	i	4966	0.3		0.7		0.0	0.4	8.0			
		p	12438	8.0	*	1.7	*	0.0	0.9	2.2	•	•	ě
564		i	9241	0.6		1.2	×	•	0.9	1.5		*	4
		р	0	*		•		•			•	•	
565	normal delivery dead born(s)	i	128	0.0		0.0				0.0			
		р	0										
566	complicated delivery live born	i	4027	0.3	-	0.5			0.4	0.6	0.0		
		р	0										
567	complicated delivery dead born	i	284	0.0		0.0		7		0.1		¥	
		р	0		•		•		•	•			
568	normal puerperium	i	19759	1.3	•	2.6		0.1	1.2	3.5	•		141
		p	26363	1.8	•	3.5		0.1	1.8	4.6			•
569	mastitis puerperalis	i	2646	0.2		0.4			0.2	0.5	•		
	44 4 4 4	p	2871	0.2	•	0.4	el .		0.2	0.5	•		
570	dis. of breast puerperium NEC	i	1539	0.1		0.2			0.2	0.2			
		p	2056	0.1		0.3	5.0		0.2	0.3			(5) (#)
571	complic, puerperium NEC	i	3191	0.2		0.4			0.3	0.5			
1		p	4323	0.3		0.6			0.3	0.8			
572	diseases Pr/D/Pu NEC	i	2052	0.1		0.3			0.2	0.3			
		p	3495	0.2		0.4	*		0.2	0.6			

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
555	i						3.02		0.1				•		
	р				•		1.00	X (0.1	•	•		•		
556	i		,				0.4	٠	0.8		•		•	*	•
	р	*	•	•	.#0		0.3	•	1.3			•	•	•	•
557	i					•	10.2	•	14.8 22.3	•	0.1 0.1	*	•		
	р			•	0.1	. *	14.5	(*)		•			•	•	•
558	i	.*0				. *	0.7 0.9		0.7 0.8		0.0				
	р		<u> </u>	,		•				·					
559	i	•	*	•	•	•	0.2 0.2		0.3 0.5						
	р	•	•	•		•	10.2								
560	i						0.1		0.2	· ·					
300	p			•	·		0.3		0.5						
561	i				0.0		1.0		1.8					4.	
301	p		,		0.0		1.4		2.5			*	*	•	
562	i				0.1		0.3		0.3			*	,		*
002	p p				0.1		0.9		0.5		0.0		•	•	
563	i				0.0		0.9	965	1.7	. `					
	p		*	•	0.0		1.8	•	4.5						
564	i						1.9		3.0					*	
	p		•				•	•		•	•	•			148
565	i						eri •\		0.1						*
303	p											340			
566	i						0.7		1.2		0.0			•	
300	р											3.5		*	*
567	i								0.1			1		- 2	
	p			•	•	10						4.®	21	*	iv.
568	i				0.1		2.5		7.0				*		•
	р	•			0.1	×2	3.6		9.3	7	•		**		•
569	i		88.		0.0	•	0.3		1.0	3				-	
	р		•		0.0	•	0.3		1.1	•	•	•			
570	i						0.5		0.4		•				
	р			•		*	0.5		0.7		•	•	•		•
571	i						0.6		1.1		•	₹			
•	p						0.7		1.5	*			•	•	
572	i						0.3		0.7		(*)				
	p	- :					0.5		1.2				•		

no.	episode		totals abs.	/1000 pers,	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
573	genital pain \$	i p	214 327	0.0	*	0.0 0.0	si.		0.0 0.0	0.0 0.1			0.0
574	menstruation absent/scanty	i p	5929 9607	0.4 0.7		0.8 1.3	•	0.0 0.1	1.2 1.9	0.6 1.0	0.0 0.1	•	
575	menstruation excessive	i p	14227 23868	1.0 1.6		1.9 3.2		0.2 0.3	1.2 1.8	1.6 2.8	1.1 1.9		
576	menstrual pain	i p	12100 27158	0.8 1.9		1.6 3.6		0.7 1.2	2.2 4.8	1.0 2.3	0.1 0.6		
577	sympt./complt. menstruation NEC	i p	15493 23381	1.1 1.6	•	2.1 3.1	*	0.1 0.2	2.3 3.2	1.7 2.6	0.5 1.0		· ·
578	premenstrual symptoms	i p	1938 3837	0.1 0.3	*	0.3 0. 5	•	0.0	0.2 0.3	0.2 0.5	0.1 0.2	3	
579	sympt./complt. menopausal	i p	14721 45565	1.0 3.1		2.0 6.1	•			0.5 1.1	4.0 12.8	0.2 2.1	0.0 0.2
580	postmenopausal bleeding	i p	1016 1767	0.1 0.1		0.1 0.2			*	0.0 0.0	0.3 0.4	0.1 0.3	0.2 0.4
581	painful intercourse \$	i p	2523 3940	0.2 0.3		0.3 0.5			0.5 0.7	0.2 0.3	0.1 0.2		0.0 0.0
582	postcotal bleeding	i P	1238 1284	0.1 0.1		0.2 0.2	:		0.1 0.1	0.2 0.2	0.0 0.0		<u>v</u>
583	vaginal discharge	i p	11699 15507	0.8 1.1		1.6 2.1	0.1 0.1	0.1	1.4 2.3	1.3 1.6	0.5 0.6	0.3 0.3	0.1 0.2
584	sympt./complt. vagina NEC	i p	3417 6285	0.2 0.4		0.4 0.8	0.2 0.3	0.2 0.2	0.3 0.4	0.3 0.4	0.3 0.6	0.1 0.4	0.1
585	sympt./complt. vulva	i p	2782 3918	0.2 0.3		0.4 0.5	0.0 0.0	0.1 0.1	0.4 0.5	0.1 0.2	0.2 0.3	0.1 0.4	0.0 0.2
586	sympt./complt. pelvis \$	i p	144 411	0.0 0.0		0.0 0.1	0.0 0.0		0.0	0.0 0.1	0.0 0.0	0.0 0.0	0.0
587	lump/mass mamma ¥	i p	2112 2812	0.1 0.2		0.3 0.4			0.1 0.2	0.2 0.3	0.2 0.2	0.2 0.2	
588	pain mamma \$	i p	4883 6459	0.3 0.4		0.7 0.9			0.3 0.4	0.6 0.8	0.3 0.4	0.2 0.3	0.1 0.1
589	sympt./complt. mamma NEC \$	i p	14642 19287	1.0 1.3		2.0 2.6	0.1 0.1	0.3 0.4	1.1 1.4	1.8 2.3	0.8 1.1	0.3 0.5	0.2 0.5
590	postponement of menstruation	i p	14232 17098	1.0 1.2		1.9 2.3	•	0.5 0.6	1.6 2.0	1.5 1.8	0.7 0.9		
591	fear genital/mamma dis. \$	i p	3557 6999	0.2 0.5		0.5 0.9		0.1 0.1	0.1 0.2	0.3 0.7	0.4 0.8	0.2 0.3	0.2 0.4
592	disab./impairm.gen. syst. \$	i p	10 10	0.0 0.0		0.0 0.0				0.0 0.0	:		•
593	sympt./complt. gen. syst. \$	i p	665 1174	0.0		0.1 0.2	0.0	0.0	0.0	0.1 0.2	0.0		, il
594	syphilis (genit. and NOS) 9	i	42 201	0.0		0.0 0.0			0.0 0.1	0.0 0.0			
595	gonorrhea (genit. and NOS) \$	p i p	67 453	0.0 0.0 0.0		0.0 0.1	•	•	0.0 0.1	0.0 0.1			Van
596	veneral dis. NEC \$	i p	2061 2863	0.1 0.2		0.3 0.4			0.3 0.5	0.1 0.2 0.3	0.0 0.0		
597	urogenital candidiasis \$	i p	36813 47156	2.5 3.2	•	4.9 6.3	0.5 0.9	0.2 0.2	4.4 5.3	4.3 5.4	1.4 1.8	0.4 1.0	0.8 1.3

ю.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
573	i						0.0		0.1 0.1			*	٠	:	0.0
	р	**			•	9	0.0	•		•		•	•	-	
74	i			÷	0.0		2.4	•	1.3 2.0	•	0.1 0.2	•	•		•
	p	•	•	•	0.1	•	3.8	٠		•		•	•	•	•
75	i	•			0.4		2.5		3.2		2.3				•
	р	•			0.6	•	3.7	*	5.7	1.00	3.8	•	•	•	•
76	i				1.5	3	4.5	*	2.1	3 3 0.	0.3	•	•	•	•
	р				2.5	•	9.8	*	4.8	•	1.2	•	•	•	
77	i				0.2		4.7	•	3.5		1.1		•	•	
	р	•			0.5	•	6.5		5.2	•	2.0		•		
78	i				•:		0.4		0.5		0.2	¥	ž		
	р		•	÷	0.0	•	0.6	•	1.1	•	0.4			•	
79	i							50	1.1		8.0		0.4	•	0.0
	р	•				*	•		2.2	•	25.2	•	3.8	•	0.4
80	i								0.0		0.5		0.2		0.2
-	p							•	0.0		8.0		0.5	•	0.6
81	i	-					1.1		0.4		0.2	•			0.1
٠.	p p			,			1.4		0.7	•	0.4			•	0.1
82	i		_	_			0.2	•	0.4	•	0.0				
-	p						0.2	36	0.4	0.6	0.0	•		•	
83	i		0.2		0.2		2.9	(#)	2.6		0.9		0.5		0.2
	р		0.2		0.2		4.6		3.2	•	1.2		0.5	•	0.3
84	i		0.3		0.3		0.6	7.0	0.6		0.4		0.2		0.2
•	р	:	0.6		0.3		8.0		0.9		1.2	•	0.7		0.6
85	i		0.0		0.2		0.9		0.3		0.5		0.1		0.0
00	p	:	0.0		0.2		0.9	•	0.5		0.6		0.7	•	0.3
86	i		0.0						0.0	14	0.0	•:	0.0		
00	p		0.0				0.0		0.1		0.0		0.0	•	0.1
07	i						0.3		0.5		0.3		0.3		
87	р			•			0.4	•	0.7		0.3	٠	0.3		
88	i						0.6		1.3		0.6		0.4		0.2
	p p	·				j.	8.0	*	1.7		0.7		0.6		0.2
89	i		0.2		0.6		2.2		3.7		1.6		0.5		0.4
03	p		0.2		0.7		2.8		4.8		2.2	*	8.0		0.7
90	i	-			1.0		3.3		3.1		1.3		•		
3 U	p				1.1		4.0		3.7		1.7		(4)		
0.4		-	-	(49)	0.1		0.3		0.6		0.9		0.2		0.3
91	i	•	•		0.1		0.5		1.5		1.6		0.3		0.6
	P		٠			•									
92	i				•	•			0.0	*		•			
	р	·	·				· · · · · · · · · · · · · · · · · · ·								
93	i		0.1		0.0		0.0	*	0.2 0.4				d # C Vari	*	ř.
	р	•	0.1	•	0.0	*	0.1			•				•	•
94	i		•		•	*	0.0	•	0.0	•	•	*	9.60	*	
	р	•	•	•	*		0.1	•	0.0	•	•	*	**	•	•
95	i						0.0	•	0.0	ě	*	*	•	•	•
	р		*	,	•		0.1		0.1	•	•	•	•	•	÷
96	i	-					.0.7		0.5	•	0.1	•	•	•	*
	р			•	•		1.0	•	0.6	•	0.1	*	•	*	
597	i		1.1		0.3		8.9		8.8		2.7		0.6		1.2
	p p		1.9		0.5		10.7		11.1		3.6	*	1.8		2.0

no.	episode		totals	/1000 pers.	sex male	female	age 0-4	5-14	15-24	2 5-44	45-64	65-74	≥75
598	urogenital trichomoniasis ?	i	3866	0.3		0.5			0.5	0.3	0.3		
599	pelvic inflammatory disease	p i	4557 4426	0.3	<u>.</u>	0.6 0.6		:	0.7 0.5	0.4 0.5	0.3 0.2	0.1	4
000	power interminatory dioceso	p p	6729	0.5		0.9		0.0	0.7	0.9	0.2	0.2	0.2
600	carcinoma in situ cervix	i p	238 1150	0.0 0.1		0.0 0.2	÷	·		0.0 0.2	0.0	0.1	0.0 0.0
601	cervix carcinoma NEC	i	192	0.0		0.0				0.0	0.0		0.1
602	mal. neopl. mamma ¥	p i	1834 2849	0.1 0.2	*	0.2 0.4	•	·	0.0	0.1 0.1	0.3 0.5	0.4 0.5	0.2 0.9
002	was roops marinia +	p	23595	1.6		3.2		· ·	0.0	0.7	3.2	4.6	7.7
603	mal. neopl. genit. syst. ?	i	988	0.1		0.1		•		0.0	0.2	0.4	0.0
604	fibroid/myoma (uterus/cervix)	p i	6137 3711	0.4	•	0.8 0.5	٠	•	•	0.1 0.6	0.9	1.6 0.0	1.5 0.1
004	noroid/myoma (dierus/cervix)	р	10318	0.7		1.4			0.0	1.4	1.1	0.2	0.1
605	ben. neopl. mamma ?	i	3074 4713	0.2 0.3	*	0.4 0.6	•	0.1 0.1	0.3 0.5	0.3 0.5	0.1 0.2	0.1	
606	ben. neopl. genit. syst. ♀	p i	2465	0.2		0.3		0.0	0.2	0.4	0.1	0.0	0.1
000	bon. noops. gome syste v	p	4379	0.3		0.6		0.0	0.2	0.6	0.2	0.4	·
607	unspec. neopl. genit. syst. 9	i	973 2076	0.1 0.1		0.1			0.0 0.1	0.1	0.1 0.3	0.1	
	*	Р	2076	0.1	•	0.3				0.2		0.2	•
608	injury genit. syst./mamma 9	i p	346 945	0.0 0.1		0.0 0.1	0.1 0.1	0.0 0.0	0.0 0.1	0.1	0.0 0.0		
609	cong. anom. genit. syst./mamma 9	i	24	0.0		0.0	0.0						
		р	562	0.0		0.1	0.1	0.0	0.1	0.0	0.0	•	
610	vaginitis/vulvitis NOS	i p	13668 20678	0.9 1.4		1.8 2.7	0.2 0.2	0.5 0.5	1.5 1.9	1.4 2.0	0.7 1.2	0.2 1.0	0.4 1.4
611	cervicitis/cerv. dis. NEC	i	2877	0.2		0.4			0.2	0.4	0.1	0.1	
	ă.	р	5145	0.4	•	0.7			0.4	0.7	0.2	0.1	•
612	abnormal PAP-smear	i	675	0.0	* ;	0.1				0.1	0.1	0.0	
		р	4074	0.3		0.5	•		0.1	0.6	0.4	0.1	•
613	uterovaginal prolapse	i	7823	0.5		1.1			0.1	0.5	0.9	1.3	1.6
		р	32130	2.2	o.ē.	4.3	•		0.1	1.2	3.2	6.7	12.5
614	cystic breast (chronic)	i p	4619 6671	0.3 0.5		0.6 0.9		0.1 0.2	0.2 0.3	0.6 0.8	0.3 0.5	0.0 0.1	•
615	premenstrual tension syndrome	i	2698	0.2		0.4			0.2	0.4	0.1		*
		р	4379	0.3		0.6			0.2	0.7	0.1		
616	gardnerella infection	i	2635	0.2		0.4	•		0.4	0.3	0.1		*
617	infaction/shages at Portholini	p ;	4284 1427	0.3	•	0.6	•	•	0.6 0.0	0.5 0.2	0.3		
617	infection/abscess gl. Bartholini	i p	1830	0.1 0.1		0.2 0.2	:	• (£)	0.0	0.3	0.1 0.1		0.1
618	endometriosis	i	1349	0.1		0.2			0.1	0.2	0.0		
		р	3466	0.2	•	0.5		•	0.2	0.5	0.2	0.1	
619	atrophial vaginae/vulvae	i n	2769 7405	0.2 0.5		0.4 1.0		•	0.0	0.0 0.0	0.5 1.1	0.6 1.7	0.7 2.1
620	dis. genital syst./mamma NEC 9	p i	6047	0.3	181	0.8	•	0.3	0.6	0.0	0.1	0.2	
U2U	alo. goriilai oyou/maiimia NEO 4	р	10556	0.7		1.4	0.1	0.4	0.7	1.3	0.4	0.2	0.7

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
598	i						1.1 1.4		0.7 0.8		0.6 0.6				
	p	•	•	•	•	•			1.1		0.3		0.2		
599	i p	•			0.0		1.1 1.4		1.7		0.5	•	0.3		0.3
600	i	·	·						0.1		0.0		ia:		0.1
000	p	·						,	0.4		0.1		0.3		0.1
601	i								0.0	140	0.1				0.1
	р	•				*	•		0.1	•	0.6	٠	0.7	*	0.4
602	i						0.0		0.3		1.1		0.9		1.8
	р	3	•	•	•	•	0.1		1.4		6.3	¥	8.1	•	11.8
603	i								0.0		0.3		0.6		0.0
	p		•		•	¥	•	*	0.3	•	1.8		2.9		2.2
604	i				3			•	1.2 2.8	•	0.6 2.2	,	0.1 0.3		0.1 0.8
	р					•	0.0	•		3•3	0.3	*		•	
605	i p	٠			0.1 0.1		0.7 1.1		0.7 1.1		0.3		0.2		0.2
					0.1		0.3		0.8		0.1		0.0		
606	i p				0.1		0.4		1.2		0.5		0.7		ě
607	i						0.1		0.2		0.3		0.1		
301	p				•		0.2		0.3	3.01	0.5		0.3		
808	i		0.2		0.0		0.1				0.1				
	р		0.2		0.0		0.3	*	0.2		0.1				*
609	i		0.0					,							8
	р	•	0.2	×	0.0		0.2		0.1	• '	0.0	8	*	•	
610	i		0.3		1.0		3.1	•	2.8	*	1.3	*	0.4		0.5 2.1
	р	•	0.3	*	1.0		3.8	•	4.0	•	2.3	•	1.7	•	2.1
611	i		*				0.5		0.8 1.5	•	0.2 0.4		0.1 0.2	•	•
	р	•	٠		•		8.0	•		•		•		•	,
612	i		•	*	÷	•	0.2	•	0.2 1.2	5.00	0.2 0.8		0.1 0.1	•	
	р				•		0.2		1.2	•		•		· · · · · · · · · · · · · · · · · · ·	
613	i						0.1		1.1		1.8		2.2		2.5
	р		¥ E		100	•	0.1	•	2.5	•	6.4	•	11.9	•	19.1
614	i				0.1		0.4		1.2		0.7		0.0		
	р				0.2		0.5	٠	1.7	•	1.1	•	0.2	•	
615	i		•		<u>.</u>	*	0.3	•	0.9	•	0.1 0.2		•		
	р	*	•	9		•	0.5		1.5	•					,
616	i		. •	•	[8]		0.8 1.1		0.6 0.9		0.2 0.5		*		
	p	•		*	187	•						*	€	,	
617	i p				•		0.1 0.1		0.4 0.5	*	0.3 0.3				0.2
							0.1		0.5		0.1				
618	i p	•			•		0.1	(%) (*)	1.1		0.3	•	0.1		
640		•	•	•	, = 1			•	0.0		1.0		1.1		1.0
619	i p						0.1		0.1		2.2		3.1		3.2
620		•	-		0.7		1.1	v a c	1.5		0.3	:	0.4		
620	i p		0.2		0.8		1.5		2.6		0.7		0.6		1.1

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
621	sympt./complt. gen. syst. ರ	i p	3550 4781	0.2 0.3	0.5 0.7		0.4 0.4	0.3 0.4	0.2 0.2	0.2 0.3	0.3 0.4	0.1 0.2	0.1 0.3
622	discharge penis/urethra	i p	244 244	0.0 0.0	0.0 0.0					0.0 0.0		0.1 0.1	
623	sympt./complt. prostate	i p	494 1242	0.0 0.1	0.1 0.2					0.0 0.0	0.0 0.2	0.1 0.2	0.3 0.7
624	sympt./complt. potency	i p	961 2182	0.1 0.1	0.1 0.3				0.0 0.0	0.0 0.1	0.2 0.4	0.0 0.5	
625	sympt./complt. sexual dysf. o	i p	498 1000	0.0 0.1	0.1 0.1	:	•		0.0	0.1 0.1	0.0 0.1	0.1 0.2	0.0
626	sub-/infertility &	i p	930 2208	0.1 0.2	0.1 0.3			•	0.0	0.2 0.4	ı.		
627	fam. plan. &	i p	4979 5968	0.3 0.4	0.7 0.8				0.1 0.1	1.0 1.1	0.1 0.1		
628	sympt./complt. mamma ♂	i p	905 921	0.1 0.1	0.1 0.1	· ·	•	0.2 0.2	0.2 0.2	:	0.0 0.0	0.1 0.1	
629	fear dis. gen. syst./mamma ♂	i p	1244 1753	0.1 0.1	0.2 0.2			•	0.1 0.2	0.1 0.2	0.1 0.1	0.2 0.2	
630	disab./impairm. gen. syst./mamma ਰਾ	i p	0 69	0.0	0.0	•							0.1
631	sympt./complt. gen. syst./mamma NEC &	i p	742 832	0.1 0.1	0.1 0.1			0.0	0.1 0.1	0.1 0.1	w (*)		
632	syphilis o''	i p	207 310	0.0 0.0	0.0 0.0			:		0.0 0.0	0.0	0.0	
633	gonorrhea &	i p	1731 1787	0.1 0.1	0.2 0.2				0.5 0.4	0.1 0.1	0.0 0.0	0.0	0.1 0.1
634	venereal disease NEC &	i p	653 906	0.0 0.1	0.1 0.1				0.0 0.0	0.1 0.1	0.0		
635	urogenital trichomoniasis o	i p	413 761	0.0 0.1	0.1 0.1		•	0.0 0.0	0.0 0.0	0.0 0.1	0.0 0.1	0.0	
636	prostatitis/seminal vesiculitis	i p	4236 7468	0.3 0.5	0.6 1.0		*		0.1 0.2	0.3 0.5	0.5 1.0	0.4 0.9	0.7 1.1
637	orchitis/epididymitis	i p	4865 5752	0.3 0.4	0.7 0.8		•	0.1 0.2	0.3 0.3	0.6 0.6	0.3 0.4	0.3 0.4	0.2 0.4
638	infection gen. syst. NEC &	i p	9160 10942	0.6 0.7	1.3 1.5		1.4 1.7	0.5 0.5	0.5 0.7	0.7 0.9	0.6 0.7	0.3 0.3	0.4 0.7
639	malign. neopl. prostate	i p	840 6260	0.1 0.4	0.1 0.9						0.1 0.2	0.3 2.2	0.5 4.2
640	malign. neopl. testis	i p	232 918	0.0 0.1	0.0 0.1		•	0.0	0.0 0.0	0.0 0.1	0.0	0.0 0.3	0.0
641	malign. neopl. gen. syst. NEC &	i p	13 276	0.0 0.0	0.0					0.0	. 0.0	0.0 0.0	. 0.3
642	benign. neopl. gen. syst. &	i p	196 301	0.0 0.0	0.0 0.0				0.0 0.0	0.0 0.0	0.0	0.0	0.1 0.1
643	unspecif. neopl. gen. syst. &	i p	380 402	0.0 0.0	0.1 0.1				0.0 0.0	0.0 0.0	0.0 0.0	0.1 0.1	0.1 0.1
644	unspecif. neopl. mamma ฮ	i p	440 475	0.0 0.0	0.1 0.1			0.1 0.1	0.0 0.0	0.0 0.0	0.0 0.0	0.1 0.1	
645	injury gen. syst./mamma ್	i p	1169 1205	0.1 0.1	0.2 0.2		0.1 0.1	0.2 0.2	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1	· ·

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 mal e	≥75 female
621	i p	8.0 8.0		0.7 0.9		0.4 0.5		0.4 0.6		0.6 0.8		0.2 0.4		0.4 0.9	
622	i p							0.1 0.1				0.2 0.2		9 <u>4</u>	
623	i p				•			0.0		0.1 0.3		0.2 0.4		0.9 1.9	
624	i					0.1 0.1		0.1		0.4		0.0 1.2			
625	p i							0.1		0.0		0.2		•	
	Р	•		1.00	•	0.1	•	0.2	•	0.2	•	0.5	•	0.0	•
626	i p			•		0.1	•	0.4 0.8		•	•				
627	i p			•		0.1 0.2		1.9 2.2		0.1 0.3					
628	i p			0.3 0.3		0.3 0.3				0.1 0.1		0.2 0.2			
629	i				•	0.2 0.3	•	0.3 0.3		0.1 0.2		0.4 0.5			
630	p i p			*					·				•	0.3	· ¥
631	i p		•	0.1 0.1		0.1 0.1	:	0.2 0.3		4	4		:		
632	i p		:		•			0.1 0.1		0.1					
633	i					0.9 0.8		0.2		0.1	•	0.0		0.2 0.2	*
634	p i					0.1		0.2		0.1					
635	p i p			0.1 0.1		0.1 0.1 0.1		0.1 0.1		0.0	·	0.1 0.1			
636	i i					0.2	·	0.6		1.1		1.0		2.0	
	р				÷	0.4	·	0.9		2.1		2.0	*	3.1 0.6	** **
637	i p	· 8:		0.2 0.3		0.5 0.6		1.1 1.2		0.6 0.8	•	0.8 1.0	•	1.1	
638	i p	2.8 3.2		0.9 1.0		1.0 1.3		1.4 1.7		1.3 1.4		0.7 0.8		1.1 1.9	
639	i p						•			0.1 0.5		0.7 4.9		1.3 11.9	š
640	i p			0.0		0.1 0.1		0.0 0.1	•	0.1		0.1 0.8		0.1	
641	i p	•				:		0.0		0.0		0.0		0.9	
642	i					0.0		0.0	*		(*)		v.E	0.3	×
643	p i					0.0		0.0		0.1		0.1	•	0.3	
644	p i			0.3		0.1		0.0		0.1		0.2 0.2		0.3	ž
	р	0.2	Ĭ.	0.3		0.0	•	0.0	•	0.0		0.2 0.2			
645	i p	0.2		0.3		0.3		0.1		0.1		0.2			

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	2 5-44	45-64	65-74	≥75
646	nhimonia/radund nannua						0.7	0.6	0.1	0.1	0.1		
646	phimosis/redund. prepuce	p	2689 3901	0.2 0.3	0.4 0.5		1.5	0.6 0.8	0.1 0.1	0.1 0.1	0.1 0.1	0.0	0.1 0.1
647	hypospadia	i	0			7•1					•		
		р	208	0.0	0.0		0.2	0.0	8.0	**			
648	undesc. testicle/cryptorchism	i	1596	0.1	0.2		0.4	0.5	0.1	0.0			
		р	2420	0.2	0.3		0.5	0.9	0.1	0.0			
649	cong. anom. gen. syst./mamma NEC &	i	260	0.0	0.0			0.0				•	
		р	370	0.0	0.1			0.0	0.0	0.0	0.0		
650	benign prostatic hypertrophy	i	2080	0.1	0.3					0.0	0.2	0.8	0.9
		р	6691	0.5	0.9	•			*	0.0	0.5	2.6	3.1
651	hydrocele	i	1526	0.1	0.2		0.2	0.1	0.0	0.1	0.2	0.1	0.1
	•	р	1896	0.1	0.3	•	0.3	0.1	0.0	0.1	0.2	0.1	0.2
652	dis. gen. syst./mamma NEC ರ	i	4024	0.3	0.6		0.1	0.7	0.4	0.1	0.2	0.1	0.2
		р	5926	0.4	0.8		0.2	0.7	0.6	0.2	0.3	0.7	0.3

Y MALE GENITAL SYSTEM (INCLUDING BREAST)

no.		0-4 male	0-4 female	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
646	i	1.5		1.2		0.2		0.2		0.1				0.2	÷
	р	2.9		1.7		0.2	•	0.2		0.2		0.1		0.2	
647	i				•								•	*	
	р	0.3		0.1		*	•		•	•		*		•	
648	i	8.0		1.0		0.2		0.0			•				•
	р	1.0		1.8		0.2	•	0.0		•	•	•		*	•
649	i			0.1						2.00			÷		
	р	•		0.1	•	0.0	-	0.1	•	0.1				•	•
650	i							0.0		0.3		1.9		2.6	
	р						•	0.0	•	1.0	•	6.1	•	9.0	
651	i	0.5		0.2		0.0		0.2	•	0.4		0.1		0.3	
	p	0.7		0.2		0.1		0.2		0.4		0.3		0.4	
652	i	0.2		1.3		0.9	٠.	0.3		0.4		0.3		0.5	
- 34	p	0.3		1.5	•	1.2		0.4	•	0.6		1.7		0.9	•

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
653	poverty/financial probl.	i p	1699 3934	0.1 0.3	0.2 0.3	0.1 0.2			0.1 0.1	0.1 0.4	0.3 0.5	0.0 0.1	0.3 0.3
654	problem food/water	i p	39 89	0.0 0.0		0.0 0.0		¥ •	:	0.0 0.0			0.1
655	probl. housing/neighborh.	i p	3645 10716	0.2 0.7	0.2 0.5	0.3 1.0	0.0 0.2	0.1	0.3 0.8	0.2 0.7	0.3 0.7	0.6 1.6	0.5 2.1
656	probl. house moving	i p	1580 7980	0.1 0.5	0.1 0.4	0.1 0.7	0.1 0.1	0.1 0.1	0.2 0,6	0.0 0.5	0.1 0.5	0.2 0.9	0.5 1.8
657	fear of having a social probl.	i p	191 534	0.0 0.0	0.0 0.0	0.0 0.0		uj.	0.0	0.0 0.0	0.0 0.1		•
658	probl. working conditions	i p	2935 7956	0.2 0.5	0.3 0.7	0.1 0.4			0.3 0.6	0.2 0.9	0.4 0.7	. 0.3	:
659	probl. job/employment NEC	i p	9011 20422	0.6 1.4	0.7 1.6	0.5 1.1			0.7 1.5	1.0 2.2	0.9 2.2	0.2	
660	probl. w. being unemployed	i p	638 2119	0.0 0.1	0.1 0.2	0.0 0.1			0.1 0.1	0.1 0.3	0.0 0.2	:	
661	probl. w. education	i p	3507 7183	0.2 0.5	0.2 0.4	0.3 0.6		0.9 1.3	0.7 1.4	0.0 0.2	0.0 0.1		
662	probl. soc. insurrance/welfare	i p	1778 5379	0.1 0.4	0.2 0.5	0.1 0.2	0.0 0.0	0.0	0.0 0.1	0.1 0.5	0.3 0.9	0.1 0.2	0.1 0.1
663	probl. legal/police	i p	130 906	0.0 0.1	0.0	0.0		:	0.0	0.0	. 0.1		•
664	probl. health care syst./access	i p	2705 6088	0.2 0.4	0.2 0.3	0.2 0.5	0.3 0.5	0.0 0.0	0.1 0.2	0.1 0.4	0.3	0.2 0.9	0.5 0.6
665	probl. soc./cultural syst.	i p	1463 6113	0.1 0.4	0.2 0.5	0.0 0.3	0.1 0.1	0.1 0.1	0.2 0.6	0.1 0.7	0.1 0.4	0.0 0.0	
666	relation problems partners	i p	13535 28576	0.9 1.9	0.7 1.3	1.2 2.6	•	0.0 0.1	0.6 1.0	1.5 2.9	1.1 3.1	0.9 1.9	0.7 1.8
667	problems w. behaving partner	i p	950 3125	0.1 0.2	0.0 0.1	0.1 0.3	:		0.1	0.1 0.3	0.1 0.4	0.1 0.2	0.1
668	probl. w. partner being ill	i p	6600 22276	0.4 1.5	0.4 1.1	0. 5 1.9		. 0.0	0.1 0.1	0.4 1.1	0.9 2.9	1.2 4.5	1.2 4.8
669	probl. loss of partner	i p	9818 39445	0.7 2.7	0.5 1.4	0.9 3.9		0.1 0.1	0.2 0.4	0.5 1.7	1.3 4.5	1.3 8.5	2.3 10.1
670	relation probl. with child	i p	9171 16677	0.6 1.1	0.3 0.5	1.0 1.7	0.8 2.0	0.4 0.8	0.2 0.3	0.7 1.1	1.0 1.8	0.7 1.3	0.6 0.9
671	probl. behaving child	i p	2012 3415	0.1 0.2	0.1 0.1	0.2 0.4		0.1 0.2	0.0	0.2 0.4	0.2 0.3	0.1 0.1	
672	probl. with child being ill	i p	1563 6218	0.1 0.4	0.1 0.2	0.1 0.6	0.0 0.0	0.1	0.1	0.1 0.6	0.1 0.7	0.4 0.7	0.2 0.5
673	loss or death of child	i p	1640 4355	0.1 0.3	0.0 0.2	0.2 0.4	0.0	·	0.1 0.2	0.1	0.1	0.1 0.4	0.4 0.8
674	relation probl. parent/other family	i p	9089 21014	0.6 1.4	0.4	0.9	0.3 0.7	0.2 0.9	0.7 1.6	0.6 1.5	0.9	0.7 1.7	0.3 1.3
675	probl. w. behaving parent/other family		586 1013	0.0 0.1	0.0	0.0	0.1	0.1 0.1		0.0	0.1 0.1	0.1 0.1	0.1 0.1
676	probl. w. parent/other family being ill	i p	3128 9232	0.2 0.6	0.1 0.3	0.3 1.0	0.1 0.3	0.2	0.1 0.5	0.2 0.7	0.4	0.3 0.6	0.4 0.6
677	loss parent/family	i p	5505 14109	0.4 1.0	0.2 0.6	0.5 1.3	0.1 0.6	0.1 0.2	0.2 0.8	0.4 1.2	0.5 1.2	0.5 0.8	0.9 1.6

no.		0-4 male	0-4 femal e	5-14 male	5-14 female	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
653	i p	:				0.0	0.1 0.1	0.2 0.5	0.1 0.3	0.5 0.7	0.0 0.3		0.0 0.2	0.2 0.2	0.4 0.4
654	i p	:	:•:	•					0.0				•	:	0.1
655	i p	0.1 0.1	0.2	0.1	0.0	0.4 0.6	0.2 1.0	0.1 0.4	0.3 1.0	0.3 0.6	0.3 0.8	0.4 0.9	0.7 2.1	0.7 1.6	0.4 2.4
656	i p	0.2 0.3		0.2 0.2	0.0	0.2 0.3	0.1 0.9	0.0 0.4	0.0 0.6	0.1 0.5	0.0 0.6	0.3 0.5	0.1 1.2	0.6 1.5	0.4 2.0
657	i p	:	•		•	0.0	0.1	0.0	0.0 0.0	0.1 0.1	0.0				
658	i p	:				0.2 0.5	0.4	0.4	0.1 0.7	0.5 1.0	0.2	0.5	. 0.0		
659	i p	:				0.4	1.0 1.8	1.4	0.7 1.6	1.2 2.7	0.5 1.6	0.2	0.3		
660	i p			*	*	0.1 0.1	0.0 0.2	0.2 0.3	0.0 0.2	0.0 0.2	0.2				
661	i p	*		1.1 1.5	0.6 1.2	0.3 0.7	1.0 2.1	0.0 0.2	0.0 0.2	0.1	0.0 0.1				
662	i p		0.0 0.0	•	0.1	0.0 0.2	0.0	0.2 0.7	0.1 0.3	0.3 1.2	0.3 0.5	0.2 0.3	0.0 0.1	0.0 0.0	0.1 0.1
663	i	•	٠	Ŀ		0.0	. 0.0	0.0	0.0	. 0.1	0.0	ika po	•		
664	p i p	0.4 0.7	0.2 0.3	0.1	0.0 0.0	0.2	0.0	0.1 0.4	0.1 0.4	0.1 0.2	0.5 1.0	0.5 0.8	0.0	0.2 0.2	0.6 0.8
665	i p	0.2	0.0	0.2 0.2	0.0	0.3 0.7	0.1 0.4	0.1 0.6	0.1 0.7	0.2 0.7	0.0 0.2	0.1 0.1			
666	i p		.		0.1 0.2	0.1 0.5	1.1 1.6	1.0 1.8	2.1 4.1	1.0 2.1	1.2 3.9	0.8 1.8	0.9 2.0	1.0 1.8	0.6 1.7
667	i p			:			0.1	0.0 0.1	0.2 0.7	0.1 0.3	0.1 0.5	0.1 0.2	0.1 0.2	0.1	0.1
668	i		•			0.1	0.1	0.3 0.7	0.4 1.4	0.7 2.0	1.0 3.8	1.1 2.7	1.3 5.8	1.8 6.6	0.8
669	p i			. 0.0	0.0 0.1 0.3	0.1 0.2	0.2 0.3 0.6	0.7 0.4 1.1	0.6	0.9 2.4	1.6 6.6	0.8 4.4	1.7 11.7	2.5 7.6	2.3 11.5
670	p i p	0.6 1.4	1.0 2.5	0.2 0.5	0.6 1.1	0.2 0.4	0.1 0.3	0.1 0.3	1.2 2.0	0.6	1.5 2.6	0.1 0.2	1.1 2.1	0.1	0.8
671	i p				0.2	*	0.1	0.1	0.3	0.2	0.2 0.4	0.1	0.1 0.1		:
672	i p	0.0		0.2			0.2	0.0 0.1	0.2 1.1	0.1 0.5	0.2 0.9	0.5 0.8	0.3 0.6	0.2 0.3	0.2 0.6
673	i		0.0			0.0	0.3	0.0 0.2	0.2	0.1 0.2	0.2 0.5	0.2	. 0.5	0.2	0.5 0.8
674	p i	0.0	0.1 0.3 1.0	0.2 0.9	0.2 0.9	0.1 0.4 1.1	0.3 1.0 2.1	0.5 0.8	0.8 2.1	0.4 1.2	1.3 2.4	0.1 0.9	1.2 2.3	0.0	0.5 1.6
675	p i	0.4		0.9 0.1 0.1	0.9 0.0 0.1			0.0 0.1	0.0		0.1 0.1		0.1 0.1	o.o	0.2 0.2
676	p i	0.1 0.1	0.2 0.4	0.1 0.1	. 0.4	0.0 0.3	0.2 0.7	0.1 0.4	0.1 0.3 1.1	0.1 0.3	0.8 1.6	0.4 0.5	0.3 0.7	0.2 0.2	0.6 0.8
677	p i	0.1	0.4 0.2 0.2	0.1 0.1 0.1	0.4 0.1 0.3	0.3 0.2 0.8	0.7 0.2 0.9	0.4 0.2 0.8	0.6 1.5	0.1 0.4	0.9 2.1	0.3 0.6	0.7 1.0	0.7 0.9	1.0 1.9

no.	episode		totals abs.	/1000 pers.	sex male	female	age 0-4	5-14	15-24	25-44	45-64	65-74	≥75
678	loss or death of friend	i p	352 1413	0.0 0.1	0.0 0.1	0.0 0.1	•		0.1 0.1	0.0 0.1	0.0 0.1	0.1 0.4	0.1 0.1
679	relation probl. w. friend	i p	787 1140	0.1 0.1	0.0 0.0	0.1 0.1		0.0	0.0 0.0	0.1 0.1	0.1 0.1	0.2 0.2	0.0 0.1
680	probl. assault/harmfull events	i p	1950 4394	0.1 0.3	0.1 0.1	0.2 0.5	0.1 0.1	0.2 0.2	0.2 0.5	0.1 0.4	0.1 0.1	0.1 0.3	0.1
681	probl. with being ill	i p	525 2720	0.0 0.2	0.0 0.1	0.0 0.2		:	0.0	0.1 0.1	0.1 0.3	0.0 1.0	0.0 0.1
682	social handicap	i p	747 2460	0.1 0.2	0.0 0.1	0.1 0.2	0.0	0.1	0.1 0.1	0.1 0.2	0.0 0.2	0.0	0.1 0.5
683	social isolation	i p	2483 14286	0.2 1.0	0.1 0.5	0.2 1.5			. 0.1	0.1 0.2	0.1 0.8	0.7 3.3	1.6 9.7
684	social problems	i p	3683 13608	0.3 0.9	0.2 0.6	0.3 1.2	0.1 0.7	0.1 0.2	0.2 0.7	0.2 1.0	0.4 1.0	0.2 1.5	0.8 2.2

no.		0-4 male	0-4 female	5-14 male	5-14 femal e	15-24 male	15-24 female	25-44 male	25-44 female	45-64 male	45-64 female	65-74 male	65-74 female	≥75 male	≥75 female
678	i					0.1		0.0			0.0	0.0	0.1	0.1	0.1
0.0	р		•			0.1	0.1	0.1	0.1	0.0	0.2	0.0	0.6	0.1	0.1
679	i						0.0	0.0	0.1	0.1	0.0	0.4		5 • %	0.1
0.0	p				0.0		0.1	0.0	0.2	0.1	0.1	0.4	0.0	(*)	0.1
680	i	0.0	0.2	0.1	0.2	0.0	0.4	0.0	0.2	0.1	0.1		0.2	(0)	
000	p	0.0	0.2	0.2	0.2	0.1	1.0	0.1	0.7	0.1	0.2		0.5	0.4	
681	i							0.0	0.1	0.1		0.0			0.1
	p		,				0.0	0.0	0.2	0.4	0.2	0.7	1.2	100	0.1
682	i					0.1	0.1	0.1	0.1	0.0	*				0.1
	р	0.0			0.1	0.1	0.1	0.2	0.3	0.2	0.2	0.1	0.0	0.1	0.7
683	i							0.0	0.1	0.1	0.0	0.4	1.0	2.1	1.4
000	p					0.0	0.1	0.2	0.3	0.6	0.9	1.4	4.6	5.4	11.9
684	i	0.1	0.1	0.1		0.2	0.1	0.1	0.4	0.5	0.3	0.0	0.3	0.6	8.0
004	p	0.4	0.9	0.4	0.0	0.4	1.0	0.6	1.4	8.0	1.1	0.3	2.5	2.4	2.2

17:12

A.4 BASIC TABLE B: MORBIDITY IN GENERAL PRACTICE BY URBANIZATION DEGREE, REGION, SEASON AND INSURANCE MODE

(not standardized for age and sex)

no.	episode		degree of	urbanization			region			
			rural	suburban	urban	city	north	centre	south	
001	pain: generalized/unspec.	i p	0.3 5.6	0.2 2.6	0.3 2.4	0.3 2.9	0.4 9.9	0.3 3.0	0.2 2.2	
002	chills/fever	i p	0.8 1.0	0.6 0.8	0.4 0.6	0.4 0.6	0.7 0.8	0.5 0.7	0.8 1.0	
003	general weak-/tiredness	i P	1.6 4.5	2.6 5.6	2.8 5.5	2.6 6.0	2.2 4.7	2.4 5.7	2.3 4.4	
004	fainting (syncope)	i p	0.9 1.1	0.9 1.1	0.9 1.1	0.5 0.7	1.0 1.3	0.7 0.9	1.1 1.4	
005	symptoms infant	i p	0.1 0.2	0.2 0.2	0.2 0.2	0.3	0.2 0.2	0.2 0.2	0.1 0.2	
006	allergy NEC	i p	3.2 6.5	2.5 5.3	2.4 5.1	3.3 9.4	2.6 5.8	3.2 6.8	2.0 4.3	
007	feeling/behaving old/senile	i p	0.2 1.2	0.2 1.1	0.1 1.4	0.6 4.3	0.2 1.9	0.2 1.6	0.1 1.3	
800	fear of disease/death	i p	0.4 1.1	0.4 1.2	0.6 1.4	0.5 1.4	0.5 1.3	0.5 1.1	0.6 1.4	
009	disability/impairment NOS	i p	0.0 0.2	0.0 0.1	0.0 0.2	0.1	0.0 0.1	0.0 0.1	0.0 0.3	
010	general sympt./complt. NEC	i p	0.8 1.9	1.2 2.0	1.6 2.6	1.0 1.9	0.9 2.1	1.1 1.8	1.5 2.8	
011	tuberculosis, general, excl. lung	i p	0.0 0.1	0.0	0.0 0.1	0.1	0.1	0.0 0.1	0.0 0.1	
012	measles	i p	0.3 0.3	0.2 0.2	0.2 0.2		0.0 0.1	0.2 0.2	0.2 0.2	
013	chickenpox	i p	0.6 0.6	0.6 0.7	0.5 0.6	0.7 0.8	0.7 0.8	0.5 0.6	0.8 0.9	
014	malaria	i p	0.0 0.0	0.0 0.0	0.0 0.0	0.1 0.1	0.0 0.0	0.0 0.0	0.0	
015	rubella	i p	0.8 0.9	1.3 1.3	0.5 0.6	0.6 0.6	0.3	1.1 1.2	0.6 0.6	
016	infectious mononucleosis	i p	0.6 0.9	0.3 0.7	0.4 0.7	0.6 0.8	0.7 0.9	0.4 0.8	0.4 0.7	
017	viral dis. with exanthems NEC	i p	0.5 0.5	0.6 0.6	0.5 0.6	0.3 0.4	0.6 0.7	0.4 0.5	0.6 0.7	
018	viral dis. NOS/NEC	i p	5.3 5.5	7.2 7.7	6.0 6.4	3.1 3.3	7.8 8.1	5.6 6.0	5.6 6.0	
019	infectious dis. NOS/NEC	i p	0.1 0.3	0.3 0.5	0.2 0.5	0.1 0.2	0.2 0.5	0.2 0.4	0.2 0.4	
020	carcinomatosis (prim. site unkn)	i p	0.1 0.3	0.0 0.2	0.2 0.3	0.1 0.3	0.1	0.1 0.3	0.0	
021	accident/injury NOS	i p	0.9 1.4	0.6 1.0	0.8 1.3	0.7 1.4	0.9 1.6	0.7 1.1	0.8 1.4	
022	mult. trauma/internal injury	i p	0.0 0.0	0.0 0.0	0.0		0.0 0.0	0.0 0.0	0.1 0.1	
023	late effects of trauma	i p	0.2 0.5	0.1 0.4	0.2 0.5	0.3 0.9	0.1 0.5	0.1 0.4	0.3 0.8	
024	poisoning by/abuse of med. agents	i P	0.1 0.2	0.1 0.2	0.1 0.4	0.1 0.3	0.0 0.1	0.1 0.3	0.1 0.2	
025	poisoning by benzodiazepines	i p		0.0 0.0	0.0	•	0.0 0.0	0.0 0.0		

no.		season		a. d. me -	winter	type of insu public	rance private
		spring	summer	autumn			•
001	i	0.2	0.3 5.5	0.3 3.2	0.3 2.9	0.3 4.4	0.2 2.3
000	p i	2.6 0.4	0.6	0.8	0.6	0.5	0.6
002	p P	0.5	0.8	1.0	0.9	8.0	0.6
003	i	3.2	1.6	2.1	2.4	2.6	1.8
	P	6.0	4.5	4.3	6.0	5.8	4.4
004	i	0.7 0.9	0.6 0.8	1.3 1.5	0.7 1.0	1.0 1.2	0.5 0.6
005	p :	0.9	0.1	0.2	0.1	0.2	0.1
005	i p	0.2	0.2	0.2	0.2	0.2	0.1
			4.4	1.8	2.6	2.9	2.6
006	i p	2.5 4.9	4.4 8.0	4.8	6.7	6.4	5.5
007	i	0.1	0.6	0.1	0.1	0.2	0.3
	р	1.1	2.7	1.4	1.1	1.4	1.6
800	i	0.4	0.5	0.6 1.7	0.5 1.3	0.5 1.4	0.4 0.9
	р	0.8	1.3		0.0	0.0	0.0
009	i P	0.0 0.1	0.1 0.2	0.0 0.1	0.2	0.2	0.1
010	i	0.8	0.9	1.6	1.4	1.3	8.0
0.0	р	1.6	1.7	2.7	2.5	2.3	1.5
011	i		0.0	0.0		0.0	
011	p	0.0	0.1	0.1	0.1	0.1	0.0
012	i	0.3	0.2	0.1	0.2	0.1	0.2
	р	0.3	0.2	0.1	0.2	0.2	0.3
013	i	0.8 0.9	0.4 0.4	0.3 0.3	0.9 1.0	0.7 0.7	0.4 0.5
014	р :			0.0	0.0	0.0	0.0
014	i p		0.0	0.0	0.0	0.0	0.0
015	i	2.3	0.4	0.5	0.3	0.8	0.9 0.9
	р	2.4	0.4	0.5	0.5	0.9	0.9
016	i	0.4	0.3	0.7	0.5	0.5	0.4
J.0	p	0.6	0.5	1.0	0.9	0.7	0.7
017	i	0.7	0.3	0.4	0.5	0.5 0.5	0.5 0.6
	р	0.8	0.4	0.4	0.7	5.8	5.4
018	i p	4.2 4.5	4.1 4.5	6.1 6.3	9.0 9.5	6.1	5.7
019	i	0.2	0.3	0.2	0.1	0.2	0.2
515	p	0.3	0.5	0.5	0.2	0.4	0.3
020	i	0.0	0.2	0.1	0.1	0.1 0.3	0.0 0.2
	р	0.1	0.5	0.2	0.3		V.E
021	i	0.7	0.8	0.9	0.6	0.9	0.4
	р	1.2	1.1	1.5	1.0	1.3	0.9
022	i -	0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	
000	p :	0.1 0.1	0.0	0.3	0.1	0.1	0.2
023	i p	0.1	0.4	0.8	0.6	0.5	0.5
024	i	0.0	0.1	0.1	0.1	0.1	0.0
	р	0.2	0.2	0.3	0.3	0.3	0.2
025	i	•	0.0	0.0	0.0 0.0	0.0 0.0	0.0
	р	•	0.0	0.0	0.0		

no.	episode		degree of	f urbanization			region		
	·		rural	suburban	urban	city	north	centre	south
026	poisoning by med. agents NOS	i p	0.1 0.2	0.1 0.2	0.2 0.3	0.1 0.2	0.1 0.2	0.1 0.2	0.1 0.1
027	adv. eff. med. agent proper dose: all.	i p	0.7 0.9	0.7 0.9	0.7 1.0	0.6 0.8	0.3 0.4	0.7 1.0	0.6 0.8
028	adv. eff. OAC	i p	0.5 0.8	0.5 0.7	0.7 0.9	1.1 1.6	0.7 0.9	0.7 0.9	0.6 0.8
029	adv. eff. med. agent NEC	i p	1.1 2.1	1.1 2.2	1.6 2.6	1.7 2.9	1.4 2.4	1.3 2.3	1.1 2.3
030	toxic eff. other substances	j p	0.1 0.2	0.3 0.5	0.1 0.3	0.1 0.2	0.2 0.2	0.2 0.3	0.2 0.3
031	complic. surg./med. treatm.: hematoma	i p	0.0 0.0	0.1 0.2	0.0 0.0	0.1	0.0 0.1	0.0 0.1	0.1 0.1
032	complic. surg./med. treatm.: wounds	i p	0.1 0.3	0.2 0.4	0.2 0.4	0.1 0.3	0.2 0.4	0.1 0.4	0.2 0.4
033	complic. surg./med. treatm.: NEC	i p	0.0 2.7	0.0 2.6	2.1	0.1 1.6	0.0 2.8	0.0 2.1	0.0 3.0
034	adv. eff. physical factors NEC	i p	0.2 0.7	0.5 0.7	0.3 0.6	0.2 0.6	0.2	0.4	0.2 0.5
035	adv. eff. prosthetic device	j p	0.1 0.2	0.0 0.1	0.2 0.4	0.1 0.1	0.0 0.2	0.1 0.2	0.1 0.2
036	mult.congenital syndromes	i p	0.0 0.1	0.0 0.4	0.0 0.3	0.1	0.0 0.2	0.0 0.3	0.0 0.3
037	abnormal results investigation NEC	i p	0.1 0.1	0.0 0.3	0.1 0.2	0.1 0.2	0.0 0.1	0.1 0.2	0.0 0.1
038	toxoplasmosis	i p	0.0 0.0	0.0 0.0	0.1	0.1		0.0	0.0
039	premat./immature liveborn infant	i p	0.0 0.1	0.0 0.1	0.1 0.1	•	0.0	0.0	0.0
040	all perinatal morbidity	i p	0.1 0.2	0.1 0.1	0.0	0.1 0.1	0.1	0.1 0.2	0.1 0.2
041	perinatal mortality	i p	0.0		•	•		0.0	
042	death (excl. perinatal)	i p	0.8	0.8	1.3	0.6	1.1	0.8	0.9
043	no disease	i p	9.8 16.1	11.5 20.0	10.4 18.2	12.0 20.7	10.4 17.4	9.5 16.1	14.2 24.8
044	disease NEC	i p	0.2 0.4	0.1 0.2	0.1 0.5	1.0 1.5	0.1 0.2	0.3 0.6	0.1 0.3

						type of insu	rance
no.		season spring	summer	autumn	winter	public	private
		• -			0.1	0.1	0.1
026	i	0.1 0.1	0.1 0.2	0.2 0.2	0.3	0.2	0.1
007	p i	0.5	0.5	1.0	0.7	0.6	0.7
027	р	0.6	0.8	1.2	1.0	0.9	0.8
028	i	0.5	0.5	0.9	8.0	0.8	0.4 0.5
	р	0.7	0.7	1.1	1.0	1.1	
029	i	1.7	1.2	1.3	0.9 2.0	1.5 2.8	1.0 1.7
	р	2.6	2.2	2.4		0.2	0.2
030	i	0.2 0.5	0.3 0.4	0.1 0.2	0.1 0.2	0.4	0.2
	р	0.5					
031	i	0.0		0.0	0.1	0.0	0.0
	р	0.2	0.0	0.0	0.1	0.1	0.0
032	i	0.2	0.1	0.2	0.2 0.4	0.2 0.4	0.1 0.2
	р	0.4	0.3	0.4	0.0	0.0	0.0
033	i	0.1 1.6	0.0 2.8	0.0 2.4	2.9	2.5	2.0
	р		0.4	0.2	0.2	0.3	0.3
034	i p	0.5 1.1	1.0	0.3	0.3	8.0	0.5
035	i		0.1	0.2	0.1	0.1	0.1
000	p p	0.0	0.3	0.4	0.1	0.3	0.2
					0.0	0.0	•
036	i	0.0 0.4	0.0 0.1	0.0 0.3	0.2	0.3	0.2
007	p i	0.0	0.1	0.1	0.0	0.1	0.1
037	p	0.1	0.3	0.2	0.2	0.3	0.2
038	i		0.0	0.0			0.0 0.1
	р	0.0	0.1	0.0	0.0	0.0	
039	i		0.0	0.0	0.0 0.1	0.0 0.1	0.1
	р	0.1	0.0	0.1		0.1	0.1
040	i	0.1 0.1	0.0 0.2	0.1 0.3	0.1 0.3	0.2	0.2
	р	U. I	J.E				
041	i		0.0			0.0	•
J	p p		•		*	•	
042	i	1.0	0.7	0.9	1.0	0.6	0.4
	р	•	7₩4	•			9.1
043	i	13.8	10.4	11.1 17.8	7.8 14.1	11.4 19.3	15.9
	р	23.4	18.4	0.5	0.1	0.3	0.2
044	i P	0.0 0.1	0.4 0.7	0.5	0.1	0.5	0.3
	۲	2					

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
045	enlarged lymph gland(s)	i P	0.9 1.1	1.0 1.2	1.1 1.4	0.9 1.2	0.9 1.2	1.0 1.3	0.8 1.0
046	sympt. lymph glands(s) NEC	i p	0.0 0.1	0.0 0.0	0.0 0.1		0.0 0.1	0.0 0.0	0.0 0.1
047	fear of blood/lymph disease	i p	0.2 0.2	0.2 0.3	0.2 0.3	0.5 0.5	0.2 0.3	0.2 0.3	0.1 0.2
048	disability/impairment blood	i p	:			<u>.</u>	:		· ·
049	sympt./complt. blood NOS/NEC	i p	0.0	0.0	0.0 0.0	•	0.0	0.0	0.0
050	acute lymphadenitis/-angitis	i p	0.5 0.5	0.4 0.5	0.9 1.0	0.8 0.7	0.5 0.6	0.6 0.6	0.8
051	chron. aspec. lymphadenitis	i p	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.1 0.1
052	malignant lymphoma	i p	0.0 0.1	0.0 0.2	0.2	0.0 0.1	0.0 0.1	0.0 0.2	0.0 0.1
053	leukemia	i p	0.0 0.3	0.0 0.3	0.0 0.2	0.1 0.3	0.0 0.3	0.0 0.3	0.0 0.2
054	malignant neopl. blood NEC	i p	0.0	0.1 0.2	0.0	0.1 0.2	0.1 0.4	0.1 0.3	0.0 0.2
055	benigne neopl. blood/bloodform.org.	i p	0.0 0.0	0.0 0.0	0.0 0.0		0.0 0.0	0.0 0.0	0.0 0.0
056	ruptured spleen	i p		0.0 0.0					0.0 0.0
057	injuries blood/bloodform.org. NEC	i p	0.0		:		0.0		
058	hered. haemolytic anaemias	i p	0.0 0.0	0.0	0.0 0.0	0.1	0.0 0.0	0.0	0.0 0.0
059	cong. anom. blood/bloodform.org. NEC	i p	0.0	0.0	0.1	0.0 0.1	0.0	0.0	0.0
060	iron deficiency anemia	i p	1.2 6.7	0.8 3.3	1.6 4.1	0.7 3.5	1.4 6.6	1.1 4.5	1.0 4.1
061	pernic./other deficiency anemia	i p	0.1 2.4	0.1 1.4	0.4 2.7	0.0 1.5	0.1 2.7	0.2 2.1	0.2 1.6
062	anemia NOS/NEC	i p	0.5 2.3	0.5 1.5	0.5 1.7	0.7 2.3	0.4 1.6	0.5 2.0	0.6 1.9
063	hemophilia/coagulation disorders	i p	0.1 0.3	0.1 0.3	0.0 0.4	0.2 0.6	0.1 0.7	0.1 0.3	0.0 0.4
064	abnormal white cells	i p	0.0 0.1	0.0	0.0	0.1	0.0	0.0	0.0 0.1
065	unexplained abn. blood test	i p	0.0 0.1	0.0 0.2	0.1 0.1	0.1 0.1	0.0 0.2	0.0 0.1	0.1 0.2
066	abn. blood test NOS	i P	0.0 0.2	0.0 0.2	0.1 0.1	0.1 0.4	0.0 0.3	0.0 0.2	0.1 0.2
067	splenomegaly	i p	0.0	0.0	0.1 0.1	0.1	0.0	0.0 0.0	0.0
068	HIV-infection (AIDS/ARS)	i p		0.0 0.0	0.0	0.1	0.0	0.0	0.0 0.0
069	diseases blood/bloodform.org. NOS/NEC	i p	0.1 0.2	0.1 0.2	0.0 0.4	0.1	0.1 0.3	0.0 0.2	0.1 0.3

						type of insu	ranca	
no.		season spring	summer	autumn	winter	type or insui public	private	
045	i p	0.9 1.0	0.8 1.0	1.2 1.3	1.0 1.4	1.0 1.2	0.9 1.2	
046	i	0.0	0.0	0.0	0.0 0.0	0.0 0.1	0.0 0.1	
047	p i	0.0 0.3	0.1 0.2	0.1 0.2	0.2	0.2	0.2	
	р	0.4	0.2	0.2	0.3	0.3	0.2	
048	i p	:				:	•	
049	i p	0.0 0.0	0.0	0.0 0.0	0.0	0.0 0.0	0.0	
050	i	0.6	0.6 0.6	0.8 0.9	0.4 0.5	0.6 0.7	0.5 0.6	
051	p i	0.6 0.2	0.1	0.1	0.0	0.1	0.1	
	р	0.2	0.1	0.1	0.1	0.1	0.1 0.0	
052	i p	0.1	0.0 0.1	0.1 0.2	0.0 0.2	0.0 0.1	0.1	
053	i	0.0 0.1	0.4	0.0 0.2	0.1 0.4	0.0 0.2	0.0 0.2	
054	p i	0.0	0.1	0.1		0.1 0.3	0.1 0.2	
	р	0.2	0.3	0.3	0.2			
055	i p	0.0 0.0	0.0 0.0	0.0		0.0 0.0	0.0 0.0	
056	i i	•			0.0	0.0	(8)	
057	р	•		•	0.0	0.0	•	
057	i p	•	0.0		•	••		
058	i p	0.0 0.0	0.1	0.0	0.0 0.1	0.0 0.1	0.0 0.0	
059	i		>*C	0.0		0.0 0.0	0.0	
	р	0.0	0.0	0.1	0.0			
060	i	1.2 4.4	1.3 6.4	0.7 3.6	1.1 4.0	1.1 4.9	1.3 4.1	
061	p i	0.1	0.1	0.2	0.2	0.2	0.0	
	p	2.0	2.4	1.9	1.8	2.3 0.4	1.4 0.6	
062	i p	0. 4 2.1	0.5 1.9	0.6 1.9	0.5 1.7	1.7	2.0	
063	i	0 <i>2</i> 0.5	0.1 0.4	0.0 0.3	0.0 0.4	0.1 0.4	0.1 0.3	
064	p i	•			0.0	0.0		
	р	0.0	0.0	0.1	0.0	0.1	0.0	
065	i	0.0 0.1	0.0 0.1	0.1 0.2	0.1 0.2	0.0 0.2	0.1 0.1	
066	p i	0.1	0.0	0.0	0.0	0.0	0.0	
	р	0.2	0.2 0.0	0.2	0.3	0.3	0.1	
067	i p	0.0	0.0	•	0.0	0.0	0.0	
068	i p		:	0.0 0.1	0.0	0.0 0.0	0.0	
069	i	0.0	0.1	0.0	0.1	0.1	0.0 0.2	
	р	0.2	0.3	0.3	0.2	0.3	U.Z	

no.	episode		degree of	f urbanization			region		
	ор.		rural	suburban	urban	city	north	centre	south
070	generalized abd. pain/cramps	i p	1.8 3.3	2.6 3.9	2.0 3.1	1.0 1.5	2.5 3.4	1.7 2.8	2.8 4.3
071	stomach pain	i p	0.7 5.4	0.8 4.0	0.6 3.4	1.0 4.2	0.7 4.1	0.7 4.5	0.9 4.0
072	heartburn	i p	0.3 1.8	0.3 1.1	0.5 1.6	0.0 0.9	0.5 2.9	0.3 1.2	0.5 1.4
073	peri-anal itching	i p	0.3 0.4	0.3 0.5	0.4 0.8	0.2 0.3	0.2 0.3	0.3 0.5	0.4 0.7
074	localised abd. pain	i p	0.5 0.7	0.5 0.8	0.8 1.0	0.7 0.9	0.5 0.8	0.5 0.8	0.7 1.0
075	flatulence/belching	i p	0.2 0.3	0.1 0.2	0.3 0.4	0.2 0.2	0.2 0.2	0.2 0.3	0.1 0.2
076	nausea	i p	0.2 0.6	0.4 0.9	0.2 0.6	0.1 0.1	0.2 1.1	0.2 0.6	0.3 0.6
077	vomiting	i p	0.3 0.5	0.2 0.4	0.1 0.3	0.3 0.5	0.2 0.5	0.2 0.4	0.3 0.5
078	diarrhoea	i p	1.4 2.5	1.1 1.8	1.1 1.8	1.0 1.8	1.1 1.7	1.2 2.1	1.2 1.9
079	constipation	i p	1.2 7.0	1.3 5.6	1.2 5.6	1.4 5.0	1.4 7.0	1.2 6.0	1.3 5.6
080	jaundice	i p	0.0	0.0 0.0	0.0 0.0		0.0	0.0	0.1 0.1
081	blood vomiting	i p	0.0 0.0	0.0 0.0			0.0 0.1	0.0 0.0	0.0 0.0
082	melena	i p	0.1 0.2	0.1 0.3	0.0 0.1	0.2 0.2	0.1 0.3	0.1 0.2	0.1 0.2
083	rectal bleeding	i p	0.1 0.1	0.1 0.2	0.0 0.1	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.2
084	fecal incontinence	i p	0.0 0.1	0.0 0.1	0.0 0.1		0.0 0.1	0.0 0.1	0.0 0.1
085	defecation anomalies NEC	i p	0.2 0.2	0.2 0.2	0.2 0.3	0.4 0.4	0.1 0.3	0.2 0.3	0.2 0.2
086	sympt./complt. of teath, gums	i p	0.3 1.1	0.2 0.4	0.5 0.7	0.2 0.4	0.2 1.0	0.2 0.6	0.5 0.8
087	sympt./complt. mouth, tongue, lip	i p	0.4 0.8	0.5 0.7	0.2 0.6	0.3 0.3	0.4 0.6	0.4 0.7	0.5 0.6
088	swallowing problems	i p	0.2 0.4	0.5 0.6	0.5 0.6	0.2 0.4	0.4 0.6	0.3 0.4	0.4 0.6
089	fear of digestive diseases	i p	0.1 0.1	0.1 0.1	0.2 0.5	0.2 0.5	0.0 0.1	0.1 0.3	0.2
090	digestive disability/impairment	i p	0.0	:					0.0 0.0
091	sympt./complt. digestive NEC	i p	0.3 0.5	0.3 0.4	0.3 0.6	0.1 0.2	0.3 0.6	0.2 0.4	0.3 0.5
092	infectious diarrhoea/dysentery	i p	0.3 0.4	0.5 0.6	0.3 0.4	0.5 0.8	0.3 0.4	0.5 0.6	0.2 0.2
093	mumps	i p	1.3 1.3	0.8 0.8	0.5 0.5	0.5 0.5	0.3 0.3	1.0 1.1	0.6 0.6
094	infectious hepatitis	i p	0.0 0.1	0.0 0.1	0.1 0.1	0.2	0.1	0.0 0.2	0.0 0.1

20		season				type of insur	ance
no.		spring	summer	autumn	winter	public	private
			4.6	0.4	2.5	2.1	1.8
070	i n	2.0 2.9	1.6 3.0	2.1 3.3	2.5 3.8	3.4	2.7
	р		0.9	0.5	0.7	0.9	0.4
071	i p	0.9 3.8	4.8	3.9	4.9	5.0	3.1
070		0.2	0.3	0.5	0.4	0.4	0.2
072	i p	1.1	1.4	1.4	1.7	1.6	1.0
073	i	0.4	0.3	0.3	0.3	0.3	0.3
0/0	p P	0.6	0.4	0.6	0.5	0.6	0.4
074	i	0.6	0.5	0.6	0.6	0.6	0.5
	р	0.9	8.0	0.9	8.0	0.9	0.7
				0.0	0.2	0.2	0.1
075	i	0.2 0.3	0.1 0.2	0.3 0.4	0.2	0.3	0.1
	р			0.2	0.3	0.3	0.2
076	i P	0.3 0.6	0.2 0.8	0.5	0.7	0.7	0.6
		0.3	0.2	0.2	0.2	0.2	0.1
077	i p	0.5	0.5	0.4	0.3	0.5	0.3
078	i	1.6	1.4	1.0	0.8	1.3	8.0
076	p	2.1	2.6	1.7	1.5	2.3	1.5
079	i	1.0	1.5	1.1	1.3	1.4	0.9
0.0	p	5.3	6.9	6.0	5.6	7.1	3.9
						0.0	0.0
080	i	0.0	•	0.0 0.0	0.0 0.0	0.0	0.0
	р	0.0			0.0	0.0	
081	i	0.0 0.0	0.0 0.0		0.0	0.0	
	р		0.1	0.1	0.2	0.1	0.1
082	i p	0.0 0.1	0.3	0.2	0.3	0.3	0.1
002	i	0.1	0.1	0.1	0.1	0.1	0.1
083	p	0.1	0.2	0.1	0.1	0.1	0.1
084	i	0.0	0.0	0.0	0.0	0.0	0.0
001	p P	0.0	0.1	0.1	0.0	0.1	0.0
						0.0	0.2
085	i	0.2	0.2	0.2 0.3	0.2 0.4	0.2 0.3	0.3
	р	0.2	0.3		0.2	0.4	0.1
086	i	0.4 0.7	0.2 0.8	0.4 0.8	0.5	0.8	0.5
	р		0.3	0.4	0.5	0.4	0.3
087	i p	0.4 0.7	0.5	0.7	0.7	0.7	0.5
088	i	0.4	0.3	0.4	0.3	0.4	0.3
000	p	0.5	0.4	0.6	0.5	0.6	0.4
089	i	0.2	0.1	0.1	0.1	0.1	0.1
200	p	0.3	0.1	0.4	0.2	0.3	0.2
						0.0	
090	i	**	*	0.0 0.0		0.0	
	р			0.2	0.3	0.3	0.2
091	i	0.3 0.5	0.2 0.5	0.4	0.4	0.5	0.3
000	p :	0.6	0.4	0.3	0.3	0.4	0.3
092	i p	0.8	0.4	0.4	0.3	0.5	0.4
093	i	2.1	0.9	0.3	0.1	0.7	1.0
USO	p	2.1	0.9	0.4	0.1	0.7	1.1
		0.0	0.0	0.0	0.0	0.0	0.0 0.1
094	i				0.1	0.1	

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
095	parasites/worms	i p	3.5 3.8	3.2 3.3	3.7 3.9	2.1 2.1	3.3 3.4	3.2 3.3	3.4 3.8
096	other presumed infections	i p	6.2 6.6	6.5 6.9	7.5 7.8	6.2 6.7	5.5 5.8	5.9 6.2	9.0 9.3
097	malign. neopl. stomach	, a i p	0.0 0.3	0.2	0.1 0.3	0.1	0.0 0.3	0.0 0.2	0.0 0.3
098	malign. neopl. colon, rectum	i p	0.1 0.7	0.0 0.5	0.1 1.1	0.2 0.5	0.1 0.7	0.1 0.7	0.1 0.8
099	malign. neopl. colon, rectum	i p	0.1 0.3	0.0 0.3	0.0 0.2	0.1 0.4	0.0 0.2	0.1 0.3	0.0
100	malign. neopl. pancreas	i p	0.0 0.1	0.0 0.0	0.1 0.2	0.1 0.2	0.0 0.1	0.0 0.1	0.1 0.1
101	malign. neopl. dig. syst. NEC	i p	0.0 0.4	0.0 0.4	0.1 0.4	0.2 1.0	0.1 0.4	0.1 0.5	0.1 0.3
102	benign. neoplasms dig. syst. NEC	i p	0.1 0.1	0.0 0.1	0.0 0.2	≆	0.0 0.1	0.0 0.1	0.1 0.1
103	neoplasms dig. syst. NEC	i p	0.1 0.1	0.1 0.2	0.0 0.2	0.1	0.0 0.1	0.0 0.1	0.1 0.3
104	foreign body through orifice	i p	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.1
105	injuries dig. syst. NEC	i p	0.0	0.0	. 0.0		0.0 0.0	0.0 0.0	0.0 0.0
106	cong. anom. digest. system	i p	0.1 0.2	0.0 0.1	0.0 0.1	0.2	0.0 0.2	0.0 0.1	0.1 0.2
107	disease of teeth/gums	i p	0.8 1.5	0.7 1.0	1.6 2.0	0.7 1.3	0.8 1.3	0.8 1.3	1.2 1.7
108	disease of mouth/tongue/lips	i p	2.0 2.8	1.9 2.7	3.0 3.8	2.1 2.3	2.0 2.6	2.2 3.0	2.2 2.9
109	disease of esophagus	i p	0.4 0.9	0.5 1.1	1.0 1.6	0.8 1.2	0.3 1.1	0.6 1.1	0.6 1.3
110	duodenal ulcer	i p	0.5 1.5	0.5 1.4	1.3 3.7	0.6 2.2	0.6 2.0	0.7 2.1	0.5 1.9
111	gastric ulcers NEC	i p	0.3 0.9	0.2 0.6	0.1 0.6	0.2 1.6	0.2 1.0	0.2 0.9	0.2 0.7
112	peptic ulcers NEC	i p	0.1 0.4	0.1 0.4	0.2 0.4	0.1 0.4	0.1 0.4	0.1 0.4	0.1 0.5
113	disord. stomach function	, i	2.4 4.4	3.7 5.4	3.3 5.3	3.2 5.7	2.4 5.1	2.9 4.4	4.2 6.7
114	appendicitis	i p	0.4 0.5	0.3 0.4	0.6 0.8	0.4 0.4	0.4 0.5	0.4	0.5 0.5
115	inguinal hernia	i p	0.7	0.7 1.0	0.3 0.5	0.5 0.5	0.5 0.8	0.6 0.8	0.5 0.8
116	hiatus (diaphr.) hernia	i p	0.4 1.4	0.5 1.8	1.7 3.6	0.5 1.6	0.4 1.5	0.9 2.2	0.5 1.8
117	abdominal hernia NEC	i	0.2	0.2 0.2	0.2	0.3	0.3 0.3	0.2	0.1 0.2
118	diverticular dis. intestines	i p	0.2 0.6	0.3	0.5 1.3	0.6 1.0	0.2 0.6	0.4 0.9	0.3 0.9
119	irritable bowel syndrome	i p	2.5 3.8	4.5 6.9	4.6 7.3	5.9 8.4	2.5 4.2	4.5 6.8	3.4 5.1

		season				type of insu	rance	
no.		spring	summer	autumn	winter	public	private	
095	i	3.3	2.8	3.4	3.7	3.4	3.0	
	p	3.3	3.0	3.7	3.9	3.6	3.1	
096	i	6.3	6.0	5.9	8.1	7.3	4.9 5.3	
	р	6.8	6.3	6.3	8.5	7.6		
097	i	0.0	0.1	0.1	0.2	0.1 0.2	0.0 0.2	
	р	0.2	0.3	0.3		0.1	0.0	
098	i	0.0 0.6	0.1 0.9	0.1 0.7	0.0 0.7	0.7	0.7	
	р			0.1	0.0	0.0	0.1	
099	i p	0.1	0.1 0.4	0.4	0.3	0.3	0.3	
							0.0	
100	i	0.0	0.1	0.0	0.0 0.1	0.0 0.1	0.0	
	р	0.1	0.2	0.1		0.1	0.1	
101	i	0.0 0.3	0.1 0.6	0.1 0.6	0.0 0.3	0.5	0.3	
	p				0.0	0.0	0.0	
102	i p	0.0 0.1	0.1 0.1	0.0 0.1	0.1	0.1	0.1	
400	4	0.1	0.0	0.0	0.1	0.1	0.0	
103	і ["] р	0.1	0.1	0.2	0.2	0.2	0.1	
104	i	0.1		0.0	0.2	0.0	0.1	
104	p	0.1	0.0	0.1	0.3	0.1	0.2	
					0.0	0.0	0.0	
105	i	0.0 0.0	*	0.0 0.0	0.0	0.0	0.0	
	p				0.1	0.0	0.0	
106	i p	0.0 0.2	0.0 0.1	0.1 0.2	0.2	0.1	0.2	
407		0.7	0.7	1.1	1.0	1.0	0.7	
107	i p	1.2	1.2	1.6	1.8	1.6	1.1	
108	. i	2.3	2.4	2.4	1.8	2.4	1.9	
100	р	3.0	3.3	3.0	2.4	3.1	2.5	
109	i	0.6	0.7	0.7	0.5	0.7	0.3	
	p	1.0	1.0	1.3	1.2	1.4	0.6	
440		0.5	0.6	0.9	0.7	0.7	0.6	
110	i p	0.5 2.1	1.2	2.8	2.0	2.3	1.5	
111	i	0.2	0.2	0.2	0.2	0.2	0.1	
111	p	0.8	1.0	0.9	0.6	0.9	0.5	
112		0.1	0.0	0.1	0.2	0.1	0.0	
	p	0.4	0.3	0.3	0.6	0.5	0.2	
113	i	3.7	2.2	3.7	3.0	3.5	2.2	
-	Р	5.4	3.7	5.4	5.8	5.8	3.5	
114	i	0.4	0.6	0.5	0.2	0.4	0.4	
	р	0.5	0.6	0.6	0.3	0.5	0.5	
445		0.6	0.6	0.4	0.7	0.5	0.6	
115	i p	0.9	0.8	0.6	0.9	0.8	0.8	
116	i	0.4	1.4	0.6	0.5	0.7	0.8	
116	p	1.9	2.3	2.3	1.6	2.2	1.7	
117	i	0.2	0.2	0.3	0.2	0.2	0.1	
/	p	0.2	0.3	0.4	0.2	0.3	0.2	
118	i	0.3	0.4	0.5	0.2	0.4	0.4	
0	p	0.8	0.9	1.0	8.0	1.0	8.0	
119	i	4.1	2.6	4.3	5.0	4.3	3.3	
	p	6.5	4.2	6.3	7.6	6.7	5.0	

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
120	chron, enteritis/colitis ulc.	i	0.2	0.2	0.2	0.1	0.3	0.2	0.3
120	ornori. Ornorido/combo disp.	р	1.1	1.1	8.0	8.0	1.2	0.9	1.1
121	anal fissure/perianal abscess	i	0.6	0.9	0.8	0.7	0.7	0.8	0.7
121	and history permitted about the	p	0.9	1.3	1.1	0.9	0.9	1.1	1.1
122	hepatomegaly	i		0.0	0.1	•	0.0	0.0	0.0
122	nepatomegaly	p p	0.0	0.0	0.1) = 0	0.0	0.0	0.1
123	cirrhosis/liver disease NEC	i	0.1	0.2	0.2	0.5	0.1	0.2	0.2
120	Olificolo, invol. diodado 1.120	р	0.4	0.7	0.7	1.6	0.6	0.7	0.7
124	diseases of gall-bladder/biliary duct	i	0.5	0.4	0.8	0.6	0.4	0.6	0.6
124	discussor of gain brades, a many a con-	р	1.4	1.2	1.5	1.6	1.4	1.3	1.4
125	diseases digestive system NEC	i	0.3	0.6	0.6	0.7	0.4	0.5	0.4
123	useases uigestive system NEO	p	1.2	1.3	1.1	1.2	1.3	1.2	1.2

no.		season				type of insu	pe of insurance	
		spring	summer	autumn	winter	public	private	
120	i	0.3	0.2	0.2	0.2	0.2	0.2	
120	p P	1.0	1.1	1.0	8.0	1.1	0.9	
121	i	0.9	0.7	0.9	0.6	8.0	0.6	
12.	p P	1.2	1.0	1.3	0.9	1.2	8.0	
122	i	0.0		0.0	0.0	0.0	0.0	
1 Carlos	p p	0.0	0.0	0.0	0.1	0.0	0.0	
123	i	0.2	0.1	0.2	0.3	0.2	0.1	
120	p	0.6	0.6	0.7	0.9	8.0	0.4	
124	i	0.4	0.8	0.6	0.4	0.6	0.5	
,,,,	p	0.9	1.5	1.3	1.6	1.5	1.1	
125		0.6	0.5	0.5	0.4	0.5	0.4	
120	p	1.2	1.2	1.4	1.0	1.3	0.9	

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
126	complaints of vision	i p	0.7 2.4	0.8 2.3	1.0 2.2	0.9 3.2	0.6 1.1	0.8 2.1	1.1 3.7
127	fear of eye disease	i p	0.0	0.0	0.0		0.1 0.1	0.0	0.0
128	disability/impairment eye	i	. 0.0	0.0	. 0.0	0.1	0.0	. 0.0	. 0.1
129	sympt./complt. eye NEC	p i	1.1 2.8	1.0 2.1	1.0	1.2	1.0 2.3	1.1 2.5	1.0
130	infectious conjunctivitis	p i p	1.7 1.9	1.9	1.9	1.5 1.8	1.7 1.8	1.8	1.8 1.9
131	allergic conjunctivitis	i p	5.1 5.7	5.8 6.5	6.3 7.0	3.5 3.6	5.4 5.9	5.4 6.1	5.4 6.0
132	blepharitis/stye/chalazion	i p	1.2 1.3	1.5 1.6	1.4 1.6	0.9 1.1	1.2 1.3	1.2 1.4	1.5 1.8
133	infection of eye NEC	i p	0.5 1.0	0.5 0.9	0.5 1.0	0.5 0.7	0.5	0.5 0.9	0.5
134	corneal ulcer	i p	0.1 0.1	0.0	0.1 0.1	0.1	0.0	0.1 0.1	0.0
135	neoplasms of eye/adnexa	i p	0.1 0.1	0.0 0.1	0.1	0.1	0.1 0.1	0.0 0.1	0.0 0.0
136	contusion/abrasion/black eye	i p	0.6 0.6	0.7 0.8	0.6 0.7	0.7 0.8	0.5 0.6	0.7 0.7	0.7 0.8
137	foreign body in eye	i p	2.2 2.5	1.3 1.5	1.0	0. 2 0.4	1.9	1.2 1.4	1.8 1.9
138	injuries eye NEC	i p	0.2 0.3	0.2 0.2	0.2 0.3	0.2 0.3	0.2 0.3	0.2 0.3	0.3 0.4
139	blocked lacrimal duct of infants	i p	0.1 0.1	0.0 0.0		0.1	0.1 0.1	0.0 0.0	0.1 0.1
140	cong. anom. of eye NEC	i p	0.1 0.1	0.0 0.1			0.0 0.0	0.0 0.0	0.0 0.1
141	refractive errors	i p	0.9 4.0	0.9 4.6	1.3 5.1	1.0 3.6	1.2 5.9	0.9 4.1	1.0
142	cataract	i p	0.2 1.4	0.2 0.9	0.2 1.5	0.2 1.0	0.2 1.1	0.2 1.3	0.2 1.0
143	glaucoma	i p	0.1 2.1	0.1 0.9	0.4 1.2	0.2 0.6	0.1 2.0	0.2 1.4	0.2 0.9
144	blindness, all types	i p	0.0 0.3	0.0 0.2	0.3	0.1 0.3	0.0 0.2	0.0 0.2	0.0 0.3
145	strabismus	i p	0.2 0.6	0.1 0.4	0.1 0.4	0.1 0.2	0.2 0.5	0.1 0.4	0.2 0.6
146	retinopathy	i	0.2	0.2	0.0	0.3	0.0	0.2	0.1
147	diseases of eye NEC	p i p	0.4 0.6 1.1	0.5 0.7 1.2	0.6 0.8 1.2	0.3 0.8 2.0	0.3 0.8 1.4	0.5 0.7 1.2	0.4 0.6 1.3

		season				type of insur	ance	
no.		spring	summer	autumn	winter	public	private	
126	i p	0.7 1.8	0.5 2.0	1.2 2.6	0.9 3.3	0.9 3.0	0.5 1.0	
127	i p	0.0	0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0	
128	i p	0.0	0.1	0.0	0.0 0.0	0.0 0.0	0.0	
129	i p	1.1 1.7	0.9 2.1	1.2 2.8	1.0 2.7	1.2 2.7	0.8 1.7	
130	i p	3.4 3.6	1.5 1.6	1.1 1.2	1.3 1.4	1.9 2.0	1.5 1.6	
131	i p	4.8 5.2	5.3 5.9	5.9 6.6	5.7 6.3	5.6 6.4	4.7 5.2	
132	i p	1.2 1.4	1.1 1.3	1.6 1.7	1.3 1.5	1.4 1.6	0.9 1.1	
133	i p	0.4 0.8	0.7 · 1.2	0.5 0.9	0.4 0.9	0.5 1.0	0.5 0.9	
134	i p	0.0	0.1 0.1	0.1 0.1	0.0 0.1	0.0 0.0	0.1 0.1	
135	i p	0.0 0.1	0.1 0.2	0.0 0.1		0.0	0.0	
136	i p	0.9 1.0	0.4 0.4	0.6 0.7	0.7 0.8	0.7 0.8	0.5 0.7	
137	i p	1.1 1.3	1.7 1.9	1.5 1.7	1.3 1.6	1.6 1.8	1.0 1.1	
138	i p	0.3 0.4	0.2 0.3	0.1 0.2	0.2 0.3	0.2 0.3	0.1 0.2	
139	i p	0.0 0.0	0.0 0.0	0.0 0.1	0.0 Q.1	0.0 0.1	0.0	
140	i p	0.0 0.1	0.1 0.1	0.0	0.1	0.0	0.0	
141	i p	0.8 5.0	0.7 3.8	1.2 5.0	1.1 3.8	1.2 6.0	0.6 1.3	
142	i p	0.2 0.8	0.3 1.9	0.1 1.3	0.1 0.9	0.2 1.6	0.1 0.4	
143	i p	0.2 1.1	0.1 1.4	0.2 1.5	0.2 1.4	0.2 1.6	0.2 0.9	
144	i p	0.0 0.1	0.0 0.3	0.0 0.3	0.2	0.0 0.2	0.0 0.2	
145	i p	0.2 0.5	0.1 0.3	0.2 0.5	0.1 0.4	0.2 0.5	0.0	
146	i	0.1 0.5	0.2 0.5	0.3 0.6	0.1 0.4	0.1 0.5	0.2 0.3	
147	p i p	0.8 1.3	0.6 1.1	0.7 1.2	0.6 1.4	0.8 1.5	0.5 0.8	

no.	episode		degree of urb	anization			region		
			rural	suburban	urban	city	north	centre	south
148	earache	i p	0.2 0.6	0.2 0.6	0.3 0.5	0.3 0.6	0.2 0.4	0.2 0.6	0.4 0.7
149	hearing complt.	i p	0.2 0.5	0.2 0.5	0.1 0.3	0.1 0.3	0.2 0.3	0.2 0.4	0.2 0.7
150	ringing/buzzing/tinnitus	i	0.2 0.3	0.2 0.2	0.2 0.3	0.2 0.4	0.2 0.3	0.2 0.3	0.2
151	blood/discharge from ear	p i	0.1	0.2	0.1	0.1	0.1	0.1	0.2
152	fear of ear disease	p i	0.2	0.4	0.1	0.1	0.2	0.2	0.3
		р	0.0	0.0	0.0	0.1	0.0	0.0	0.0
153	disability/impairment of ear	i p	0.0	0.0 0.0	je) or				0.0 0.0
154	symp./complt. of ear NEC	i p	0.2 0.5	0.3 0.4	0.3 0.5	0.3 0.4	0.3 0.4	0.3 0.4	0.3 0.5
155	otitis externa	i p	3.6 5.2	3.2 4.1	4.0 5.0	2.6 3.9	3.1 4.7	3.3 4.4	3.8 5.1
156	acute otitis media/myringitis	i p	5.6 5.8	7.4 7.8	7.0 7.3	6.9 7.2	5.8 5.9	6.8 7.0	6.8 7.2
157	serous otitis media/glue ear	i p	1.4 1.8	1.1 1.8	2.2 2.9	1.1 1.7	1.0 1.4	1.7 2.4	0.9 1.4
158	eustachian tube dysfunction	i p	2.1 2.5	2.6 3.2	2.3 3.0	1.4 1.7	2.7 3.1	2.1 2.7	2.3
159	infections of ear NEC	i p	0.3 0.6	0.4 0.6	0.4 0.9	0.2 0.3	0.3 0.6	0.3 0.6	0.6 0.9
160	neoplasm of ear	i p	0.0 0.0	0.0		0.1 0.1		0.0 0.0	0.0
161	foreign body in ear	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2
162	perforation tymp. membrane	i p	0.1 0.3	0.1 0.2	0.3 0.5	0.1 0.4	0.2 0.3	0.1 0.3	0.2
163	superficial injury of ear	i	0.1 0.1	0.0	0.0		0.0	0.0	0.0
164	injuries of ear NEC	p i	0.0	0.1 0.1	0.1 0.2	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.1 0.1
165	cong. anom. of ear	p i p	0.0	0.0	0.1 0.1		0.0	0.0 0.1	0.0
166	ear wax (excessive)	i	8.0 9.0	8.2 9.2	9.0 10.0	8.2 8.9	9.3 10.3	8.2 9.1	8.2 9.1
167	vertiginous syndromes	p i p	0.3 0.9	0.6 1.1	0.8 1.4	0.8 1.3	0.4 1.2	0.5 1.0	0.8 1.5
168	otosclerosis	i	0.0	0.0	0.1	0.1	0.0	0.0	0.1
169	presbyacusis	p i	0.0	0.1	0.2 0.4	0.2 0.3	0.1 0.5	0.1 0.4	0.2 0.3
170		p i	0.5	0.6	0.5	0.7	0.6	0.6	0.5
170		p	0.1	0.1	0.1		0.1	0.1	0.1
171		i p	0.4 0.8	0.3 0.6	0.2 0.6	0.2 0.9	0.3 0.7	0.3 0.7	0.4 0.8
172	• -	i p	0.2 0.3	0.2 0.3	0.4 0.7	0.4 0.8	0.2 0.4	0.3 0.5	0.2 0.4

no.		season				type of insur	ance	
110.		spring	summer	autumn	winter	public	private	
148	i p	0.4 0.8	0.1 0.4	0.3 0.6	0.2 0.6	0.3 0.6	0.2 0.5	
149	i p	0.1 0.2	0.1 0.3	0.2 0.6	0.3 0.7	0.2 0.4	0.2 0.4	
150	i	0.1	0.2	0.2	0.2	0.2 0.2	0.2 0.4	
151	p i	0.3 0.1	0.4 0.1	0.3 0.1	0.2 0.2	0.1	0.1	
	р	0.3	0.2	0.2	0.3	0.2	0.2	
152	i p		0.0 0.0	0.0	0.0 0.0	0.0 0.0		
153	i	•		0.0	•	0.0 0.0		
154	p i	0.2	0.2	0.0 0.3	0.4	0.3	0.2	
	р	0.4	0.3	0.6	0.5	0.5	0.3	
155	i p	2.9 4.0	4.1 5.5	4.0 5.1	2.7 3.8	3.4 4.7	3.4 4.3	
156	i p	7.9 8.3	3.8 4.1	6.4 6.6	8.5 8.9	6.5 6.8	6.9 7.1	
157	i	1.1	1.0	1.6	2.0	1.4 2.0	1.5 2.0	
	р	1.9	1.3	2.3	2.6			
158	i p	2.3 2.6	1.9 2.4	2.5 3.1	2.3 2.9	2.2 2.8	2.1 2.5	
159	i p	0.5 0.8	0 <i>.</i> 2 0.5	0.3 0.6	0.3 0.6	0.4 0.7	0.2 0.4	
160	i p	0.1 0.1		0.0	0.0 0.0	0.0 0.0	0.0	
161	i	0.2	0.1	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.1	
162	p i	0.2 0.2	0.1	0.2	0.1	0.1	0.2	
	р	0.5	0.2	0.3	0.3	0.3	0.2	
163	i p	0.0 0.0	0.1 0.1	0.0 0.0	0.1	0.0 0.1	0.0 0.0	
164	i	0.0 0.0	0.0 0.0	0.2 0.2		0.1 0.1	0.1 0.1	
165	p i	0.0	0.0	0.0	0.1	0.0	0.0	
	р	0.0	0.0	0.1	0.1	0.0	0.0	
166	i p	8.3 9.5	10.0 11.1	7.0 7.5	7.9 9.0	8.2 9.3	8.2 9.0	
167	i p	0.7 1.1	0.6 1.2	0.8 1.4	0.3 0.9	0.6 1.1	0.7 1.2	
				0.1	0.1	0.0	0.1	
168	i p	0.0 0.1	0.0	0.1	0.1	0.0	0.1	
169	i p	0.4 0.7	0.5 0.7	0.3 0.4	0.3 0.5	0.4 0.6	0.3 0.4	
170	i	0.1	0.0	0.1	0.1	0.1	0.1	
4774	p :	0.1 0.3	0.0 0.4	0.1 0.3	0.2 0.3	0.1 0.3	0.1 0.3	
171	i p	0.5	0.9	0.7	0.8	8.0	0.5	
172	i P	0.2 0.4	0.3 0.4	0.5 0.7	0.1 0.3	0.3 0.5	0.2 0.3	

f

no.	episode		degree of	urbanization suburban	urban	city	region north	centre	south
173	complaints of heart	i	0.4 1.2	0.4 1.1	0.8 1.7	0.4 0.8	0.4 1.1	0.4 1.2	0.7 1.3
174	edema of extremities	p i p	0.9	0.8 3.2	0.9 5.3	0.6 2.4	0.9 6.5	0.8 4.2	0.9 5.1
175	fear of dis. circ. system	i p	0.4 0.7	0.4 0.8	0.8 1.3	0.6 0.9	0.6 1.1	0.4 0.8	0.7 1.1
176	disability/impairment circ. syst. NEC	i p	0.0		0.0			0.0	0.0
177	sympt./complt. circ. syst. NEC	i p	0.2 0.5	0.1 0.2	0.2 0.2	0.2 0.6	0.2 0.5	0.1 0.3	0.2 0.4
178	infections dis. circ. syst.	i p	0.0	0.0 0.0	0.0 0.1	0.3	0.0 0.1	0.0 0.1	0.0
179	neoplasm circ. syst.	i p	0.0 0.0	0.1 0.1	0.0 0.0	0.1	0.0	0.0 0.0	0.1 0.1
180	injuries heart/circ. syst.	i p	0.0 0.0	0.0 0.0	0.0		0.0 0.0		0.0 0.1
181	cong. anom. heart/circ. syst.	i p	0.0 0.3	0.0 0.2	0.4	0.0	0.1 0.4	0.0 0.3	0.2
182	rheumatic fever/heart dis.	i p	0.0 0.1	0.0 0.1	0.0 0.0	0.1 0.4	0.1	0.0 0.1	0.0
183	acute myocardial infarction	i p	0.4	0.4	0.6	0.4	0.4	0.4	0.6
184	angina pectoris	i p	1.2 10.9	1.0 6.5	1.5 7.0	2.0 5.8	1.2 12.3	1.2 7.8	1.5 6.6
185	healed myocardial infarction	i p	5.3	4.8	5.1	3.0	8.1	4.1	5.4
186	chron. ischemic heart dis. NEC	i p	0.2 6.7	0.2 3.9	0.2 5.4	0.1 3.0	0.2 4.7	0.1 3.6	0.2 8.8
187	heart failure	i p	1.0 7.4	0.7 5.9	0.8 5.2	1.3 7.3	0.8 7.0	0.9 6.4	0.8 6.0
188	atrial fibrillation/flutter	i p	0.2 2.2	0.2 2.3	0.3 2.7	0.2 2.5	0.2 2.5	0.2 2.3	0.1 2.5
189	paroxysmal tachycardia	i p	0.2 0.5	0.3 0.7	0.1 0.7	0.4 0.7	0.2 0.7	0.2 0.6	0.3 0.7
190	ectopic beats, all types	i p	0.2 0.3	0.2 0.4	0.2 0.4	0.2 0.8	0.2 0.6	0.2 0.4	0.1 0.3
191	heart murmur NOS	i P	0.1 0.2	0.0 0.1	0.1 0.2	0.2 0.3	0.0 0.2	0.1 0.2	0.0 0.1
192	pulmonary heart dis.	i p	0.0 0.1	0.1	0.2	0.1	0.0 0.2	0.0 0.1	0.1
193	heart valve dis. NOS, non-rheum.	i p	0.0	0.0	0.0	0.1 1.4	0.0 0.9	0.0 0.7	0.0 0.7
194	heart disease NEC	i p	0.4 3.2	0.4 2.5	0.4 2.9	0.6 2.4	0.3 4.6	0.4	0.4 2.9
195	elevated blood pressure w.o. hypertension		0.1 0.5	0.2 1.9	0.3 1.7	0.3 2.0	0.3 1.0	0.2 1.8	0.1 0.6
196	uncomplicated hypertension	i p	2.7 48.6	2.5 41.7	4.7 44.0	3.1 45.5	2.9 52.4	3.5 44.3	2.2 43.1
197	hypertension with involv.targ. organs	i p	0.3 9.8	0.3 5.8	0.5 5.9	0.7 5.4	0.3 10.1	0.5 6.5	0.3 7.4

		season				type of insur	ance	
no.		spring	summer	autumn	winter	public	private	
173	i	0.5	0.3	0.5	0.6	0.5	0.4	
170	p P	1.1	1.0	1.3	1.4	1.3	1.0	
174	i	0.9	1.4	0.6	0.4	1.0	0.6	
	р	4.0	8.2	3.7	2.9	5.4	3.1	
175	i	0.6	0.4	0.3	0.7	0.6 1.0	0.5 0.9	
	р	1.0	8.0	8.0	1.0	1.0		
176	i		0.0	0.0		0.0	0.0	
	р			0.2	0.2	0.2	0.1	
177	i p	0.1 0.2	0.1 0.3	0.4	0.5	0.4	0.2	
178	i	0.0	0.0	0.0	0.0	0.0	0.0	
	р	0.1	0.2	0.1	0.0	0.1	0.1	
179	i	0.0	•	0.0	0.0	0.0	0.0	
	p	0.1	0.1	0.0	0.1	0.1	0.0	
180	i	•	0.0			0.0	0.0 0.0	
	р	0.0	0.0	*	0.0		0.0	
181	i	0.0	0.0 0.2	0.0 0.4	0.3	0.0 0.3	0.2	
	р	0.2			0.0	0.0	0.0	
182	i p	0.0 0.1	0.0 0.1	0.0 0.1	0.1	0.1	0.1	
	Р	···						
183	i	0.5	0.3	0.5	0.4	0.4	0.4	
	р					•		
184	i	0.9	1.2	1.7	1.3	1.3	1.0	
	р	5.7	9.9	8.2	8.0	9.4	5.5	
185	р	3.9	5.8	4.4	5.2	5.5	3.5	
	i	340		•	•			
186	i	0.1	0.2	0.2	0.0 5.7	0.1 5.7	0.2 3.5	
	р	3.5	3.7	7.2		1.0	0.4	
187	i	0.7 5.7	1.0 6.6	0.8 8.4	0.9 4.8	7.2	4.1	
	р	5.7						
188	i	0.1	0.3	0.3	0.1	0.2	0.3	
100	p	1.6	2.6	3.5	1.8	2.7	1.8	
189	i	0.2	0.2	0.3	0.3	0.3	0.2	
	р	8.0	0.6	0.7	0.6	0.7	0.6	
190	i	0.1	0.3	0.2	0.1	0.2	0.1 0.4	
	р	0.4	0.5	0.6	0.2	0.4		
191	i	0.1	0.1	0.1	0.0 0.1	0.0 0.2	0.1 0.2	
	р	0.2	0.2	0.2		0.0		
192	i	0.0 0.1	0.1	0.0 0.2	0.0 0.1	0.0	0.0	
	р	0.1						
193	i	0.0	0.0	0.0	0.0	0.1	0.0	
,55	p	0.7	0.5	1.1	0.6	8.0	0.5	
194	i	0.3	0.7	0.3	0.3	0.4	0.4	
-	р	2.2	3.3	3.0	2.5	3.0	2.3	
195	i	0.2	0.2	0.3	0.1	0.1	0.2	
	р	1.8	1.0	1.8	1.1	1.3	1.3	
196	i	2.8	5.0	2.2	2.5	3.0	3.5 42.3	
	р	39.8	51.1	43.4	45.2	46.8		
197	i	0.3	0.6	0.4 8.5	0.2 6.3	0.4 8.4	0.4 5.1	
	р	5.3	8.2	8.5	0.0			

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
198	(postural) hypotension	i p	0.5 0.9	0.6 1.0	1.0 1.6	0.9 1.1	0.7 1.0	0.7 1.0	0.7 1.3
199	transient cerebral ischemia	i p	0.5 1.6	0.5 1.5	0.9 1.9	0.5 1.7	0.6 1.9	0.6 1.6	0.7 1.7
200	cerebrovascular diseases	i p	0.7 3.0	0.5 2.9	0.7 3.4	1.1 4.1	0.7 3.2	0.7 3.1	0.6 3.3
201	atherosclerosis, excl. heart/brain	i p	0.1 1.1	0.1 0.8	0.2 1.2	0.1 0.2	0.1 0.9	0.1 0.7	0.1 1.4
202	arterial vascular diseases NEC	i p	0.6 3.9	0.5 2.5	0.7 3.1	0.6 2.7	0.6 3.2	0.5 2.6	0.8 4.6
203	pulmonary embolism	i p	0.1 0.4	0.1 0.2	0.1 0.6	0.1 0.1	0.1 0.5	0.1 0.3	0.0 0.3
204	(thrombo) phlebitis	i p	0.4 0.7	0.6 0.8	0.4 0.8	0.3 0.5	0.4 0.6	0.4 0.7	0.5 0.8
205	venous thrombosis	i P	0.1 1.4	0.1 0.7	0.3 1.2	0.3 1.2	0.2 1.4	0.2 1.1	0.2 0.8
206	various veins of legs	i P	0.9 3.3	1.4 3.5	1.7 4.5	1.0 2.7	1.1 3.6	1.2 3.4	1.5 4.0
207	various ulcer of skin	i p	0.3 1.4	0.3 1.1	0.3 1.0	0.3 1.1	0.5 1.4	0.3 1.2	0.2 0.9
208	hemorrhoids	i p	1.4 4.0	1.8 3.6	1.8 3.8	1.7 3.1	1.3 3.9	1.6 3.6	2.0 3.9
209	dis. circulatory system NEC	i p	0.4 1.9	0.6 1.8	0.7 2.0	0.3 1.0	0.5 2.4	0.5 1.7	0.6 1.9

no.		season				type of insu	rance
		spring	summer	autumn	winter	public	private
198	i	0.5	1.2	0.6	0.5	0.7	0.6
100	p p	1.0	1.9	0.9	0.7	1.1	1.0
199	i	0.5	0.6	0.7	0.6	0.7	0.5
	р	1.2	2.1	1.9	1.4	1.8	1.3
200	i	0.5	1.1	0.5	0.7	0.6	0.5
	р	2.7	4.1	3.2	2.7	3.3	2.3
201	i	0.1	0.2	0.1	0.0	0.1	0.1
	р	8.0	1.0	1.0	8.0	1.1	0.5
202	i	0.6	0.6	0.5	0.6	0.7	0.4
LUL	p	2.3	3.3	3.3	3.5	3.9	1.9
203	i	0.1	0.1	0.1	0.0	0.1	0.1
	p	0.3	0.3	0.5	0.3	0.4	0.3
204	i	0.4	0.5	0.6	0.3	0.5	0.3
	p	0.6	8.0	8.0	0.6	8.0	0.6
205	i	0.3	0.2	0.2	0.1	0.2	0.2
	р	8.0	1.0	1.4	1.1	1.3	0.6
206	i	1.4	1.3	1.2	1.2	1.4	1.0
	р	3.4	3.9	3.9	3.2	4.2	2.4
207	i	0.2	0.3	0.4	0.3	0.3	0.1
	р	0.9	1.1	1.8	0.8	1.3	0.7
208		1.8	2.0	1.6	1.3	1.7	1.7
	p	3.8	3.9	3.6	3.6	3.9	3.5
209	i	0.5	0.4	0.8	0.5	0.5	0.5
	p p	1.2	1.6	2.7	1.8	1.9	1.4

1	no.	episode		degree c	of urbanization			region		
P 1.2 1.2 1.3 1.5 1.8 1.2 1.2 1.3 1.5 1.8 1.2 1.2 1.3 1.5 1.8 1.2 1.2 1.3 1.5 1.8 1.2 1.5 1.8 1.2 1.5 1.8 1.2 1.5 1.8 1.2 1.5 1.8 1.2 1.5 1.8 1.2 1.3 1.6 1.2 1.5 1.8 1.2 1.3 1.6 1.2 1.5 1.8 1.2 1.3 1.6 1.2 1.5 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5 1.8 1.5				rural	suburban	urban	city	_	centre	south
211 back symp_/complt. 1 4 14 12 1.3 1.6 1.2 1.5	210	neck symp./complt., excl. headache								
P 0.3 0.8 0.7 0.2 0.3 0.7 0.4	211	back symp./complt.	i							
P 1.2 1.0 1.6 0.7 1.2 1.0 1.6 1.2 1.0 1.6 1.0	212	low back symp./complt. w/o radiation								
P	213	chest sympt./complt.								
P 0.0 0.0 0.0 0.1 . 0.0 0.0 0.0 0.1 . 0.0	214	flank sympt.complt.								
P	215	axilla sympt./complt.								
P	216	jaw sympt./complt.								
P 0.6	217	shoulder sympt./complt.								
P 0.2 0.1 0.2 . 0.2 0.1 0.2 . 0.2 0.1 0.2 . 0.2 0.1 0.2 . 0.2 0.1 0.2 . 0.2 . 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.3 0.3 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.5 0.6 0.4 0.5 0.6	218	arm sympt./complt.								
P 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.3	219	elbow sympt./complt.								
P 0.7 0.9 0.7 0.4 0.8 0.7 0.8	220	wrist sympt./complt.								
P 0.7 0.6 0.6 0.4 1.0 0.5 0.6 0.6 0.2 0.7 0.5 0.6 0.6 0.2 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.5 0.7 0.6 0.8 0.8 0.8 0.8 0.7 0.4 1.2 0.6 0.8 0.8 0.8 0.7 0.4 0.2 0.2 0.1 0.3 0.2 0.3	221	hand/finger sympt./complt.								
P 1.5 1.4 1.3 1.0 1.6 1.2 1.6	222	hip sympt./complt.								
P 1.5 1.3 1.3 0.9 1.7 1.2 1.4	223	leg/thigh sympt./complt.								
P 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2	224	knee sympt./complt.								
P 1.0 1.3 1.1 0.9 0.9 1.1 1.2	225	ankle sympt./complt.								
P 15.3 22.2 21.1 17.7 16.5 17.6 24.5	226	foot/toe sympt./complt.								
P 2.7 2.4 4.1 3.1 3.5 3.0 2.7	227	muscle pain/fibrositis								
p 2.3 1.2 1.4 0.7 1.8 1.5 1.6 230 limbs sympt./complt. NOS	228	(mult.) muscle sympt./complt. NEC								
P 0.0 0.0 0.1 0.1 0.1 0.1 0.0 231 fear of dis. musculoskeletal syst. i 0.1 0.1 0.1 0.2 . 0.1 0.1 0.1 p 0.1 0.1 0.3 0.1 0.2 0.1 0.2 232 disability/impairment musc. skel. syst. i 0.5 1.1 1.0 1.3 1.1 1.0 0.8 p 1.4 2.2 2.4 2.4 2.1 2.0 1.9 233 sympt/compl. musc. skel. syt. i 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.2 234 infections musc. skel. syst. i 0.1 0.1 0.2 0.1 0.3 0.1 0.2 0.2	229	(mult.) joints sympt./complt. NEC								
231 fear of dis. musculoskeletal syst. i 0.1 0.1 0.2 . 0.1 0.1 0.1 p 0.1 0.1 0.3 0.1 0.2 0.1 0.2 232 disability/impairment musc. skel. syst. i 0.5 1.1 1.0 1.3 1.1 1.0 0.8 p 1.4 2.2 2.4 2.4 2.1 2.0 1.9 233 sympt./compl. musc. skel. syt. i 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.2 p 0.2 0.3 0.4 0.1 0.2 0.3 0.3 234 infections musc. skel. syst. i 0.1 0.1 0.2 0.1 0.3 0.1 0.2 0.2	230	limbs sympt./complt. NOS								
p 1.4 2.2 2.4 2.4 2.1 2.0 1.9 233 sympt./compl. musc. skel. syt. i 0.1 0.1 0.2 0.0 0.1 0.1 0.2 p 0.2 0.3 0.4 0.1 0.2 0.3 0.3 234 infections musc. skel. syst. i 0.1 0.2 0.1 0.3 0.1 0.2 0.2	231	fear of dis. musculoskeletal syst.								
p 0.2 0.3 0.4 0.1 0.2 0.3 0.3 234 infections musc. skel. syst. i 0.1 0.2 0.1 0.3 0.1 0.2 0.2	232	disability/impairment musc. skel. syst.								
	233	sympt./compl. musc. skel. syt.								
p 0.2 0.0 0.7 0.2 0.0 0.3	234	infections musc. skel. syst.	i p	0.1 0.2	0.2 0.3	0.1 0.3	0.3 0.4	0.1 0.2	0.2 0.3	0.2 0.3

20		season				type of insur	ance	
no.		spring	summer	autumn	winter	public	private	
210	i p	0.4 0.9	0.7 1.2	0.6 1.1	1.3 1.9	0.9 1.5	0.5 0.8	
211	i p	1.6 3.4	1.0 3.5	1.4 3.4	1.3 4.4	1.5 4.3	1.0 2.5	
212	i	0.9	0.2	0.2 0.3	0.2 0.4	0.4 0.7	0.3 0.4	
213	p i	1.3 0.8	0.4	0.9	1.0	0.9	0.8	
	р	1.3	0.9	1.2 0.1	1.2 0.1	1.2 0.1	0.9	
214	i P	0.1	0.0	0.2	0.2	0.2	0.1	
215	i p	0.0	0.0	0.0 0.0	0.0	0.0 0.0	0.0 0.0	
216	i	0.3	0.4	0.2	0.3 0.4	0.4 0.6	0.2 0.3	
217	p i	0.4 0.3	0.7 0.3	0.4 0.3	0.4	0.4	0.2	
217	p	0.7	0.7	8.0	0.5	8.0	0.5 0.4	
218	i p	0.5 0.8	0.4 0.6	0.6 1.1	0.5 1.1	0.6 1.1	0.6	
219	i p	0.1 0.1	0.0 0.1	0.1 0.2	0.1 0.2	0.1 0.2	0.1 0.1	
220	i	0.1 0.2	0.1 0.2	0.1 0.1	0.1	0.1 0.2	0.1 0.1	
221	p i	0.6	0.3	0.5	0.5	0.5	0.5 0.7	
000	р	0.8	0.6 0.2	0.9 0.2	0.7 0.1	0.8 0.2	0.7	
222	i P	0.3 0.7	0.7	0.5	0.4	0.7	0.4	
223	i p	0.5 1.4	0.5 1.4	0.6 1.3	0.6 1.4	0.7 1.6	0.4 0.8	
224	i	0.8 1.3	0.7 1.4	0.7 1.4	0.8 1.2	0.8 1.5	0.5 0.8	
	р 	1.5	1.7					
225	i p	0.2 0.3	0.1 0.3	0.2 0.4	0.1 0.2	0.2 0.3	0.1 0.2	
226	i	0.7	0.5	0.7	0.9	0.7 1.2	0.6 0.8	
227	p :	1.0 15.5	0.9 9.6	1.1 16.1	1.5 16.5	16.7	10.0	
227	p	21.1	13.9	20.4	21.4	22.6	12.7	
228	i p	1.0 2.0	3.0 4.3	2.3 3.1	1.8 2.5	2.2 3.5	1.7 2.1	
229	i	0.4	0.4	0.6	1.2	0.7	0.6 1.4	
	P	0.9	1.7	1.1	2.5	1.7	1.4	
230	i	0.1 0.1	0.0 0.0	0.0	0.0 0.0	0.0 0.0	0.1 0.1	
231	p i	0.1	0.0	0.1	0.1	0.1	0.1	
201	р	0.2	0.0	0.2	0.2	0.1	0.1	
232	i	0.6	0.8	0.9 2.1	1.4 2.6	0.9 2.2	0.9 1.6	
000	р	1.4	1.9 0.1	0.1	0.3	0.1	0.1	
233	i p	0.0 0.3	0.1	0.3	0.4	0.3	0.2	
234	i	0.2	0 <i>2</i> 0.3	0.0 0.1	0.3 0.4	0.2 0.3	0.1 0.3	
	р	0.3	0.3	0.1				

no.	episode		aegree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
235	neoplasms musc. skel. syst.	i p	0.0 0.2	0.2 0.4	0.1 0.2	0.2 0.3	0.1 0.2	0.1 0.3	0.1 0.3
236	fracture: radius/ulna	i P	0.4 0.7	0.4 0.5	0.4 0.5	0.3 0.5	0.5 0.7	0.3 0.5	0.4 0.6
237	fracture: tibia/fibula	i p	0.2 0.4	0.2 0.4	0.2 0.5	0.1 0.3	0.2 0.3	0.2 0.4	0.2 0.5
238	fracture: hand/foot bones	i P	0.9 1.1	0.8 0.9	0.7 0.9	0.8 1.1	0.8 1.0	0.8 1.0	0.9 1.1
239	fracture: collum femoris	i p	0.1 0.2	0.1 0.2	0.2 0.3	0.2 0.4	0.1 0.3	0.1 0.2	0.1 0.3
240	fracture: femur NEC	i p	0.1 0.1	0.1 0.2	0.0 0.1	0.0 0.0	0.0 0.1	0.1 0.1	0.1 0.1
241	fracture: skull	i p	0.0 0.0	0.0 0.0	0.0 0.0	:	0.0 0.0	0.0 0.0	0.0 0.1
242	fracture: facial bones	i P	0.1 0.1	0.1 0.1	0.1 0.2	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.2
243	fracture: spine	i p	0.1 0.3	0.0 0.1	0.1 0.2	0.1 0.3	0.0 0.2	0.1 0.2	0.1 0.2
244	fracture: rib	i p	0.1 0.1	0.1 0.1	0.3 0.4	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.2
245	fracture: clavicula	i p	0.1 0.2	0.2 0.3	0.0 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.2
246	fracture: humerus	i p	0.1 0.2	0.1 0.1	0.0 0.1	0.1 0.3	0.1 0.2	0.1 0.2	0.1 0.1
247	fracture: pelvis	i p	0.0 0.0	0.0 0.1	0.1 0.1	0.1 0.1	0.0 0.0	0.0 0.1	0.0 0.0
248	fracture: NEC	i p	0.8 1.0	0.6 0.8	0.3 0.6	0.5 0.6	0.7 1.2	0.6 0.8	0.4 0.7
249	sprains/strains ankle(s)	i p	3.2 3.8	3.5 4.0	3.6 4.4	1.8 2.5	3.4 4.1	2.9 3.5	4.0 4.9
250	sprains/strains knee(s)	i p	2.3 2.5	2.5 3.1	2.2 2.6	1.6 1.9	2.2 2.6	2.2 2.5	2.7 3.2
251	sprains/strains shoulder/arm	i p	1.4 1.6	1.7 1.9	1.4 1.8	0.9 1.1	1.7 1.9	1.3 1.5	1.7 2.0
252	sprains/strains wrist/hand	i p	2.8 3.0	3.3 3.6	2.4 3.1	2.0 2.0	2.2 2.4	2.7 3.0	3.3 3.8
253	sprains/strains foot/toe	i p	2.4 2.7	2.5 2.7	2.2 2.5	0.9 1.0	1.9 2.1	2.2 2.4	2.5 2.7
254	sprains/strains spine, excl. cerv. spine	i p	0.7 0.9	0.8 0.9	0.7 0.9	0.6 0.9	0.6 0.7	0.8 0.9	0.8 1.0
255	sprains/strains cerv. spine	i p	0.3 0.5	0.3 0.4	0.4 0.6	0.5 0.6	0.2 0.3	0.4 0.5	0.3 0.4
256	whiplash calf	i p	0.4 0.4	0.4 0.5	0.4 0.5	0.1 0.1	0.3 0.3	0.3 0.4	0.5 0.6
257	sprains/strains musc. skel. syst. NEC	i p	4.0 4.6	3.6 4.0	3.4 4.1	3.0	3.2 3.7	3.5 4.0	4.1 4.8
258	(sub)luxation, dislocation	i p	0.4 0.6	0.5 0.6	0.6 0.7	0.5 0.8	0.6 0.8	0.5 0.6	0.5 0.7
259	cong. luxation of hip	i p	0.1 0.3	0.1 0.2	0.1 0.2	0.1 0.1	0.2 0.5	0.1 0.2	0.1 0.2

no.		season				type of insu	rance	
110.		spring	summer	autumn	winter	public	private	
235	i	0.3	0.0	0.1	0.0	0.1	0.0	
	р	0.4	0.2	0.3	0.2	0.4	0.2	
236	i	0.4	0.3	0.5	0.3	0.4 0.6	0.4 0.5	
	p	0.5	0.6	0.6	0.5	0.2	0.3	
237	i p	0.3 0.5	0.2 0.4	0.3 0.5	0.2 0.3	0.4	0.4	
238	i	0.8	1.2	0.7	0.7	0.7	0.8	
200	p	1.0	1.4	0.8	0.8	0.9	0.9	
239	i	0.1	0.2	0.1	0.1	0.2	0.1	
	p	0.2	0.4	0.3	0.2	0.3	0.2	
040	:	0.0	0.2	0.1	0.0	0.1	0.1	
240	i p	0.1	0.3	0.1	0.1	0.1	0.1	
241	i		0.0	0.0	0.0	0.0		
	р	0.0	0.0	0.0	0.0	0.0	0.0	
242	i	0.1	0.0	0.2	0.0	0.1	0.1	
	p	0.2	0.1	0.2	0.1	0.1	0.1	
243	i	0.2	0.1	0.0 0.1	0.1 0.2	0.1 0.2	0.1 0.1	
	p	0.3	0.2				0.1	
244	i p	0.1 0.1	0.2 0.2	0.2 0.2	0.2 0.2	0.2 0.2	0.2	
245	i	0.1	0.1	0.1	0.1	0.1	0.1	
	р	0.2	0.2	0.1	0.2	0.2	0.1	
246	i	0.0	0.1	0.1 0.2	0.0 0.1	0.0 0.1	0.1 0.1	
	р	0.2	0.1			0.0	0.0	
247	i p	0.0 0.0	0.0 0.1	0.1 0.1	0.0	0.1	0.0	
248	i	0.4	0.8	0.5	0.5	0.6	0.6	
240	p	0.7	1.0	0.7	8.0	8.0	0.7	
249	i	3.6	2.5	3.4	3.3	3.1	2.9	
	р	4.4	3.1	4.2	3.9	3.9	3.4	
050		2.2	2.0	2.1	2.8	2.4	1.9	
250	i p	2.2 2.5	2.3	2.4	3.4	2.8	2.3	
251	i	1.2	1.2	1.5	1.8	1.6	1.0	
	р	1.4	1.5	1.7	2.1	1.9	1.2	
252	i	2.6	2.6	3.0	3.0	3.0	2.1	
	þ	3.0	2.8	3.4	3.2	3.5	2.2	
253	i	1.7 1.9	2.2 2.4	2.2 2.4	2.8 3.0	2.5 2.7	1.6 1.7	
05.4	р :			0.8	0.6	0.9	0.5	
254	i p	0.6 0.7	1.0 1.2	0.8	0.8	1.1	0.6	
	•							
255	i	0.4	0.3	0.4	0.3	0.3	0.3	
	р	0.5	0.6	0.5	0.3	0.5	0.4	
256	i	0.4 0.4	0.3 0.5	0.3 0.3	0.5 0.5	0.4 0.4	0.4 0.5	
057	p :			3.8	3.4	3.9	2.8	
257	i p	3.7 4.3	3.7 4.2	4.4	3.8	4.5	3.1	
258	i	0.5	0.5	0.5	0.5	0.5	0.4	
	p	0.7	0.5	0.7	8.0	0.7	0.5	
259	i	0.2	0.0	0.1	0.0	0.1	0.1	
	р	0.4	0.2	0.2	0.1	0.2	0.2	

no.	episode	degree of	urbanization		region				
	•		rural	suburban	urban	city	north	centre	south
260	cong. anom. musc. skel. syst. NEC	i p	0.2 0.5	0.2 0.3	0.0 0.3	0.1 0.4	0.1 0.3	0.1 0.4	0.2 0.4
261	syndromes cervical spine	i p	1.5	1.0	1.2	1.9 2.7	1.3 1.9	1.2 2.0	1.6 2.4
262	osteoarthritis of cervical spine	i p	0.6 1.4	0.6 1.2	1.3 2.5	0.8 1.6	0.7 1.4	0.9 1.7	0.7 1.3
263	osteoarthritis of spine NEC	i p	0.6 1.7	0.7 1.5	0.6 1.2	0.4 1.4	0.5 1.3	0.6 1.5	0.6 1.8
264	acquired deformities of spine	i p	0.4 1.2	0.9 1.8	0.7 1.6	0.8 1.8	0.7 1.7	0.7 1.5	0.8 1.6
265	back pain with radiating sympt.	i p	0.4 0.7	0.5 1.0	0.4 0.9	0.5	0.5 0.9	0.5 0.9	0.4 0.8
266	lumbago	i p	6.7 8.5	6.8 9.1	7.1 9.9	4.3 6.4	5.8 7.2	6.2 8.4	7.9 10.4
267	sciatica	i p	1.0 1.7	1.0 1.6	1.1 1.6	1.4 2.1	1.5 2.4	1.1 1.7	0.8 1.3
268	slipped lumbar disc	i p	1.5 3.4	1.2 3.0	1.3 2.9	0.7 3.0	0.7 2.3	1.2 2.9	1.8 4.0
269	ganglion joint/tendon	i p	0.6 0.7	0.7 0.8	0.8 0.9	0.6 0.8	0.8 0.8	0.6 0.7	0.9 1.1
270	rheumatoid arthritis	i p	0.5 4.2	0.5 2.2	0.8	0.4 3.0	0.5 3.2	0.5 2.9	0.7 3.3
271	spondylitis (ankylosing)	i p	0.1 0.4	0.1 0.4	0.1 0.4	0.1 0.2	0.1 0.4	0.1 0.3	0.1 0.5
272	osteoarthritis hip	i p	0.7 2.0	0.6 1.6	0.8 2.1	0.6 1.7	0.5 1.6	0.7 1.7	0.8 2.3
273	osteoarthritis knee	i p	1.1 2.3	0.9 2.0	1.2 3.0	1.6 4.0	1.3 2.4	1.0 2.5	1.3 2.7
274	osteoarthritis NEC	i p	0.8 3.1	0.9 2.7	1.4 4.0	1.6 3.4	0.8 2.6	1.1 3.2	1.0 3.5
275	arthritis in allied conditions NEC	i p	1.0 1.9	1.0 1.8	1.4 3.0	0.9 2.2	1.1 2.3	1.0 2.0	1.3 2.4
276	shoulder syndrome	i p	2.5 3.6	2.8 4.2	4.2 5.9	2.5 3.5	2.4 3.4	3.0 4.3	3.2 4.8
277	dis. bursa, excl. shoulder	i p	1.5 1.9	1.0 1.3	1.9 2.1	1.2 1.5	1.3 1.7	1.3 1.6	1.6 1.9
278	epicondilytis lateralis	i p	1.5 2.1	2.0 2.7	1.8 2.4	1.3 1.9	1.6 2.0	1.6 2.2	2.1 2.8
279	tendinitis/synovitis	i p	3.5 4.2	5.0 6.1	5.4 6.8	2.3 3.3	4.0 4.7	4.4 5.4	4.4 5.5
280	osteochondrosis	i p	0.3 0.6	0.3 0.5	0.2 0.3	0. 2 0.5	0.4 0.7	0.2 0.4	0.3 0.5
281	osteoporosis	i p	0.2 1.6	0.2 1.0	0.3 1.6	0.2 2.1	0.2	0.2	0.1 1.1
282	ac. traum. meniscus/lig. knee	i p	1.3	1.2 1.4	1.1 1.3	1.3 1.4	1.2	1.2 1.3	1.2 1.5
283	retropatellar chondropathy	i p	0.8 1.1	1.0 1.2	1.2 1.7	1.1 1.3	0.9 1.2	1.0 1.3	1.0 1.4
284	chron. internal knee derangement	i p	0.2 0.3	0.3 0.5	0.3 0.6	0.3 0.4	0.2 0.3	0.2 0.4	0.5 0.6

		season				type of insura	ance	
no.		spring	summer	autumn	winter	public	private	
260	i	0.1	0.1	0.2	0.2	0.2	0.1	
200	p	0.4	0.4	0.4	0.4	0.4	0.3	
261	i	0.8	1.7	1.6 2.3	1.1 2.1	1.5 2.2	1.0 1.7	
	р	1.5	2.3	0.9	0.6	0.9	0.6	
262	i p	0.7 1.7	1.0 1.5	1.9	1.3	1.9	1.1	
263	i	0.7	0.5	0.8	0.3	0.7	0.5	
200	р	1.8	1.3	1.9	1.1	1.7	1.2	
264	i	0.7	0.6	0.5	0.9	0.7 1.6	0.7 1.4	
	р	1.5	1.3	1.6	1.8	1.0		
265	i	0.5	0.3	0.5	0.5	0.5	0.4	
	р	8.0	8.0	0.9	0.9	1.0	0.6	
266	i	5.7	6.4	6.2	8.0 10.7	7.5 10.3	4.8 6.1	
	р	7.7	8.3	8.5		1.1	0.9	
267	i p	1.0 1.9	1.1 1.7	1.4 1.9	0.7 1.3	1.9	1.3	
268	i	0.9	1.5	1.4	1.3	1.4	1.1	
200	p	2.6	2.9	3.3	3.7	3.3	2.6	
269	i	0.5	0.6	1.1	0.5	0.7	0.6 0.7	
	р	0.7	0.7	1.3	0.6	0.8	0.7	
270	i	0.5	0.7	0.4	0.5	0.6	0.4	
210	р	3.1	4.0	2.6	2.5	3.5	2.3	
271	i	0.1	0.0	0.1	0.2	0.1	0.0	
	р	0.4	0.2	0.4	0.4	0.4	0.2	
272	i	0.6	0.8	0.7 1.9	0.6 1.9	0.8 2.1	0.4 1.4	
	p	1.6	1.9		1.3	1.3	0.7	
273	i P	1.2 2.6	1.0 2.3	1.0 2.4	2.8	2.9	1.6	
274	i	0.9	1.1	1.3	0.8	1.2	8.0	
217	p p	3.1	2.9	4.3	2.5	3.6	2.4	
				4.0	0.8	1.2	0.8	
275	i p	1.3 2.3	1.1 2.3	1.2 2.6	1.6	2.5	1.5	
276	i	2.3	2.8	3.1	3.8	3.3	2.3	
210	p p	3.5	3.9	4.6	5.3	4.7	3.6	
277	i	1.5	1.7	1.3	1.1	1.4	1.4	
	р	1.8	1.9	1.7	1.3	1.7	1.6	
278	i	1.7	1.5 2.3	1.7 2.2	2.0 2.6	1.9 2.6	1.6 2.1	
070	р :	2.2	4.2	5.1	3.7	4.6	3.7	
279	i p	4.4 5.4	4.9	6.7	4.4	5.6	4.6	
	•						0.5	
280	i	0.2	0.1	0.3 0.6	0.4 0.5	0.2 0.5	0.3 0.5	
	р	0.6	0.3		0.1	0.2	0.2	
281	i p	0.2 1.7	0.3 1.4	0.2 1.4	1.3	1.6	1.2	
282	i	0.9	1.6	1.1	1.3	1.2	1.1	
	p p	1.1	1.7	1.2	1.5	1.5	1.2	
283	i	0.7	0.5	1.4	1.2	1.1	0.7	
	р	1.0	0.9	1.8	1.6	1.5	0.9	
284	i	0.3	0.2	0.3 0.5	0.3 0.5	0.3 0.5	0.2 0.3	
	р	0.5	0.2	0.5	0.0			

no.	episode		degree of	urbanization		region	region		
			rural	suburban	urban	city	north	centre	south
285	acquired deformities of limbs	i	1.3	1.7	2.1	2.3	1.3	1.8	1.6
		р	1.9	2.5	3.2	3.5	1.9	2.6	2.7
286	dis. musc. skel, system NEC	i	1.3	1.5	1.6	1.0	1.4	1.3	1.6
		р	2.1	2.3	2.4	1.8	2.2	2.1	2.4

L MUSCULOSKELETAL

no.		season				type of insurance		
110.		spring	summer	autumn	winter	public	private	
285	i	2.0	1.6	1.9	1.4	1.7	1.7	
	p	2.9	2.3	2.9	2.3	2.7	2.2	
286	i	1.0	1.3	2.0	1.3	1.4	1.2	
	p	1.6	2.3	3.0	1.9	2.4	1.9	

no.	o. episode			f urbanization			region		
			rural	suburban	urban	city	north	centre	south
287	headache/facial pain	i p	1.8 6.8	1.6 4.8	1.4 4.9	1.1 3.2	1.4 5.0	1.4 4.9	2.0 6.3
288	sensibility disturbance	i p	0.2 0.7	0.4 0.7	0.5 1.0	0.4 0.7	0.3 0.6	0.4 0.8	0.4 0.8
289	restless legs syndrome	i p	0.3 1.2	0.3 0.8	0.5 1.2	0.4 0.8	0.3 1.3	0.3 0.9	0.5 1.1
290	convulsions	i	0.1 0.2	0.1 0.1	0.3	0.1 0.2	0.0	0.1 0.2	0.1 0.2
291	symptoms sense/smell/taste	p i p	0.0 0.0	0.0 0.0			0.0	0.0 0.0	0.0
292	vertigo	i p	1.9 5.3	1.6 3.8	1.2 3.3	1.5 3.6	1.5 4.9	1.6 4.2	1.6 4.0
293	paralysis	i p	0.1 0.6	0.1 0.5	0.1 0.3	0.3	0.1 0.5	0.1 0.4	0.1 0.6
294	sympt./complt. speech	i p	0.1 0.3	0.2 0.5	0.3 0.5	0.1 0.2	0.1 0.2	0.2 0.4	0.2 0.4
295	fear of neurological disease	i p	0.0	0.1 0.1	0.1 0.2		0.0 0.0	0.0 0.1	0.0 0.1
296	disability/impairment neurol. syst.	i p	0.0	0.0	0.0		0.0	. 0.0	. 0.0
		۲							
297	sympt./complt. neurol. syst. NEC	i p	0.1 0.2	0.1 0.2	0.0 0.2	0.1 0.1	0.0 0.2	0.1 0.2	0.1 0.2
298	poliomyelitis	i p	0.1	0.1	0.1	0.1	0.1	0.1	0.1
299	meningitis/encefalitis	i p	0.0 0.1	0.0 0.1	0.0 0.1	0.1 0.1	0.1 0.2	0.0 0.1	0.0 0.1
300	tetanus	i p		0.0	:		0.0	*	:
301	infections neur. syst. NEC	i		0.0	0.0		0.0	0.0	
001	and distribution of the state o	р	0.0	0.0	0.0	Y	0.0	0.0	0.0
302	malignant neoplasm neur. syst.	i p	0.0 0.2	0.0 0.1	0.0 0.2	0.1 0.2	0.0 0.2	0.0 0.1	0.0 0.3
303	benigne neopl. neur. syst.	i p	0.0	0.0	. 0.1	0. 2 0.3	0.0 0.1	0.0 0.1	0.1 0.2
304	unspecified neopl. neur. syst.	i p	0.0	0.0	0.1 0.1	0.1 0.3	0.0 0.1	0.0 0.1	0.0 0.1
305	concussion: commotio cer.	i	0.6 0.7	0.6 0.7	0.5 0.6	0.4 0.7	0.7 0.8	0.5	0.7 0.8
306	concussion: contusio cer.	p i	0.1	0.1	0.1	0.1	0.2	0.1	0.1
		р	0.2	0.1	0.1	0.1	0.3	0.1	0.1
307	head injury NOS/NEC, w/o skull fract.	i p	0.1 0.1	0.2 0.2	0.1 0.1		0.0 0.1	0.1 0.1	0.1 0.1
308	injuries neur. syst. NEC	i	0.0	0.0	0.1	0.1	0.0	0.0	0.1
	•	р	0.1	0.1	0.1	0.1	0.1	0.1	0.2
309	cong. anom. neur. syst.	i	0.0	0.0	0.0		0.0	0.0	0.0
	N. I. Alexandr	р :	0.3	0.2	0.3	0.2	0.2	0.2	0.3
310	multiple sclerosis	i p	0.1 0.5	0.1 0.6	0.0 0.4	0.2	0.1 0.6	0.1 0.5	0.0 0.3
311	Parkinsonism	i p	0.1 1.5	0.1 1.1	0.1 1.3	0.3 1.7	0.2 1.8	0.1 1.2	0.1 1.5

						type of insu	rance	
no.		season spring	summer	autumn	winter	public	private	
287	i p	1.8 5.6	1.2 4.5	1.6 5.4	1.7 5.6	1.7 6.1	1.0 3.4	
288	i	0.5	0.2	0.4	0.3	0.3	0.3	
	р	8.0	0.7	1.0	0.5	0.8	0.6 0.2	
289	i p	0.4 0.8	0.4 1.1	0.5 1.3	0.2 0.7	0.5 1.2	0.7	
290	i	0.1	0.1	0.2	0.1	0.1	0.1	
200	p	0.2	0.1	0.3	0.1	0.2	0.2	
291	i			0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	
	р	* 1						
292	i	1.3	1.5	1.7	1.8	1.8 5.0	1.2 2.8	
	р	3.6	4.4	4.4	4.4 0.1	0.1	0.1	
293	i p	0.1 0.5	0.2 0.5	0.1 0.4	0.6	0.5	0.4	
294	i	0.1	0.2	0.4	0.2	0.2	0.1	
	р	0.3	0.3	0.7	0.4	0.5	0.2	
295	i	0.1 0.1	0.0 0.1	0.1	0.1 0.1	0.0 0.1	0.1 0.2	
006	р :				0.0	0.0		
296	i p		0.0		0.1	0.0	0.0	
		0.1	0.1	0.0	0.1	0.0	0.1	
297	i p	0.1	0.2	0.1	0.1	0.2	0.2	
298	i	•				0.4		
	p	0.1	0.1	0.1	0.1	0.1	0.1 0.0	
299	i p	0.0 0.1	0.1 0.1	0.0 0.1	0.1 0.1	0.0 0.1	0.1	
300	i			.•/				
000	p		0.0	•	•	0.0	٠	
301	i		0.0	0.0	0.0	0.0 0.0	0.0	
	р	0.0						
302	i	0.0	0.0	0.1	0.0	0.0	0.0 0.2	
	р	0.2	0.1	0.2	0.1	0.1	0.0	
303	i p	0.0 0.0	0.0 0.1	0.0 0.2	0.0 0.1	0.1	0.1	
304	i	0.1	0.1	0.0	0.0	0.0	0.1	
001	p	0.1	0.2	0.1	0.0	0.1	0.1	
305	i	0.5	0.4	0.6	0.6 0.8	0.5 0.7	0.6 0.7	
	р	0.6	0.6 0.1	0.8 0.1	0.1	0.1	0.1	
306	i p	0.1 0.1	0.1	0.2	0.1	0.2	0.1	
						0.1	0.1	
307	i p	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.0	0.1	0.1	
308	i	0.0	0.1	0.1	0.0	0.0	0.1	
	p	0.1	0.1	0.1	0.1	0.1	0.1	
309	i	0.0	0.0	0.0	0.0 0.2	0.0 0.3	0.0 0.2	
- · -	р	0.4	0.2	0.2	0.2	0.0	0.1	
310	i p	0.1 0.3	0.1 0.5	0.1 0.5	0.5	0.5	0.4	
311	i	0.1	0.1	0.2	0.1	0.1	0.1	
	p	0.9	1.4	1.6	1.5	1.6	1.0	

no.	episode		degree of	urbanization					
			rural	suburban	urban	city	north	centre	south
312	epilepsy, all types	i	0.3	0.3	0.3	0.3	0.2	0.3	0.4
		р	5.1	2.7	2.9	2.2	5.5	3.3	3.1
313	migraine	i	1.3	1.4	1.3	0.6	1.0	1.2	1.4
		р	5.0	4.3	3.8	2.6	4.9	4.1	4.3
314	facial paralysis, Bell's palsy	i	0.1	0.1	0.1	0.2	0.1	0.1	0.1
		р	0.1	0.1	0.2	0.3	0.1	0.1	0.2
315	trigeminal neuralgia	i	0.1	0.1	0.2	0.1	0.1	0.1	0.1
		р	0.2	0.2	0.4	0.2	0.3	0.3	0.3
316	carpal tunnel syndrome	i	0.2	0.3	0.2	0.3	0.3	0.3	0.3
	,	р	0.4	0.5	0.4	0.5	0.6	0.4	0.6
317	cluster headache	i	0.0	0.0	0.0	0.1	0.1	0.0	0.0
		р	0.1	0.1	0.0	0.1	0.1	0.1	0.0
318	dis. of periph. nerv. syst. NEC	i	2.3	2.3	2.2	1.7	2.6	2.2	1.9
		р	4.3	3.8	4.0	2.8	4.6	3.9	3.5
319	dis. of central nerv. syst. NEC	i	0.2	0.2	0.3	0.4	0.2	0.2	0.3
	•	р	0.8	8.0	1.6	0.7	1.3	0.9	1.2

no.		season				type of insu	irance
		spring	summer	autumn	winter	public	private
312	i	0.3	0.2	0.4	0.3	0.3	0.2
012	p p	3.0	3.7	3.2	4.0	3.9	2.4
313	i	1.1	1.4	1.5	0.9	1.4	1.0
0.0	p	3.9	5.3	4.3	3.5	4.5	3.7
314	i	0.1	0.1	0.2	0.1	0.1	0.1
011	p	0.1	0.1	0.2	0.1	0.1	0.1
315	i	0.2	0.2	0.1	0.0	0.2	0.0
010	p P	0.4	0.3	0.3	0.1	0.3	0.2
316	i	0.1	0.2	0.5	0.3	0.3	0.2
010	р	0.3	0.3	8.0	0.4	0.5	0.3
317	i	0.0	0.0	0.0	0.1	0.0	0.0
017	p	0.1	0.0	0.1	0.1	0.1	0.0
318	i	1.7	1.9	2.2	2.9	2.3	1.9
5 10	p	2.9	3.8	4.0	4.8	4.3	3.1
240		0.2	0.4	0.3	0.2	0.3	0.3
319	p	0.8	0.9	1.0	1.2	1.1	0.7

no.	episode	degree o	f urbanization			region			
			rural	suburban	urban	city	north	centre	south
320	feeling anxious/nervous/tense	i p	2.9 22.9	4.5 21.5	4.6 20.2	3.7 15.4	2.8 21.7	3.8 21.0	4.5 20.4
321	acute stress (transient) reaction	i p	1.1 3.0	1.5 3.6	2.8 5.1	2.7 11.1	1.4 4.0	2.0 5.0	1.5 3.8
322	feeling depressed	i	0.2	0.4	0.4	0.6	0.4	0.4	0.4
		р	2.4	1.3	0.9	2.1	2.1	1.7	1.2
323	feeling/behaving irritable	i P	0.1 1.2	0.2 0.8	0.3 1.1	0.2 0.8	0.2 0.9	0.2 0.7	0.2 1.7
324	suicide attempt	i p	0.1 0.2	0.1 0.1	0.1 0.1	0.1 0.2	0.2 0.2	0.1 0.1	0.2 0.2
325	disturbances of sleep	i p	0.8 22.7	1.3 18.2	1.1 19.4	0.9 16.9	0.8 25.0	1.1 20.8	1.0 14.6
326	sexual problems	i	0.2	0.4	0.4	0.4	0.1	0.3	0.3
		р	0.3	0.5	0.6	0.7	0.3	0.5	0.5
327	hypochondr. dis./probl. with being ill	i P	0.1 0.5	0.2 0.8	0.2 1.3	0.2 1.1	0.1 0.7	0.2 0.7	0.2 1.2
328	tension headache	i p	1.4 2.3	2.7 4.1	2.3 3.5	2.3 2.7	1.7 2.6	2.1 3.0	2.5 4.0
329	hyperventilation	i	1.5	2.3	2.1	2.8	1.8	2.2	1.7
	,,	р	2.3	3.6	3.4	3.8	2.8	3.4	2.9
330	enuresis	i p	0.2 1.3	0.3 0.7	0.3 0.9	0.2 0.6	0.2 1.4	0.3 0.9	0.3 0.9
331	anorexia nervosa/boulimia	i	0.1	0.1	0.2	0.2	0.0	0.1	0.1
220	anting fooding probl. NEC	р :	0.3	0.2	0.4	0.4	0.2	0.3	0.3
332	eating/feeding probl. NEC	i p	0.0 0.0	0.1 0.1	0.0 0.3	0.1 0.1	0.0 0.1	0.0 0.1	0.0 0.1
333	chronic alcohol abuse	i	0.2	0.4	0.4	0.6	0.4	0.4	0.3
004	and alabalahara	р :	1.3	1.6	2.1	3.0	1.3	1.9	1.6
334	acute alcohol abuse	i p	0.1 0.1	0.0 0.1	0.0 0.1	0.1 0.1	0.1 0.2	0.0 0.1	0.1 0.1
335	tobacco abuse	i	0.5	0.4	0.6	0.5	0.4	0.4	0.6
000		p	1.8	1.6	3.3	2.3	1.7	2.0	2.5
336	drug abuse	i	0.0	0.0	0.1	0.1	0.0	0.1	0.0
007	and the trade of the trade of	р	0.2	0.1	0.6	1.1	0.2	0.5	0.2
337	medicinal abuse	р	0.0 0.2	0.0 0.5	0.4	0.1 0.7	0.0 0.5	0.0 0.4	0.0 0.5
338	abuse substances NEC	i		0.0				•	0.0
		р	0.1	0.0	0.0	0.1	•	0.0	0.1
339	dist. memory/concentration	i p	0.1 0.4	0.1 0.6	0.1 0.5	0.3 0. 6	0.2 0.7	0.1 0.5	0.2 0.4
340	disturbance behaviour child	i	0.2	0.1	0.2	0.1	0.2	0.2	0.2
		р	0.2	0.3	0.3	0.2	0.4	0.2	0.3
341	sympt./complt. behaviour adolescent	i p	0.0 0.1	0.1 0.1	0.2 0.3	0.1 0.4	0.1 0.1	0.0 0.2	0.2 0.3
342	sympt./complt. adult	i	0.1	0.1	0.1	0.4	0.1	0.2	0.2
		р	0.5	0.7	0.6	0.9	0.6	0.6	0.6
343	phase of live problem adult	i p	0.0 0.1	0.1 0.3	0.1 0.3	0.0 0.3	0.1 0.5	0.0 0.2	0.0 0.3
344	dist. learning/mental development	i	0.0	0.1	0.1		0.0	0.0	0.1
	g,g,	p	0.2	0.3	0.2	0.2	0.2	0.2	0.2

no.		season				type of insur	ance	
IIO.		spring	summer	autumn	winter	public	private	
320	i	3.7	3.9	4.0	3.9	4.3	3.2	
	p	19.3	22.3	19.9	22.4	23.8	15.7	
321	i -	1.7 3.9	1.3 2.9	1.7 3.8	2.6 7.7	1.9 5.0	1.4 3.5	
000	р :	0.6	0.3	0.3	0.4	0.4	0.3	
322	i p	1.8	1.8	1.7	1.4	1.8	1.4	
323	i	0.1	0.2	0.3	0.2	0.2	0.2	
	р	0.7	1.6	1.0	8.0	1.1	0.8	
324	i	0.2 0.2	0.0 0.1	0.2 0.2	0.1 0.1	0.1 0.1	0.1 0.1	
	р							
325	i	1.0	1.4	1.0	0.8	1.1	1.0	
	р	17.0	23.5	19.5	19.0	22.3	15.4 0.3	
326	i	0.3 0.5	0.2 0.3	0.4 0.6	0.3 0.5	0.3 0.5	0.5	
207	p :	0.2	0.1	0.1	0.3	0.2	0.1	
327	i p	1.2	0.4	0.7	1.1	1.0	0.6	
328	i	2.1	1.7	2.7	2.1	2.6	1.4	
	р	3.3	2.3	4.0	3.2	3.7	2.2	
329	i	2.0 3.3	1.6 2.3	2.7 3.9	2.0 3.2	2.3 3.6	1.4 2.1	
	р	3.3	2.5					
330	i	0.3	0.2	0.2	0.3	0.3	0.2	
	p	1.1	0.7	8.0	1.1	1.1	0.6	
331	i	0.1	0.2 0.3	0.1 0.3	0.2 0.3	0.1 0.3	0.2 0.3	
	р	0.3	0.1	0.0	0.0	0.1	0.0	
332	i P	0.1 0 <i>.</i> 2	0.1	0.1	0.1	0.1	0.1	
333	i	0.4	0.3	0.5	0.3	0.4	0.3	
	р	1.6	1.6	2.2	1.7	2.2	0.9	
334	i	0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.0	
	р	0.0	0.1					
335	i	0.4	0.4	0.5	0.6	0.6	0.3	
	р	1.4	1.4	2.9	2.9	2.7	1.2	
336	i	0.0	0.0	0.1 0.5	0.1 0.2	0.1 0.4	0.0 0.1	
	p	0.4	0.3		0.1	0.0	0.0	
337	i p	0.0 0.5	0.0 0.3	0.0 0.6	0.4	0.5	0.3	
338	i		s•.	0.0		0.0		
	p	0.0	0.1	0.0	0.0	0.1	•	
339	i	0.1	0.1	0.1	0.2	0.1 0.5	0.0 0.4	
	р	0.3	0.6	0.5	0.6			
340	i	0.1	0.1	0.2	0.2	0.2	0.1	
	p	0.2	0.2	0.3	0.3	0.3	0.2	
341	i	0.0	0.0	0.2	0.1	0.1 0.2	0.1 0.2	
	p	0.0	0.2	0.3	0.3	0.2	0.1	
342	i p	0.2 0.5	0.1 0.6	0.1 0.7	0.2 0.6	0.7	0.4	
343	i	0.0	0.0	0.1	0.0	0.0	0.1	
040	p	0.1	0.3	0.3	0.3	0.3	0.2	
344	i	0.1		0.0	0.0	0.0	0.1	
	р	0.2	0.1	0.3	0.3	0.2	0.2	

no.	episode		degree of	urbanization		region			
			rural	suburban	urban	city	north	centre	south
345	fear of mental disorder	i p	0.0 0.0	0.0 0.1	0.0 0.0		0.0 0.0	0.0 0.0	0.0 0.0
346	psychic disability/impairment	i p	0.0	0.0 0.0	0.1		0.0	0.0	0.0 0.1
347	psychic sympt./compit. NEC	i P	0.4 1.4	0.4 1.0	1.0 2.1	0.2 3.3	1.0 1.9	0.4 1.6	0.5 1.7
348	dementia (pre)senile	i p	0.2 0.9	0.2 0.9	0.3 1.4	0.2 1.5	0.1 1.2	0.2 1.0	0.3 1.2
349	organic psychosis	j p	0.0	0.0	0.1 0.3	0.1	0.1 0.2	0.1 0.2	0.0
350	schizophrenia, all types	i p	0.0 0.5	0.1 0.5	0.0 0.7	0.3 0.9	0.1 0.6	0.1 0.6	0.0 0.5
351	affective psychosis	i p	0.2 1.1	0.1 0.6	0.2 0.9	0.4 1.2	0.2 1.0	0.2 1.0	0.2 0.8
352	unspecified psychosis NEC	i p	0.1 1.2	0.1 0.9	0.2 1.2	0.2 1.7	0.2 1.5	0.1 1.1	0.1 1.1
353	anxiety disorder/anxiety state	i p	0.1 0.6	0.2 0.7	0.3 0.9	0.4 0.8	0.1 1.0	0.3 0.7	0.2 0.7
354	hysterical/hypochondriacal dis.	j p	0.2 1.2	0.3 1.5	0.4 1.5	0.6 2.0	0.4 1.4	0.3 1.4	0.2 1.5
355	depressive disorder	i p	2.2 9.7	2.5 8.2	2.1 7.4	1.9 6.5	1.7 8.0	2.4 8.6	2.0 7.6
356	mental retardation	i p	0.0 0.7	0.0 0.9	0.0 0.7	0.4	0.0 1.1	0.0 0.7	0.0 0.8
357	neurasthenia, surmenage	i p	2.5 4.7	3.8 6.4	4.6 8.4	3.4 5.5	4.1 7.3	3.5 6.1	3.1 5.9
358	personality disorder	i p	0.0 0.3	0.0 0.2	0.1 0.2	0.1 0.2	0.2	0.0 0.2	0.1 0.3
359	phobia/neurotic disorder NEC	i P	0.3 1.1	0.4 1.7	0.7 3.4	0.4 1.7	0.3 1.9	0.4 2.0	0.5 1.7
360	mental/psychological dis. NEC	i p	0.2 1.2	0.7 2.5	0.4 2.2	0.7 2.7	0.7 2.4	0.6 2.2	0.3 1.4

DO		season				type of insu	rance
no.		spring	summer	autumn	winter	public	private
		0.0	0.0	0.0	0.0	0.0	0.0
345	i . P	0.0 0.0	0.0	0.0	0.0	0.0	0.0
					0.0		0.0
346	i	0.0	0.0	0.1	0.0	0.1	0.0
	p			0.3	8.0	0.5	0.4
347	i	0.4	0.4 1.3	2.2	1.7	1.9	1.2
	р	1.4				0.2	0.2
348	i	0.2	0.2	0.3	0.1 0.8	0.2	1.1
	р	8.0	1.3	1.5			
349	i	0.0	0.1	0.0	0.0	0.1	0.1 0.1
	р	0.2	0.3	0.1	0.3	0.3	0.1
350	i	0.1	0.1	0.2	0.1	0.1	0.1
330	p	0.6	0.5	0.8	0.5	0.7	0.3
				0.2	0.1	0.2	0.2
351	i	0.2 1.0	0.4 1.1	0.9	0.6	0.9	0.9
	р					0.2	0.1
352	i	0.1	0.2	0.2	0.1 1.2	1.3	0.7
	р	0.7	1.5	1.2			
353	i	0.4	0.3	0.3	0.1	0.3	0.2 0.5
	р	0.9	0.7	0.9	0.5	0.9	
354	i	0.3	0.2	0.3	0.3	0.4	0.2
	р	1.5	1.5	1.3	1.4	1.7	1.0
055		4.7	2.5	2.7	2.1	2.5	1.8
355	i	1.7 7.6	9.3	8.9	7.5	9.1	6.9
	р				0.0	0.0	0.0
356	i	0.0	0.0 0.5	0.0 1.0	0.9	1.0	0.3
	р	0.7					3.3
357	i	2.8	3.6	4.7	2.9	3.7 6.5	5.9
	р	5.0	6.4	8.1	5.3	6.5	
358	i		0.0	0.1	0.1	0.0	0.0
	р	0.0	0.2	0.5	0.2	0.3	0.1
359	i	0.2	0.4	0.4	0.7	0.4	0.4
555	p	0.6	1.6	2.5	2.9	2.0	1.7
		0.0	0.2	0.2	0.4	0.5	0.5
360	i	0.3 2.4	0.2 1.9	1.8	1.1	2.2	1.8
	р	2.4	1.5	1.0			

no.	episode	degree o	f urbanization			region			
			rural	suburban	urban	city	north	centre	south
361	pain attr. to respiratory system	i p	0.0	0.0 0.1	0.0 0.0			0.0 0.0	0.0 0.0
362	shortness of breath, dyspnoe	i p	0.4 1.4	0.2 0.6	0.2 1.0	0.3 0.8	0.2 0.9	0.3 0.9	0.3 1.1
363	wheezing	i p	0.0 0.0	0.0 0.0	0.0 0.1	0.1	0.0 0.0	0.0 0.0	0.0 0.0
364	breathing problems NEC	i p	0.0 0.1	0.1 0.1	0.3 0.4	0.2 0.2	0.0 0.1	0.1 0.2	0.1 0.1
365	cough	i p	9.5 9.5	10.2 10.3	9.0 9.2	6.2 6.5	10.3 10.6	9.1 9.2	9.0 9.4
366	epistaxis/nose bleed	i p	0.5 0.6	0.6 0.8	0.5 0.6	0.1 0.1	0.4 0.5	0.5 0.6	0.5 0.6
367	sneezing/nasal congestion	i p	0.3 1.0	0.2 0.4	0.5 1.0	0.3 0.5	0.2 0.6	0.3 0.8	0.3 0.7
368	sympt./complt. nose NEC	i p	0.2 0.4	0.2 0.4	0.3 0.4	0.3 0.6	0.3 0.5	0.2 0.4	0.3 0.5
369	sympt./complt. sinus (incl. pain)	i p	0.1 0.1	0.2 0.3	0.1	0.0	0.1	0.1	0.2 0.2
370	sympt./complt. throat	i p	0.9 2.5	1.5 2.5	1.5 2.9	1.8 2.7	1.1 2.1	1.2 2.5	1.7 3.0
371	sympt./complt. tonsils	i p	0.0 0.1	0.0 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.0 0.0	0.1 0.1
372	sympt./complt. voice/vocal cords	i p	0.3 0.5	0.3 0.5	0.2 0.2	0.4 0.4	0.2 0.3	0.3 0.4	0.4 0.5
373	haemoptysis	i p	0.0 0.0	0.1 0.1	0.1 0.2		0.0 0.0	0.0 0.1	0.1 0.1
374	abnormal sputum/phlegm NEC	i p	0.1 0.5	0.2 0.6	0.4 1.1	0.2 0.2	0.2 0.5	0.2 0.5	0.3 1.1
375	fear of respiratory disease	i p	0.1 0.1	0.1 0.3	0.3	0.1 0.2	0.0	0.1 0.2	0.3 0.5
376	disability/impairment resp. syst.	i p	0.0 0.0	0.0			0.0 0.0	0.0 0.0	0.0
377	sympt./complt. resp. syst. NEC	i p	0.3 0.6	0.1 0.2	0.6 1.1	0.0 0.2	0.3 0.9	0.2 0.5	0.3 0.5
378	tuberculosis resp. (excl. A70)	i p	0.2	0.0 0.1	0.1 0.3	0.2	0.0 0.3	0.0 0.1	0.0 0.2
379	whooping cough	i p	0.6 0.9	0.2 0.3	0.1 0.2	0.1 0.2	0.3 0.5	0.3 0.5	0.3 0.4
380	scarlet fever	i p	0.2 0.2	0.3 0.4	0.2 0.2	0.3 0.3	0.2 0.2	0.3 0.4	0.1 0.1
381	streptoc. inf. throat NEC	i p	0.0	0.1 0.1	0.1 0.1	0.0	0.0 0.0	0.0 0.1	0.1 0.1
382	boil/abscess nose	i p	0.0 0.1	0.0 0.0	0.1 0.1	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1
383	URI (head cold)	i p	27.3 30.3	32.4 34.6	32.6 35.1	32.4 36.3	22.9 25.2	28.6 31.5	40.0 42.5
384	sinusitis acute/chronic	i p	8.5 10.4	8.5 10.3	10.1 12.4	7.3 9.5	9.0 10.5	8.3 10.4	9.5 11.7
385	acute tonsillitis/adenoiditis	i p	7.4 7.5	4.9 5.1	5.8 6.0	5.7 6.1	8.8 8.9	6.1 6.3	4.6 4.8

		000000				type of insu	rance	
10.		season spring	summer	autumn	winter	public	private	
361	i p	0.0	0.0	0.0	0.0 0.1	0.0 0.0	0.0	
62	i p	0.2	0.4 1.5	0.3 0.9	0.2 0.6	0.3 1.1	0.2 0.6	
63	i	0.0	0.0	0.0 0.1	0.0	0.0 0.0	0.0	
64	p i	0.2	0.0 0.1	0.1 0.2	0.1 0.1	0.1 0.2	0.1 0.1	
65	p i	0.2 8.7 8.9	8.0 8.3	9.6 10.0	10.1 10.2	10.3 10.7	6.7 6.9	
	р				0.5	0.5	0.4	
166	i p	0.5 0.6	0.3 0.5	0.5 0.6	0.6	0.6	0.6	
67	i p	0.1 0.4	0.2 0.7	0.4 0.8	0.5 1.1	0.4 0.8	0.6	
68	i p	0.2 0.3	0.2 0.3	0.3 0.4	0.4 0.6	0.3 0.4	0.2 0.3	
369	i p	0.2 0.3	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.2	0.2 0.2	
370	i p	1.1 2.3	1.3 2.3	1.6 2.9	1.3 2.8	1.5 3.0	1.1 2.0	
371	i	0.2 0.2	0.0	0.0	0.0	0.1 0.1	0.0 0.1	
372	p i	0.1 0.3	0.3 0.4	0.2 0.3	0.5 0.7	0.4 0.5	0.2 0.3	
373	p i	0.1 0.1	0.0	0.1 0.1	0.0	0.1 0.1	0.0 0.1	
374	p i	0.2 0.8	0.1 0.7	0.2	0.2 0.8	0.2 0.7	0.1 0.4	
375	p i p	0.2 0.2	0.1 0.1	0.2 0.3	0.1 0.3	0.1 0.3	0.1 0.2	
376	i		0.0	0.0	0.0	. 0.0	0.0	
377	p i	0.0	0.2 0.4	0.5 1.0	0.3 0.6	0.3 0.6	0.2 0.5	
378	p i	0.2	0.4 0.1	0.0 0.3	0.0 0.2	0.0 0.2	0.0 0.1	
379	p i	0.1	0.3	0.3 0.4	0.1 0.2	0.2	0.5 0.6	
380	p i p	0.9 0.6 0.7	0.4 0.0 0.0	0.4 0.2 0.3	0.2 0.2	0.2	0.3 0.4	
381	 і	0.1	0.1	0.1	0.0	0.1	0.1	
	р	0.1	0.1	0.1	0.0	0.1 0.1	0.1 0.0	
382	i p	0.1 0.1	0.1	0.0	0.0	0.1	0.0	
383	i p	31.4 34.3	19.7 21.4	38.1 40.8	34.1 37.5	34.7 37.8	24.8	
384	i p	7.1 9.2	5.0 6.6	10 <i>.</i> 2 12.0	12.4 15.2	8.8 11.0	8.6 10.1	
385	i p	3.8 4.0	5.4 5.5	6.7 7.0	8.0 8.3	5.8 6.1	5.7 5.9	

no	no. episode			f urbanization			region	region		
110.	орысче		rural	suburban	urban	city	north	centre	south	
386	acute laryngitis/tracheitis/croup	i	2.0	3.7	5.7	3.2	1.9	3.6	4.2	
300	acute atyrigitis/tracricitis/croup	p	2.0	3.9	6.1	3.3	2.0	3.7	4.6	
387	acute bronchi(oli)tis	i	9.5	9.1	10.9	9.4	12.0	9.0	10.5	
	, ,	р	13.0	12.0	14.5	13.4	14.4	12.5	13.9	
388	influenza w/o pneumonia	i	5.4	5.7	6.8	8.2	2.9	5.7	8.6	
		р	5.5	5.9	7.0	8.4	3.1	5.9	8.7	
389	pneumonia	i	1.9	1.6	3.4	1.8	1.1	2.1	2.9	
		р	2.0	1.6	3.5	2.0	1.2	2.1	3.0	
390	pleurisy all (excl. R70)	i	0.0	0.0 0.1	0.1 0.2	0.1 0.1	0.0 0.1	0.1 0.1	0.0 0.1	
		р	0.1	0.1	0.2	0.1	0.1	U. I		
391	infection resp. syst. NEC	i	0.6	0.8	1.0	0.4	1.2	0.5	1.1	
001	anocaen resp. eyea ria	р	1.1	1.5	1.5	0.4	2.0	0.9	2.0	
392	mal. neopl. bronchus/lung	i	0.1	0.1	0.1	0.2	0.1	0.1	0.1	
		р	1.0	0.8	1.4	1.2	1.1	1.0	1.0	
393	mal. neopl. resp. syst. NEC	i	0.0	0.0	0.1	0.1	0.0	0.0	0.0	
		р	0.2	0.2	0.3	0.6	0.3	0.3	0.2	
394	ben. neopl. resp. syst.	i		0.1	0.0		0.0	0.0	0.0	
		р	0.0	0.1	0.1	•	0.0	0.1	0.1	
395	unspecified neopl. resp. syst.	i p	0.0 0.1	0.0 0.2	0.1 0.2	0.1	0.0 0.1	0.0 0.2	0.0 0.1	
		ρ	0.1		0.2	0.1				
396	foreign body resp. syst.	i	0.1	0.0	0.0		0.1	0.0	0.1	
000	ioroight body recept cycle	р	0.1	0.0	0.0	•	0.2	0.0	0.1	
397	injuries resp. syst. NEC	i	0.1	0.1	0.0		0.0	0.0	0.0	
	•	p	0.1	0.1	0.0	•	0.0	0.0	0.1	
398	cong. anom. resp. syst.	i		0.0	0.0	•		0.0	0.0	
		р	0.0	0.0	0.1	•	•	0.0	0.1	
399	hypertrophy/chron. inf. tonsills/aden.	i	0.5	0.5	0.7	1.2	0.6	0.7	0.6	
		р	0.7	0.7	1.2	2.0	0.9	1.1	8.0	
400	chronic bronchitis	i	1.2	0.8	1.0 8.6	0.8 9.7	1.3 18.0	1.0 10.0	0.8 8.4	
		р	14.4	8.2 	0.0	9.7	10.0		0.4	
401	pleural effusion NOS	i	0.0	0.1	0.2	0.1	0.0	0.1	0.0	
401	piedrai endsien 1400	p p	0.0	0.1	0.2	0.1	0.1	0.1	0.1	
402	emfysema	i	0.1	0.2	0.3	0.2	0.1	0.2	0.3	
102	omi, com	р	3.1	3.0	3.7	3.0	3.2	2.8	4.0	
403	asthma	i	1.8	1.6	2.4	1.5	2.1	1.7	2.1	
		р	9.5	10.3	11.5	9.1	10.9	9.2	12.3	
404	allergic rhinitis/hay fever	i	1.7	2.5	2.5	1.7	1.8	2.1	2.5	
		р	6.7	7.3	6.3	4.6	6.8	6.4	6.8	
405	diseases resp. syst. NEC	i	0.7	0.6	0.5	0.4	0.7	0.6	0.5	
		р	1.8	1.4	1.5	0.7	1.3	1.4	1.9	

no.		season				type of insu	rance
110.		spring	summer	autumn	winter	public	private
206	:	4.4	1.3	4.2	4.3	3.6	3.3
386	i P	4.6	1.3	4.5	4.6	3.8	3.5
387	i	8.6	7.2	11.9	11.0	10.1	8.9
007	p	11.7	9.6	14.8	16.1	13.7	11.4
388	i	5.3	3.5	8.3	7.7	7.2	4.1
	р	5.3	3.6	8.5	7.8	7.4	4.2
389	i	1.3	2.3	2.7	2.1	1.9	2.2
	р	1.3	2.4	2.8	2.3	2.0	2.3
390	i	0.0	0.0	0.1	0.1	0.0	0.0
	р	0.0	0.0	0.2	0.2	0.1	0.1
			0.5	1.6	0.6	0.8	0.7
391	i p	0.2 0.7	0.9	2.2	1.3	1.4	1.0
392	i	0.1	0.1	0.1	0.0	0.2	0.1
392	p	1.0	1.1	1.0	0.9	1.0	0.6
393	i	0.1	0.0	0.1	0.0	0.1	0.0
333	p	0.3	0.2	0.4	0.1	0.3	0.1
394	i	0.1	0.0	p.	0.0	0.0	0.0
034	p	0.1	0.0	0.1	0.1	0.1	0.0
395	i	0.0	0.1	0.0	•	0.0	0.0
000	p	0.3	0.1	0.1	0.1	0.2	0.1
							0.0
396	i	0.1	0.1	0.0	0.1	0.1 0.1	0.0 0.1
	р	0.1	0.1	0.0	0.1		0.0
397	i	0.0	0.1 0.1	0.1 0.1	0.0 0.0	0.0 0.0	0.0
	р	0.0	0.1				0.0
398	i	0.1	•	0.0 0.0	0.0 0.0	0.0 0.0	0.0
	p				0.5	0.5	0.8
399	i	1 <i>.</i> 2 1.7	0.6 0.9	0.3 0.6	0.8	0.9	1.2
	р		0.9	1.0	0.9	1.2	0.6
400	i p	1.1 8.8	10.2	12.0	10.9	12.5	6.7
401	i	0.1	0.1	0.1	0.0	0.1	0.0
	p	0.2	0.1	0.1	0.1	0.1	0.0
402	i	0.2	0.2	0.2	0.2	0.3	0.1
	р	2.1	2.7	4.5	3.3	3.7	2.0
403	i	1.5	1.8	2.3	1.6	1.9	1.6
	р	7.4	8.7	13.8	10.8	11.3	8.2
404	i	3.6	2.1	1.7	1.2	2.2	2.1 6.1
	р	11.4	5.4	4.1	5.4	6.8	
405	i	0.7	0.5	0.7	0.4	0.6 1.6	0.4 1.2
	р	1.6	1.7	1.2	1.4	1.0	1.2

no.	episode	degree of	degree of urbanization region						
	·		rural	suburban	urban	city	north	centre	south
406	pain/tenderness of skin	i p	0.0 0.1	0.1 0.1	0.0	0.1 0.2	0.0 0.1	0.1 0.1	0.0 0.1
407	pruritus, skin itching	i P	0.6 1.8	0.9 1.9	1.2 2.5	0.7 1.3	0.7 1.9	0.8 1.7	1.1 2.3
408	warts	i p	4.4 5.8	5.0 7.6	7.0 8.3	3.1 4.2	5.9 7.3	4.8 6.7	5.4 6.9
409	condyloma acuminata	i p	0.2 0.2	0.2 0.2	0.6 0.6	0.8 0.8	0.3 0.3	0.4 0.4	0.3 0.3
410	local swelling/papul/lump	i p	0.5 0.6	0.5 0.7	0.5 0.6	0.4 0.8	0.8 0.9	0.4 0.5	0.6 0.8
411	multiple swelling/papul/lump	i p	0.1 0.2	0.2 0.2	0.1 0.1	0.1 0.4	0.2 0.2	0.1 0.2	0.2 0.3
412	local redness/erythema	i p	0.6 1.1	0.7 1.4	0.6 1.0	0.7 0.8	0.6 1.0	0.6 0.9	0.8 1.9
413	general redness/erythema	i p	0.1 0.4	0.2 0.5	0.3 0.4	0.2 0.2	0.2 0.4	0.1 0.3	0.4 0.7
414	changes in skin color NEC	i p	0.1 0.2	0.0 0.1	0.2 0.2	0.3 0.5	0.0 0.1	0.2 0.2	0.1 0.1
415	local infection finger/toe	i p	1.4 1.5	1.9 2.0	1.3 1.4	1.1 1.1	1.7 1.7	1.5 1.6	1.6 1.7
416	boil/carbuncle/cellulitis	i p	1.7 2.1	2.4 2.8	1.4 1.7	2.2 3.1	1.6 1.9	2.0 2.4	1.9
417	local infection skin NEC	i p	1.4 1.9	1.2 1.6	1.0 1.5	1.1 1.2	1.4 1.8	1.0 1.5	1.5 1.9
418	insect bite	i p	1.5 1.6	1.2 1.3	0.8 0.9	0.7 0.7	0.9 0.9	1.1 1.2	1.3 1.3
419	animal/human bite	i p	0.6 0.7	0.6 0.7	0.4 0.5	0.4 0.5	0.7 0.8	0.5 0.6	0.5 0.6
420	burns/scalds	i p	0.9 1.4	0.8 1.1	0.6 0.8	0.8 1.0	0.6 0.8	0.8	0.8 1.3
421	foreign body in skin	i p	0.6 0.7	0.5 0.5	0.4 0.5	0.2 0.2	0.4 0.4	0.4 0.5	0.6 0.6
422	bruise/contusion intact skin	i p	2.1 2.4	1.9 2.2	2.3 2.5	1.9 1.9	2.0 2.1	1.9 2.2	2.5 2.8
423	abrasion/scratch/blister	i p	1.1 1.2	0.8 0.9	0.9 0.9	1.0 1.0	0.8 0.8	1.0 1.1	0.9 0.9
424	laceration/cut	i p	4.5 5.0	4.1 4.5	2.6 3.0	2.1 2.3	3.2 3.5	3.6 4.0	4.1 4.6
425	injury to skin NEC	i p	2.5 3.5	1.8 2.8	1.2 2.0	1.9 2.8	3.2 4.4	1.5 2.4	2.2 3.4
426	corns/callosities	i p	0.8	0.9 1.1	0.7 0.9	1.2 1.2	0.6 0.7	0.8 1.1	1.0 1.2
427	sympt./complt. of skin texture	i p	0.4	0.7 1.7	0.4	0.5 1.4	0.4	0.6 1.5	0.6 1.0
428	sympt./complt. nails	i p	0.2 0.3	0.1 0.3	0.2 0.3	0.1	0.2 0.4	0.1 0.2	0.2 0.3
429	losing hair/baldness	i p	0.1 0.2	0.2 0.5	0.3 0.7	0.5 1.1	0.2 0.3	0.2 0.6	0.2 0.5
430	sympt./complt. hair NEC	i p	0.1 0.4	0.1 0.2	0.3 0.4	0.2 0.5	0.1 0.4	0.1 0.3	0.2 0.4

20		season				type of insu	rance
no.		season spring	summer	autumn	winter	public	private
06	i	0.1 0.3	0.0 0.1	0.0 0.0	0.0 0.1	0.0 0.1	0.1 0.1
)7	p i	0.9	0.1	0.9	1.0	1.0	0.7
J1	p p	2.1	1.5	1.9	2.2	2.2	1.3
80	i	5.5	3.8	6.2	4.7	4.9 6.5	4.9 6.9
	p	7.9	5.8	7.6	6.0	0.4	0.9
09	i p	0.3 0.3	0.1 0.1	0.5 0.5	0.5 0.5	0.4	0.2
10	i	0.4	0.5	0.4	0.7	0.5	0.4
	p	0.6	0.6	0.6	0.8	0.7	0.5
11	i	0.1	0.1	0.1	0.1	0.1	0.1
	р	0.2	0.3	0.1	0.2	0.2	0.2
12	i	0.9	0.5	0.8 1.0	0.4 1.0	0.7 1.3	0.5 0.9
15	р	1.5	1.0	0.1	0.2	0.2	0.1
13	i p	0.3 0.5	0.2 0.5	0.1	0.3	0.5	0.3
14	i	0.1	0.2	0.2	0.1	0.2	0.1
	p	0.1	0.2	0.2	0.2	0.2	0.1
15	i	1.8	1.0	1.8 1.9	1.6 1.6	1.5 1.6	1.3 1.4
	р	1.9	1.1	1.8	1.0		
16	i	1.6	1.6	2.4	2.1	2.1	1.6 1.8
	р	2.0	1.9	2.9	2.7	2.6	0.9
17	i n	0.9 1.3	1.1 1.4	1.3 1.9	1.5 2.0	1.3 1.8	1.3
10	p i	0.9	2.8	0.7	0.1	1.1	1.0
18	p	0.9	3.0	0.8	0.2	1.2	1.1
119	i	0.6	0.7	0.5	0.4	0.6	0.4
	р	0.7	0.7	0.6	0.5	0.6	0.5 0.6
20	i	1.0 1.4	1.1 1.4	0.5 0.8	0.6 0.8	0.9 1.3	0.8
	р	1.79			·		
21	i	0.6	0.5	0.3	0.5	0.5 0.6	0.4 0.5
	p	0.7	0.5	0.4	0.6		1.4
22	i p	1.6 1.8	2.0 2.3	2.6 3.0	2.0 2.2	2.4 2.7	1.6
423	i	1.1	1.2	0.7	0.8	1.1	0.6
720	р	1.2	1.4	0.7	0.8	1.2	0.7
124	i	4.9	3.9	3.1	2.9	3.6	3.5 3.8
	р	5.4	4.3	3.5	3.1	4.0 2.0	1.6
425	i p	1.3 2.2	2.7 3.7	1.8 2.9	1.7 2.6	3.1	2.3
							0.7
126	i	1.1	0.8 1.0	0.7	0.7 0.9	1.0 1.2	0.7 0.9
107	p i	1.4 0.4	0.5	0.8	0.5	0.6	0.4
127	i p	1.0	1.3	1.7	1.3	1.5	1.0
128	i	0.2	0.2	0.1	0.1	0.2	0.1
	р	0.3	0.3	0.2	0.2	0.3	0.2
429	i	0.2	0.2	0.3 0.6	0.1 0.3	0.2 0.6	0.2 0.5
430	р :	0.5	0.7	0.8	0.1	0.2	0.0
	i	0.1	0.1 0.4	0.3	0.3	0.5	0.2

no.	episode	degree of	urbanization		region				
	·		rural	suburban	urban	city	north	centre	south
431	fear of skin disease	i p	0.0 0.0	0.0 0.0	0.0 0.2	0.1 0.1	0.1 0.1	0.0 0.1	0.0 0.0
432	disability/impairment of skin	i p		0.0	0.0		0.0	0.0	
433	sympt./complt. of skin NEC	i p	0.3 0.8	0.3 0.5	0.2 0.6	0.4 0.7	0.2 0.6	0.3 0.7	0.2 0.6
434	herpes zoster	i p	0.8 1.3	0.9 1.1	1.1 1.2	1.7 2.0	0.9 1.1	1.0 1.3	1.0 1.2
435	herpes simplex lip/mouth	i p	0.6 1.3	0.7 1.2	0.9 1.4	0.7 1.8	0.5 1.0	0.7 1.4	0.9 1.3
436	herpes simplex genitalis	i p	0.0 0.1	0.1 0.2	0.1 0.1	0.5 0.7	0.0 0.1	0.2 0.2	0.1 0.1
437	herpes simplex NEC	i p	0.2 0.3	0.2 0.2	0.3 0.5	0.2 0.5	0.1 0.2	0.2 0.4	0.2 0.3
438	scabies/other ascariasis	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.5 0.7	0.2 0.2	0.2 0.3	0.0 0.1
439	pediculosis/skininfestation	i p	0.2 0.4	0.4 0.5	0.5 0.6	0.4 0.5	0.3 0.5	0.3 0.4	0.4 0.5
440	dermatophytosis/dermatomycosis	i p	5.1 8.1	6.0 8.2	6.0 9.0	6.5 8.8	4.2 6.3	6.0 8.6	5.8 8.9
441	moniliasis/candidiasis (excl. GU)	i p	0.8 1.4	0.7 1.1	0.9 1.2	1.4 1.7	1.1 2.0	0.7 1.1	1.1 1.5
442	erysipelas	i p	1.0 1.4	0.5 0.6	0.7 0.8	1.0 1.3	0.7 0.9	0.7 0.9	0.9 1.3
443	mollusca contagiosa	i P	0.5 0.6	1.0 1.1	1.0 1.0	0.3 0.3	0.3 0.3	0.8 0.9	0.6 0.8
444	infection skin NEC	i p	0.7 0.9	0.6 0.9	0.6 0.7	0.4 0.6	0.9 1.1	0.6 0.8	0.6 0.8
445	malign. neoplasm skin	i p	0.3 0.7	0.3 0.6	0.1 0.4	0.3 0.7	0.2 0.6	0.2 0.6	0.3 0.6
446	lipoma	i p	0.6 0.7	0.9 1.0	0.8 1.0	1.4 1.6	0.7 0.9	1.0 1.1	0.5 0.6
447	benign. neoplasm skin NEC	i p	1.1 1.4	1.9 2.1	1.6 1.8	0.8 1.3	1.6 1.9	1.3 1.6	1.6 1.9
448	unspecified neoplasm skin	i p	0.1 0.1	0.2 0.2	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.2
449	hemangioma/lymfangioma	i p	0.1 0.1	0.2 0.2	0.0 0.0	0.5 0.5	0.1 0.2	0.2 0.2	0.1 0.1
450	nevus/mole	i p	0.7 0.9	0.8 1.0	0.9 1.3	0.8 1.1	1.3 1.8	0.8 1.1	0.6 0.7
451	cong. anom. of skin NEC	i p	. 0.0	0.0		0.1 0.1	•	0.0	0.0
452	impetigo	i p	2.0 2.1	1.3 1.4	1.2 1.3	1.0 0.9	1.4 1.4	1.4 1.4	1.8 1.9
453	pilonidal cyst/fistula	i p	0.1 0.2	0.1 0.2	0.1	0.1	0.1 0.2	0.1 0.2	0.1
454	seborrheic dermatitis	i p	0.9 1.5	1.3	0.9	1. 2 1.8	0.9 1.7	1.0 1.5	1.1 1.8
455	atopic dermatitis/eczema	i p	0.8 1.5	1.4 2.6	1.0 2.1	1.7 2.8	1.3 2.3	1.1 2.2	1.2

		season				type of insu	rance	
no.		spring	summer	autumn	winter	public	private	
131	i	0.0	0.0	0.0	0.0	0.0	0.0	
	р	0.0	0.1	0.1	0.0	0.1	0.1	
32	i			1.0	0.0	0.0	.e.	
	р	0.0	0.0 0.3	0.3	0.2	0.3	0.2	
133	i P	0.4 0.7	0.5	0.3	0.7	0.7	0.5	
134	i	1.0	0.8	1.1	1.0	1.0	1.0	
	p	1.4	1.2	1.4	1.2	1.3	1.3	
135	i	0.6	0.8	8.0	0.7	0.8	0.5 1.1	
	þ	1.2	1.5	1.1	1.6	1.5	1.1	
36	i	0.1	0.2	0.1	0.1	0.1	0.1	
	p	0.2	0.2	0.1	0.1	0.1	0.2	
137	i	0.2	0.2	0.2	0.1	0.2	0.2	
	р	0.5	0.4	0.3	0.1	0.4	0.2	
138	i	0.2 0.2	0.0 0.1	0.4 0.5	0.0 0.1	0.2 0.2	0.1 0.2	
120	p i	0.3	0.3	0.4	0.4	0.4	0.2	
139	i p	0.3	0.4	0.5	0.5	0.5	0.3	
140	i	5.8	6.6	5.8	4.9	6.0	5.5	
	р	8.4	9.3	8.9	7.0	8.8	7.8	
		0.7	0.9	1.2	0.8	0.9	0.8	
441	i p	0.7 0.8	1.2	1.7	1.5	1.4	1.1	
442	i i	0.6	1.0	0.7	0.8	0.9	0.4	
	p	8.0	1.2	0.9	1.2	1.2	0.6	
443	i	1.0	0.5	0.4	1.0	0.5 0.6	1.1 1.2	
	р	1.2	0.5	0.5	1.1	0.6	0.6	
444	i p	0.7 1.0	0.9 1.0	0.4 0.7	0.4 0.5	0.9	0.7	
445	i	0.2	0.3	0.2	0.2	0.3	0.2	
	p	0.5	8.0	0.6	0.5	0.6	0.5	
			4.0	10	0.6	0.9	0.7	
446	i p	0.6 0.8	1.0 1.1	1.2 1.3	0.6 0.8	1.0	0.8	
447	i	1.8	0.9	1.5	1.6	1.4	1.6	
771	p	2.1	1.2	1.7	1.9	1.6	1.8	
448	i	0.2	0.1	0.1	0.1	0.1	0.1	
	р	0.2	0.1	0.2	0.1	0.1	0.2	
449	i	0.2 0.2	0.2 0.2	0.1 0.1	0.1 0.2	0.1 0.1	0.2 0.2	
450	р :		0.7	0.8	0.9	0.8	0.8	
450	i p	0.9 1.1	0.9	0.9	1.2	1.0	1.0	
451	i	0.0	0.0		0.0	0.0 0.0	0.0 0.1	
450	р	0.1	0.1		1.2	1.6	1.3	
452	i P	0.9 0.9	1.9 1.9	2.0 2.0	1.3	1.6	1.4	
453	i	0.1	0.1	0.1	0.1	0.1	0.0	
.50	p	0.1	0.2	0.2	0.1	0.2	0.1	
454	i	1.3	0.9	1.0	1.0	1.0	1.1	
	р	2.0	1.3	1.5	1.7	1.6	1.7	
455	i	1.3 2.9	0.9 1.6	1.3 2.0	1.1 2.2	1.1 2.1	1.2 2.1	
	р	٤.3	1.0	2.0				

no.	episode		degree of	urbanization		region			
	•		rural	suburban	urban	city	north	centre	south
456	contact dermatitis	i p	1.3 1.8	1.2 1.9	1.6 2.2	1.0 1.3	1.2 1.8	1.1 1.7	1.6 2.4
457	eczema NEC	i p	6.4 16.7	7.8 15.2	9.0 17.1	6.1 12.7	5.6 15.1	7.4 15.7	8.3 16.5
458	diaper rash	i p	0.5 0.7	0.5 0.7	0.5 0.7	0.5 0.9	0.6 0.9	0.4 0.7	0.6 0.8
459	pityriasis rosea	i p	0.3 0.4	0.4 0.5	0.6 0.7	0.3 0.4	0.4 0.6	0.3 0.5	0.5 0.5
460	psoriasis w/wo arthropathy	i p	0.5 2.1	0.5 1.9	0.5 2.0	0.2 1.1	0.7 2.3	0.4 1.5	0.5 2.7
461	pompholyx/dis. sweat glands	i p	0.3 0.4	0.5 0.6	0.6 0.7	0.1 0.2	0.3 0.4	0.5 0.5	0.3 0.5
462	sebaceous cyst	i p	2.0 2.5	2.3 2.7	2.9 3.4	2.9 2.9	2.1 2.6	2.3 2.6	2.8 3.4
463	ingrown toenail/dis. of nail NEC	i p	0.9 1.2	1.2 1.5	1.0 1.3	0.6 0.8	0.9 1.1	0.9 1.2	1.2 1.5
464	alopecia/folliculitis/dis. of hair NEC	i p	0.9 1.1	0.8 1.1	1.5 1.8	0.3 1.0	0.4 0.6	0.9 1.2	1.2 1.6
465	acne vulgaris	i P	1.3 5.9	1.9 5.8	1.7 6.2	1.9 4.2	1.4 4.8	1.6 5.7	1.8 6.2
466	chron. ulcer skin, incl. varicose	i p	0.4 1.4	0.3 1.1	0.3 0.7	0.6 1.5	0.4 1.4	0.3 1.0	0.4 1.4
467	urticaria	i p	1.4 1.6	1.2 1.4	1.4 1.6	0.5 0.6	1.4 1.7	1.2 1.3	1.3 1.5
468	seborrheic warts	i p	0.2 0.3	0.3 0.3	0.2 0.3	0.2 0.3	0.3 0.4	0.2 0.3	0.3 0.3
469	acne rosacea	i p	0.2 0.3	0.3 0.5	0.3 0.5	0.2 0.3	0.2 0.4	0.2 0.4	0.3 0.4
470	dis. skin/subcut. tissue NEC	i P	1.1 2.3	1.6 2.6	1.6 2.3	1.6 3.2	1.3 2.1	1.5 2.5	1.3 2.7

						type of insu	rance
no.		season spring	summer	autumn	winter	public	private
		shina	341111101			-	
456	i	1.1	1.2	1.8	1.0	1.4	1.0
	р	1.6	2.0	2.3	1.5	2.1	1.4
457	i	7.9	6.1	8.0	7.7	7.7	6.9
457		15.0	14.1	15.7	18.4	16.9	13.9
	р				0.5	0.5	0.3
458	i	0.4	0.5	0.6	0.6	0.8	0.5
	р	0.7	8.0	0.9			
459	i	0.3	0.3	0.5	0.4	0.4	0.3
	Р	0.5	0.3	0.6	0.6	0.5	0.4
460	i	0.4	0.6	0.5	0.3	0.4	0.5
400	p	2.0	1.7	1.9	1.9	2.1	1.5
	г						
464		0.3	0.2	0.7	0.4	0.4	0.3
461	i	0.5	0.3	0.8	0.4	0.6	0.3
	р				2.3	2.5	2.0
462	i	2.3	2.4	2.6	2.3	3.0	2.3
	р	2.8	2.8	3.1			
463	i	1.1	0.7	0.9	1.1	1.0	0.8
	р	1.5	1.0	1.2	1.3	1.3	1.0
464		0.9	1.1	0.9	0.8	1.0	8.0
464	i P	1.2	1.3	1.5	1.0	1.4	1.1
				2.0	1.4	1.8	1.3
465	i	1.8	1.4	2.0 6.0	6.4	6.3	4.6
	р	5.1	5.3	0.0	0.4		
					0.0	0.4	0.2
466	i	0.2	0.5	0.6	0.2 1.0	1.3	0.6
	р	0.9	1.4	1.3			
467	i	1.2	1.4	1.2	1.1	1.3	0.9
	р	1.5	1.6	1.4	1.3	1.6	1.0
468		0.3	0.2	0.3	0.2	0.3	0.2
400	i	0.4	0.3	0.3	0.2	0.3	0.2
	р				0.2	0.2	0.2
469	i	0.3	0.2	0.3 0.4	0.3	0.4	0.3
	Р	0.6	0.3				
470	i	1.6	1.8	1.3	1.0	1.5	1.2 2.0
	р	2.7	2.5	2.2	2.5	2.7	2.0

no.	episode	degree of	f urbanization			region			
			rural	suburban	urban	city	north	centre	south
471	excessive thirst	i p	0.0 0.0	0.0 0.0	0.1 0.1	0.1 0.1		0.0 0.1	0.0 0.0
472	excessive appetite, excl. boulimia	i p	0.0 0.0	0.0 0.0	0.0 0.0	0.1 0.5	0.0 0.0	0.0 0.1	0.0 0.0
473	loss of appetite, excl. anorexia nerv.	i p	0.0 0.1	0.1 0.1	0.1 0.1	0.2 0.3	0.1 0.1	0.1 0.2	0.1 0.1
474	feeding problem infant, excl. P11	i p	0.1 0.2	0.2 0.2	0.1 0.1	0.3 0.3	0.1 0.2	0.1 0.2	0.2 0.2
475	feeding problem adult, excl. T06	i P	0.1 0.3	0.1 0.3	0.1	0.3 1.4	0.1 0.2	0.1 0.4	0.1 0.2
476	feeding problem NEC	i p	0.0 0.1	0.0 0.1	0.0 0.1	. 0.1	0.0	0.0 0.1	0.0 0.1
477	weight gain, excl. T82	i p	0.0 0.0	0.1 0.1	0.0 0.0	0.2 0.6	0.0 0.1	0.1 0.2	0.1 0.1
478	weight loss, excl. T06	i p	0.1 0.2	0.1 0.3	0.1 0.2	0.2 0.5	0.2 0.3	0.1 0.2	0.1 0.3
479	weight problem NEC	i p	0.1 0.2	0.2 0.5	0.1 0.4	0.2 0.6	0.0 0.1	0.2 0.4	0.1 0.5
480	failure to thrive	i p	0.2 0.3	0.1 0.2	0.2 0.3	0.2 0.4	0.0 0.2	0.1 0.3	0.1 0.3
481	dehydration	i p	0.0 0.1	0.0 0.1	0.0 0.1		0.1 0.1	0.0	0.0
482	thyroid lump/mass	i p	0.0 0.0	0.0 0.0	0.0 0.0			0.0 0.0	0.0
483	fear of endocr. metab. nutr. dis.	i p	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.1 0.1	0.1 0.1	0.2 0.2
484	disability/impairment end. gl.	i p	0.0						0.0
485	sympt./complt. end./met./nutr. NEC	i p	0.2 0.3	0.1 0.1	0.2 0.3	0.3 0.4	0.1 0.2	0.2 0.2	0.2 0.3
486	infectious dis. endocrine glands	i p	0.0						. 0.0
487	malign. neopl. thyroid	i p	0.1	0.0	0.0 0.1	0.1	0.0	0.0 0.0	0.0
488	benign. neopl. thryroid	i p	0.0	0.0 0.0	0.0	*	0.0 0.0		0.0
489	unspecified neopl. endocr. NEC	i p	0.0 0.0	0.0 0.1	0.0 0.1		0.0 0.1	0.0 0.1	0.0
490	injury thyroid	i p		0.0			0.0	0.0	*
491	thyroglosal duct(cyst)	i	0.0	0.0	0.0	0.1 0.1	0.0	0.0	.,
492	cong. anom. endocr. NEC	p i p	0.0	0.0 0.0	0.0 0.1	0.1 0.1	0.0 0.0	0.0 0.0	0.0
493	goiter/module w/o thyrotox	i P	0.0 0.3	0.1 0.2	0.0 0.3		0.0 0.1 0.5	0.0 0.0 0.2	0.0 0.1 0.2
494	obesity/overweight	i p	1.1 4.9	1.5 5.6	1.6 7.7	1.4 5.0	1.0 6.2	1.3 5.3	1.7 6.8
495	hyperthyrroidism/thyrotoxicosis	i p	0.2 1.4	0.1 1.2	0.1 0.9	0.2 1.8	0.2 1.4	0.2 1.3	0.0 0.1 1.3

no.		season				type of insu	rance	
IIO.		spring	summer	autumn	winter	public	private	
471	i	0.1	36	0.1	0.0	0.1	0.0	
	р	0.1	100	0.1	0.0	0.1	0.0	
472	i	0.0	0.0 0.1	0.1 0.1	0.0 0.1	0.0 0.1	0.0 0.1	
470	p i	0.1	0.1	0.0	0.0	0.1	0.0	
473	p	0.2	0.1	0.1	0.1	0.1	0.1	
474	i	0.1	0.1	0.2	0.1	0.2	0.1	
	р	0.3	0.1	0.3	0.1	0.2	0.2	
475	i	0.1	0.2	0.1 0 <i>.</i> 2	0.2 0.7	0.1 0.5	0.1 0.1	
	р	0.2	0.4	0.2				
476	i	0.0	0.0	0.0	0.0	0.0	0.0	
	р	0.1	0.0	0.1	0.2	0.1	0.1	
477	i	0.2	0.0	0.1	0.0	0.1	0.1 0.1	
	р	0.2	0.1	0.1	0.2	0.2		
478	i	0.1 0.1	0.1 0.1	0.1 0.4	0.2 0.4	0.1 0.3	0.1 0.1	
470	p i	0.1	0.0	0.1	0.2	0.1	0.1	
479	p	0.6	0.3	0.2	0.4	0.5	0.3	
480	i	0.3	0.1	0.1	0.0	0.1	0.2	
	р	0.4	0.3	0.3	0.2	0.2	0.3	
404			0.1	0.0	0.0	0.0	0.0	
481	i p	0.0	0.1	0.0	0.1	0.1	0.0	
482	i		0.0	0.1	0.0	0.0	0.0	
102	p		0.0	0.1	0.0	0.0	0.0	
483	i	0.1	0.1	0.1	0.1	0.1	0.1	
	р	0.1	0.1	0.1	0.2	0.1	0.1	
484	i		0.0			•	0.0	
485	p i	0.0	0.3	0.2	0.2	0.2	0.1	
400	p	0.0	0.4	0.3	0.3	0.3	0.1	
486	i	0.0	•	*		0.0		
407	р :		0.0	0.0	0.0	0.0	0.0	
487	i p	0.0	0.1	0.0	0.1	0.1	0.0	
488	i	0.0				0.0		
	р	0.0	0.0		0.0	0.0	0.0	
489	i	0.1	0.0	0.0	0.0	0.0 0.0	0.1 0.1	
	р	0.1	0.0	0.1	0.0			
490	i p	0.0	0.0			0.0		
	۲			•				
491	i	0.0		0.0	0.0	0.0	0.0	
	р	0.0	0.0	0.0	0.0	0.0	0.0	
492	i	0.0	0.0	0.0 0.0	0.0	0.0 0.0	•	
400	p :	0.0	0.0	0.1	0.1	0.1	0.1	
493	i p	0.1	0.2	0.1	0.3	0.3	0.2	
494	i	1.2	1.6	1.1	1.6	1.5	1.1	
	p	5.2	5.9	5.5	6.5	6.6	4.2	
495	i	0.1	0.1	0.2	0.2	0.2	0.1	
	р	1.0	1.2	1.7	1.2	1.6	8.0	

no.	episode		degree of	urbanization			region	region			
			rural	suburban	urban	city	north	centre	south		
496	hypothyroidism/myxedema	i	0.1	0.1	0.1	0.0	0.1	0.1	0.0		
		р	1.9	1.4	1.3	1.0	2.4	1.6	0.9		
497	hypoglycemia	i	0.1	0.1	0.2	0.3	0.1	0.2	0.1		
		р	0.2	0.2	0.2	0.3	0.1	0.3	0.2		
498	renal glucosuria	i	0.0	0.0				0.0	0.0		
		р	0.0	0.0		0.0	0.0	0.0	0.0		
499	diabetes mellitus	i	0.9	0.7	1.2	0.7	0.8	0.9	0.9		
		р	14.6	10.1	11.7	10.9	14.9	12.0	10.8		
500	vitamin defic./nutr. dis. NEC	i	0.1	0.1	0.1	0.3	0.1	0.1	0.1		
		р	2.1	0.8	0.9	2.3	1.8	1.4	1.0		
501	gout	i	0.4	0.4	0.4	0.7	0.4	0.5	0.4		
		р	1.3	1.1	1.0	1.8	1.3	1.2	1.1		
502	lipid metabolism dis.	i	0.2	0.1	0.2	0.2	0.2	0.2	0.1		
	·	р	1.6	1.4	1.9	1.3	2.6	1.5	1.4		
503	dis. thyroid NEC	i	0.0	0.1	0.0	0.1	0.1	0.1	0.0		
	•	р	0.4	0.2	0.6	0.4	0.3	0.5	0.3		
504	dis. endocr. gland NEC	i	0.1	0.0	0.2	0.1	0.1	0.1	0.1		
	· ·	р	0.5	0.4	0.9	0.3	0.7	0.5	0.5		
505	metabolic disease NEC	i	0.1	0.1	0.1	0.1	0.1	0.1	0.1		
		р	1.3	0.9	0.4	0.6	1.8	0.8	0.7		

T ENDOCRINE/METABOLIC/NUTRITIONAL

no.		season				type of insu	e of insurance	
110.		spring	summer	autumn	winter	public	private	
496		0.1	0.1	0.1	0.0	0.1	0.1	
490	р	1.0	1.6	1.6	1.7	1.7	1.3	
497	i	0.0	0.1	0.1	0.2	0.1	0.1	
	р	0.0	0.3	0.2	0.3	0.3	0.2	
498	i		0.0	0.0		0.0	0.0	
	р	0.0	0.0	0.0	0.0	0.0	0.0	
499	i	0.7	1.1	0.9	8.0	1.0	0.6	
	р	10.9	13.1	11.6	12.4	14.1	7.7	
500	i	0.1	0.2	0.1	0.1	0.1	0.1	
	р	0.7	1.3	1.3	2.2	1.6	0.9	
501	i	0.4	0.4	0.6	0.4	0.5	0.5	
	p p	1.1	1.2	1.2	1.3	1.3	1.1	
502	i	0.1	0.1	0.2	0.2	0.1	0.2	
	р	0.9	1.2	1.9	2.3	1.6	1.5	
503	i	0.0	0.1	0.1	0.0	0.0	0.1	
	р	0.2	8.0	0.3	0.3	0.5	0.3	
504	i	0.0	0.2	0.1	0.1	0.1	0.1	
	р	0.3	0.6	0.6	0.6	0.6	0.5	
505	i	0.1	0.2	0.1	0.0	0.1	0.1	
	р	0.7	1.1	0.6	1.1	1.0	8.0	

no.	episode		degree o	f urbanization		region				
			rural	suburban	urban	city	north	centre	south	
506	complaints urination	i	0.4	0.5	0.3	0.7	0.4	0.4	0.5	
		р	0.7	0.8	0.5	0.9	0.7	0.6	0.9	
507	incontinence (excl. P12)	i	0.2	0.3	0.5	0.2	0.2	0.3	0.4	
		р	4.5	3.9	2.8	2.9	5.0	3.3	4.2	
508	anuria/oliguria	i	0.0 0.0	0.0 0.0	•	•	•	0.0 0.0	0.0 0.0	
F00	- determine	р								
509	complaints of urine	i p	0.1 0.2	0.2 0.3	0.3 0.5	0.1 0.2	0.2 0.4	0.2 0.3	0.2 0.3	
510	sympt./complt. bladder NEC	i	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
	-,	р	0.2	0.1	0.5	0.1	0.4	0.3	0.1	
	and to see the bidge of			- 00				0.0	0.0	_
511	sympt./complt. kidney	i p	0.0 0.1	0.0 0.0	0.0 0.0		0.0	0.0 0.1	0.0 0.0	
512	fear of urinary diseases	i	0.0	0.0	0.0	0.1	0.0	0.0	0.0	
312	real of unitary diseases	p	0.0	0.0	0.1	0.1	0.0	0.1	0.0	
513	disability/impairment urinary syst.	i		0.0			0.0	(●)		
		р		0.0	*		0.0			
514	sympt./complt. urin. syst. NEC	i	0.0	0.0		0.0	0.0	0.0	0.0	
		p	0.1	0.0	0.1	0.0	0.2	0.1	0.1	
515	acute pyelonefritis/pyelitis	i	0.2	0.2	0.6	0.3	0.3	0.3	0.2	
		р	0.3	0.3	0.6	0.3	0.4	0.4	0.3	
516	cystitis/urinary inf. NEC	i	11.0	11.1	13.2	11.7	12.0	11.6	11.4	
		р	12.8	12.2	14.6	12.3	14.0	12.9	12.5	
517	non-specific urethritis	i	0.2	0.3	0.4	0.6	0.3	0.3	0.3	
		р	0.2	0.4	0.5	0.6	0.3	0.4	0.4	
518	malign. neoplasm kidney	i		0.0	0.0		0.0	*.	0.0	
		р	0.1	0.1	0.3	0.2	0.2	0.1	0.3	
519	malign. neoplasm bladder	i	0.1 0.3	0.0 0.2	0.1 0.2	0.1 0.3	0.0 0.4	0.1 0.3	0.0 0.2	
500	The second second second NEO	р :				0.3	0.4			
520	malign. neoplasm urinary tract NEC	i p	0.0 0.0	0.0 0.1	0.0 0.0	0.1	0.0	0.0 0.1	0.0 0.0	
521	benign. neoplasm urinary tract	i	0.0	0.0	0.0		0.0	0.0	0.0	
		р	0.1	0.0	0.0		0.1	0.0	0.0	
522	unspecified neopl. urin. tract	i	0.0	0.0	0.0		0.0	0.0	0.0	
		p	0.1	0.0	0.1	0.1	0.1	0.0	0.1	
523	injury urinary tract	i p	0.0 0.0	0.0 0.0			0.0 0.0	0.0 0.0	0.0 0.0	
524	cong. anom. urinary tract	i	0.0	0.0	0.0		0.0		0.0	
324	cong. anom. umary tract	p	0.1	0.1	0.0	0.1	0.1	0.1	0.1	
525	glomerulonephritis/nephrosis	i	0.0	0.1	0.0	0.1	0.0	0.0	0.0	
		р	0.3	0.3	0.2	0.3	0.3	0.3	0.2	
						· · · · · ·				_
526	orthostatic albuminuria	i p	0.0 0.0	0.0 0.0	0.0		0.0 0.0	0.0 0.0	0.0	
527	urin, calculus, all types/sites	i	0.4	0.6	0.7	0.7	0.5	0.5	0.7	
JEI	ann, odiodios, an typosistos	p	0.4	1.2	1.4	1.3	1.0	1.1	1.3	
528	abnormal urine test/findings NOS	i	0.1	0.1	0.0		0.1	0.1	0.1	
	•	р	0.2	0.3	0.2	0.2	0.2	0.3	0.2	
529	dis. urinary system NEC	i	0.3	0.2	0.5	0.6	0.4	0.4	0.2	
		р	2.0	1.4	1.5	1.8	2.1	1.7	1.3	

no					type of insurance		
no.		season spring	summer	autumn	winter	public	private
506	i p	0.4 0.6	0.3 0.6	0.4 0.8	0.6 0.9	0.5 0.8	0.3 0.4
507	i	0.3	0.2	0.5	0.3	0.4	0.2
301	p	2.8	3.8	4.0	4.3	4.7	1.8
508	i		0.0	0.0		0.0	
	p	•	0.0	0.0	•	0.0	
509	i	0.2	0.0	0.2	0.3 0.4	0.2 0.3	0.2 0.3
	р	0.3	0.1	0.4		0.1	0.1
510	i p	0.0 0.1	0.0 0.2	0.2 0.4	0.0 0.2	0.2	0.2
511	i	0.0	0.0	0.0	•	0.0	0.0
011	p p	0.0	0.1	0.1		0.1	0.0
512	i	0.0	0.0	0.1	0.0	0.0	0.0
	р	0.0	0.0	0.1	0.0	0.1	0.0
513	i		0.0			0.0	•
	Р	•	0.0	•	0.0	0.0	
514	i	0.0	0.0	0.0	0.1	0.0 0.1	0.0 0.1
	р	0.1	0.1	0.1		0.3	0.2
515	i p	0.2 0.3	0.3 0.4	0.4 0.5	0.2 0.2	0.4	0.3
				10.1	44.0	12.5	9.5
516	i	10.6 11.4	11.0 12.7	13.1 14.4	11.8 13.3	13.9	10.6
- 47	р		0.3	0.4	0.3	0.4	0.3
517	i p	0.4 0.4	0.3	0.4	0.4	0.4	0.4
518	i			0.0	0.0	0.0	•
310	p	0.1	0.2	0.3	0.2	0.2	0.1
519	i	0.0	0.1	0.0	0.1	0.1	0.0
	р	0.1	0.4	0.2	0.4	0.3	0.2
520	i	0.0	0.0	0.0	0.0	0.0	0.0 0.1
	р	0.0	0.0	0.1	0.1	0.0	0.1
		0.0	0.0	0.0	0.0	0.0	0.0
521	i p	0.0 0.1	0.1	0.0	0.0	0.0	0.1
522	i		0.0	0.1	290	0.0	0.0
JZZ	p p	0.1	0.1	0.1	0.1	0.1	0.0
523	i		0.0		0.0	0.0	0.0
	р	0.0	0.0		0.0	0.0	0.0
524	i	0.0	0.0	0.0	0.0	0.0	0.0
	р	0.2	0.0	0.0	0.1	0.1	
525	i	0.1	0.0	0.1 0.3	0.0 0.2	0.0 0.3	0.0 0.1
	р	0.2	0.3			0.0	
526	i		0.0	.(*)	0.0		0.0
	р	•	0.0	0.0	0.0	0.0	0.0
527	i.	0.6	0.5	0.7	0.5	0.6	0.6 0.9
	р	1.2	1.1	1.2	1.1	1.3	
528	i	0.1	0.1	0.1 0.3	0.0 0.1	0.1 0.2	0.1 0.3
	p	0.2	0.2		0.1	0.4	0.3
529	i	0.3 1.2	0.4 2.2	0.5 1.8	1.5	1.8	1.2
	р	1-6					

no.	episode		degree o	of urbanization			region				
			rural	suburban	urban	city	north	centre	south		
530	question of pregnancy (excl. W02)	i p	0.2 0.3	0.1 0.1	0.3 0.4	0.4 0.5	0.3 0.4	0.2 0.3	0.2 0.2		
531	fear of being pregnant	i p	0.1 0.2	0.1 0.2	0.2 0.3	0.1 0.1	0.2 0.2	0.1 0.2	0.2 0.3		
532	ante-partum bleeding	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.1		
533	vaginal discharge in pregn.	i p	0.1 0.1	0.1 0.1	0.1 0.1	:	0.1 0.1	0.1 0.1	0.1 0.1		
534	vomiting/nausea of pregn.	i p	0.1 0.1	0.0 0.1	0.0 0.0	0.0 0.2	0.0 0.1	0.1 0.1	0.0 0.1		
535	wanted pregnancy	i p	0.2 0.3	0.2 0.5	0.4 0.8	0.4 0.6	0.2 0.4	0.2 0.5	0.4		
536	morning-after pill	i p	0.2 0.2	0.1 0.2	0.1 0.3	0.1 0.3	0.0 0.1	0.2 0.3	0.1 0.2		
537	fam. plan./oral contraceptive	i p	2.9 35.7	2.7 34.5	3.5 37.1	2.5 32.0	2.9 32.4	3.1 34.9	2.4 37.0		
538	fam. plan./IUD	i p	0.4 1.5	0.2 1.2	0.5 1.7	0.7 2.1	0.3 1.2	0.5 1.6	0.4 1.4		
539	fam. plan./sterilization \$	i p	0.2 0.3	0.3 0.5	0.2 0.3	0.2 0.3	0.2 0.3	0.2 0.4	0.3 0.4		
540	fam. plan./ NEC \$	i p	0.1 0.6	0.2 1.0	0.1 0.4	0.2 0.9	0.2 0.8	0.1 0.7	0.1 0.7		
541	sub-/infertility \$	i p	0.3 0.9	0.3 0.8	0.2 0.6	0.3 0.8	0.2 0.4	0.3 0.8	0.3 0.9		
542	heavy post-partum bleeding	i p	0.0 0.1	0.0 0.0		0.1 0.1	0.0 0.0	0.0 0.1	0.0 0.0		
543	complt. post partum NEC	i p	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.2	0.0 0.1	0.1 0.1	0.0 0.1		
544	sympt./complt. lactation	i p	0.1 0.2	0.0 0.1	0.0 0.0	0.0 0.3	0.0 0.1	0.1 0.1	0.1 0.2		
545	sympt./complt. breast in pregn. NEC	i p	0.1 0.1	0.0 0.1	0.1 0.1		0.0 0.1	0.0 0.1	0.1 0.1		
546	starting delivery	i p	0.1 0.1	0.0 0.0	0.0 0.1	•	0.0 0.1	0.0 0.1	0.0 0.0		
547	fear of complic of pregn./deliv.	i p	0.0 0.1	0.1 0.1	0.1 0.2		0.1 0.1	0.1 0.1	0.1 0.1		
548	disability/impairment Pr/D/Pu/Fp	i p		0.0		:	0.0	:			
549	sympt./complt. Pr/D/Pu/Fp NEC	i p	0.1 0.2	0.1 0.2	0.1 0.2	0.0	0.1 0.2	0.1 0.1	0.1 0.2		
550	infect. dis. urinary tr. pregn./puerp.	i p	0.3 0.3	0.2 0.2	0.0 0.1	0.2 0.2	0.1 0.2	0.2 0.3	0.1 0.1		
551	infect, dis. pregn. NEC	i p	0.2 0.2	0.1 0.1	0.2 0.2	0.1 0.2	0.1 0.1	0.1 0.2	0.2 0.2		
552	malign. neoplasm pregn.	i p	:	0.0			0.0				
553	benign. neoplasm pregn.	i p		0.0 0.0				0.0 0.0			
554	injuries complicating pregn.	i p	:	*							

		season				type of insur	rance	
no.		spring	summer	autumn	winter	public	private	
530	i p	0.3 0.3	0.2 0.3	0.1 0.2	0.3 0.3	0.2 0.3	0.2 0.2	
531	i p	0.2 0.3	0.1 0.2	0.2 0.2	0.1 0.2	0.2 0.3	0.1 0.1	
532	i p	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	
533	i p	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	
534	i p	0.0 0.1	0.1 0.1	0.0 0.1	0.1 0.1	0.1 0.1	0.0	
535	i	0.3	0.1 0.3	0.3 0.5	0.4 0.6	0.4 0.6	0.1 0.2	
536	p i	0.0	0.1 0.1	0.3 0.5	0.2	0.1 0.2	0.2 0.2	
537	p i	3.1 37.5	2.9 31.7	2.6 34.4	3.0 37.1	3.3 39.9	1.9 24.9	
538	p i p	0.4 1.7	0.3 1.1	0.4 1.7	0.5 1.6	0.4 1.5	0.4 1.4	
539	i p	0.3 0.5	0.1	0.2 0.4	0.3 0.4	0.2 0.4	0.2 0.3	
540	i p	0.1 0.6	0.1 0.5	0.2 0.8	0.2	0.2 0.9	0.1 0.4	
541	i p	0.4	0.2	0.3 0.8	0.2 0.9	0.3 0.9	0.1 0.4	
542	i p	0.0	0.0	0.0 0.1	0.1 0.1	0.0 0.0	0.0	
543	i p	0.0 0.1	0.1 0.2	0.0	0.0 0.0	0.0 0.1	0.1 0.1	
544	i p	0.0 0.1	0.1 0.3	0.0 0.2	0.0 0.1	0.1 0.2	0.0 0.1	
545	i	0.0 0.1	0.1 0.1	0.1 0.1	0.0 0.1	0.0 0.0	0.1 0.1	
546	p i		0.1 0.1	0.0	0.0	0.0 0.0	0.0 0.1	
547	p i p	0.1 0.2	0.0	0.1 0.1	0.0	0.1 0.1	0.0 0.0	
548	i p			•		0.0		
549	i p	0.1 0.2	0.1 0.1	0.2 0.3	0.0 0.1	0.1 0.2	0.0 0.1	
550	i	0.2 0.2	0.2 0.2	0.3 0.4	0.2 0.2	0.2 0.3	0.1 0.1	
551	p i	0.0 0.0	0.1 0.1	0.2 0.3	0.3	0.2	0.1 0.1	
552	p i	0.0 0.0				0.0		
553	p i		*	•	0.0 0.0	0.0		
554	p i					•		
	р		•		*	· · · · · · · · · · · · · · · · · · ·		

no.	episode		degree of	urbanization			region		
			rural	suburban	urban	city	north	centre	south
555	cong. anom. of mother/complic. pregn.	i p	0.0 0.0	0.0	0.0 0.1		0.0 0.0	0.0 0.0	
556	non-obst. cond. complic. pregn. NEC	i p	0.2 0.3	0.1 0.1	0.2 0.3	0.1 0.1	0.1 0.2	0.1 0.2	0.2 0.2
557	pregnancy: confirmed	i p	4.2 6.6	2.7 3.8	2.6 3.9	2.7 3.7	2.9 4.8	3.5 5.0	2.5 3.9
558	unwanted pregnancy: confirmed	i p	0.1 0.1	0.1 0.1	0.2 0.2	0.7 0.7	0.2 0.2	0.2 0.3	0.0 0.0
559	ectopic pregnancy	i p	0.0	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.1 0.1	0.0 0.1
560	toxemia/(pre)eclampsia	i p	0.0 0.1	0.0 0.0	0.1 0.2		0.1 0.1	0.0 0.1	0.1 0.1
561	abortion, imminens/spontan.	i p	0.4 0.6	0.3 0.5	0.4 0.5	0.3 0.4	0.4 0.5	0.4 0.5	0.4 0.6
562	abortion, (il)legally induced	i p	0.0 0.1	0.1 0.2	0.1 0.2	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.2
563	pregnancy, high risk	i p	0.5 1.3	0.3 0.6	0.4 0.8	0.0 0.3	0.3 0.8	0.3 0.8	0.4 1.0
564	normal delivery live born(s)	i p	1.0	0.4	0.5	0.4	0.6	0.7	0.6
565	normal delivery dead born(s)	i p	0.0	0.0	0.0		•		0.0
566	complicated delivery live born	i p	0.5	0.2	0.2	0.0	0.3	0.3	0.2
567	complicated delivery dead born	i p	0.0	0.0		0.1	0.0	0.0	0.0
568	normal puerperium	i p	2.1 2.8	1.1 1.5	1.0 1.4	0.5 0.6	1.8 2.6	1.3 1.8	1.2 1.5
569	mastitis puerperalis	i p	0.3 0.3	0.1 0.2	0.2 0.2	0.1 0.1	0.2 0.2	0.2 0.2	0.1 0.1
570	dis. of breast puerperium NEC	i p	0.1 0.2	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.2	0.1 0.1	0.1 0.2
571	complic. puerperium NEC	i p	0.4 0.5	0.1 0.2	0.2 0.3	0.0	0.1 0.2	0.2 0.3	0.2 0.3
572	diseases Pr/D/Pu NEC	i p	0.2 0.3	0.1 0.2	0.2 0.4	0.1 0.2	0.1 0.2	0.2 0.2	0.1 0.2

						type of insurance				
no.		season spring	summer	autumn	winter	public	private			
		Spring	our				0.0			
555	i			0.0	0.0 0.1	0.0 0.0	0.0 0.0			
	р	•	0.0	0.0						
556	i	0.2	0.2	0.1	0.1 0.2	0.2 0.3	0.1 0.2			
	р	0.2	0.3	0.2			2.6			
557	i	2.8	4.1	2.7	3.0	3.2 4.7	4.1			
	р	4.3	5.8	4.3	4.6					
558	i	0.1	0.1	0.2	0.2	0.1 0.2	0.1 0.2			
	Р	0.2	0.1	0.3	0.2					
559	i	0.1	0.1	0.1	0.0	0.1	0.0			
	р	0.1	0.1	0.1	0.0	0.1	0.1			
		0.0	0.0	0.0	0.0	0.0	0.0			
560	i p	0.0 0.1	0.1	0.0	0.1	0.1	0.1			
				0.4	0.5	0.4	0.3			
561	i	0.2 0.4	0.3 0.4	0.7	0.6	0.5	0.5			
	р				0.1	0.1	0.0			
562	i	0.1 0.3	0.0	0.2 0.2	0.1	0.2	0.1			
	р					0.4	0.2			
563	i	0.4	0.5	0.3 0.7	0.2 1.0	0.9	0.7			
	р	8.0	0.9			0.7	0.5			
564	i	0.5	1.0	0.5	0.5	0.7				
	р		•	•	•					
565	i		0.0	0.0	0.0	0.0				
300	p		0.0				•			
566		0.1	0.4	0.3	0.3	0.3	0.2			
000	i P		•			± •				
E07		0.0		0.0	0.0	0.0	0.0			
567	i p	•	•	•		*				
500		1.1	1.4	1.4	1.4	1.4	1.2			
568	i p	1.1	2.1	1.8	1.8	1.8	1.7			
			0.3	0.1	0.1	0.2	0.2			
569	i	0.2 0.2	0.3	0.1	0.1	0.2	0.2			
	р	U.E								
570	i	0.1	0.1	0.1	0.1	0.1	0.1			
570	p	0.2	0.1	0.2	0.1	0.1	0.1			
571	i	0.3	0.2	0.1	0.2	0.3	0.1			
3/ 1	p	0.3	0.3	0.3	0.3	0.3	0.2			
570	i	0.2	0.1	0.2	0.1	0.2	0.1			
572	p	0.2	0.2	0.3	0.2	0.3	0.2			
	P									

no.	episode		degree of	urbanization			region				
			rural	suburban	urban	city	north	centre	south		
573	genital pain \$	í	0.0	0.0	0.0	·		0.0	0.0		
	g	р	0.0	0.0	0.0		0.0	0.0	0.0		
574	menstruation absent/scanty	i	0.4	0.5	0.4	0.2	0.2	0.4	0.5		
		р	0.6	0.8	8.0	0.4	0.4	0.7	0.8		
575	menstruation excessive	i	0.9 1.5	1.0 1.6	1.1 2.0	0.8 1.1	0.9	1.0	1.0		
F70		р :					1.6	1.6	1.7		
576	menstrual pain	i p	0.9 2.3	0.7 1.6	1.1 2.0	0.4 1.1	1.1 2.3	0.8 1.9	0.8 1.6		
577	sympt./complt. menstruation NEC	i	0.9	1.1	1.4	0.8	1.5	1.0	1.1		
	· , · · , · · · · · · · · · · · · · · ·	р	1.5	1.6	2.0	1.1	2.2	1.5	1.7		
			· · · · · · · · · · · · · · · · · · ·				· . · · · · · · · · · · · · · · · · · ·				
578	premenstrual symptoms	i	0.1	0.1	0.2 0.3	0.2	0.2	0.1	0.1		
F70		р	0.2	0.2		0.5	0.3	0.3	0.2		
579	sympt./complt. menopausal	i p	0.8 2.8	1.0 2.7	1.1 3.9	1.1 3.7	1.1 2.9	1.0 3.4	0.9 2.5		
580	postmenopausal bleeding	i	0.1	0.1	0.1	0.1	0.1	0.1	0.1		
300	postner:opausai bieeding	p	0.1	0.1	0.2	0.2	0.1	0.1	0.1		
581	painful intercourse 9	i	0.2	0.2	0.1	0.1	0.2	0.2	0.1		
	•	р	0.3	0.3	0.3	0.1	0.2	0.3	0.3		
582	postcoïtal bleeding	i	0.0	0.2	0.1	0.1	0.0	0.1	0.1		
		Р	0.0	0.2	0.1	0.1	0.0	0.1	0.1		
F02	veginal discharge	i	0.6	1.3	0.5	0.5	0.6	0.9	0.7		
583	vaginal discharge	p	0.8	1.6	0.5	0.7	0.9	1.1	0.7 0.9		
584	sympt./complt. vagina NEC	i	0.2	0.2	0.3	0.3	0.4	0.2	0.3		
	.,,,	р	0.4	0.4	0.5	0.4	0.7	0.4	0.5		
585	sympt./complt. vulva	i	0.2	0.2	0.2	0.2	0.1	0.2	0.3		
		р	0.3	0.2	0.3	0.2	0.3	0.2	0.4		
586	sympt./complt. pelvis ♀	i	0.0	0.0			0.0	0.0	0.0		
		p	0.0	0.1	0.0	•	0.0	0.0	0.1		
587	lump/mass mamma \$	i p	0.1 0.2	0.2 0.3	0.1 0.1	0.1 0.1	0.1 0.1	0.2 0.2	0.1 0.2		
		Р	0.2					····	U.Z		
588	pain mamma ¥	i	0.3	0.5	0.3	0.0	0.1	0.3	0.6		
		р	0.4	0.6	0.4	0.1	0.2	0.4	0.7		
589	sympt./complt. mamma NEC 9	i	0.8	1.0	1.2	1.4	0.7	1.0	1.1		
		р	1.1	1.2	1.5	1.9	1.0	1.3	1.6		
590	postponement of menstruation	i	1.2	1.1 1.3	0.8 0.9	0.5 0.5	0.9 1.1	1.0	1.0		
504		р	1.4					1.2	1.2		
591	fear genital/mamma dis. ₽	i p	0.2 0.4	0.2 0.4	0.3 0.7	0.2 0.7	0.2 0.4	0.2 0.5	0.2 0.4		
592	disab./impairm.gen.syst. 9	i	0.0				r.•		0.0		
002	abab./impaini. goil. byot 4	p	0.0						0.0		
						···········					
593	sympt./complt. gen. syst. \$	i	0.0	0.1	0.0	0.1	0.0	0.1	0.0		
		р	0.1	0.1	0.1	0.2	0.0	0.1	0.1		
594	syphilis, (genit. and NOS) \$	i p	0.0 0.0	0.0	0.0 0.0	0.1	0.0	0.0 0.0	0.0 0.0		
EO.E	gonorrhea, (genit. and NOS) \$	i				0.1					
595	gonomiea, (genic and NOS) *	p	0.0 0.0	0.0 0.0	0.0 0.1	0.0	0.0 0.0	0.0	0.0 0.0		
596	veneral dis. NEC 9	i	0.0	0.2	0.2	0.4	0.1	0.2	0.0		
		p	0.0	0.2	0.3	0.5	0.1	0.3	0.1		
597	urogenital candidiasis \$	i	2.1	2.6	2.9	2.4	2.7	2.4	2.8		
		р	3.0	3.3	3.4	3.2	3.4	3.2	3.2		

i p i p i p i p i p	season spring 0.0 0.0 0.4 0.7 1.2 1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.2 0.1 0.2 0.2 0.2	0.0 0.0 0.4 0.6 0.8 1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.0 0.0 1.0 1.3	autumn 0.0 0.0 0.4 0.7 0.9 1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	winter	type of insurpublic 0.0 0.0 0.5 0.9 1.1 1.9 0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1 0.1 0.1	0.0 0.0 0.2 0.2 0.6 1.2 0.6 1.5 0.9 1.2
p i p i p i p i p i p i p i p i p i p i	0.0 0.0 0.4 0.7 1.2 1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.6 0.8 0.2	0.0 0.0 0.4 0.6 0.8 1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.1 0.1 0.0 1.3	0.0 0.0 0.4 0.7 0.9 1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.0 0.4 0.7 1.0 1.8 0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	0.0 0.0 0.5 0.9 1.1 1.9 0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	0.0 0.0 0.2 0.2 0.6 1.2 0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
p i p i p i p i p i p i p i p i p i p i	0.0 0.4 0.7 1.2 1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.6 0.8 0.2	0.0 0.4 0.6 0.8 1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.0 0.0 1.0 1.3	0.0 0.4 0.7 0.9 1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.4 0.7 1.0 1.8 0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	0.0 0.5 0.9 1.1 1.9 0.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	0.0 0.2 0.2 0.6 1.2 0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
i p i p i p i p i p i p i p i p i p i p	0.4 0.7 1.2 1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.3 0.4 0.5 0.5 0.6 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	0.4 0.6 0.8 1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.0 1.0	0.4 0.7 0.9 1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.4 0.7 1.0 1.8 0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	0.9 1.1 1.9 0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	0.2 0.6 1.2 0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
p i p i p i p i p i p i p i p i p i p i	0.7 1.2 1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.6 0.8 0.2	0.6 0.8 1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.0 1.0 1.0 1.3	0.7 0.9 1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.7 1.0 1.8 0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1 0.1	0.9 1.1 1.9 0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	0.6 1.2 0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.2
p i p i p i p i p i p i p i p i p i p i	1.9 0.9 2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.6 0.8 0.2	1.3 0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.0 1.0 1.0 1.0	1.5 0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	1.8 0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1 0.1	1.9 0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	1.2 0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
i p i p i p i p i p i p i p i p i p i p	0.9 2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2	0.7 1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.0 0.0	0.8 1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.9 2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	0.9 1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	0.6 1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2
p i p i p i p i p i p i p i p i p i p	2.1 1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2	1.7 1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.0 0.0 1.0 1.3	1.6 1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	2.0 1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	1.9 1.1 1.8 0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3 0.1	1.5 0.9 1.2 0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
i p i p i p i p i p i p i p i p i p	1.0 1.5 0.1 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2	1.0 1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.0 0.0	1.2 1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	1.0 1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1	0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3	0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2
p i p i p i p i p i p i p i p i	1.5 0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2	1.4 0.0 0.1 1.4 3.5 0.1 0.1 0.1 0.1 0.1 1.0 1.0 1	1.8 0.2 0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	1.5 0.2 0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1 0.1	0.1 0.3 1.1 3.2 0.1 0.1 0.2 0.3	0.2 0.3 0.9 2.9 0.1 0.1 0.1 0.2
p i p i p i p i p i p i p	0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2	0.1 1.4 3.5 0.1 0.1 0.1 0.0 0.0 1.0	0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1 0.1	0.3 1.1 3.2 0.1 0.1 0.2 0.3	0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
p i p i p i p i p i p i p	0.1 0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.5 0.5 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	0.1 1.4 3.5 0.1 0.1 0.1 0.0 0.0 1.0	0.3 0.9 3.1 0.1 0.1 0.2 0.4 0.0 0.1	0.5 0.9 3.0 0.0 0.1 0.3 0.4 0.1 0.1	0.3 1.1 3.2 0.1 0.1 0.2 0.3	0.3 0.9 2.9 0.1 0.1 0.1 0.2 0.1
i p i p i p i p i p i p	0.8 2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.2	3.5 0.1 0.1 0.1 0.0 0.0 1.0 1.3	3.1 0.1 0.1 0.2 0.4 0.0 0.1	3.0 0.0 0.1 0.3 0.4 0.1	3.2 0.1 0.1 0.2 0.3	2.9 0.1 0.1 0.1 0.2 0.1
p i p i p i p i p i p	2.8 0.1 0.2 0.1 0.2 0.2 0.2 0.6 0.8 0.2	0.1 0.1 0.1 0.1 0.0 0.0	0.1 0.1 0.2 0.4 0.0 0.1	0.0 0.1 0.3 0.4 0.1	0.1 0.1 0.2 0.3	0.1 0.1 0.1 0.2 0.1
p i p i p i p	0.2 0.1 0.2 0.2 0.2 0.6 0.8	0.1 0.1 0.1 0.0 0.0 1.0 1.3	0.1 0.2 0.4 0.0 0.1	0.1 0.3 0.4 0.1 0.1	0.1 0.2 0.3 0.1	0.1 0.1 0.2 0.1
i p i p	0.1 0.2 0.2 0.2 0.6 0.8 0.2	0.1 0.1 0.0 0.0 1.0 1.3	0.2 0.4 0.0 0.1	0.3 0.4 0.1 0.1	0.2 0.3 0.1	0.1 0.2 0.1
p i p i p	0.2 0.2 0.2 0.6 0.8 0.2	0.1 0.0 0.0 1.0 1.3	0.4 0.0 0.1	0.4 0.1 0.1	0.3	0.2 0.1
i p i p	0.6 0.8 0.2	1.0 1.3	0.1	0.1		
i p i	0.6 0.8 0.2	1.0 1.3	0.8		0.1	0.1
p i	0.8 0.2	1.3		0.9		
p i	0.8 0.2	1.3		0.0	8.0	0.7
		0.1	_	1.1	1.1	1.0
n		0.1	0.3	0.3	0.3	0.2 0.4
р	0.4	0.3	0.5	0.5	0.5 0.2	0.1
i p	0.1 0.3	0.1 0.2	0.3 0.3	0.2 0.2	0.2	0.2
i	0.0	0.0	0.0	0.0	0.0	0.0
p	0.0	0.0	0.0	0.0	0.0	0.0
i	0.2	0.1	0.1	0.2	0.1	0.1 0.2
р	0.3	0.1	0.2	0.2		
i	0.4	0.2	0.4	0.3	0.4	0.3
p	0.7	0.3	0.5	0.3		0.3
i	0.7	8.0	1.4	1.1 1.6	1.1 1.4	0.8 1.0
p						1.1
i p			0.3	0.8	1.1	1.3
i	0.2	0.2	0.4	0.2	0.2	0.3
p	0.4	0.5	0.6	0.4		0.4
i		0.0			0.0	
Р		0.0		•		-
i	0.0	0.1	0.0	0.0	0.0	0.0
p	0.1	0.1	0.0	0.1		0.1
i	0.0	0.0				0.0 0.0
i p	0.0	0.0	0.0	0.0	0.0	0.0
i	0.3	0.1	0.1	0.1	0.2	0.1
р	0.3	0.1				0.2
		2.2	3.3			2.0 2.8
	p i p i p i p i p i p i p i p	p 0.3 i 0.4 p 0.7 i 0.7 p 0.9 i 1.5 p 1.8 i 0.2 p 0.4 i . p . i 0.0 p 0.1 i 0.0 p 0.0 i 0.0 p 0.0 i 0.0 p 0.0 i 0.0	p 0.3 0.1 i 0.4 0.2 p 0.7 0.3 i 0.7 0.8 p 0.9 0.9 i 1.5 1.4 p 1.8 1.6 i 0.2 0.2 p 0.4 0.5 i . 0.0 p 0.0 i 0.0 0.1 p 0.1 0.1 i 0.0 0.0 p 0.0 0.0 i 0.0 0.0 p 0.0 0.0 i	p 0.3 0.1 0.2 i 0.4 0.2 0.4 p 0.7 0.3 0.5 i 0.7 0.8 1.4 p 0.9 0.9 1.8 i 1.5 1.4 0.3 p 1.8 1.6 0.5 i 0.2 0.2 0.4 p 0.4 0.5 0.6 i . 0.0 . 0.0 p 0.1 0.1 0.0 p 0.1 0.1 0.0 p 0.0 0.0 0.0 i 0.0 0.0 0.3 0.1 0.1	p 0.3 0.1 0.2 0.2 i 0.4 0.2 0.4 0.3 p 0.7 0.3 0.5 0.3 i 0.7 0.8 1.4 1.1 p 0.9 1.8 1.6 i 1.5 1.4 0.3 0.7 p 1.8 1.6 0.5 0.8 i 0.2 0.2 0.4 0.2 p 0.4 0.5 0.6 0.4 i . 0.0 . . p 0.1 0.0 . . p 0.1 0.1 0.0 0.0 p 0.1 0.1 0.0 0.0 p 0.0 0.0 0.0 0.0 p 0.3	0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2

no.	o. episode			urbanization		region	region			
			rural	suburban	urban	city	north	centre	south	
598	urogenital trichomoniasis \$	i	0.2	0.2	0.5	0.3	0.4	0.3	0.2	
		р	0.2	0.3	0.5	0.4	0.5	0.3	0.2	
599	pelvic inflammatory disease	i	0.3	0.2	0.3	0.4	0.2	0.3	0.3	
		р	0.5	0.4	0.4	0.7	0.4	0.5	0.4	
600	carcinoma in situ cervix	i	0.0	0.0		•	0.0	0.0		
		р	0.1	0.1	0.0	0.1	0.1	0.1	0.1	
601	cervix carcinoma NEC	i	0.0	0.0	0.0		0.0	0.0	0.0	
		þ	0.1	0.1	0.2	0.2	0.2	0.1	0.1	
602	mal. neopl. mamma \$	i	0.3	0.2	0.2	0.1	0.2	0.2	0.2	
		р	1.6	1.4	2.1	1.1	1.7	1.7 	1.4	
603	mal. neopl. genit. syst. 9	i	0.0	0.1	0.0	0.1	0.1	0.1	0.0	
		р	0.4	0.5	0.3	0.5	0.5	0.4	0.4	
604	fibroid/myoma (uterus/cervix)	i	0.2	0.3	0.3	0.3	0.2	0.3	0.2	
	, ,	р	0.6	8.0	0.5	1.0	0.7	0.7	0.6	
605	ben. neopl. mamma ♀	i	0.3	0.2	0.1	0.1	0.3	0.2	0.2	
		р	0.3	0.4	0.2	0.2	0.3	0.3	0.3	
606	ben. neopl. genit. syst. 9	i	0.1	0.2	0.2	0.1	0.2	0.2	0.1	
		р	0.3	0.3	0.4	0.4	0.4	0.3	0.2	
607	unspec. neopl. genit. syst. 9	i	0.1	0.1	0.1		0.0	0.1	0.0	
		р	0.2	0.1	0.2	0.1	0.1	0.2	0.1	
608	injury genit. syst./mamma \$	i	0.0	0.0	0.0	٠.	0.0	0.0	0.0	_
000	injury genit. syst/mamma *	р	0.0	0.0	0.0	0.1	0.0	0.0	0.0	
609	cong. anom. genit. syst./mamma ♀	i	0.0	0.0			0.0			
000	oong. anom. gom. syst./mamma +	p	0.1	0.0	0.0		0.0	0.0	0.0	
610	vaginitis/vulvitis NOS	i	0.6	0.8	1.3	1.3	0.9	0.9	1.0	
		р	1.1	1.2	2.0	2.0	1.4	1.4	1.4	
611	cervicitis/cerv. dis. NEC	i	0.1	0.2	0.4	0.1	0.1	0.2	0.3	
		р	0.2	0.4	0.7	0.1	0.3	0.4	0.4	
612	abnormal PAP-smear	i	0.0	0.0	0.1	0.1		0.1	0.0	
		р	0.2	0.2	0.4	0.5	0.1	0.3	0.2	
040			0.0	0.4	0.0	0.4	0.0	0.0	0.4	-
613	uterovaginal prolapse	i p	0.6 2.5	0.4 2.0	0.6 2.2	0.4 2.1	0.6 2.6	0.6 2.2	0.4 1.9	
61/	cystic breast (chronic)	i	0.3	0.3	0.4	0.4	0.3	0.3	0.3	
614	cystic breast (critoric)	р	0.4	0.4	0.4	0.6	0.5	0.4	0.5	
615	premenstrual tension syndrome	i	0.1	0.2	0.2	0.2	0.2	0.1	0.3	
0.0	promotoural toroion syriaromo	p	0.3	0.3	0.3	0.3	0.4	0.2	0.4	
616	gardnerella infection	i	0.1	0.0	0.2	0.9	0.0	0.2	0.1	
		р	0.1	0.1	0.3	1.4	0.1	0.4	0.1	
617	infection/abscess gl. Bartholini	i	0.1	0.1	0.1	0.1	0.0	0.1	0.1	
		р	0.1	0.2	0.1	0.2	0.0	0.1	0.2	
040			0.4	0.4		0.1	0.4	0.4	0.0	-
618	endometriosis	i p	0.1 0.3	0.1 0.2	0.0 0.2	0.1 0.2	0.1 0.3	0.1 0.2	0.0 0.2	
640	etrophial veginge have a									
619	atrophial vaginae/vulvae	i p	0.1 0.3	0.2 0.7	0.2 0.6	0.0 0.3	0.2 0.6	0.2 0.5	0.2 0.5	
600	dia ganital avet /mamma NEC 0	i								
620	dis. genital syst./mamma NEC \$	p	0.4 0.6	0.3 0.6	0.5 1.0	0. 5 0.9	0.5 0.8	0.4 0.7	0.4 0.7	
		1.				-				

season spring summer autumn winter type of insurance public private i 0.2 0.3 0.4 0.1 0.3 0.2 p 0.3 0.4 0.4 0.1 0.3 0.2 p 0.3 0.4 0.3 0.2 0.3 0.3 i 0.3 0.4 0.3 0.2 0.3 0.2 p 0.5 0.5 0.5 0.3 0.5 0.3 i 0.0 0.0 0.0 0.0 0.0 0.0 p 0.1 0.1 0.1 0.0 0.1 0.0 p 0.1 0.1 0.1 0.1 0.2 0.1 i 0.1 0.2 0.2 0.1 0.2 0.1 p 0.4 0.4 0.5 0.5 0.4 0.3 i 0.1 0.0 0.1 0.1 0.1 0.0 p 0.4
D
i 0.3 0.4 0.3 0.2 0.3 0.2 0.3 0.2 pp 0.5 0.5 0.5 0.5 0.3 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.
p 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 p 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1
p 0.1 0.1 0.1 0.1 0.1 0.2 0.1 i 0.1 0.2 0.2 0.1 0.2 0.1 p 1.4 1.9 1.8 1.3 1.7 1.3 i 0.1 0.0 0.1 0.1 0.1 0.0 p 0.4 0.4 0.4 0.5 0.5 0.5 0.4 0.3 i 0.3 0.2 0.2 0.2 0.3 0.3 0.3 i 0.3 0.2 0.2 0.5 0.8 0.7 0.6 i 0.3 0.2 0.2 0.2 0.2 0.2 p 0.9 0.6 0.5 0.8 0.7 0.6 i 0.3 0.2 0.2 0.2 0.2 0.2 0.2 i 0.1 0.1 0.1 0.2 0.2 0.2 p 0.5 0.3 0.3 0.3 0.3 0.3 i 0.1 0.1 0.1 0.2 0.2 0.2 p 0.2 0.3 0.3 0.3 0.3 0.3 i 0.1 0.1 0.1 0.2 0.2 0.2 0.2 p 0.2 0.3 0.3 0.3 0.3 0.3 0.3
i 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1
p 0.4 0.4 0.5 0.5 0.5 0.4 0.3 i 0.3 0.2 0.2 0.3 0.3 0.3 p 0.9 0.6 0.5 0.8 0.7 0.6 i 0.3 0.2 0.2 0.2 0.2 0.2 0.1 p 0.5 0.3 0.3 0.3 0.3 0.3 i 0.1 0.1 0.2 0.2 0.2 0.2 p 0.2 0.3 0.4 0.3 0.3 0.3
i 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.9 0.6 0.5 0.8 0.7 0.6 i 0.3 0.2 0.2 0.2 0.2 0.1 0.5 0.5 0.3 0.3 0.3 0.2 i 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
i 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.5 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
p 0.5 0.3 0.3 0.3 0.3 0.2 i 0.1 0.1 0.2 0.2 0.2 0.2 p 0.2 0.3 0.4 0.3 0.3 0.3
p 0.2 0.3 0.4 0.3 0.3 0.3
p 02
i 0.1 0.0 0.0 0.1 0.1 0.1
p 0.2 0.1 0.1 0.2 0.2 0.1
i 0.0 0.0 0.0 0.0 0.0
p 0.0 0.1 0.1 0.0 0.1 0.1
i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.
i 1.1 0.9 1.1 0.6 1.0 0.7
p 1.5 1.4 1.6 1.1 1.5 1.2
i 0.1 0.1 0.2 0.3 0.2 0.2 0.2 0.0 0.3 0.3 0.4 0.5 0.4 0.3
i 0.0 0.1 0.1 0.0 0.0 0.0
p 02 0.2 0.4 0.3 0.3 0.2
i 0.5 0.6 0.4 0.6 0.5 0.6
p 1.9 2.8 1.9 2.1 2.1 2.3
i 0.4 0.4 0.3 0.2 0.3 0.2 p 0.5 0.6 0.4 0.3 0.5 0.4
i 02 0.1 0.2 0.2 0.2 0.2
p 02 0.2 0.4 0.4 0.3 0.2
i 0.1 0.1 0.4 0.2 0.2 0.2 0.2 p 0.1 0.2 0.4 0.4 0.3 0.3
i 0.1 0.2 0.1 0.0 0.1 0.1
p 0.2 0.2 0.1 0.1 0.2 0.1
i 0.1 0.1 0.0 0.1 0.1 0.1
p 02 0.3 0.2 0.2 0.2 0.2
i 0.2 0.1 0.3 0.1 0.2 0.2 p 0.3 0.4 0.8 0.5 0.5 0.6
i 0.4 0.5 0.4 0.3 0.5 0.3
p 0.7 0.7 0.9 0.6 0.8 0.5

	no.	episode		degree of	urbanization			region		
P		·		rural	suburban	urban	city	north	centre	south
P	621	sympt./complt. gen. syst. &								
P	622	discharge penis/urethra								
P	623	sympt./complt. prostate								
P	624	sympt./complt. potency								
P 0.2 0.1 0.2 . 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.3 0.3 0.5 0.3 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.4 0.5	625	sympt./complt. sexual dysf. &								
P	626	sub-/infertility ਰਾ								
P	627	fam. plan. o ^a								
P	628	sympt./complt. mamma 🕫								
631 sympt/complt. gen. syst./mam.NEC σ* i 0.0 0.0 0.1 0.1 0.0 0.0 0.1 632 syphilis σ* i 0.0 0.0 0.2 0.1 0.0 0.1 0.1 632 syphilis σ* i 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	629	fear dis. gen. syst./mamma ♂								
P	630	disab./impairm.gen.syst./mamma &			0.0	•			0.0	
P 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1	631	sympt./complt. gen. syst./mam.NEC &								
p 0.0 0.0 0.2 0.4 0.0 0.1 0.1 634 venereal disease NEC & i 0.0 0.0 0.0 0.2 0.0 0.1 0.1 635 urogenital trichomoniasis & i 0.0 0.0 0.0 0.1 0.3 0.1 0.1 635 urogenital trichomoniasis & i 0.0 0.0 0.0 0.0 0.1 0.1 0.1 636 prostatitis/seminal vesiculitis i 0.3 0.2 0.3 0.3 0.5 0.3 0.3 637 orchitis/epididymitis i 0.3 0.2 0.3 0.3 0.5 0.7 0.5 0.5 637 orchitis/epididymitis i 0.3 0.2 0.3 0.4 0.7 0.5 0.7 0.5 0.5 638 infection gen. syst. NEC & i 0.4 0.7 0.9 0.7 0.5 0.6 0.6 639 malign. neopl. prostate i 0.0 0.1 0.1 0.1 0.1 0.0 0.1 640 malign. neopl. testis i 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 641 malign. neopl. gen. syst. NEC & i 0.0 0.0 0.0 0.0 0.0 0.0 642 benign. neopl. gen. syst. & i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 644 unspecif. neopl. gen. syst. & i 0.0 0.1 0.1 0.0 0.1 0.0 0.0 645 injury gen. syst./mamma & i 0.0 0.1 0.1 0.0 0.0 0.0 645 injury gen. syst./mamma & i 0.0 0.1 0.1 0.1 0.0 0.0 646 injury gen. syst./mamma & i 0.0 0.1 0.1 0.1 0.0 0.0 0.0 647 injury gen. syst./mamma & i 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 648 injury gen. syst./mamma & i 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0	632	syphilis &								
P 0.0 0.0 0.1 0.3 0.1 0.1 0.0	633	gonorrhea o								
P	634	venereal disease NEC &								
p 0.5 0.4 0.7 0.5 0.7 0.5 0.5 0.5 0.5 0.5 0.7 0.5 0.5 0.5 0.5 0.5 0.7 0.5 0.5 0.5 0.5 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	635	urogenital trichomoniasis &								
P 0.4 0.3 0.4 0.7 0.4 0.4 0.3 0.4 0.7 0.5 0.6 0.7 0.5 0.8 0.7 0.6 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.7 0.5 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.4 0.5	636	prostatitis/seminal vesiculitis								
P 0.5 0.8 1.0 0.9 0.7 0.8 0.7 639 malign. neopl. prostate	637	orchitis/epididymitis								
P 0.4 0.5 0.4 0.7 0.5 0.4 0.4	638	infection gen. syst. NEC &								
p 0.1 0.1 0.0 . 0.1 0.1 0.1 0.1 0.1 0.1 0	639	malign. neopl. prostate	-							
p 0.0 0.0 0.0 0.0 0.1 642 benign. neopl. gen. syst. & i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 643 unspecif. neopl. gen. syst. & i 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 644 unspecif. neopl. mamma & i 0.0 0.1 0.0 0.0 0.0 645 injury gen. syst./mamma & i 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1	640	malign. neopl. testis						0.1		
642 benign. neopl. gen. syst. 8 i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	641	malign. neopl. gen. syst. NEC ♂					•			
643 unspecif. neopl. gen. syst. 8 i 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0	642	benign. neopl. gen. syst. 🎳	i	0.0	0.0					
p 0.0 0.1 0.0 . 0.0 0.0 0.0 645 injury gen. syst/mamma & i 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1	643	unspecif. neopl. gen. syst. σ	i							
	644	unspecif. neopl. mamma &								
y 5.0 6.1 6.1 6.1 6.0 6.1 6.1	645	injury gen. syst./mamma &	i p	0.0 0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.0 0.0	0.1 0.1	0.1 0.1

10.		season spring	summer	autumn	winter	type of insu public	rance private	
21	i p	0.3 0.4	0.2 0.3	0.2 0.3	0.2 0.3	0.2 0.3	0.2 0.3	
22	i p		0.0 0.0	0.0 0.0		0.0	0.0 0.0	
23	i p	0.0	0.1 0.1	0.0 0.0	0.0 0.2	0.0 0.1	0.1 0.1	
624	i p	0.1 0.1	0.1 0:1	0.1 0.2	0.0 0.1	0.1 0.2	0.0 0.0	
625	i p	0.1 0.1	0.0 0.1	0.0 0.1	0.0 0.1	0.0 0.1	0.0 0.0	
26	i	0.1 0.2	0.0 0.2	0.1 0.2	0.0	0.1 0.2	0.1 0.1	
627	p i	0.3	0.3	0.4	0.4	0.2 0.3	0.5 0.6	
528	p i	0.3 0.1	0.4	0.5	0.1	0.0	0.1 0.1	
629	p i	0.1 0.1	0.1 0.1	0.0 0.1	0.1	0.1	0.1	
	р	0.2	0.1	0.1	0.1	0.1	0.1	
630	i p	*	:	0.0		0.0	*	
631	i p	. 0.0	0.1 0.1	0.1 0.1	0.0 0.0	0.1 0.1	0.0 0.1	
632	i p	0.0 0.0	0.0 0.0	0.0		0.0 0.0	0.0	
633	i p	0.2 0.2	0.0 0.0	0.2 0.2	0.0	0.1 0.1	0.1 0.1	
634	i p	0.1 0.1	0.0 0.0	0.0 0.1	0.0 0.0	0.1 0.1	0.0	
635	i P	0.0 0.1	0.0 0.0	0.0 0.1	0.1 0.1	0.0 0.0	0.0 0.1	
636	i	0.2 0.6	0.2 0.3	0.3 0.5	0.4 0.6	0.3 0.5	0.3 0.5	
637	p i	0.3	0.4 0.5	0.3 0.3	0.4 0.4	0.3 0.3	0.4 0.4	
638	p i	0.4	0.4	0.7 0.8	0.7 0.7	0.7 0.8	0.5 0.6	
639	p i	0.0	0.7 0.1	0.1	0.0	0.0 0.4	0.1 0.5	
640	p i	0.0	0.5	0.5 0.1	0.0 0.0	0.0 0.1	. 0.0	
	р	0.1	0.1	U.1				
641	i p	0.0	0.0	•	0.1	0.0		
642	i p	0.0 0.0	0.0 0.0	0.0		0.0	0.0	
643	i P		0.0 0.0	0.1 0.1	0.0	0.0 0.0	0.1 0.1	
644	i	0.1 0.1	0.0	0.0	0.0	0.0 0.0	0.1 0.1	
645	p i p	0.1 0.2	0.0	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.1	

no.	no. episode			urbanization		region	region		
			rural	suburban	urban	city	north	centre	south
646	phimosis/redund. prepuce	i	0.2 0.2	0.2 0.4	0.2 0.3	0.1 0.1	0.2 0.2	0.2	0.2
		р	0.2	0.4	0.3	0.1	0.2	0.2	0.3
647	hypospadia	p	0.0	0.0		5. 5.	:	0.0	0.0
648	undesc. testicle/cryptorchism	i p	0.1 0.2	0.1 0.1	0.1 0.2	0.2 0.3	0.2 0.3	0.1 0.1	0.1 0.2
649	cong. an. gen. syst./mamma NEC ♂	i p	0.0 0.0	0.0	0.0 0.0		0.1	0.0 0.0	0.0
650	benign prostatic hypertrophy	i P	0.2 0.4	0.1 0.4	0.1 0.5	0.2 0.5	0.2 0.6	0.1 0.5	0.1 0.4
651	hydrocele	i p	0.1 0.2	0.1 0.1	0.1 0.1	0.1 0.1	0.1 0.2	0.1 0.1	0.1 0.1
652	dis. gen. syst./mamma NEC ♂	i p	0.3 0.5	0.3 0.4	0.2 0.4	0.3 0.3	0.3 0.5	0.2 0.3	0.4 0.6

Y MALE GENITAL SYSTEM (INCLUDING BREAST)

no.		season				type of insu	rance
		spring	summer	autumn	winter	public	private
646	i	0.3	0.1	0.1	0.2	0.2	0.2
	р	0.4	0.2	0.2	0.3	0.2	0.4
647	i			Y.	•		
	р	0.0	0.0	0.0	0.0	0.0	
648	i	0.1	0.1	0.1	0.1	0.1	0.1
	р	0.1	0.1	0.2	0.2	0.2	0.1
649	i	0.0		0.0	0.0	0.0	0.0
	р	0.0	0.0	0.0	0.0	0.0	0.0
650	i	0.1	0.2	0.2	0.1	0.1	0.2
	р	0.3	0.4	0.7	0.4	0.5	0.4
651	i	0.1	0.1	0.1	0.1	0.1	0.1
	р	0.1	0.1	0.1	0.1	0.2	0.1
652	i	0.3	0.2	0.3	0.2	0.3	0.3
	р	0.5	0.3	0.5	0.4	0.4	0.4

no.	episode		degree of	f urbanization			region		
110.	opioodo		rural	suburban	urban	city	north	centre	south
653	poverty/financial probl.	i	0.1	0.1	0.1	0.4	0.0	0.1	0.1
		р	0.1	0.3	0.3	0.6	0.1	0.3	0.4
654	problem food/water	i		0.0				0.0	0.0 0.0
		р		0.0	•				
655	probl. housing/neighborh.	i p	0.2 0.4	0.3 0.7	0.4 1.2	0.3 0.9	0.2 0.5	0.3 0.7	0.2 0.9
656	probl. house moving	i	0.1	0.1	0.1	0.1	0.1	0.1	0.1
000	proble floate moving	p	0.3	0.3	1.2	0.5	0.3	0.6	0.5
657	fear of having a social probl.	i	0.0	0.0	0.0	(**		0.0	0.0
		р	0.0	0.0	0.1	0.1	0.0	0.0	0.0
658	probl. working conditions	i	0.1	0.3	0.1	0.3	0.1	0.2	0.1
		р	0.3	0.7	0.4	0.9	0.4	0.6	0.6
659	probl. job/employment NEC	i	0.5	0.6	0.8	0.8	0.6	0.6	0.6
		р	1.0	1.3	1.8	2.0	1.1	1.4	1.5
660	probl. w. being unemployed	i	0.0	0.0 0.2	0.1	0.1	0.1 0.2	0.0 0.1	0.1 0.2
		р	0.1		0.2	0.1			
661	probl. w. education	i p	0.2 0.6	0.1 0.4	0.4 0.7	0.2 0.3	0.3 0.5	0.2 0.4	0.3 0.6
662	probl. soc. insurrance/welfare	i	0.1	0.1	0.1	0.2	0.2	0.1	0.1
OOL	proble dec. mountaines/wonare	р	0.3	0.3	0.4	0.8	0.4	0.3	0.5
663	probl. legal/police	i p	0.0 0.0	0.0 0.1	0.1		0.0 0.1	0.0 0.0	0.0 0.1
664	probl. health care syst./access	i	0.1	0.2	0.2	0.3	0.1	0.2	0.2
	p. 5.5.	р	0.2	0.5	0.5	0.6	0.3	0.4	0.5
665	probl. soc./cultural syst.	i	0.1	0.1	0.2	0.1	0.2	0.1	0.1
		р	0.2	0.4	0.3	1.4	0.4	0.4	0.4
666	relation problems partners	i	0.7 1.5	0.9 2.1	1.0 1.9	1.4 3.0	0.9 1.6	0.9 2.0	1.1 2.0
667	problems w. behaving partner	p i	0.1	0.1	0.0	0.1	0.1	0.1	0.0
667	problems w. benaving parties	p	0.2	0.2	0.2	0.2	0.3	0.2	0.3

668	probl. w. partner being ill	i	0.3 1.0	0.6 1.7	0.4 2.0	0.5 1.5	0.5 1.4	0.4 1.4	0.6 1.9
000	model loss of modern	р :							
669	probl. loss of partner	i p	0.4 2.0	0.6 2.6	0.8 3.4	1.3 3.6	0.6 2.3	0.7 2.7	0.6 2.8
670	relation probl. with child	i	0.6	0.5	0.8	0.7	0.4	0.6	0.8
		р	1.1	1.1	1.3	1.0	0.7	1.0	1.8
671	probl. behaving child	i	0.1	0.2	0.1	0.1	0.0	0.2	0.1
		р	0.1	0.4	0.2	0.2	0.1	0.2	0.3
672	probl. with child being ill	i	0.1	0.1	0.1 0.4	0.1	0.2 0.6	0.1	0.1
		Р	0.5	0.5	0.4	0.1	0.0	0.4	0.5
673	loss or death of child	i	0.1	0.1	0.2	0.1	0.1	0.1	0.2
		р	0.2	0.3	0.4	0.3	0.3	0.2	0.5
674	relation probl. parent/other family	i	0.7	0.6	0.8	0.3	0.6	0.6	0.7
		p	1.4	1.3	1.9	1.1	1.2	1.3	1.9
675	probl. w. behaving parent/other family	i p	0.1 0.1	0.0 0.1	0.0		0.0 0.0	0.1 0.1	0.0 0.1
676	problem parent/other family being ill		0.1	0.1			0.3		
676	probl. w. parent/other family being ill	i p	0.2	0.2	0.2 0.9	0.1 0.5	0.8	0.2 0.5	0.3 0.8
677	loss parent/family	i	0.4	0.3	0.5	0.4	0.4	0.3	0.4
		р	0.7	0.9	1.4	0.9	1.0	0.9	1.2

						type of insura	ance	
no.		season spring	summer	autumn	winter	public	private	
653	i p	0.2 0.4	0.1 0.2	0.1 0.3	0.1 0.2	0.1 0.3	0.1 0.2	
654	i p	•			0.0 0.0	0.0 0.0	*	
655	i p	0.3 0.7	0.2 0.5	0.3 1.1	0.2 0.6	0.3 0.9	0.1 0.4	
656	i	0.1	0.1 0.5	0.1 0.7	0.1 0.6	0.1 0.6	0.1 0.3	
657	p i	0.4		0.0 0.1	0.0	0.0	0.0	
	р	0.0	0.0	0.1	0.0			
658	i p	0.3 0.6	0.1 0.4	0.1 0.5	0.2 0.6	0.2 0.5	0.2 0.6	
659	i	0.6	0.4	0.7	0.8	0.7 1.5	0.5 1.1	
	р	1.3	0.0	1.7 0.1	1.7 0.1	0.1	0.0	
660	i p	0.0 0.1	0.1	0.2	0.2	0.2	0.1	
661	i p	0.3 0.6	0.1 0.3	0.2 0.5	0.4 0.6	0.2 0.5	0.3 0.5	
662	i p	0.1 0.3	0.1 0.3	0.1 0.5	0.1 0.5	0.1 0.4	0.1 0.2	
					0.0	0.0		
663	i p	0.0 0.0	0.0	0.1	0.1	0.1	0.0	
664	i	0.1	0.2	0.2	0.3	0.2	0.2	
	р	0.2	0.3	0.5	0.7	0.4 0.1	0.3	
665	i p	0.1 0.3	0.0 0.5	0.1 0.4	0.2 0.5	0.6	0.1	
666	i p	1.0 2.4	0.6 1.4	1.0 1.9	1.1 2.1	0.9 2.0	0.9 1.6	
667	i	0.0	0.1	0.1	0.0	0.1	0.1	
	р	0.2	0.2	0.2	0.2	0.2	0.1	
668	i p	0.3 1.3	0.4 1.4	0.5 1.6	0.6 1.8	0.4 1.4	0.6 1.7	
669	i	0.6	0.4	1.0	0.7	0.7	0.5	
	р	3.0	2.1	3.1	2.6	2.9	1.9	
670	i p	0.5 1.1	0.8 1.1	0.5 1.1	0.7 1.3	0.8 1.4	0.4 0.7	
671	i	0.2	0.0	0.1	0.1	0.1	0.1	
	р	0.3	0.1	0.2	0.2	0.2 0.1	0.2 0.1	
672	i P	0.1 0.4	0.0 0.3	0.1 0.5	0.1 0.5	0.4	0.3	
673	i	0.1 0.2	0.1 0.2	0.2 0.4	0.1 0.3	0.1 0.3	0.1 0.3	
674	p ;	0.4	0.6	0.6	0.9	0.7	0.4	
674	p	1.2	1.1	1.5	2.0	1.6	0.9	
675	i	0.0	0.1	0.0	0.0 0.1	0.1 0.1	0.0 0.0	
0=0	р	0.1	0.1	0.0 0.3	0.1	0.2	0.2	
676	i p	0.1 0.4	0.2 0.5	0.8	0.8	0.7	0.5	
677	i	0.3	0.3	0.6	0.3	0.4	0.3 0.7	
	р	0.6	0.8	1.4	1.1 	1.1	0.1	

no.	episode		degree of urbanization				region	region		
			rural	suburban	urban	city	north	centre	south	
678	loss or death of friend	i	0.0	0.0	0.0	0.1	0.1	0.0	0.0	
		р	0.0	0.1	0.1	0.2	0.1	0.1	0.1	
679	relation probl. w. friend	i	0.1	0.1	0.1	•	0.0	0.1	0.0	
		р	0.1	0.1	0.1		0.0	0.1	0.1	
680	probl. assault/harmfull events	i	0.1	0.1	0.2	0.2	0.0	0.1	0.2	
		р	0.2	0.2	0.6	0.4	0.2	0.3	0.4	
681	probl. with being ill	i	0.0	0.0	0.0	0.1	0.1	0.0	0.1	
		р	0.1	0.1	0.5	0.2	0.1	0.2	0.2	
682	social handicap	i	0.1	0.0	0.0	0.1	0.1	0.0	0.1	
		р	0.2	0.2	0.2	0.1	0.2	0.2	0.2	
683	social isolation	i	0.1	0.3	0.1	0.4	0.1	0,2	0.1	
		р	0.7	1.1	0.8	1.9	0.7	1.1	0.7	
684	social problems	i	0.2	0.2	0.2	0.8	0.2	0.3	0.2	
		р	0.5	0.9	0.5	3.0	0.7	1.0	0.7	

no.		season				type of insu	rance	
1101		spring	summer	autumn	winter	public	private	
678	i		0.0	0.0	0.1	0.0	0.0	
0,0	p		0.1	0.1	0.2	0.1	0.1	
679	i	0.0	0.0	0.0	0.1	0.1	0.0	
	р	0.0	0.1	0.1	0.2	0.1	0.0	
680	i	0.1	0.1	0.2	0.1	0.2	0.0	
	р	0.3	0.1	0.5	0.2	0.4	0.2	
681	i		0.0	0.1	0.1	0.0	0.0	
	р	•	0.1	0.2	0.5	0.2	0.2	
682	i	0.0	0.1	0.0	0.1	0.0	0.1	
	р	0.1	0.2	0.2	0.1	0.2	0.1	
683	i	0.1	0.2	0.1	0.2	0.2	0.2	
530	p p	0.9	1.4	8.0	0.9	1.0	8.0	
684	i	0.3	0.1	0.4	0.2	0.3	0.1	
004	p p	1.0	0.6	1.3	0.7	1.1	0.5	

APPENDIX B Diagnosis(-numbers) used in tables related to the ICPC-codes from the NIVEL-edition (1989) and the Oxford-edition (1987)

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
Α	GENERAL AND UNSPECIFIED		
1	pain: generalized/unspec.	A010	A01
2	chills/fever		100
	cold (chills)	A020	A02
	fever	A030	A03
3	general weak-/tiredness	A040	A04 A06
4	fainting (syncope)	A060	A06
5	symptoms infant	A111	A14
	infantile colic	A111	A15
	excess. crying infant	A112 A119	A16/A17
	irrit, infant/sympt, NEC	A120	A12
6	allergy NEC	A140	P05
7	feeling/behaving old/senile	A140	. 00
8	fear of disease/death fear of medical treatment	A240	-
	fear of death	A250	A25
	fear of cancer NEC	A260	A26
	fear of disease NEC	A270	A27
9	disability/impairment NOS	A28	A28
10	general sympt./complt. NEC		
10	general deterioriation	A050	A05
	coma	A070	A07
	swelling NEC	A080	A08
	sweating problems	A090	A09
	bleeding, site NOS	A100	A10
	concern about drug reaction	A130	A13
	euthanasia by request	A150	A20
	concern about health family	A230	-65
	general sympt./complt. NEC	A290	A29
11	tuberculosis, general, excl. lung	A700	A70
12	measles	A710	A71
13	chickenpox	A720	A72
14	malaria	A730	A73
15	rubella	A740	A74
16	infectious mononucleosis	A750	A75
17	viral dis. with exanthems NEC	A760	A76
18	viral dis. NOS/NEC	A770	A77
19	infectious dis. NOS/NEC	A780	A78
20	carcinomatosis (prim. site unkn)	A790	A79
21	accident/injury NOS	A800	A80
22	mult. trauma/internal injury	A810	A81
23	late effects of trauma	A820	A82
24	poisoning by/abuse of med. agents	A830	A84/P18
25	poisoning by benzodiazepines	A841	A84 A84
26	poisoning by med. agents NOS	A849 A851	A85/S88
27	adv. eff. med. agent proper dose: allergy		A85
28	adv. eff. OAC	A852 A859	A85
29	adv. eff. med. agent NEC	A860	A85 A86
30	toxic eff. other substances	A871	A87
31	complic. surg./med. treatm.: hematoma complic. surg./med. treatm.: wounds	A872	A87
32	· · · · · · · · · · · · · · · · · · ·	A879	A87
33	complic. surg./med. treatm.: NEC	7.07.0	,,

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
34	adv. eff. physical factors NEC		
	motion sickness	A881	A88
	adv. eff. physical factors NEC	A889	A88
35	adv. eff. prosthetic device	A890	A89
36	mult.congenital syndromes	A900	A90
37	abnormal results investigation NEC	A910	A91
38	toxoplasmosis	A920	A92
39	premat./immature liveborn infant	A930	A93
40	all perinatal morbidity		
	icterus neonatorum	A941	A94
	aphyxia neonatorum/RDS	A942	A94
	dyspepsia/diarrhoea neonatorum	A943	A94
	conjunctivitis neonatorum	A944	A94
	anomalies perinatal period NEC	A949	A94
41	perinatal mortality	A950	A95
42	death (excl. perinatal)	A960	A96
43	no disease	A970	A97
44	disease NEC	A990	A99
В	BLOOD, BLOODFORM. ORG.,LYMPHSYSTEM AND SPLEEN		
45	enlarged lymph gland(s)	B020	B02
46	sympt. lymph glands(s) NEC	B030	B03
47	fear of blood/lymph disease		
	fear of AIDS	B250	B25
	fear of cancer blood/blood org.	B260	B26
	fear of other blood/lymph dis.	B270	B27
48	disability/impairment blood	B280	B28
49	sympt./complt. blood NOS/NEC		220
	sympt. blood/bloodform. organs	B040	B04
	sympt./complt. blood/lymph/spleen	B290	B29
50	acute lymphadenitis/-angitis	B700	B70
51	chron. aspec. lymphadenitis	B710	B71
52	malignant lymphoma	B721	B72
53	leukemia	B722	B73
54	malignant neopl. blood NEC	B730	B74
55	benigne neopl. blood/bloodform. org.	B740	B75
56	ruptured spleen	B760	B76
57	injuries blood/bloodform. org. NEC	B770	B77
58	hered, haemolytic anaemias	B780	B78
59	cong. anom. blood/bloodform. org. NEC	B790	B79
60	iron deficiency anemia	B800	B80
61	pernic./other deficiency anemia	2000	200
0.	pernic, anemia	B811	B81
	folate deficiency anemia	B812	B81
	deficiency anemia NEC	B819	B82
62	anemia NOS/NEC	B820	B82
63	hemophilia/coagulation disorders	D020	D02
55	hemophilia	B831	B83
	purpura/abn. plate/coag. dis. NOS	B839	B83
64	abnormal white cells	B840	B84
65	unexplained abn. blood test		
66	abn. blood test NOS	B850	B85
		B860	B86
67	splenomegaly	B870	B87
68	HIV-infection (AIDS/ARS)	B900	B90
69	diseases blood/bloodform. org. NOS/NEC	B990	B99

D 70 71	DIGESTIVE SYSTEM		
71	generalized abd. pain/cramps	D010	D01
, ,	stomach pain	D020	D02
72	heartburn	D030	D03
73	peri-anal itching	D050	D05
74	localised abd. pain	D060	D06
75	flatulence/belching	D080	D08
76	nausea	D090	D09
77	vomiting	D100	D10
78	diarrhoea	D110	D11
79	constipation	D120	D12
80	jaundice	D130	D13 D14
81	blood vomiting	D140 D150	D14
82	melena	D160	D16
83	rectal bleeding	D170	D17
84	fecal incontinence defecation anomalies NEC	D170	D18
85	sympt./complt. of teath, gums	D190	D19
86	sympt./compit. or teath, guins sympt./compit. mouth, tongue, lip	D200	D20
87 88	swallowing problems	D210	D21
89	fear of digestive diseases		
09	fear of cancer of dig. system	D260	D26
	fear of other digestive diseases	D270	D27
90	digestive disability/impairment	D280	D28
91	sympt./complt. digestive NEC		
0.	perianal itching	D040	D04
	indigestion	D070	D29/T29
	localised abd. mass NOS	D240	D24
	ascites	D251	D25
	change in abd. size/distension NEC	D259	D25
	sympt./complt. digest. NEC	D290	D29
92	infectious diarrhoea/dysentery	D700	D70
93	mumps		D710D71
94	infectious hepatitis	D704	D72
	hepatitis A	D721 D722	D72
	hepatitis B	D723	D72
	hepatitis non A non B	D730	D22
95	parasites/worms	D740	D73
96	other presumed infections malign. neopl. stomach	D751	D74
97	malign, neopl. colon, rectum	D752	D75
98 99	malign, neopl. colon, rectum	D753	D75
100	malign. neopl. pancreas	D761	D76
101	malign, neopl. dig. syst. NEC		
101	malign. neopl.stomach/intestine NEC	D759	D77
	malign. neopl. liver/bileduct NEC	D769	D77
102	benign, neoplasms dig. syst. NEC	D770	D78
103	neoplasms dig. syst. NEC	D780	D77
104	foreign body through orifice	D790	D79
105	injuries dig. syst. NEC	D800	D80
106	cong. anom. digest. system	D810	D81
107	disease of teeth/gums	D820	D82
108	disease of mouth/tongue/lips	D830	D83
109	disease of esophagus	D840	D84
110	duodenal ulcer	D850	D85
111	gastric ulcers NEC	D861	D86
112	peptic ulcers NEC	D869	D86

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
113	disord. stomach function	D870	D87
114	appendicitis	D880	D88
115	inguinal hernia	D890	D89
116	hiatus (diaphr.) hernia	D900	D90
117	abdominal hernia NEC	D910	D91
118	diverticular dis. intestines	D920	D92
119	irritable bowel syndrome	D930	D93
120	chron. enteritis/colitis ulc.	D940	D94
121	anal fissure/perianal absces s anal fissure	D951	D95
	anal fist.	D952	D95
	perianal abscess	D953	D95
122	hepatomegaly	D960	D96
123	cirrhosis/liver disease NEC		
	livercirrhosis	D971	D97
	chron, hepatitis NEC	D979	D97
124	diseases of gall-bladder/biliary duct		
	cholecystitis	D981	D98
	cholelithiasis	D982	D98
125	diseases bile duct/-bladder NEC diseases digestive system NEC	D989	D99
	anomalies pancreas NEC	D991	D99
	adhesions	D992	D99
	(sub)acute diseases of bowel	D993	D99
	diseases digestive system NEC	D999	D99
F	EYE		
126	complaints of vision	F050	F05
127	fear of eye disease	F270	F27
128 129	disability/impairment eye sympt./complt. eye NEC	F280	F28
	eye pain	F010	F01
	red eye	F020	F02
	discharge from eye	F030	F03
	floaters/spots	F040	F04
	abn. sensations of eye	F130	F13
	abn. eye movements	F140	F14
	abn. appearance of eyes	F150	F15
	symptoms of eyelids	F160	F16
	sympt./complt. glasses	F170	F17
	sympt./complt. contact lens	F180	F18
	sympt./complt. eye NEC	F290	F29
130	infectious conjunctivitis	. 200	120
	inf. conjunctivitis: viral NOS	F701	F70
	inf. conjunctivitis: bact. NOS	F702	F70
	inf. conjunctivitis NEC/Trachoma	F709	F70/F86
131	allergic conjunctivitis	F710	F71
132	blepharitis/stye/chalazion	F720	F72
133	infection of eye NEC	1720	F72
100	iridocyclitis	F731	F73
	keratitis herpetica	F732	F85
	infection of eye NEC	F739	F73
134	corneal ulcer	F733	F85
135	neoplasms of eye/adnexa	F740	F74
136	contusion/abrasion/black eye	F750	F75
137	foreign body in eye	F760	F76
138	injuries eye NEC	F790	F79
	,	1 750	1/3

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
139	blocked lacrimal duct of infants	F800	F80
140	cong. anom. of eye NEC	F810	F81
141	refractive errors	F910	F91
142	cataract	F920	F92
		F930	F93
143	glaucoma	F940	F94
144	blindness, all types	F991	F95
145	strabismus	F992	F 8 2/F83/F84
146	retinopathy	1 302	1 02/1 00/1 0 1
147	diseases of eye NEC	F993	F99
	ectropion/entropion	F999	F99
	diseases of eye NEC	F999	1 33
Н	EAR		
148	earache	H010	H01
149	hearing complt.	H020	H02
150	ringing/buzzing/tinnitus	H030	H03
151	blood/discharge from ear		
131	discharge from ear	H040	H04
	blood in/from ear	H050	H05
150	fear of ear disease	H270	H27
152	disability/impairment of ear	H280	H28
153	***	11200	
154	symp./complt. of ear NEC	H130	H13
	plugged feeling	H150	H15
	concern with appear. of ears	H290	H29
	symp./complt. of ear NEC	H700	H70
155	otitis externa	H710	H71
156	acute otitis media/myringitis	H720	H72
157	serous otitis media/glue ear		H73
158	eustachian tube dysfuction	H730	П/3
159	infections of ear NEC	1.1744	1.174
	cholesteatoma	H741	H74
	chronic supp. otitis media	H742	H74
	mastoiditis	H743	H74
	infections of ear NEC	H749	H74
160	neoplasm of ear	H750	H75
161	foreign body in ear	H760	H76
162	perforation tymp. membrane	H770	H77
163	superficial injury of ear	H780	H78
164	injuries of ear NEC	H790	H79
165	cong. anom. of ear	H800	H80
166	ear wax (excessive)	H810	H81
167	vertiginous syndromes		
	M. Méniere	H821	H82
	otogenous vert. synndr. NEC	H829	H82
168	otosclerosis	H830	H83
169	presbyacusis	H841	H84
170	acoustic trauma	H842	H85
171	deafness NEC	H849	H86
172	disease of ear/mastoid NEC	H990	H99
K	CIRCULATORY SYSTEM		
173	complaints of heart	1/040	1/04
	pain attributed to heart	K010	K01
	pressure tightness	K020	K02
	palpitations	K040	K04
	abnorm./irreg. heartbeat/pulse	K050	K05

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
174	edema of extremities	K070	K07
175	fear of dis. circ. system		
	fear of heart attack	K240	K24
	fear of hypertension	K250	K25
	fear of dis. heart/circ. syst. NEC	K270	K27
176	disability/impairment circ. syst. NEC	K280	K28
177	sympt./complt. circ. syst. NEC		
	pain attributed to bloodvessels	K030	K03
	prominent veins	K060	K06
	sympt./complt. circ. syst. NEC	K290	K29
178	infections dis. circ. syst.	K700	K70
179	neoplasm circ. syst.	K710	K72
180	injuries heart/circ. syst.	K720	K99/K84
181	cong. anom. heart/circ. syst.	K730	K73
182	rheumatic fever/heart dis.	K740	K71
183	acute myocardial infarction	K751	K75
184	angina pectoris		
	imminent heart attack	K752	K75
	angina pectoris	K761	K74
185	healed myocardial infarction	K762	K76
186	chron. ischemic heart dis. NEC		
	coronary sclerosis	K763	K76
	chron. isch. heart dis. NEC	K769	K76
187	heart failure	K770	K77
188	atrial fibrillation/flutter	K780	K78
189	paroxysmal tachycardia	K790	K79
190	ectopic beats, all types	K800	K80
191	heart murmur NOS	K810	K81
192	pulmonary heart dis.	K820	K82
193	heart valve dis. NOS, non-rheum.	K830	K83
194	heart disease NEC		
	atrio ventr./bundle branch block	K841	K84
	cardiomyopathy	K842	K84
	dis. of heart rhythm NEC	K843	K84
	heart diseases NEC	K849	K84
195	elevated blood pressure w.o. hypertension	K850	K85
196	uncomplicated hypertension	K860	K86
197	hypertension with involv.targ. organs	K870	K87
198	(postural) hypotension	K880	K88
199	transient cerebral ischemia	K890	K89
200	cerebrovascular diseases	1/00 /	
	cerebrovasculair accident	K901	K90
	subarachnoid hemorrhage	K902	K90
001	cerebrovascular dis. NEC	K909	K92
201	atherosclerosis, excl. heart/brain	K910	K91
202	arterial vascular diseases NEC		
	intermittent claudication	K921	K92
000	art. obstr./periph. art. vasc. dis. NEC	K929	K92
203	pulmonary embolism	K930	K93
204	(thrombo) phlebitis	K941	K94
205	venous thrombosis	K942	K94
206	various veins of legs	K951	K95
207	various ulcer of skin	K952	S97
208	hemorrhoids	K960	K96
209	dis. circulatory system NEC	1/004	1/00
		K991	K99
	dis. circulatory system NEC	K999	K99

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
L	MUSCULOSKELETAL SYSTEM		
210	neck symp./complt., excl. headache	L010	L01
211	back symp./complt.	L020	L02
212	low back symp./complt. w/o radiation	L030	L03
213	chest sympt./complt.	L040	L04
214	flank sympt.complt.	L050	L05
215	axilla sympt./complt.	L060	L06
216	jaw sympt./complt.	L070	L07
217	shoulder sympt./complt.	L080	L08
218	arm sympt./complt.	L090	L09
219	elbow sympt./complt.	L100	L10
220	wrist sympt./complt.	L110	L11
221	hand/finger sympt./complt.	L120	L12
222	hip sympt./complt.	L130	L13
223	leg/thigh sympt./complt.	L140	L14
224	knee sympt./complt.	L150	L15
225	ankle sympt./complt.	L160	L16
226	foot/toe sympt./complt.	L170	L17
227	muscle pain/fibrositis	L180	L18
228	(mult.) muscle sympt./complt. NEC	L190	L19
229	(mult.) joints sympt./complt. NEC	L200	L20
230	limbs sympt./complt. NOS	L250	L29
231	fear of dis. musculoskeletal syst.		
201	fear of cancer musc. skeletal syst.	L260	L26
	fear of musculoskeletal dis. NEC	L270	L27
000	disability/impairment musc. skel. syst.	L280	L28
232	- · ·	L290	L29
233	sympt./compl. musc. skel. syt. infections musc. skel. syst.		
234	Bornholm disease	L701	L70
		L702	L70
	osteomyelitis/osteiis pyog./abscess	L703	L70
	infections musc. skel. syst. NEC	2,00	
235	neoplasms musc. skel. syst. benign. neopl. musc. skel. syst.	L711	L71
		L712	L71
	malign. neopl. musc. skel. syst. unspecified neopl. musc. skel. syst.	L713	L71
		L720	L72
236	fracture: radius/ulna	L730	L73
237	fracture: tibia/fibula	L740	L74
238	fracture: hand/foot bones		L75
239	fracture: collum femoris	L751 L759	L75
240	fracture: femur NEC	L761	L76
241	fracture: skull	L762	L76
242	fracture: facial bones	L762 L763	L76
243	fracture: spine	L764	L76
244	fracture: rib		
245	fracture: clavicula	L765	L76
246	fracture: humerus	L766	L76
247	fracture: pelvis	L767	L76
248	fracture: NEC	L769	L76
249	sprains/strains ankle(s)	L770	L77
250	sprains/strains knee(s)	L780	L78
251	sprains/strains shoulder/arm	L791	L79
252	sprains/strains wrist/hand	L792	L79
253	sprains/strains foot/toe	L793	L79
254	sprains/strains spine, excl. cerv. spine	L794	L79
255	sprains/strains cerv. spine	L795	L79
256	whiplash calf	L796	L81
257	sprains/strains musc. skel. syst. NEC	L799	L79/L81

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
258	(sub)luxation, dislocation		
	(sub)luxation/dislocation shoulder	L801	L80
	(sub)luxation/dislocation jaw	L802	L80
	(sub)luxations/dislocation NEC	L809	L80
259	cong. luxation of hip	L821	L82
260	cong. anom. musc. skel. syst. NEC	L829	L82
261	syndromes cervical spine	L830	L83
262	osteoarthritis of cervical spine	L841	L84
263	osteoarthritis of spine NEC	L842	L84
264	acquired deformities of spine	L850	L85
265	back pain with radiating sympt.	L861	L86
266	lumbago	L862	L03
267	sciatica	L863	L86
268	slipped lumbar disc	L864	L86
269	ganglion joint/tendon	L870	L87
270	rheumatoid arthritis	L881	L88
271	spondylitis (ankylosing)	L882	L88
272	osteoarthritis hip	L891	L89
273	osteoarthritis knee	L892	L90
274	osteoarthritis NEC	L899	L91
275	arthritis in allied conditions NEC	L910	L99
276	shoulder syndrome	L920	L92
277	dis. bursa, excl. shoulder	L931	L99
278	epicondilytis lateralis	L932	L93
279	tendinitis/synovitis	L939	L99
280	osteochondrosis	L940	L94
281	osteoporosis	L950	L95
282	ac. traum. meniscus/lig. knee	L960	L96
283	retropatellar chondropathy	L971	L97
284	chron. internal knee derangement	L979	L97
285	acquired deformities of limbs		
	pes planus	L981	L98
	hallux valgus	L982	L98
	genua valga/vara	L983	L98
	acquired deformities limbs NEC	L989	L98
286	dis. musc. skel. system NEC	L990	L99
N	NEUROLOGICAL SYSTEM		
287	headache/facial pain		
	headache	N010	N01
	pain facial	N020	N03
288	sensibility disturbance		
	tingling fingers/feet/toes	N030	N05
	sens. dist./abn. invol. movements	N050	N06
289	restless legs syndrome	N040	N04
290	convulsions	N070	N07
291	symptoms sense/smell/taste	N160	N16
292	vertigo	N170	N17
293	paralysis	N180	N18
294	sympt./complt. speech	N190	N19
295	fear of neurological disease		
	fear of cancer neurol. syst.	N260	N26
	fear of other neurological disease	N270	N27
296	disability/impairment neurol. syst.	N280	N28
297	sympt./complt. neurol. syst. NEC	N290	N29
298	poliomyelitis	N700	N70

nr.	description	ICPC-code	ICPC-code
		NIVEL	OXFORD
299	meningitis/encefalitis	N710	N71
300	tetanus	N720	N72
301	infections neur. syst. NEC	N730	N73
302	malignant neoplasm neur. syst.		
-	mal. neopl. brains	N741	N74
	mal. neopl. neur. syst. NEC	N749	N74
303	benigne neopl. neur. syst.	N750	N75
304	unspecified neopl. neur. syst.	N760	N76
305	concussion: commotio cer.	N791	N79
306	concussion: contusio cer.	N792	N79
307	head injury NOS/NEC, w/o skull fract.	N800	N80
308	injuries neur. syst. NEC	N810	N81
309	cong. anom. neur. syst.	N850	N85
310	multiple sclerosis	N860	N86
311	Parkinsonism	N870	N87
312	epilepsy, all types	N880	N88 N89
313	migraine	N890	N91
314	facial paralysis, Bell's palsy	N991 N992	N92
315	trigeminal neuralgia	N992 N993	N93
316	carpal tunnel syndrome	N994	N90
317	cluster headache	N998	N94
318	dis. of periph. nerv. syst. NEC	N999	N99
319	dis. of central nerv. syst. NEC	14333	1400
Р	PSYCHOLOGICAL SYSTEM		
320	feeling anxious/nervous/tense	P010	P01
321	acute stress (transient) reaction	P020	P02
322	feeling depressed	P030	P03
323	feeling/behaving irritable		
	irritated/angry feeling/behaving	P040	P04
	feeling restless/agitated	P050	P29
324	suicide attempt	P060	P77
325	disturbances of sleep	P070	P06
326	sexual problems	P080	P07/P08
327	hypochondr. dis./probl. with being ill	P090	P75/Z11
328	tension headache	P100	N02
329	hyperventilation	P110	R98
330	enuresis	P120	P12
331	anorexia nervosa/boulimia	P131	T06
332	eating/feeding probl. NEC	P139 P150	P11/T04/T05/T29 P15
333	chronic alcohol abuse	P160	P16
334	acute alcohol abuse	P170	P17
335	tobacco abuse	P181	P19
336	drug abuse	P189	P18
337	medicinal abuse	P190	P19
338	abuse substances NEC	P200	P20
339	dist. memory/concentration disturbance behaviour child	1 200	5
340	encopresis	P221	P13
	overactive child, hyperkin. syndr.	P222	P21
	Minimal Brain Dysfunction	P223	P22
	sympt./complt. behaviour child	P229	P22
341	sympt./compit. behaviour adolescent	P260	P23
342	sympt./complt. adult	P230	P80
343	phase of live problem adult	P240	P25
344	dist. learning/mental development	P250	P24
345	fear of mental disorder	P270	P27

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
346	psychic disability/impairment	P280	P28
347	psychic sympt./complt. NEC	P290	P29
348	dementia (pre)senile		
	presenile dementia Alzheimer	N995	P70
	dementia senile	P701	P70
349	organic psychosis		
	puerperal psychosis	P702	P71
	organic psychosis NEC	P709	P71
350	schizophrenia, all types	P710	P72
351	affective psychosis		
	endogenous unipolar depression	P721	P73
	manic depressive psychosis	P722	P73
	affective psychosis NEC	P729	P73
352	unspecified psychosis NEC	P730	P98
353	anxiety disorder/anxiety state	P740	P74
354	hysterical/hypochondriacal dis.	r/4U	F/4
554	hysteria	P751	D75
	hypochondriasis		P75
355		P752	P75
	depressive disorder	P760	P76
356	mental retardation	P770	P85
357	neurasthenia, surmenage	P780	P78
358	personality disorder	P800	P80
359	phobia/neurotic disorder NEC		
	phobia	P991	P79
	neurotic disorders NEC	P998	P79
360	mental/psychological dis. NEC	P999	P99
R	RESPIRATORY SYSTEM		
361	pain attr. to respiratory system	R010	R01
362	shortness of breath, dyspnoe	R020	R02
363	wheezing	R030	R03
364	breathing problems NEC	R040	R04
365	cough	R050	R05
366	epistaxis/nose bleed	R060	R06
367	sneezing/nasal congestion	R070	R07
368	sympt./complt. nose NEC	R080	R08
369	sympt./complt. sinus (incl. pain)	R090	R09
370	sympt./complt. throat	R210	R21
371	sympt./complt. timoat	R220	R22
372	sympt./complt. torisis sympt./complt. voice/vocal cords	R230	R23
373	haemoptysis		
374	abnormal sputum/phlegm NEC	R240	R24
374 375		R250	R25
3/3	fear of capper of resp. syst	Dooo	Doc
	fear of cancer of resp. syst.	R260	R26
276	fear of respiratory dis. NEC	R270	R27
376	disability/impairment resp. syst.	R280	R28
377	sympt./complt. resp. syst. NEC		mar.
	cyanosis	R291	R29
	hiccup	R292	R29
	sympt./complt. resp. syst. NEC	R299	R29
378	tuberculosis resp. (excl. A70)	R700	R70
379	whooping cough	R710	R71
380	scarlet fever	R721	R72
381	streptoc. inf. throat NEC	R729	R72
382	boil/abscess nose	R730	R73
	URI (head cold)	R740	R74
383			
383 384	sinusitis acute/chronic	R750	R75

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
385	acute tonsillitis/adenoiditis	R760	R76
386	acute laryngitis/tracheitis/croup	R770	R77
387	acute bronchi(oli)tis	R780	R78
388	influenza w/o pneumonia	R800	R80
389	pneumonia	R810	R81
390	pleurisy all (excl. R70)	R820	R82
391	infection resp. syst. NEC	R830	R83
392	mal. neopl. bronchus/lung	R841	R84
393	mal. neopl. resp. syst. NEC	R849	R85
394	ben, neopl. resp. syst.	R850	R86
395	unspecified neopl. resp. syst.	R860	R85
396	foreign body resp. syst.	R870	R87
397	injuries resp. syst. NEC	R880	R88
398	cong. anom. resp. syst.	R890	R89
399	hypertrophy/chron. inf. tonsills/aden.	R900	R90
400	chronic bronchitis		
400	chronic bronchitis/bronchiectasis	R911	R91
	COPD	R912	R95
401	pleural effusion NOS	R930	R93
402	emfysema	R950	R95
402	asthma	R960	R96
403	allergic rhinitis/hay fever	R970	R97
405	diseases resp. syst. NEC		
405	deviation nasal septum	R991	R99
	polyp of nose	R992	R99
	vocal cord nodes	R993	R85/R86
	disorder resp. syst. NEC	R999	R99
S	SKIN/SUBCUTANEOUS TISSUE		
406	pain/tenderness of skin	S010	S01
407	pruritus, skin itching	S020	S02
408	warts	S031	S03
409	condyloma acuminata	S032	X91/Y76
410	local swelling/papul/lump	S040	S04
411	multiple swelling/papul/lump	S050	S05
412	local redness/erythema	S060	S06
413	general redness/erythema	S070	S07
414	changes in skin color NEC	S080	S08
415	local infection finger/toe	S090	S09
416	boil/carbuncle/cellulitis	S100	S10
417	local infection skin NEC	S110	S11
418	insect bite	S120	S12
419	animal/human bite	S130	S13
420	burns/scalds	S140	S14
421	foreign body in skin	S150	S15
422	bruise/contusion intact skin	S160	S16
423	abrasion/scratch/blister	S170	S17
424	laceration/cut	S180	S18
425	injury to skin NEC	S190	S19
426	corns/callosities	S200	S20
427	sympt./complt. of skin texture	S210	S21
428	sympt./complt. nails	S220	S22
429	losing hair/baldness	S231	S23
430	sympt./complt. hair NEC		
700	hirsutismu s	S232	S24
	sympt./complt. hair NEC	S239	S24
	-Assistant continue on		

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
431	fear of skin disease		
	fear of cancer of skin	S260	S26
	fear of diseases of skin NEC	S270	S27
432	disability/impairment of skin	S280	S28
433	sympt./complt. of skin NEC	S290	S29
434			
	herpes zoster	S700	S70
435	herpes simpley genitelia	S711	S71
436	herpes simplex genitalis	S712	X90/Y72
437	herpes simplex NEC	S719	S71
438	scables/other ascariasis	S720	S72
439	pediculosis/skininfestation	S730	S73
440	dermatophytosis/dermatomycosis	_	
	athlete's foot	S741	S74
	pityriasis versicolor	S742	S74
	onychomycosis	S743	S74
	dermatophytosis/-mycosis NEC	S749	S74
441	moniliasis/candidiasis (excl. GU)	S750	S74
442	erysipelas	S761	S76
443	mollusca contagiosa	S762	S95
444	infection skin NEC	S769	S76
445	malign. neoplasm skin	S770	S77
446	lipoma	S780	S78
447	benign. neoplasm skin NEC	S790	S79
448	unspecified neoplasm skin	S800	S80
449	hemangioma/lymfangioma		
450		S810	S81
	nevus/mole	S820	S82
451	cong. anom. of skin NEC	S830	S83
452	impetigo	S840	S84
453	pilonidal cyst/fistula	S850	S85
454	seborrheic dermatitis	S860	S86
455	atopic dermatitis/eczema	S870	S87
456	contact dermatitis	S881	S88
457	eczema NEC	S882	S88
458	diaper rash	S890	S89
459	pityriasis rosea	S900	S90
460	psoriasis w/wo arthropathy	S910	S91
461	pompholyx/dis. sweat glands	S920	S92
462	sebaceous cyst	S930	S93
463	ingrown toenail/dis. of nail NEC	S940	S94
464	alopecia/folliculitis/dis. of hair NEC	S950	S23/S11/S24
465	acne vulgaris	S960	S96
466	chron. ulcer skin, incl. varicose	S970	S97 (incl. ulcus cruris)
467	urticaria	S980	S98
468	seborrheic warts	S991	S99
469	acne rosacea	S992	S99
470	dis. skin/subcut. tissue NEC	S999	S99
Т	ENDOCRINE/METABOLIC/NUTRITITIONAL SYSTEM		
471	excessive thirst	TO10	T01
471	excessive appetite, excl. boulimia	T010	T01
	11 /	T020	T02
473	loss of appetite, excl. anorexia nerv.	T030	T03
474	feeding problem infant, excl. P11	T040	T04
475	feeding problem adult, excl. T06	T050	T05
476	feeding problem NEC	T060	T06
477	weight gain, excl. T82	T070	T07
478	weight loss, excl. T06	T080	T08
479	weight problem NEC	T090	T07/T08

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
480	failure to thrive	T100	T10
481	dehydration	T110	T11
482	thyroid lump/mass	T120	T15
483	fear of endocr. metab. nutr. dis.		
	fear of cancer of endocr. syst.	T260	T26
	fear of end. met. nutr. dis. NEC	T270	T27
484	disability/impairment end. gl.	T280	T28
485	sympt./complt. end./met./nutr. NEC	T290	T29
486	infectious dis. endocrine glands	T700	T70
487		T710	T71
488		T720	T72
489		T730	T73
490		T740	T74
491		T780	T78 T80
492		T800 T810	T81
493		T820	T82/T83
494		T850	T85
495		T860	T86
496		T870	T87
497		T880	T88
498		T900	T90
499		T910	T91
500	•	T920	T92
501	•	T930	T93
502	•	T991	T99
503	·	T992	T99
504 505		T993	T99
, U	URINARY SYSTEM		
506	•	11040	1101
	painful urination, dysuria	U010	U01 U02
	frequent/urgent urination	U020	U05
	retention of urine	U051 U059	U05
	urination problems NEC	U040	U04
507	· · · · · · · · · · · · · · · · · · ·	U052	U05
508		0032	000
509	•	U060	U06
	blood in urine complaints urine NEC	U070	U07
E 1 C		U130	U13
510		U140	U14
511 512		3	
512	fear of cancer of urinary syst.	U260	U26
	fear of urinary dis. NEC	U270	U27
513	the state of the s	U280	U28
514		U290	U29
515		U700	U70
516		U710	U71
517		U720	U72
518	· · · · · · · · · · · · · · · · · · ·	U750	U75
519		U760	U76
520		U770	U77
521		U780	U78
522		U790	U79
523	•	U800	U80
524		U850	U85
. —	•		

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
525	glomerulonephritis/nephrosis	U880	U88
526	orthostatic albuminuria	U900	U90
527	urin, calculus, all types/sites	U950	U95
528	abnormal urine test/findings NOS		
	glucosuria	U981	U98
	albuminuria	U982	U98
	abnorm, urine testfinding NEC	U989	U98
529	dis. urinary system NEC		
	chron. pyelitis/pyelonephritis	U991	U99
	urethral stricture	U992	U99
	uremia	U993	U99
	dis. urinary system NEC	U999	U99
W	PREGNANCY, FAMILY PLANNING (Pr/D/Pu/Fp)		
530	question of pregnancy (excl. W02)	W010	W01
531	fear of being pregnant	W020	W02
532	ante-partum bleeding		
	ante-partum bleeding < 16 wks	W031	W03
	ante-partum bleeding > 16 wks	W032	W03
533	vaginal discharge in pregn.	W040	W29
534	vomiting/nausea of pregn.	W050	W05
535	wanted pregnancy	W060	W01
536	morning-after pill	W100	W10
537	fam. plan./oral contraceptive	W110	W11
538	fam. plan./IUD	W120	W12
539	fam. plan./sterilization 9	W130	W13
540	fam. plan./ NEC ♀	W140	W14
541	sub-/infertility ♀	W150	W15
542	heavy post-partum bleeding	W170	W17
543	complt. post partum NEC	W180	W18
544	sympt./complt. lactation	W190	W19
545	sympt./complt. breast in pregn. NEC	W200	W20
546	starting delivery	W210	W29
547	fear of complic of pregn./deliv.	W270	W27
548	disability/impairment Pr/D/Pu/Fp	W280	W28
549	sympt./complt. Pr/D/Pu/Fp NEC		
	albuminuria in pregn.	W291	W29
	excessive "weight" in pregn.	W292	W29
	sympt./complt. Pr/D/Pu/Fp NEC	W299	W29
550	infect. dis. urinary tr. pregn./puerp.	W700	U71
551	infect. dis. pregn. NEC	W710	W71
552	malign. neoplasm pregn.	W720	W72
553	benign. neoplasm pregn.	W730	W73
554	injuries complicating pregn.	W750	W75
555	cong. anom. of mother/complic. pregn.	W760	W76
556	non-obst. cond. complic. pregn. NEC	W770	W77
557	pregnancy: confirmed	W780	W78
558	unwanted pregnancy: confirmed	W790	W79
559	ectopic pregnancy	W800	W80
560	toxemia/(pre)eclampsia	W810	W81
561	abortion, imminens/spontan.		
	abortion imminens	W821	W03
F0.0	abortion spontaneous NOS	W822	W82
562	abortion, (il)legally induced	W830	W83

nr.	description	ICPC-code	ICPC-code
••••		NIVEL	OXFORD
563	pregnancy, high risk	14/0.44	MOE
	hyperemesis gravidarum	W841	W05
	cervical incompetence	W842	W84
	multiple pregnancy	W843	W84
	elderly primipare	W844	W84
	fetal malposition	W845	W84
	premature labour	W846	W84
	post-term pregnancy	W847	W84
	previous obst. cond. in pregn.	W848	W84
	high risk pregnancy NEC	W849	W84
564	normal delivery live born(s)	W900	W90
565	normal delivery dead born(s)	W910	W91
566	complicated delivery live born		
	abn. forces of labour complic. deliv.	W921	W92
	disproportion complic. deliv.	W922	W92
	umbilical cord complic.	W923	W92
	cesarean section live born	W924	W92
	ventouse extr./forceps deliv. live born	W925	W92
	perineal rupture	W926	W92
	episiotomy	W927	W92
	retained placenta	W928	W92
	complic. deliv. live born NEC	W929	W92
567	complicated delivery dead born	W930	W93
568	normal puerperium	W310	•
569	mastitis puerperalis	W940	W94
570	dis. of breast puerperium NEC	W950	W95
571	complic. puerperium NEC		
	fever puerp.	W961	W70
	thrombosis puerp.	W962	W96
	endometritis puerp.	W963	W70
	infection puerp. NEC	W968	W70
	complic. puerp. NEC	W969	W96/W99/W18/W29
572	diseases Pr/D/Pu NEC		
	abnormalities placenta	W991	W99
	dysmaturit a s	W992	W92
	premature rupture of membranes	W993	W92
	dis. Pr/D/Pu NEC	W999	W99
X	FEMALE GENITAL SYSTEM and MAMMA		
		X010	X01
573	genital pain ♀	2010	701
574	menstruation absent/scanty	X021	X05
	primary amenorrhea	X029	X05
	secondary amenorrhea, hypo-/am. NEC	A029	703
575	menstruation excessive	X031	X06
	menstr. excess. (regular)	X032	X07
	menstr. excess. (irregular/freq.)	X051	X08
	metrorrhagia	7031	700
576	menstrual pain	X041	X02
	dysmenorrhea	X042	X03
	ovulation pain	X042 X059	X08
577	sympt./complt. menstruation NEC	X060	X09
578	premenstrual symptoms		X11
579	sympt./complt. menopausal	X070	X11 X12
580	postmenopausal bleeding	X080	
581	painful intercourse 9	X090	X04
582	postcoïtal bleeding	X100	X13 X14
583	vaginal discharge	X110	^1 4

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
584	sympt./complt. vagina NEC	X120	X15
585	sympt./complt. vulva	X130	X16
586	sympt./complt. pelvis 9	X140	X17
587	lump/mass mamma 9	X150	X17 X19
588	pain mamma 9	X160	X19 X18
589	sympt./complt. mamma NEC 9	X170	X20/X21
590	postponement of menstruation	X170 X180	X10
591	fear genital/mamma dis. 9	A100	X10
001	fear venereal dis. 9	X230	X23
	fear of sexual dysfunction 9	X240	X24
	fear genital cancer 9	X250	
	fear mamma cancer 9		X25
	fear genital/mamma dis. 9 NEC	X260	X26
592	- ,	X270	X27
592 593	disab./impairm. gen. syst. 9	X280	X28
593 594	sympt./complt. gen. syst. 9 syphilis, (genit. and NOS) 9	X290	X29
595	gonorrhea, (genit. and NOS) ?	X700	X70
596	veneral dis. NEC 9	X711	X71
597	urogenital candidiasis 9	X712	X90/X91/X99
598	urogenital trichomoniasis 9	X720	X72
		X730	X73
599	pelvic inflammatory disease	X740	X74
600	carcinoma in situ cervix	X751	X75
601	cervix carcinoma NEC	X759	X75
602	mal. neopl. mamma ?	X760	X76
603	mal. neopl. genit. syst. 9	X770	X77
604	fibroid/myoma (uterus/cervix)	X780	X78
605	ben. neopl. mamma ?	X790	X79
606	ben. neopl. genit. syst. 9	X800	X80
607	unspec. neopl. genit. syst. 9	X810	X81
608	injury genit. syst./mamma 9	X820	X82
609	cong. anom. genit. syst./mamma 9	X830	X83
610	vaginitis/vulvitis NOS	X840	X84
611	cervicitis/cerv. dis. NEC	X850	X85
612	abnormal PAP-smear	X860	X86
613	uterovaginal prolapse		
	uterovaginal prolapse	X871	X87
	stress-incontinence female	X872	X87
614	cystic breast (chronic)	X880	X88
615	premenstrual tension syndrome	X890	X89
616	gardnerella infection	X900	X99
617	infection/abscess gl. Bartholini	X991	X99
618	endometriosi s	X992	X99
619	atrophial vaginae/vulvae	X993	X99
620	dis. genital syst./mamma NEC 9		
	menarche sympt.	X994	X08
	dis. gen. syst. NEC 9	X999	X99
Υ	MALE GENITAL SYSTEM and MAMMA		
621	sympt./complt. gen. syst. o		
	pain in penis	Y010	Y01
	pain in testis/scrotum	Y020	Y02
	sympt./complt. penis NEC	Y040	Y04
	sympt./complt. testis/scrotum	Y050	Y05
622	discharge penis/urethra	Y030	Y03
623	sympt./complt. prostate	Y060	Y06
624	sympt./complt. potency	Y070	Y07
625	sympt./complt. sexual dysf. of	Y080	Y08
	, ,,,,,,,,	. 500	100

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
626	sub-/infertility of	Y100	Y10
627	fam. plan.♂		
	fam. plan./sterilization of	Y130	Y13
	fam. plan./NEC o	Y140	Y14
628	sympt./complt. mamma o	Y160	Y16
629	fear dis. gen. syst./mamma o		
	fear sexual dysf. o	Y240	Y24
	fear venereal dis. ♂	Y250	Y25
	fear cancer gen. syst./mamma ơ	Y260	Y26
	fear dis. gen. syst./mamma NEC o	Y270	Y27
630	disab./impairm. gen. syst./mamma 🗸	Y280	Y28
631	sympt./complt. gen. syst./mamma NEC o	Y290	Y29
632	syphilis ♂	Y700	Y70
633	gonorrhea o	Y711	Y71
634	venereal disease NEC σ	Y712	Y72/Y76/Y99
635	urogenital trichomoniasis ♂	Y720	Y99
636	prostatitis/seminal vesiculitis	Y730	Y73
637	orchitis/epididymitis	Y740	Y74
638	infection gen. syst. NEC ♂	Y750	Y75/Y99
639	malign, neopl, prostate	Y761	Y77
640	malign, neopl, testis	Y762	Y78
641	malign. neopl. gen. syst. NEC of	Y769	Y78
642	benign. neopl. gen. syst. ♂	Y770	Y79
643	unspecif. neopl. gen. syst. of	Y780	Y78
644	unspecif. neopl. mamma o	Y790	Y78
645	injury gen. syst./mamma o	Y800	Y80
646	phimosis/redund. prepuce	Y810	Y81
647	hypospadia	Y820	Y82
648	undesc. testicle/cryptorchism	Y830	Y83
649	cong. anom. gen. syst./mamma NEC o	Y840	Y84
650	benign prostatic hypertrophy	Y850	Y85
651	hydrocele	Y860	Y86
652	dis. gen. syst./mamma NEC σ	Y990	Y99
Z	SOCIAL PROBLEMS		
653	poverty/financial probl.	Z010	Z01
654	problem food/water	Z020	Z02
655	probl. housing/neighborh.	Z030	Z03
656	probl. house moving	Z040	Z03
657	fear of having a social probl.		
00.	fear losing job	Z051	Z05
	fear of having soc. probl. NEC	Z270	Z27
658	probl. working conditions	Z052	Z05
659	probl. job/employment NEC	Z059	Z05
660	probl. w. being unemployed	Z060	Z06
661	probl. w. education	Z070	Z07
662	probl. soc. insurrance/welfare	Z080	Z08
663	probl. legal/police	Z090	Z09
664	probl. health care syst./access	Z100	Z10
665	probl. soc./cultural syst.		
555	discrimination (race/rel./sex/NEC)	Z111	Z04
	extramarital pregn.	Z112	Z04
	illegal stay	Z113	Z04
	probl. w. military service	Z114	Z04
	probl. soc./cult./rel. values NEC	Z119	Z04

nr.	description	ICPC-code NIVEL	ICPC-code OXFORD
666	relation problems partners		
	battering/violence by partner	Z121	Z12
	marital problems	Z122	Z12
	relation probl. partners NEC	Z129	Z12
667	problems w. behaving partner		
	alcohol abuse partner	Z131	Z13
	drug abuse partner	Z132	Z13
	behaving probl. partner NEC	Z139	Z13
668	probl. w. partner being ill	Z140	Z14
669	probl. loss of partner		
	probl. by divorce	Z151	Z15
	probl. by death partner	Z152	Z15
	probl. loss partner NEC	Z159	Z15
670	relation probl. with child		
	battering/neglecting child	Z161	Z16
	relation probl. parent-child	Z162	Z16
	probl. parent-child NEC	Z169	Z16
671	probl. behaving child	Z170	Z16
672	probl. with child being ill	Z180	Z18
673	loss or death of child	Z190	Z19
674	relation probl. parent/other family	Z200	Z20/Z12/Z16
675	probl. w. behaving parent/other family	Z210	Z21
676	probl. w. parent/other family being ill	Z220	Z22
677	loss parent/family		
	loss or death of parents	Z231	Z23
	loss or death of family	Z232	Z23
678	loss or death of friend	Z241	Z24
679	relation probl. w. friend	Z249	Z24
680	probl. assault/harmfull events	Z250	Z25
681	probl. with being ill	Z260	Z11
682	social handicap	Z280	Z28
683	social isolation	Z291	Z29
684	social problems		
	problems environmental pollution	Z292	Z29
	social problems NEC	Z299	Z29